<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17558391</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>447</Volume><Issue>7148</Issue><PubDate><Year>2007</Year><Month>Jun</Month><Day>28</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>'Rejuvenation' protects neurons in mouse models of Parkinson's disease.</ArticleTitle><Pagination><StartPage>1081</StartPage><EndPage>1086</EndPage><MedlinePgn>1081-6</MedlinePgn></Pagination><Abstract><AbstractText>Why dopamine-containing neurons of the brain's substantia nigra pars compacta die in Parkinson's disease has been an enduring mystery. Our studies suggest that the unusual reliance of these neurons on L-type Ca(v)1.3 Ca2+ channels to drive their maintained, rhythmic pacemaking renders them vulnerable to stressors thought to contribute to disease progression. The reliance on these channels increases with age, as juvenile dopamine-containing neurons in the substantia nigra pars compacta use pacemaking mechanisms common to neurons not affected in Parkinson's disease. These mechanisms remain latent in adulthood, and blocking Ca(v)1.3 Ca2+ channels in adult neurons induces a reversion to the juvenile form of pacemaking. Such blocking ('rejuvenation') protects these neurons in both in vitro and in vivo models of Parkinson's disease, pointing to a new strategy that could slow or stop the progression of the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>C Savio</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guzman</LastName><ForeName>Jaime N</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Ilijic</LastName><ForeName>Ema</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mercer</LastName><ForeName>Jeff N</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Rick</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Tkatch</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Meredith</LastName><ForeName>Gloria E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Surmeier</LastName><ForeName>D James</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485995">Cacna1d protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020746">Calcium Channels, L-Type</NameOfSubstance></Chemical><Chemical><RegistryNumber>03L9OT429T</RegistryNumber><NameOfSubstance UI="D012402">Rotenone</NameOfSubstance></Chemical><Chemical><RegistryNumber>9P21XSP91P</RegistryNumber><NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2007 Jun 28;447(7148):1059-60. doi: 10.1038/4471059a.</RefSource><PMID Version="1">17597746</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015632" MajorTopicYN="N">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020746" MajorTopicYN="N">Calcium Channels, L-Type</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004553" MajorTopicYN="N">Electric Conductivity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="Y">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012402" MajorTopicYN="N">Rotenone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17558391</ArticleId><ArticleId IdType="doi">10.1038/nature05865</ArticleId><ArticleId IdType="pii">nature05865</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17562708</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>282</Volume><Issue>32</Issue><PubDate><Year>2007</Year><Month>Aug</Month><Day>10</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis.</ArticleTitle><Pagination><StartPage>23645</StartPage><EndPage>23654</EndPage><MedlinePgn>23645-54</MedlinePgn></Pagination><Abstract><AbstractText>Tau in Alzheimer disease brain is highly phosphorylated and aggregated into paired helical filaments comprising characteristic neurofibrillary tangles. Here we have analyzed insoluble Tau (PHF-tau) extracted from Alzheimer brain by mass spectrometry and identified 11 novel phosphorylation sites, 10 of which were assigned unambiguously to specific amino acid residues. This brings the number of directly identified sites in PHF-tau to 39, with an additional six sites indicated by reactivity with phosphospecific antibodies to Tau. We also identified five new phosphorylation sites in soluble Tau from control adult human brain, bringing the total number of reported sites to nine. To assess which kinases might be responsible for Tau phosphorylation, we used mass spectrometry to determine which sites were phosphorylated in vitro by several kinases. Casein kinase 1delta and glycogen synthase kinase-3beta were each found to phosphorylate numerous sites, and each kinase phosphorylated at least 15 sites that are also phosphorylated in PHF-tau from Alzheimer brain. A combination of casein kinase 1delta and glycogen synthase kinase-3beta activities could account for over three-quarters of the serine/threonine phosphorylation sites identified in PHF-tau, indicating that casein kinase 1delta may have a role, together with glycogen synthase kinase-3beta, in the pathogenesis of Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hanger</LastName><ForeName>Diane P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>MRC Centre for Neurodegeneration Research, Department of Neuroscience, King's College London, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byers</LastName><ForeName>Helen L</ForeName><Initials>HL</Initials></Author><Author ValidYN="Y"><LastName>Wray</LastName><ForeName>Selina</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Kit-Yi</ForeName><Initials>KY</Initials></Author><Author ValidYN="Y"><LastName>Saxton</LastName><ForeName>Malcolm J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Seereeram</LastName><ForeName>Anjan</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>C Hugh</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Malcolm A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Anderton</LastName><ForeName>Brian H</ForeName><Initials>BH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0300408</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D048148">Casein Kinase Idelta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C000605506">GSK3B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C000605508">Gsk3b protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048148" MajorTopicYN="N">Casein Kinase Idelta</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17562708</ArticleId><ArticleId IdType="doi">10.1074/jbc.M703269200</ArticleId><ArticleId IdType="pii">S0021-9258(20)54579-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17562829</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>24</Issue><PubDate><Year>2007</Year><Month>Jun</Month><Day>12</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Chronic distress and incidence of mild cognitive impairment.</ArticleTitle><Pagination><StartPage>2085</StartPage><EndPage>2092</EndPage><MedlinePgn>2085-92</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Mild cognitive impairment (MCI) is associated with increased morbidity and mortality but its development is not well understood. Here we test the hypothesis that chronic psychological distress is associated with increased incidence of MCI in old age.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Participants are older persons from two cohort studies with uniform annual clinical evaluations which included detailed cognitive testing and clinical classification of MCI. We excluded persons with dementia or MCI at baseline; follow-up data were available on 1,256 persons without cognitive impairment (95% of those eligible). At baseline, they completed a six-item measure of neuroticism (mean = 15.6, SD = 6.6), an indicator of the tendency to experience psychological distress.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During up to 12 years of follow-up, 482 persons (38%) developed MCI. Risk of MCI increased by about 2% for each one unit increase on the distress scale (relative risk [RR] = 1.02; 95% CI: 1.01, 1.04), with the association slightly stronger in men than women. Overall, a distress-prone person (score = 24, 90th percentile) was about 40% more likely to develop MCI than someone not prone to distress (score = 8, 10th percentile). Adjustment for depressive symptomatology at baseline did not substantially change results (RR = 1.02; 95% CI: 1.00, 1.03). Depressive symptoms were also related to risk of MCI but not after controlling for distress score. In mixed-effects models, higher distress score was associated with lower level of function in multiple cognitive domains at baseline and more rapid cognitive decline, especially in episodic memory.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Among older persons without manifest cognitive impairment, higher level of chronic psychological distress is associated with increased incidence of mild cognitive impairment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>R S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA. rwilson@rush.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Boyle</LastName><ForeName>P A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>S E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>D A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG23040</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG024871</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17562829</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000264930.97061.82</ArticleId><ArticleId IdType="pii">68/24/2085</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17563384</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>25</Issue><PubDate><Year>2007</Year><Month>Jun</Month><Day>19</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors.</ArticleTitle><Pagination><StartPage>10601</StartPage><EndPage>10606</EndPage><MedlinePgn>10601-6</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is an age-dependent neurodegenerative disease that causes progressive cognitive impairment. The initiation and progression of AD has been linked to cholesterol metabolism and inflammation, processes that can be modulated by liver x receptors (LXRs). We show here that endogenous LXR signaling impacts the development of AD-related pathology. Genetic loss of either Lxralpha or Lxrbeta in APP/PS1 transgenic mice results in increased amyloid plaque load. LXRs regulate basal and inducible expression of key cholesterol homeostatic genes in the brain and act as potent inhibitors of inflammatory gene expression. Ligand activation of LXRs attenuates the inflammatory response of primary mixed glial cultures to fibrillar amyloid beta peptide (fAbeta) in a receptor-dependent manner. Furthermore, LXRs promote the capacity of microglia to maintain fAbeta-stimulated phagocytosis in the setting of inflammation. These results identify endogenous LXR signaling as an important determinant of AD pathogenesis in mice. We propose that LXRs may be tractable targets for the treatment of AD due to their ability to modulate both lipid metabolic and inflammatory gene expression in the brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zelcer</LastName><ForeName>Noam</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanlou</LastName><ForeName>Negar</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Clare</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Qingguang</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Reed-Geaghan</LastName><ForeName>Erin G</ForeName><Initials>EG</Initials></Author><Author ValidYN="Y"><LastName>Landreth</LastName><ForeName>Gary E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Vinters</LastName><ForeName>Harry V</ForeName><Initials>HV</Initials></Author><Author ValidYN="Y"><LastName>Tontonoz</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HL66088</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL066088</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL30568</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HL030568</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071518">Liver X Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000605214">Nr1h3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057093">Orphan Nuclear Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018160">Receptors, Cytoplasmic and Nuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019084" MajorTopicYN="N">Fluorescent Antibody Technique, Indirect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071518" MajorTopicYN="N">Liver X Receptors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057093" MajorTopicYN="N">Orphan Nuclear Receptors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018160" MajorTopicYN="N">Receptors, Cytoplasmic and Nuclear</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>6</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17563384</ArticleId><ArticleId IdType="pmc">PMC1890560</ArticleId><ArticleId IdType="doi">10.1073/pnas.0701096104</ArticleId><ArticleId IdType="pii">0701096104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tontonoz P, Mangelsdorf DJ. Mol Endocrinol. 2003;17:985&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pubmed">12690094</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelcer N, Tontonoz P. J Clin Invest. 2006;116:607&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1386115</ArticleId><ArticleId IdType="pubmed">16511593</ArticleId></ArticleIdList></Reference><Reference><Citation>Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. Nature. 1996;383:728&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878485</ArticleId></ArticleIdList></Reference><Reference><Citation>Repa JJ, Mangelsdorf DJ. Annu Rev Cell Dev Biol. 2000;16:459&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">11031244</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Nat Med. 2003;9:213&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">12524534</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa S, Lozach J, Benner C, Pascual G, Tangirala RK, Westin S, Hoffmann A, Subramaniam S, David M, Rosenfeld MG, Glass CK. Cell. 2005;122:707&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1430687</ArticleId><ArticleId IdType="pubmed">16143103</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler AJ, Sheu MY, Schmuth M, Kao J, Fluhr JW, Rhein L, Collins JL, Willson TM, Mangelsdorf DJ, Elias PM, Feingold KR. J Invest Dermatol. 2003;120:246&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">12542530</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa D, Stone JF, Takata Y, Blaschke F, Chu VH, Towler DA, Law RE, Hsueh WA, Bruemmer D. Circ Res. 2005;96:e59&#x2013;e67.</Citation><ArticleIdList><ArticleId IdType="pubmed">15790955</ArticleId></ArticleIdList></Reference><Reference><Citation>Terasaka N, Hiroshima A, Ariga A, Honzumi S, Koieyama T, Inaba T, Fujiwara T. FEBS J. 2005;272:1546&#x2013;1556.</Citation><ArticleIdList><ArticleId IdType="pubmed">15752369</ArticleId></ArticleIdList></Reference><Reference><Citation>Valledor AF, Hsu LC, Ogawa S, Sawka-Verhelle D, Karin M, Glass CK. Proc Natl Acad Sci USA. 2004;101:17813&#x2013;17818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539759</ArticleId><ArticleId IdType="pubmed">15601766</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph SB, Bradley MN, Castrillo A, Bruhn KW, Mak PA, Pei L, Hogenesch J, O'Connell RM, Cheng G, Saez E, Miller JF, Tontonoz P. Cell. 2004;119:299&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">15479645</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitney KD, Watson MA, Collins JL, Benson WG, Stone TM, Numerick MJ, Tippin TK, Wilson JG, Winegar DA, Kliewer SA. Mol Endocrinol. 2002;16:1378&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pubmed">12040022</ArticleId></ArticleIdList></Reference><Reference><Citation>Abildayeva K, Jansen PJ, Hirsch-Reinshagen V, Bloks VW, Bakker AH, Ramaekers FC, de Vente J, Groen AK, Wellington CL, Kuipers F, Mulder M. J Biol Chem. 2006;281:12799&#x2013;12808.</Citation><ArticleIdList><ArticleId IdType="pubmed">16524875</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova RP, Lefterov IM, Ikonomovic MD, Skoko J, Lefterov PI, Isanski BA, DeKosky ST, Lazo JS. J Biol Chem. 2003;278:13244&#x2013;13256.</Citation><ArticleIdList><ArticleId IdType="pubmed">12547833</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Schuster GU, Hultenby K, Zhang Q, Andersson S, Gustafsson JA. Proc Natl Acad Sci USA. 2002;99:13878&#x2013;13883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129791</ArticleId><ArticleId IdType="pubmed">12368482</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson S, Gustafsson N, Warner M, Gustafsson JA. Proc Natl Acad Sci USA. 2005;102:3857&#x2013;3862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC553330</ArticleId><ArticleId IdType="pubmed">15738425</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, Wong CW. Biochem Biophys Res Commun. 1984;120:885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Proc Natl Acad Sci USA. 1986;83:4913&#x2013;4917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323854</ArticleId><ArticleId IdType="pubmed">3088567</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, et al. Neurobiol Aging. 2000;21:383&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T. Nat Med. 2006;12:1005&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigsknecht-Talboo J, Landreth GE. J Neurosci. 2005;25:8240&#x2013;8249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725530</ArticleId><ArticleId IdType="pubmed">16148231</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B. Neuron. 2004;41:7&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">14715130</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Rall SC., Jr Annu Rev Genomics Hum Genet. 2000;1:507&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701639</ArticleId></ArticleIdList></Reference><Reference><Citation>Mace S, Cousin E, Ricard S, Genin E, Spanakis E, Lafargue-Soubigou C, Genin B, Fournel R, Roche S, Haussy G, et al. Neurobiol Dis. 2005;18:119&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">15649702</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzov H, Chalmers K, Palmgren J, Andreasen N, Johansson B, Cairns NJ, Gatz M, Wilcock GK, Love S, Pedersen NL, et al. Hum Mutat. 2004;23:358&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">15024730</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolsch H, Lutjohann D, Ludwig M, Schulte A, Ptok U, Jessen F, von Bergmann K, Rao ML, Maier W, Heun R. Mol Psychiatry. 2002;7:899&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">12232784</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Yao J, Kim TW, Tall AR. J Biol Chem. 2003;278:27688&#x2013;27694.</Citation><ArticleIdList><ArticleId IdType="pubmed">12754201</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Deng A, Irizarry MC, Fitzgerald ML, Rebeck GW. J Biol Chem. 2002;277:48508&#x2013;48513.</Citation><ArticleIdList><ArticleId IdType="pubmed">12384498</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, Parkinson PF, Chan JY, Tansley GH, Hayden MR, et al. J Biol Chem. 2005;280:43243&#x2013;43256.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207707</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM. J Biol Chem. 2005;280:43236&#x2013;43242.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207708</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R, Staufenbiel M, Lefterov I. J Biol Chem. 2005;280:43224&#x2013;43235.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207713</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns MP, Vardanian L, Pajoohesh-Ganji A, Wang L, Cooper M, Harris DC, Duff K, Rebeck GW. J Neurochem. 2006;98:792&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">16771834</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins JL. Curr Opin Drug Discov Devel. 2004;7:692&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">15503871</ArticleId></ArticleIdList></Reference><Reference><Citation>Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ, Tontonoz P. Proc Natl Acad Sci USA. 2001;98:507&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14617</ArticleId><ArticleId IdType="pubmed">11149950</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Biomol Eng. 2001;17:157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP. Neurobiol Dis. 2006;24:516&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">17029828</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim OS, Lee CS, Joe EH, Jou I. Biochem Biophys Res Commun. 2006;342:9&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">16466690</ArticleId></ArticleIdList></Reference><Reference><Citation>Marijanovic Z, Laubner D, Moller G, Gege C, Husen B, Adamski J, Breitling R. Mol Endocrinol. 2003;17:1715&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">12829805</ArticleId></ArticleIdList></Reference><Reference><Citation>Soccio RE, Adams RM, Romanowski MJ, Sehayek E, Burley SK, Breslow JL. Proc Natl Acad Sci USA. 2002;99:6943&#x2013;6948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124508</ArticleId><ArticleId IdType="pubmed">12011452</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohnesorg T, Adamski J. Mol Cell Endocrinol. 2006;248:164&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">16356630</ArticleId></ArticleIdList></Reference><Reference><Citation>Soccio RE, Adams RM, Maxwell KN, Breslow JL. J Biol Chem. 2005;280:19410&#x2013;19418.</Citation><ArticleIdList><ArticleId IdType="pubmed">15760897</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Strohmeyer R, Kovelowski CJ, Li R. Glia. 2002;40:260&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">12379913</ArticleId></ArticleIdList></Reference><Reference><Citation>Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, Mangelsdorf DJ. Science. 2000;289:1524&#x2013;1529.</Citation><ArticleIdList><ArticleId IdType="pubmed">10968783</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangirala RK, Bischoff ED, Joseph SB, Wagner BL, Walczak R, Laffitte BA, Daige CL, Thomas D, Heyman RA, Mangelsdorf DJ, et al. Proc Natl Acad Sci USA. 2002;99:11896&#x2013;11901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129365</ArticleId><ArticleId IdType="pubmed">12193651</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster GU, Parini P, Wang L, Alberti S, Steffensen KR, Hansson GK, Angelin B, Gustafsson JA. Circulation. 2002;106:1147&#x2013;1153.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196343</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner BL, Valledor AF, Shao G, Daige CL, Bischoff ED, Petrowski M, Jepsen K, Baek SH, Heyman RA, Rosenfeld MG, et al. Mol Cell Biol. 2003;23:5780&#x2013;5789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166346</ArticleId><ArticleId IdType="pubmed">12897148</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, et al. Nat Genet. 1997;17:263&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354781</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM. J Biol Chem. 2004;279:40987&#x2013;40993.</Citation><ArticleIdList><ArticleId IdType="pubmed">15269217</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. J Neurochem. 2004;89:807&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">15140180</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM. J Neuropathol Exp Neurol. 2005;64:743&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">16141783</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoozemans JJ, O'Banion MK. Curr Drug Targets CNS Neurol Disord. 2005;4:307&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">15975032</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Z, Ho L, Yemul S, Zhao Z, Qing W, Pompl P, Kelley K, Dang A, Qing W, Teplow D, Pasinetti GM. Gene Expr. 2002;10:271&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5977525</ArticleId><ArticleId IdType="pubmed">12450219</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M, Horiba M, Buescher JL, Huang D, Gendelman HE, Ransohoff RM, Ikezu T. Am J Pathol. 2005;166:1475&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1606401</ArticleId><ArticleId IdType="pubmed">15855647</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, Obregon D, Flavell RA, Mullan MJ. Nat Neurosci. 2002;5:1288&#x2013;1293.</Citation><ArticleIdList><ArticleId IdType="pubmed">12402041</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA, Mullan M. Science. 1999;286:2352&#x2013;2355.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600748</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin S, Colin C, Hinners I, Gervais A, Cheret C, Mallat M. J Neurosci. 2006;26:3345&#x2013;3356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674113</ArticleId><ArticleId IdType="pubmed">16554485</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigsknecht J, Landreth G. J Neurosci. 2004;24:9838&#x2013;9846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730228</ArticleId><ArticleId IdType="pubmed">15525768</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, Walter M, Roth MG, Lazo JS. J Biol Chem. 2005;280:4079&#x2013;4088.</Citation><ArticleIdList><ArticleId IdType="pubmed">15557325</ArticleId></ArticleIdList></Reference><Reference><Citation>Hindinger C, Hinton DR, Kirwin SJ, Atkinson RD, Burnett ME, Bergmann CC, Stohlman SA. J Neurosci Res. 2006;84:1225&#x2013;1234.</Citation><ArticleIdList><ArticleId IdType="pubmed">16955483</ArticleId></ArticleIdList></Reference><Reference><Citation>Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ. Cell. 1998;93:693&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">9630215</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F. J Neuroimmunol. 1990;27:229&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">2110186</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald DR, Brunden KR, Landreth GE. J Neurosci. 1997;17:2284&#x2013;2294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573513</ArticleId><ArticleId IdType="pubmed">9065490</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura J, Tusell JM, Serratosa J. Glia. 2003;44:183&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">14603460</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17565981</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>282</Volume><Issue>32</Issue><PubDate><Year>2007</Year><Month>Aug</Month><Day>10</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Activation of glycogen synthase kinase 3beta promotes the intermolecular association of tau. The use of fluorescence resonance energy transfer microscopy.</ArticleTitle><Pagination><StartPage>23410</StartPage><EndPage>23417</EndPage><MedlinePgn>23410-7</MedlinePgn></Pagination><Abstract><AbstractText>Tau is hyperphosphorylated and undergoes proteolysis in Alzheimer disease brain. Caspase-cleaved tau efficiently forms fibrillary structures in vitro and in situ. Glycogen synthase kinase 3beta (GSK3beta) phosphorylates tau and induces the aggregation of caspase-cleaved tau in situ. Given the hypothesis that increased association of tau precedes the formation of fibrillar structures, we generated a cell model to quantitate the extent of tau association in situ using fluorescence resonance energy transfer (FRET) microscopy. The cyan and yellow fluorescent proteins were attached to full-length (T4) and caspase-cleaved (T4C3) tau at either the N or C termini, and a pair of cyan and yellow fluorescent protein-tagged tau were co-transfected into human embryonic kidney cells. The FRET efficiency was examined in the presence of a constitutively active or a kinase-dead GSK3beta. Active GSK3beta significantly increased FRET efficiency with both T4 and T4C3, indicating that GSK3beta activation resulted in an increase in the self-association of both T4 and T4C3, but interestingly only T4 is efficiently phosphorylated by GSK3beta. There was no significant difference in FRET efficiency between T4 and T4C3, although only T4C3 in the presence of active GSK3beta leads to the formation of Sarkosyl-insoluble inclusions. These FRET studies demonstrate that GSK3beta facilitates the association of T4 and T4C3, and the presence of caspase-cleaved tau is necessary for the evolution of tau oligomers into Sarkosyl-insoluble inclusions even though it is not extensively phosphorylated. These data imply that increased association of tau should not be regarded as a direct indicator of the formation of insoluble tau aggregates.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chun</LastName><ForeName>Wanjoo</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Gail V W</ForeName><Initials>GV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS051279</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001426">Bacterial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485182">Cyan Fluorescent Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008164">Luminescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054562">yellow fluorescent protein, Bacteria</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C000605506">GSK3B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Biol Chem. 2007 Sep 21;282(38):28296</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001426" MajorTopicYN="N">Bacterial Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="Y">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D031541" MajorTopicYN="N">Fluorescence Resonance Energy Transfer</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008164" MajorTopicYN="N">Luminescent Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008856" MajorTopicYN="N">Microscopy, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17565981</ArticleId><ArticleId IdType="doi">10.1074/jbc.M703706200</ArticleId><ArticleId IdType="pii">S0021-9258(20)54553-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17568013</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>24</Issue><PubDate><Year>2007</Year><Month>Dec</Month><Day>11</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Mixed brain pathologies account for most dementia cases in community-dwelling older persons.</ArticleTitle><Pagination><StartPage>2197</StartPage><EndPage>2204</EndPage><MedlinePgn>2197-204</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the spectrum of neuropathology in persons from the Rush Memory and Aging Project, a longitudinal community-based clinical-pathologic cohort study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study includes older persons who agreed to annual clinical evaluation and brain donation. We examined the neuropathologic diagnoses, including Alzheimer disease (AD) (NIA-Reagan Criteria), cerebral infarctions, and Parkinson disease/Lewy body disease (PD/LBD), in the first 141 autopsies. We calculated the frequency of each diagnosis alone and mixed diagnoses. We used logistic regression to compare one to multiple diagnoses on the odds of dementia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty persons (14.2%) had no acute or chronic brain abnormalities. The most common chronic neuropathologic diagnoses were AD (n = 80), cerebral infarctions (n = 52), and PD/LBD (n = 24). In persons with dementia (n = 50), 38.0% (n = 19) had AD and infarcts, 30.0% (n = 15) had pure AD, and 12% each had vascular dementia (n = 6) and AD with PD/LBD (n = 6). In those without dementia (n = 91), 28.6% (n = 26) had no chronic diagnostic abnormalities, 24.2% (n = 22) had pure AD, and 17.6% (n = 16) had infarctions. In persons with dementia, over 50% had multiple diagnoses (AD, PD/LBD, or infarcts), whereas, in persons without dementia, over 80% had one or no diagnosis. After accounting for age, persons with multiple diagnoses were almost three times (OR = 2.8; 95% CI = 1.2, 6.7) more likely to exhibit dementia compared to those with one pathologic diagnosis.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The majority of community-dwelling older persons have brain pathology. Those with dementia most often have multiple brain pathologies, which greatly increases the odds of dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Armour Academic Center, 600 S. Paulina Street, Suite 1022F, Chicago, IL 60612, USA. julie_a_schneider@rush.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arvanitakis</LastName><ForeName>Zoe</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Bang</LastName><ForeName>Woojeong</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG00849</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2007 Dec 11;69(24):2193-4. doi: 10.1212/01.wnl.0000287144.13726.3e.</RefSource><PMID Version="1">18071139</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2008 Mar 4;70(10):816; author reply 816-7. doi: 10.1212/01.wnl.0000307675.38908.39.</RefSource><PMID Version="1">18316696</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016852" MajorTopicYN="Y">Housing for the Elderly</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17568013</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000271090.28148.24</ArticleId><ArticleId IdType="pii">01.wnl.0000271090.28148.24</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17573346</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>282</Volume><Issue>34</Issue><PubDate><Year>2007</Year><Month>Aug</Month><Day>24</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations.</ArticleTitle><Pagination><StartPage>24504</StartPage><EndPage>24513</EndPage><MedlinePgn>24504-13</MedlinePgn></Pagination><Abstract><AbstractText>Abeta42-lowering nonsteroidal anti-inflammatory drugs (NSAIDs) constitute the founding members of a new class of gamma-secretase modulators that avoid side effects of pan-gamma-secretase inhibitors on NOTCH processing and function, holding promise as potential disease-modifying agents for Alzheimer disease (AD). These modulators are active in cell-free gamma-secretase assays indicating that they directly target the gamma-secretase complex. Additional support for this hypothesis was provided by the observation that certain mutations in presenilin-1 (PS1) associated with early-onset familial AD (FAD) change the cellular drug response to Abeta42-lowering NSAIDs. Of particular interest is the PS1-DeltaExon9 mutation, which provokes a pathogenic increase in the Abeta42/Abeta40 ratio and dramatically reduces the cellular response to the Abeta42-lowering NSAID sulindac sulfide. This FAD PS1 mutant is unusual as a splice-site mutation results in deletion of amino acids Thr(291)-Ser(319) including the endoproteolytic cleavage site of PS1, and an additional amino acid exchange (S290C) at the exon 8/10 splice junction. By genetic dissection of the PS1-DeltaExon9 mutation, we now demonstrate that a synergistic effect of the S290C mutation and the lack of endoproteolytic cleavage is sufficient to elevate the Abeta42/Abeta40 ratio and that the attenuated response to sulindac sulfide results partially from the deficiency in endoproteolysis. Importantly, a wider screen revealed that a diminished response to Abeta42-lowering NSAIDs is common among aggressive FAD PS1 mutations. Surprisingly, these mutations were also partially unresponsive to gamma-secretase inhibitors of different structural classes. This was confirmed in a mouse model with transgenic expression of the PS1-L166P mutation, in which the potent gamma-secretase inhibitor LY-411575 failed to reduce brain levels of soluble Abeta42. In summary, these findings highlight the importance of genetic background in drug discovery efforts aimed at gamma-secretase, suggesting that certain AD mouse models harboring aggressive PS mutations may not be informative in assessing in vivo effects of gamma-secretase modulators and inhibitors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Czirr</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Emmy Noether Research Group, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leuchtenberger</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Dorner-Ciossek</LastName><ForeName>Cornelia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>Edward H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Pietrzik</LastName><ForeName>Claus U</ForeName><Initials>CU</Initials></Author><Author ValidYN="Y"><LastName>Baumann</LastName><ForeName>Karlheinz</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Weggen</LastName><ForeName>Sascha</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017386" MajorTopicYN="N">Sequence Homology, Amino Acid</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17573346</ArticleId><ArticleId IdType="doi">10.1074/jbc.M700618200</ArticleId><ArticleId IdType="pii">S0021-9258(18)80934-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17573534</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>26</Issue><PubDate><Year>2007</Year><Month>Jun</Month><Day>26</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein.</ArticleTitle><Pagination><StartPage>11062</StartPage><EndPage>11067</EndPage><MedlinePgn>11062-7</MedlinePgn></Pagination><Abstract><AbstractText>Proteolytic processing of the amyloid precursor protein (APP) by beta-secretase, beta-site APP cleaving enzyme (BACE1), is the initial step in the production of the amyloid beta (Abeta) peptide, which is involved in the pathogenesis of Alzheimer's disease. The normal cellular function of the prion protein (PrP(C)), the causative agent of the transmissible spongiform encephalopathies such as Creutzfeldt-Jakob disease in humans, remains enigmatic. Because both APP and PrP(C) are subject to proteolytic processing by the same zinc metalloproteases, we tested the involvement of PrP(C) in the proteolytic processing of APP. Cellular overexpression of PrP(C) inhibited the beta-secretase cleavage of APP and reduced Abeta formation. Conversely, depletion of PrP(C) in mouse N2a cells by siRNA led to an increase in Abeta peptides secreted into the medium. In the brains of PrP knockout mice and in the brains from two strains of scrapie-infected mice, Abeta levels were significantly increased. Two mutants of PrP, PG14 and A116V, that are associated with familial human prion diseases failed to inhibit the beta-secretase cleavage of APP. Using constructs of PrP, we show that this regulatory effect of PrP(C) on the beta-secretase cleavage of APP required the localization of PrP(C) to cholesterol-rich lipid rafts and was mediated by the N-terminal polybasic region of PrP(C) via interaction with glycosaminoglycans. In conclusion, this is a mechanism by which the cellular production of the neurotoxic Abeta is regulated by PrP(C) and may have implications for both Alzheimer's and prion diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parkin</LastName><ForeName>Edward T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>Proteolysis Research Group, Institute of Molecular and Cellular Biology, Faculty of Biological Sciences, and Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds LS2 9JT, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watt</LastName><ForeName>Nicole T</ForeName><Initials>NT</Initials></Author><Author ValidYN="Y"><LastName>Hussain</LastName><ForeName>Ishrut</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Eckman</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Eckman</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials></Author><Author ValidYN="Y"><LastName>Manson</LastName><ForeName>Jean C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Baybutt</LastName><ForeName>Herbert N</ForeName><Initials>HN</Initials></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Hooper</LastName><ForeName>Nigel M</ForeName><Initials>NM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G9824728</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS048554</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS042192</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS042192</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS048554-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021962" MajorTopicYN="N">Membrane Microdomains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017096" MajorTopicYN="N">Prion Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>12</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17573534</ArticleId><ArticleId IdType="pmc">PMC1904148</ArticleId><ArticleId IdType="doi">10.1073/pnas.0609621104</ArticleId><ArticleId IdType="pii">0609621104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C. EMBO J. 2004;23:483&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1271800</ArticleId><ArticleId IdType="pubmed">14749724</ArticleId></ArticleIdList></Reference><Reference><Citation>Allinson TM, Parkin ET, Turner AJ, Hooper NM. J Neurosci Res. 2003;74:342&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">14598310</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A, Montrasio F, Kaeser PS. Nat Rev Mol Cell Biol. 2001;2:118&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">11252953</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown DR. Trends Neurosci. 2001;24:85&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">11164938</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins VR, Linden R, Prado MA, Walz R, Sakamoto AC, Izquierdo I, Brentani RR. FEBS Lett. 2002;512:25&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">11852045</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers JM, Liu Y, Hair LS, Kascsack RJ, Lewis LD, Levy LA. Acta Neuropathol (Berl) 1991;83:95&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1792870</ArticleId></ArticleIdList></Reference><Reference><Citation>Hainfellner JA, Wanschitz J, Jellinger K, Liberski PP, Gullotta F, Budka H. Acta Neuropathol (Berl) 1998;96:116&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">9705125</ArticleId></ArticleIdList></Reference><Reference><Citation>Voigtlander T, Kloppel S, Birner P, Jarius C, Flicker H, Verghese-Nikolakaki S, Sklaviadis T, Guentchev M, Budka H. Acta Neuropathol (Berl) 2001;101:417&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">11484812</ArticleId></ArticleIdList></Reference><Reference><Citation>Dermaut B, Croes EA, Rademakers R, Van den Broeck M, Cruts M, Hofman A, van Duijn CM, Van Broeckhoven C. Ann Neurol. 2003;53:409&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">12601712</ArticleId></ArticleIdList></Reference><Reference><Citation>Riemenschneider M, Klopp N, Xiang W, Wagenpfeil S, Vollmert C, Muller U, Forstl H, Illig T, Kretzschmar H, Kurz A. Neurology. 2004;63:364&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">15277640</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JD, Liu K-N, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ, Cerretti DP, Black RA. J Biol Chem. 1998;273:27765&#x2013;27767.</Citation><ArticleIdList><ArticleId IdType="pubmed">9774383</ArticleId></ArticleIdList></Reference><Reference><Citation>Allinson TM, Parkin ET, Condon TP, Schwager SL, Sturrock ED, Turner AJ, Hooper NM. Eur J Biochem. 2004;271:2539&#x2013;2547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15182369</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent B, Paitel E, Saftig P, Frobert Y, Hartmann D, De Strooper B, Grassi J, Lopez-Perez E, Checler F. J Biol Chem. 2001;276:37743&#x2013;37746.</Citation><ArticleIdList><ArticleId IdType="pubmed">11477090</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkin ET, Watt NT, Turner AJ, Hooper NM. J Biol Chem. 2004;279:11170&#x2013;11178.</Citation><ArticleIdList><ArticleId IdType="pubmed">14711812</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim CAF, Breiderhoff T, Jansen P, Wu X, et al. Proc Natl Acad Sci USA. 2005;102:13461&#x2013;13466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarze-Eicker K, Keyvani K, Gortz N, Westaway D, Sachser N, Paulus W. Neurobiol Aging. 2005;26:1177&#x2013;1182.</Citation><ArticleIdList><ArticleId IdType="pubmed">15917101</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera WSS, Hooper NM. Curr Biol. 2001;11:519&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">11413003</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor DR, Watt NT, Perera WS, Hooper NM. J Cell Sci. 2005;118:5141&#x2013;5153.</Citation><ArticleIdList><ArticleId IdType="pubmed">16254249</ArticleId></ArticleIdList></Reference><Reference><Citation>Watt NT, Taylor DR, Gillott A, Thomas DA, Perera WS, Hooper NM. J Biol Chem. 2005;280:35914&#x2013;35921.</Citation><ArticleIdList><ArticleId IdType="pubmed">16120605</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ. Proc Natl Acad Sci USA. 2003;100:11735&#x2013;11740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC208827</ArticleId><ArticleId IdType="pubmed">14504402</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehehalt R, Keller P, Haass C, Thiele C, Simons K. J Cell Biol. 2003;160:113&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172747</ArticleId><ArticleId IdType="pubmed">12515826</ArticleId></ArticleIdList></Reference><Reference><Citation>Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, Dingwall C, De Strooper B, Dotti CG. J Cell Biol. 2004;167:953&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172459</ArticleId><ArticleId IdType="pubmed">15583033</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner RG, Hundt C, Weiss S, Turnbull JE. J Biol Chem. 2002;277:18421&#x2013;18430.</Citation><ArticleIdList><ArticleId IdType="pubmed">11882649</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholefield Z, Yates EA, Wayne G, Amour A, McDowell W, Turnbull JE. J Cell Biol. 2003;163:97&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173449</ArticleId><ArticleId IdType="pubmed">14530380</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Zerr I, Weber T, Poser S, Kretzschmar H, Hunsmann G, Bodemer W. Brain Res Mol Brain Res. 1995;34:173&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">8750875</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegde RS, Mastrianni JA, Scott MR, DeFea KA, Tremblay P, Torchia M, DeArmond SJ, Prusiner SB, Lingappa VR. Science. 1998;279:827&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">9452375</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop MT, Hart P, Aitchison L, Baybutt HN, Plinston C, Thomson V, Tuzi NL, Head MW, Ironside JW, Will RG, Manson JC. Lancet Neurol. 2006;5:393&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">16632309</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamoto T, Iizuka R, Tateishi J. Biochem Biophys Res Commun. 1993;192:525&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">8097911</ArticleId></ArticleIdList></Reference><Reference><Citation>Finckh U, Muller-Thomsen T, Mann U, Eggers C, Marksteiner J, Meins W, Binetti G, Alberici A, Hock C, Nitsch RM, Gal A. Am J Hum Genet. 2000;66:110&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288316</ArticleId><ArticleId IdType="pubmed">10631141</ArticleId></ArticleIdList></Reference><Reference><Citation>White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S, Anstee D, Collinge J, Hawke S. Nature. 2003;422:80&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">12621436</ArticleId></ArticleIdList></Reference><Reference><Citation>Walmsley AR, Zeng F, Hooper NM. EMBO J. 2001;20:703&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC145413</ArticleId><ArticleId IdType="pubmed">11179215</ArticleId></ArticleIdList></Reference><Reference><Citation>Daude N, Marella M, Chabry J. J Cell Sci. 2003;116:2775&#x2013;2779.</Citation><ArticleIdList><ArticleId IdType="pubmed">12759373</ArticleId></ArticleIdList></Reference><Reference><Citation>Manson JC, Clarke AR, Hooper ML, Aitchison L, McConnell I, Hope J. Mol Neurobiol. 1994;8:121&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">7999308</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y, Sanjo N, Chen F, Hasegawa H, Petit A, Ruan X, Li W, Shier C, Kawarai T, Schmitt-Ulms G, et al. J Biol Chem. 2004;279:31329&#x2013;31336.</Citation><ArticleIdList><ArticleId IdType="pubmed">15123598</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvathy S, Hussain I, Karran EH, Turner AJ, Hooper NM. Biochemistry. 1998;37:1680&#x2013;1685.</Citation><ArticleIdList><ArticleId IdType="pubmed">9484239</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, et al. Nat Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan T, Wong BS, Liu T, Li R, Petersen RB, Sy MS. Biochem J. 2002;368:81&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1222984</ArticleId><ArticleId IdType="pubmed">12186633</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17581637</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0261-4189</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>13</Issue><PubDate><Year>2007</Year><Month>Jul</Month><Day>11</Day></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>3169</StartPage><EndPage>3179</EndPage><MedlinePgn>3169-79</MedlinePgn></Pagination><Abstract><AbstractText>A progressive loss of neurons with age underlies a variety of debilitating neurological disorders, including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS), yet few effective treatments are currently available. The SIR2 gene promotes longevity in a variety of organisms and may underlie the health benefits of caloric restriction, a diet that delays aging and neurodegeneration in mammals. Here, we report that a human homologue of SIR2, SIRT1, is upregulated in mouse models for AD, ALS and in primary neurons challenged with neurotoxic insults. In cell-based models for AD/tauopathies and ALS, SIRT1 and resveratrol, a SIRT1-activating molecule, both promote neuronal survival. In the inducible p25 transgenic mouse, a model of AD and tauopathies, resveratrol reduced neurodegeneration in the hippocampus, prevented learning impairment, and decreased the acetylation of the known SIRT1 substrates PGC-1alpha and p53. Furthermore, injection of SIRT1 lentivirus in the hippocampus of p25 transgenic mice conferred significant protection against neurodegeneration. Thus, SIRT1 constitutes a unique molecular link between aging and human neurodegenerative disorders and provides a promising avenue for therapeutic intervention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Dohoon</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Picower Insitute for Learning and Memory, Riken-MIT Neuroscience Research Center, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Minh Dang</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Dobbin</LastName><ForeName>Matthew M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Andre</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sananbenesi</LastName><ForeName>Farahnaz</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Rodgers</LastName><ForeName>Joseph T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Delalle</LastName><ForeName>Ivana</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Baur</LastName><ForeName>Joseph A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Sui</LastName><ForeName>Guangchao</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Armour</LastName><ForeName>Sean M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Puigserver</LastName><ForeName>Pere</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sinclair</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG027916</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013267">Stilbenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606292">Sod1 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051360">Cyclin-Dependent Kinase 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="C447939">SIRT1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="C470545">Sirt1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="D056564">Sirtuin 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="D037761">Sirtuins</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q369O8926L</RegistryNumber><NameOfSubstance UI="D000077185">Resveratrol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051360" MajorTopicYN="N">Cyclin-Dependent Kinase 5</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077185" MajorTopicYN="N">Resveratrol</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056564" MajorTopicYN="N">Sirtuin 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D037761" MajorTopicYN="N">Sirtuins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013267" MajorTopicYN="N">Stilbenes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17581637</ArticleId><ArticleId IdType="pmc">PMC1914106</ArticleId><ArticleId IdType="doi">10.1038/sj.emboj.7601758</ArticleId><ArticleId IdType="pii">7601758</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anderson RM, Bitterman KJ, Wood JG, Medvedik O, Sinclair DA (2003a) Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature 423: 181&#x2013;185</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4802858</ArticleId><ArticleId IdType="pubmed">12736687</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson RM, Latorre-Esteves M, Neves AR, Lavu S, Medvedik O, Taylor C, Howitz KT, Santos H, Sinclair DA (2003b) Yeast life-span extension by calorie restriction is independent of NAD fluctuation. Science 302: 2124&#x2013;2126</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4998187</ArticleId><ArticleId IdType="pubmed">14605207</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki T, Sasaki Y, Milbrandt J (2004) Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305: 1010&#x2013;1013</Citation><ArticleIdList><ArticleId IdType="pubmed">15310905</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordone L, Guarente L (2005) Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat Rev Mol Cell Biol 6: 298&#x2013;305</Citation><ArticleIdList><ArticleId IdType="pubmed">15768047</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossy-Wetzel E, Schwarzenbacher R, Lipton SA (2004) Molecular pathways to neurodegeneration. Nat Med 10 (Suppl): S2&#x2013;S9</Citation><ArticleIdList><ArticleId IdType="pubmed">15272266</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Miller TM, Cleveland DW (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27: 723&#x2013;749</Citation><ArticleIdList><ArticleId IdType="pubmed">15217349</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, Greenberg ME (2004) Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303: 2011&#x2013;2015</Citation><ArticleIdList><ArticleId IdType="pubmed">14976264</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, Mucke L, Gan L (2005) SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 280: 40364&#x2013;40374</Citation><ArticleIdList><ArticleId IdType="pubmed">16183991</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen HY, Lavu S, Bitterman KJ, Hekking B, Imahiyerobo TA, Miller C, Frye R, Ploegh H, Kessler BM, Sinclair DA (2004a) Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 13: 627&#x2013;638</Citation><ArticleIdList><ArticleId IdType="pubmed">15023334</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT, Gorospe M, de Cabo R, Sinclair DA (2004b) Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305: 390&#x2013;392</Citation><ArticleIdList><ArticleId IdType="pubmed">15205477</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Tsai LH (2004) A Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease. Curr Opin Neurobiol 14: 390&#x2013;394</Citation><ArticleIdList><ArticleId IdType="pubmed">15194121</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH (2003) Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40: 471&#x2013;483</Citation><ArticleIdList><ArticleId IdType="pubmed">14642273</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Kim D, Moy LY, Dobbin MM, Sun X, Bronson RT, Tsai LH (2006) p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. J Neurosci 26: 10536&#x2013;10541</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674706</ArticleId><ArticleId IdType="pubmed">17035538</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabrizio P, Gattazzo C, Battistella L, Wei M, Cheng C, McGrew K, Longo VD (2005) Sir2 blocks extreme life-span extension. Cell 123: 655&#x2013;667</Citation><ArticleIdList><ArticleId IdType="pubmed">16286010</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Sananbenesi F, Pang PT, Lu B, Tsai LH (2005) Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron 48: 825&#x2013;838</Citation><ArticleIdList><ArticleId IdType="pubmed">16337919</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Sananbenesi F, Schrick C, Spiess J, Radulovic J (2004) Distinct roles of hippocampal de novo protein synthesis and actin rearrangement in extinction of contextual fear. J Neurosci 24: 1962&#x2013;1966</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730386</ArticleId><ArticleId IdType="pubmed">14985438</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Trojanowski JQ, Lee VM (2004) Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 10: 1055&#x2013;1063</Citation><ArticleIdList><ArticleId IdType="pubmed">15459709</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Shenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373: 523&#x2013;527</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, Chen W, Sufit RL, Siddique T (1994) Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264: 1772&#x2013;1775</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamdane M, Sambo AV, Delobel P, Begard S, Violleau A, Delacourte A, Bertrand P, Benavides J, Buee L (2003) Mitotic-like tau phosphorylation by p25&#x2013;Cdk5 kinase complex. J Biol Chem 278: 34026&#x2013;34034</Citation><ArticleIdList><ArticleId IdType="pubmed">12826674</ArticleId></ArticleIdList></Reference><Reference><Citation>Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191&#x2013;196</Citation><ArticleIdList><ArticleId IdType="pubmed">12939617</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai S, Armstrong CM, Kaeberlein M, Guarente L (2000) Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403: 795&#x2013;800</Citation><ArticleIdList><ArticleId IdType="pubmed">10693811</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaeberlein M, McVey M, Guarente L (1999) The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 13: 2570&#x2013;2580</Citation><ArticleIdList><ArticleId IdType="pmc">PMC317077</ArticleId><ArticleId IdType="pubmed">10521401</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusakawa G, Saito T, Onuki R, Ishiguro K, Kishimoto T, Hisanaga S (2000) Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J Biol Chem 275: 17166&#x2013;17172</Citation><ArticleIdList><ArticleId IdType="pubmed">10748088</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamming DW, Wood JG, Sinclair DA (2004) Small molecules that regulate lifespan: evidence for xenohormesis. Mol Microbiol 53: 1003&#x2013;1009</Citation><ArticleIdList><ArticleId IdType="pubmed">15306006</ArticleId></ArticleIdList></Reference><Reference><Citation>Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S, Pelicci PG, Kouzarides T (2002) Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 21: 2383&#x2013;2396</Citation><ArticleIdList><ArticleId IdType="pmc">PMC126010</ArticleId><ArticleId IdType="pubmed">12006491</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH (2000) Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405: 360&#x2013;364</Citation><ArticleIdList><ArticleId IdType="pubmed">10830966</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SJ, Defossez PA, Guarente L (2000) Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 289: 2126&#x2013;2128</Citation><ArticleIdList><ArticleId IdType="pubmed">11000115</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombard DB, Chua KF, Mostoslavsky R, Franco S, Gostissa M, Alt FW (2005) DNA repair, genome stability, and aging. Cell 120: 497&#x2013;512</Citation><ArticleIdList><ArticleId IdType="pubmed">15734682</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137&#x2013;148</Citation><ArticleIdList><ArticleId IdType="pubmed">11672522</ArticleId></ArticleIdList></Reference><Reference><Citation>Marambaud P, Zhao H, Davies P (2005) Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 280: 37377&#x2013;37382</Citation><ArticleIdList><ArticleId IdType="pubmed">16162502</ArticleId></ArticleIdList></Reference><Reference><Citation>Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, Bultsma Y, McBurney M, Guarente L (2004) Mammalian SIRT1 represses forkhead transcription factors. Cell 116: 551&#x2013;563</Citation><ArticleIdList><ArticleId IdType="pubmed">14980222</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath R, Davis M, Probert AW, Kupina NC, Ren X, Schielke GP, Wang KK (2000) Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells. Biochem Biophys Res Commun 274: 16&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pubmed">10903889</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemoto S, Fergusson MM, Finkel T (2005) SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J Biol Chem 280: 16456&#x2013;16460</Citation><ArticleIdList><ArticleId IdType="pubmed">15716268</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen MD, Lariviere RC, Julien JP (2001) Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron 30: 135&#x2013;147</Citation><ArticleIdList><ArticleId IdType="pubmed">11343650</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen MD, Mushynski WE, Julien JP (2002) Cycling at the interface between neurodevelopment and neurodegeneration. Cell Death Differ 9: 1294&#x2013;1306</Citation><ArticleIdList><ArticleId IdType="pubmed">12478466</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen MD, Shu T, Sanada K, Lariviere RC, Tseng HC, Park SK, Julien JP, Tsai LH (2004) A NUDEL-dependent mechanism of neurofilament assembly regulates the integrity of CNS neurons. Nat Cell Biol 6: 595&#x2013;608</Citation><ArticleIdList><ArticleId IdType="pubmed">15208636</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H, Neri C (2005) Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 37: 349&#x2013;350</Citation><ArticleIdList><ArticleId IdType="pubmed">15793589</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402: 615&#x2013;622</Citation><ArticleIdList><ArticleId IdType="pubmed">10604467</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L, Thiyagarajan M, Macgrogan D, Rodgers JT, Puigserver P, Sadoshima J, Deng HH, Pedrini S, Gandy S, Sauve A, Pasinetti GM (2006) Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer's disease amyloid neuropathology by calorie restriction. J Biol Chem 281: 21745&#x2013;21754</Citation><ArticleIdList><ArticleId IdType="pubmed">16751189</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434: 113&#x2013;118</Citation><ArticleIdList><ArticleId IdType="pubmed">15744310</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ (2004) Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 6: 1054&#x2013;1061</Citation><ArticleIdList><ArticleId IdType="pubmed">15516999</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith PD, O'Hare MJ, Park DS (2004) Emerging pathogenic role for cyclin dependent kinases in neurodegeneration. Cell Cycle 3: 289&#x2013;291</Citation><ArticleIdList><ArticleId IdType="pubmed">14726693</ArticleId></ArticleIdList></Reference><Reference><Citation>St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127: 397&#x2013;408</Citation><ArticleIdList><ArticleId IdType="pubmed">17055439</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui G, Soohoo C, Affar el B, Gay F, Shi Y, Forrester WC (2002) A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 99: 5515&#x2013;5520</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122801</ArticleId><ArticleId IdType="pubmed">11960009</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang BL (2005) Alzheimer's disease: channeling APP to non-amyloidogenic processing. Biochem Biophys Res Commun 331: 375&#x2013;378</Citation><ArticleIdList><ArticleId IdType="pubmed">15850769</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang BL (2006) SIRT1, neuronal cell survival and the insulin/IGF-1 aging paradox. Neurobiol Aging 27: 501&#x2013;505</Citation><ArticleIdList><ArticleId IdType="pubmed">16464659</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149&#x2013;159</Citation><ArticleIdList><ArticleId IdType="pubmed">11672523</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Zhai Q, Chen Y, Lin E, Gu W, McBurney MW, He Z (2005) A local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol 170: 349&#x2013;355</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171458</ArticleId><ArticleId IdType="pubmed">16043516</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, Sisodia SS, Cleveland DW, Price DL (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14: 1105&#x2013;1116</Citation><ArticleIdList><ArticleId IdType="pubmed">7605627</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Krishnamurthy PK, Johnson GV (2002) Cdk5 phosphorylates p53 and regulates its activity. J Neurochem 81: 307&#x2013;313</Citation><ArticleIdList><ArticleId IdType="pubmed">12064478</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17588900</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>317</Volume><Issue>5837</Issue><PubDate><Year>2007</Year><Month>Jul</Month><Day>27</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.</ArticleTitle><Pagination><StartPage>516</StartPage><EndPage>519</EndPage><MedlinePgn>516-9</MedlinePgn></Pagination><Abstract><AbstractText>The sirtuins are members of the histone deacetylase family of proteins that participate in a variety of cellular functions and play a role in aging. We identified a potent inhibitor of sirtuin 2 (SIRT2) and found that inhibition of SIRT2 rescued alpha-synuclein toxicity and modified inclusion morphology in a cellular model of Parkinson's disease. Genetic inhibition of SIRT2 via small interfering RNA similarly rescued alpha-synuclein toxicity. Furthermore, the inhibitors protected against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease. The results suggest a link between neurodegeneration and aging.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Outeiro</LastName><ForeName>Tiago Fleming</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Alzheimer's Research Unit, MGH, Harvard Medical School, CNY 114, 16th Street, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kontopoulos</LastName><ForeName>Eirene</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Altmann</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Kufareva</LastName><ForeName>Irina</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Strathearn</LastName><ForeName>Katherine E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Amore</LastName><ForeName>Allison M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Volk</LastName><ForeName>Catherine B</ForeName><Initials>CB</Initials></Author><Author ValidYN="Y"><LastName>Maxwell</LastName><ForeName>Michele M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Rochet</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>McLean</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Anne B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Abagyan</LastName><ForeName>Ruben</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Feany</LastName><ForeName>Mel B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Kazantsev</LastName><ForeName>Aleksey G</ForeName><Initials>AG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5P50-NS38372A-06</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-NS049221</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C521855">AGK2 compound</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005663">Furans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011804">Quinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014404">Tubulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="C447939">SIRT1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="C474199">SIRT2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="D056564">Sirtuin 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="D056565">Sirtuin 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="D037761">Sirtuins</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2007 Jul 27;317(5837):461-2. doi: 10.1126/science.1146585.</RefSource><PMID Version="1">17656709</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005663" MajorTopicYN="N">Furans</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056564" MajorTopicYN="N">Sirtuin 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056565" MajorTopicYN="N">Sirtuin 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D037761" MajorTopicYN="N">Sirtuins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014404" MajorTopicYN="N">Tubulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17588900</ArticleId><ArticleId IdType="doi">10.1126/science.1143780</ArticleId><ArticleId IdType="pii">1143780</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17591969</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-9440</ISSN><JournalIssue CitedMedium="Print"><Volume>171</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of pathology</Title><ISOAbbreviation>Am J Pathol</ISOAbbreviation></Journal><ArticleTitle>Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy.</ArticleTitle><Pagination><StartPage>241</StartPage><EndPage>251</EndPage><MedlinePgn>241-51</MedlinePgn></Pagination><Abstract><AbstractText>Cerebral deposition of the amyloid beta protein (Abeta), an invariant feature of Alzheimer's disease, reflects an imbalance between the rates of Abeta production and clearance. The causes of Abeta elevation in the common late-onset form of Alzheimer's disease (LOAD) are largely unknown. There is evidence that the Abeta-degrading protease neprilysin (NEP) is down-regulated in normal aging and LOAD. We asked whether a decrease in endogenous NEP levels can prolong the half-life of Abeta in vivo and promote development of the classic amyloid neuropathology of Alzheimer's disease. We examined the brains and plasma of young and old mice expressing relatively low levels of human amyloid precursor protein and having one or both NEP genes silenced. NEP loss of function 1) elevated whole-brain and plasma levels of human Abeta(40) and Abeta(42), 2) prolonged the half-life of soluble Abeta in brain interstitial fluid of awake animals, 3) raised the concentration of Abeta dimers, 4) markedly increased hippocampal amyloid plaque burden, and 5) led to the development of amyloid angiopathy. A approximately 50% reduction in NEP levels, similar to that reported in some LOAD brains, was sufficient to increase amyloid neuropathology. These findings demonstrate an important role for proteolysis in determining the levels of Abeta and Abeta-associated neuropathology in vivo and support the hypothesis that primary defects in Abeta clearance can cause or contribute to LOAD pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Farris</LastName><ForeName>Wesley</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Department of Neurology, Harvard Institutes of Medicine, Room 730, Boston, MA 02115, USA. farrisw@upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xfc;tz</LastName><ForeName>Sonja G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Shankar</LastName><ForeName>Ganesh M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>George</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Leissring</LastName><ForeName>Malcolm A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Wei Qiao</ForeName><Initials>WQ</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG012749</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022476</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG022476</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DA07261</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS046324</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG12749</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DA007261</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS046324</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Pathol</MedlineTA><NlmUniqueID>0370502</NlmUniqueID><ISSNLinking>0002-9440</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.11</RegistryNumber><NameOfSubstance UI="D015260">Neprilysin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015260" MajorTopicYN="N">Neprilysin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17591969</ArticleId><ArticleId IdType="pmc">PMC1941603</ArticleId><ArticleId IdType="doi">10.2353/ajpath.2007.070105</ArticleId><ArticleId IdType="pii">S0002-9440(10)61958-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer&#x2019;s disease. Neuron. 2004;44:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage MJ, Trusko SP, Howland DS, Pinsker LR, Mistretta S, Reaume AG, Greenberg BD, Siman R, Scott RW. Turnover of amyloid &#x3b2;-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci. 1998;18:1743&#x2013;1752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792617</ArticleId><ArticleId IdType="pubmed">9464999</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O&#x2019;Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-&#x3b2; synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12:856&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC. Metabolic regulation of brain A&#x3b2; by neprilysin. Science. 2001;292:1550&#x2013;1552.</Citation><ArticleIdList><ArticleId IdType="pubmed">11375493</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckman EA, Adams SK, Troendle FJ, Stodola BA, Kahn MA, Fauq AH, Xiao HD, Bernstein KE, Eckman CB. Regulation of steady-state &#x3b2;-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem. 2006;281:30471&#x2013;30478.</Citation><ArticleIdList><ArticleId IdType="pubmed">16912050</ArticleId></ArticleIdList></Reference><Reference><Citation>Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid &#x3b2;-protein, and the &#x3b2;-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA. 2003;100:4162&#x2013;4167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC153065</ArticleId><ArticleId IdType="pubmed">12634421</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller BC, Eckman EA, Sambamurti K, Dobbs N, Chow KM, Eckman CB, Hersh LB, Thiele DL. Amyloid-&#x3b2; peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci USA. 2003;100:6221&#x2013;6226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC156353</ArticleId><ArticleId IdType="pubmed">12732730</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB. Alzheimer&#x2019;s disease &#x3b2;-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem. 2003;278:2081&#x2013;2084.</Citation><ArticleIdList><ArticleId IdType="pubmed">12464614</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouri A, Zou LB, Iwata N, Saido TC, Wang D, Wang MW, Noda Y, Nabeshima T. Inhibition of neprilysin by thiorphan (i.c.v.) causes an accumulation of amyloid &#x3b2; and impairment of learning and memory. Behav Brain Res. 2006;168:83&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">16360221</ArticleId></ArticleIdList></Reference><Reference><Citation>Madani R, Poirier R, Wolfer DP, Welzl H, Groscurth P, Lipp HP, Lu B, Mouedden ME, Mercken M, Nitsch RM, Mohajeri MH. Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo. J Neurosci Res. 2006;84:1871&#x2013;1878.</Citation><ArticleIdList><ArticleId IdType="pubmed">16998901</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, Gan L. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer&#x2019;s disease. Neuron. 2006;51:703&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">16982417</ArticleId></ArticleIdList></Reference><Reference><Citation>Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH, Verma IM, Masliah E. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci. 2003;23:1992&#x2013;1996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742010</ArticleId><ArticleId IdType="pubmed">12657655</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ. Enhanced proteolysis of &#x3b2;-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003;40:1087&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687544</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Mizukami H, Shirotani K, Takaki Y, Muramatsu S, Lu B, Gerard NP, Gerard C, Ozawa K, Saido TC. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J Neurosci. 2004;24:991&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729819</ArticleId><ArticleId IdType="pubmed">14749444</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Booze RM, Hersh LB. Tissue-specific expression of rat neutral endopeptidase (neprilysin) mRNAs. J Biol Chem. 1995;270:5723&#x2013;5728.</Citation><ArticleIdList><ArticleId IdType="pubmed">7890699</ArticleId></ArticleIdList></Reference><Reference><Citation>Farris W, Leissring MA, Hemming ML, Chang AY, Selkoe DJ. Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid &#x3b2;-protein. Biochemistry. 2005;44:6513&#x2013;6525.</Citation><ArticleIdList><ArticleId IdType="pubmed">15850385</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ. Insulin-degrading enzyme regulates extracellular levels of amyloid &#x3b2;-protein by degradation. J Biol Chem. 1998;273:32730&#x2013;32738.</Citation><ArticleIdList><ArticleId IdType="pubmed">9830016</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasojima K, Akiyama H, McGeer EG, McGeer PL. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of &#x3b2;-amyloid peptide. Neurosci Lett. 2001;297:97&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">11121879</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, Schellenberg GD, Jin LW, Kovacina KS, Craft S. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer&#x2019;s disease is associated with the apolipoprotein E-&#x3b5;4 allele. Am J Pathol. 2003;162:313&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851126</ArticleId><ArticleId IdType="pubmed">12507914</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama M, Higuchi M, Takaki Y, Matsuba Y, Tanji H, Nemoto M, Tomita N, Matsui T, Iwata N, Mizukami H, Muramatsu S, Ozawa K, Saido TC, Arai H, Sasaki H. Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer&#x2019;s disease. Ann Neurol. 2005;57:832&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pubmed">15929037</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer&#x2019;s disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L. Plaque-independent disruption of neural circuits in Alzheimer&#x2019;s disease mouse models. Proc Natl Acad Sci USA. 1999;96:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu B, Gerard NP, Kolakowski LF, Jr, Bozza M, Zurakowski D, Finco O, Carroll MC, Gerard C. Neutral endopeptidase modulation of septic shock. J Exp Med. 1995;181:2271&#x2013;2275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2192063</ArticleId><ArticleId IdType="pubmed">7760013</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, Selkoe DJ. Aggregation of secreted amyloid &#x3b2;-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem. 1995;270:9564&#x2013;9570.</Citation><ArticleIdList><ArticleId IdType="pubmed">7721886</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M, Seabrook TJ, Lazo ND, Jiang L, Das P, Janus C, Lemere CA. Short amyloid-beta (A&#x3b2;) immunogens reduce cerebral A&#x3b2; load and learning deficits in an Alzheimer&#x2019;s disease mouse model in the absence of an A&#x3b2;-specific cellular immune response. J Neurosci. 2006;26:4717&#x2013;4728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674171</ArticleId><ArticleId IdType="pubmed">16672644</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Sato S, Murayama O, Murayama M, Park JM, Yamaguchi H, Takashima A. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett. 2002;321:61&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">11872257</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly WT, Zheng JB, Town T, Flavell RA, Selkoe DJ. Physiological regulation of the &#x3b2;-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation. J Neurosci. 2005;25:5533&#x2013;5543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724978</ArticleId><ArticleId IdType="pubmed">15944381</ArticleId></ArticleIdList></Reference><Reference><Citation>Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ. Neurons regulate extracellular levels of amyloid &#x3b2;-protein via proteolysis by insulin-degrading enzyme. J Neurosci. 2000;20:1657&#x2013;1665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772918</ArticleId><ArticleId IdType="pubmed">10684867</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of amyloid &#x3b2;-protein begins intracellularly in cells derived from human brain. Biochemistry. 2000;39:10831&#x2013;10839.</Citation><ArticleIdList><ArticleId IdType="pubmed">10978169</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-&#x3b2; levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson JA, Turner AJ. &#x3b2;-Amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J Neurochem. 2002;81:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12067222</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpentier M, Robitaille Y, DesGroseillers L, Boileau G, Marcinkiewicz M. Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2002;61:849&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">12387451</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S. Secreted amyloid &#x3b2;-protein similar to that in the senile plaques of Alzheimer&#x2019;s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer&#x2019;s disease. Nat Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C, Small SA, Stern Y, Wisniewski HM, Mehta PD. Plasma amyloid &#x3b2;-peptide 1&#x2013;42 and incipient Alzheimer&#x2019;s disease. Ann Neurol. 1999;46:412&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">10482274</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD. Plasma A&#x3b2;40 and A&#x3b2;42 and Alzheimer&#x2019;s disease: relation to age, mortality, and risk. Neurology. 2003;61:1185&#x2013;1190.</Citation><ArticleIdList><ArticleId IdType="pubmed">14610118</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Adamson J, Schaid DJ, Blangero J, Hutton M, Younkin SG. Heritability of plasma amyloid &#x3b2; in typical late-onset Alzheimer&#x2019;s disease pedigrees. Genet Epidemiol. 2001;21:19&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">11443731</ArticleId></ArticleIdList></Reference><Reference><Citation>Enya M, Morishima-Kawashima M, Yoshimura M, Shinkai Y, Kusui K, Khan K, Games D, Schenk D, Sugihara S, Yamaguchi H, Ihara Y. Appearance of sodium dodecyl sulfate-stable amyloid &#x3b2;-protein (A&#x3b2;) dimer in the cortex during aging. Am J Pathol. 1999;154:271&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853431</ArticleId><ArticleId IdType="pubmed">9916941</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, Greengard P, Gouras GK, Lannfelt L, Nilsson LN. Amyloid-&#x3b2; oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol. 2005;58:147&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">15984012</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE. Cerebral amyloid angiopathy: amyloid &#x3b2; accumulates in putative interstitial fluid drainage pathways in Alzheimer&#x2019;s disease. Am J Pathol. 1998;153:725&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853019</ArticleId><ArticleId IdType="pubmed">9736023</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravina SA, Ho L, Eckman CB, Long KE, Otvos L, Jr, Younkin LH, Suzuki N, Younkin SG. Amyloid &#x3b2; protein (A&#x3b2;) in Alzheimer&#x2019;s disease brain: biochemical and immunocytochemical analysis with antibodies specific for forms ending at A&#x3b2; 40 or A&#x3b2; 42(43). J Biol Chem. 1995;270:7013&#x2013;7016.</Citation><ArticleIdList><ArticleId IdType="pubmed">7706234</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, Hsu CY, Holtzman DM, Lee JM. Matrix metalloproteinase-9 degrades amyloid-&#x3b2; fibrils in vitro and compact plaques in situ. J Biol Chem. 2006;281:24566&#x2013;24574.</Citation><ArticleIdList><ArticleId IdType="pubmed">16787929</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SM, Mouri A, Kokubo H, Nakajima R, Suemoto T, Higuchi M, Staufenbiel M, Noda Y, Yamaguchi H, Nabeshima T, Saido TC, Iwata N. Neprilysin-sensitive synapse-associated amyloid-&#x3b2; peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem. 2006;281:17941&#x2013;17951.</Citation><ArticleIdList><ArticleId IdType="pubmed">16636059</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudoh S, Frosch MP, Wolf BA. Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and -insoluble pools in CHO-695 cells. Biochemistry. 2002;41:1091&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">11802707</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Takaki Y, Fukami S, Tsubuki S, Saido TC. Region-specific reduction of A&#x3b2;-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res. 2002;70:493&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">12391610</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM. Age- and region-dependent alterations in A&#x3b2;-degrading enzymes: implications for A&#x3b2;-induced disorders. Neurobiol Aging. 2005;26:645&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">15708439</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter TL, Pedrini S, Ghiso J, Ehrlich ME, Gandy S. Brain neprilysin activity and susceptibility to transgene-induced Alzheimer amyloidosis. Neurosci Lett. 2006;392:235&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">16233955</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstrom-Lindahl E, Ravid R, Nordberg A: Age-dependent decline of neprilysin in Alzheimer&#x2019;s disease and normal brain: inverse correlation with A&#x3b2; levels. Neurobiol Aging 2006, [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">17098332</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, Yankner BA. Gene regulation and DNA damage in the aging human brain. Nature. 2004;429:883&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">15190254</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang DS, Lipton RB, Katz MJ, Davies P, Buschke H, Kuslansky G, Verghese J, Younkin SG, Eckman C, Dickson DW. Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J Neuropathol Exp Neurol. 2005;64:378&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">15892294</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo R, Borghi R, Markesbery W, Tabaton M, Piccini A. Neprylisin decreases uniformly in Alzheimer&#x2019;s disease and in normal aging. FEBS Lett. 2005;579:6027&#x2013;6030.</Citation><ArticleIdList><ArticleId IdType="pubmed">16226260</ArticleId></ArticleIdList></Reference><Reference><Citation>Miners JS, Van Helmond Z, Chalmers K, Wilcock G, Love S, Kehoe PG. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2006;65:1012&#x2013;1021.</Citation><ArticleIdList><ArticleId IdType="pubmed">17021406</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of a&#x3b2; 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17592044</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1355-8382</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>8</Issue><PubDate><Year>2007</Year><Month>Aug</Month></PubDate></JournalIssue><Title>RNA (New York, N.Y.)</Title><ISOAbbreviation>RNA</ISOAbbreviation></Journal><ArticleTitle>Somatodendritic microRNAs identified by laser capture and multiplex RT-PCR.</ArticleTitle><Pagination><StartPage>1224</StartPage><EndPage>1234</EndPage><MedlinePgn>1224-34</MedlinePgn></Pagination><Abstract><AbstractText>The catalog of RNAs present in dendrites represents the complete repertoire of local translation that contributes to synaptic plasticity. Most views hold that a pool of dendritic mRNAs is selectively transported to a dendritic destination. This view requires that some mRNAs in the dendrite are locally enriched relative to the cell body; however, quantitative comparisons that would support this assumption do not currently exist. These issues related to somatodendritic distribution of mRNAs also apply to the microRNAs, approximately 21 nucleotide noncoding transcripts that bind to target mRNAs and either inhibit their translation or destabilize them. We combined laser capture with multiplex real-time RT (reverse transcription) PCR to quantify microRNAs in the neuritic and somatic compartments separately. The samples were standardized by RT-PCR measurements of a set of mRNAs, including known dendritic mRNAs, in these two compartments. Most neuronal miRNAs were detected in dendrites. With a few notable exceptions, most miRNAs were distributed through the somatodendritic compartment across a nearly constant gradient. Thus for lower-abundance miRNAs, the total neuronal concentration of the miRNA can remain readily detectable in the cell body but vanish from the dendrite. A very small number of miRNAs deviate from the distribution gradient across the miRNA population as relatively enriched or depleted in the dendrite.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kye</LastName><ForeName>Min-Jeong</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California at Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Tsunglin</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Sasha F</ForeName><Initials>SF</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Nan Lan</ForeName><Initials>NL</Initials></Author><Author ValidYN="Y"><LastName>Groves</LastName><ForeName>Benjamin B</ForeName><Initials>BB</Initials></Author><Author ValidYN="Y"><LastName>Bonneau</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lao</LastName><ForeName>Kaiqin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kosik</LastName><ForeName>Kenneth S</ForeName><Initials>KS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>RNA</MedlineTA><NlmUniqueID>9509184</NlmUniqueID><ISSNLinking>1355-8382</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007834" MajorTopicYN="Y">Lasers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17592044</ArticleId><ArticleId IdType="pmc">PMC1924896</ArticleId><ArticleId IdType="doi">10.1261/rna.480407</ArticleId><ArticleId IdType="pii">rna.480407</ArticleId><ArticleId IdType="medline">9509184</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Burgin, K.E., Waxham, M.N., Rickling, S., Westgate, S.A., Mobley, W.C., Kelly, P.T. In situ hybridization histochemistry of Ca2+/calmodulin-dependent protein kinase in developing rat brain. J. Neurosci. 1990;10:1788&#x2013;1798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570308</ArticleId><ArticleId IdType="pubmed">2162385</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, C., Ridzon, D.A., Broomer, A.J., Zhou, Z., Lee, D.H., Nguyen, J.T., Barbisin, M., Xu, N.L., Mahuvakar, V.R., Andersen, M.R., et al. Real-time quantification of microRNAs by stem&#x2013;loop RT-PCR. Nucleic Acids Res. 2005;33:e179. doi: 10.1093/nar/gni178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gni178</ArticleId><ArticleId IdType="pmc">PMC1292995</ArticleId><ArticleId IdType="pubmed">16314309</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberwine, J., Belt, B., Kacharmina, J.E., Miyashiro, K. Analysis of subcellularly localized mRNAs using in situ hybridization, mRNA amplification, and expression profiling. Neurochem. Res. 2002;27:1065&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">12462405</ArticleId></ArticleIdList></Reference><Reference><Citation>Garner, C.C., Tucker, R.P., Matus, A. Selective localization of messenger RNA for cytoskeletal protein MAP2 in dendrites. Nature. 1988;336:674&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">3200318</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaern, M., Elston, T.C., Blake, W.J., Collins, J.J. Stochasticity in gene expression: From theories to phenotypes. Nat. Rev. Genet. 2005;6:451&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883588</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleiman, R., Banker, G., Steward, O. Differential subcellular localization of particular mRNAs in hippocampal neurons in culture. Neuron. 1990;5:821&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">2148488</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleiman, R., Banker, G., Steward, O. Development of subcellular mRNA compartmentation in hippocampal neurons in culture. J. Neurosci. 1994;14:1130&#x2013;1140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577594</ArticleId><ArticleId IdType="pubmed">7509864</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles, R.B., Sabry, J.H., Martone, M.E., Deerinck, T.J., Ellisman, M.H., Bassell, G.J., Kosik, K.S. Translocation of RNA granules in living neurons. J. Neurosci. 1996;16:7812&#x2013;7820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579227</ArticleId><ArticleId IdType="pubmed">8987809</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik, K.S. The neuronal microRNA system. Nat. Rev. Neurosci. 2006;7:911&#x2013;920.</Citation><ArticleIdList><ArticleId IdType="pubmed">17115073</ArticleId></ArticleIdList></Reference><Reference><Citation>Lao, K., Xu, N.L., Yeung, V., Chen, C., Livak, K.J., Straus, N.A. Multiplexing RT-PCR for the detection of multiple miRNA species in small samples. Biochem. Biophys. Res. Commun. 2006;343:85&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">16529715</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyford, G.L., Yamagata, K., Kaufmann, W.E., Barnes, C.A., Sanders, L.K., Copeland, N.G., Gilbert, D.J., Jenkins, N.A., Lanahan, A.A., Worley, P.F. Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein that is enriched in neuronal dendrites. Neuron. 1995;14:433&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">7857651</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee, A.C., Kosik, K.S., Kennedy, M.B., Kowall, N.W. Hippocampal neurons predisposed to neurofibrillary tangle formation are enriched in type II calcium/calmodulin-dependent protein kinase. J. Neuropathol. Exp. Neurol. 1990;49:49&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">2153760</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyashiro, K., Dichter, M., Eberwine, J. On the nature and differential distribution of mRNAs in hippocampal neurites: Implications for neuronal functioning. Proc. Natl. Acad. Sci. 1994;91:10800&#x2013;10804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45113</ArticleId><ArticleId IdType="pubmed">7971965</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyashiro, K.Y., Beckel-Mitchener, A., Purk, T.P., Becker, K.G., Barret, T., Liu, L., Carbonetto, S., Weiler, I.J., Greenough, W.T., Eberwine, J. RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron. 2003;37:417&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">12575950</ArticleId></ArticleIdList></Reference><Reference><Citation>Moccia, R., Chen, D., Lyles, V., Kapuya, E., Yaping, E., Kalachikov, S., Spahn, C.M., Frank, J., Kandel, E.R., Barad, M., et al. An unbiased cDNA library prepared from isolated Aplysia sensory neuron processes is enriched for cytoskeletal and translational mRNAs. J. Neurosci. 2003;23:9409&#x2013;9417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740582</ArticleId><ArticleId IdType="pubmed">14561869</ArticleId></ArticleIdList></Reference><Reference><Citation>Poon, M.M., Choi, S.H., Jamieson, C.A., Geschwind, D.H., Martin, K.C. Identification of process-localized mRNAs from cultured rodent hippocampal neurons. J. Neurosci. 2006;26:13390&#x2013;13399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675000</ArticleId><ArticleId IdType="pubmed">17182790</ArticleId></ArticleIdList></Reference><Reference><Citation>Rook, M.S., Lu, M., Kosik, K.S. CaMKII&#x3b1; 3&#x2032; untranslated region-directed mRNA translocation in living neurons: Visualization by GFP linkage. J. Neurosci. 2000;20:6385&#x2013;6393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772957</ArticleId><ArticleId IdType="pubmed">10964944</ArticleId></ArticleIdList></Reference><Reference><Citation>Schratt, G.M., Tuebing, F., Nigh, E.A., Kane, C.G., Sabatini, M.E., Kiebler, M., Greenberg, M.E. A brain-specific microRNA regulates dendritic spine development. Nature. 2006;439:283&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">16421561</ArticleId></ArticleIdList></Reference><Reference><Citation>Steward, O., Levy, W.B. Preferential localization of polyribosomes under the base of dendritic spines in granule cells of the dentate gyrus. J. Neurosci. 1982;2:284&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6564334</ArticleId><ArticleId IdType="pubmed">7062109</ArticleId></ArticleIdList></Reference><Reference><Citation>Steward, O., Schuman, E.M. Compartmentalized synthesis and degradation of proteins in neurons. Neuron. 2003;40:347&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">14556713</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung, Y.J., Weiler, I.J., Greenough, W.T., Denman, R.B. Selectively enriched mRNAs in rat synaptoneurosomes. Brain Res. Mol. Brain Res. 2004;126:81&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">15207920</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian, Q.B., Nakayama, K., Okano, A., Suzuki, T. Identification of mRNAs localizing in the postsynaptic region. Brain Res. Mol. Brain Res. 1999;72:147&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">10529473</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, K.Y., Hengst, U., Cox, L.J., Macosko, E.Z., Jeromin, A., Urquhart, E.R., Jaffrey, S.R. Local translation of RhoA regulates growth cone collapse. Nature. 2005;436:1020&#x2013;1024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1317112</ArticleId><ArticleId IdType="pubmed">16107849</ArticleId></ArticleIdList></Reference><Reference><Citation>Zalfa, F., Eleuteri, B., Dickson, K.S., Mercaldo, V., De Rubeis, S., di Penta, A., Tabolacci, E., Chiurazzi, P., Neri, G., Grant, S.G., et al. A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat. Neurosci. 2007;10:578&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2804293</ArticleId><ArticleId IdType="pubmed">17417632</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong, J., Zhang, T., Bloch, L.M. Dendritic mRNAs encode diversified functionalities in hippocampal pyramidal neurons. BMC Neurosci. 2006;7:17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1386695</ArticleId><ArticleId IdType="pubmed">16503994</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17592139</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>27</Issue><PubDate><Year>2007</Year><Month>Jul</Month><Day>03</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice.</ArticleTitle><Pagination><StartPage>11489</StartPage><EndPage>11494</EndPage><MedlinePgn>11489-94</MedlinePgn></Pagination><Abstract><AbstractText>Fragile X syndrome (FXS), the most commonly inherited form of mental retardation and autism, is caused by transcriptional silencing of the fragile X mental retardation 1 (FMR1) gene and consequent loss of the fragile X mental retardation protein. Despite growing evidence suggesting a role of specific receptors and biochemical pathways in FXS pathogenesis, an effective therapeutic method has not been developed. Here, we report that abnormalities in FMR1 knockout (KO) mice, an animal model of FXS, are ameliorated, at least partially, at both cellular and behavioral levels, by an inhibition of the catalytic activity of p21-activated kinase (PAK), a kinase known to play a critical role in actin polymerization and dendritic spine morphogenesis. Greater spine density and elongated spines in the cortex, morphological synaptic abnormalities commonly observed in FXS, are at least partially restored by postnatal expression of a dominant negative (dn) PAK transgene in the forebrain. Likewise, the deficit in cortical long-term potentiation observed in FMR1 KO mice is fully restored by the dnPAK transgene. Several behavioral abnormalities associated with FMR1 KO mice, including those in locomotor activity, stereotypy, anxiety, and trace fear conditioning are also ameliorated, partially or fully, by the dnPAK transgene. Finally, we demonstrate a direct interaction between PAK and fragile X mental retardation protein in vitro. Overall, our results demonstrate the genetic rescue of phenotypes in a FXS mouse model and suggest that the PAK signaling pathway, including the catalytic activity of PAK, is a novel intervention site for development of an FXS and autism therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hayashi</LastName><ForeName>Mansuo L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>B S Shankaranarayana</ForeName><Initials>BS</Initials></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Jin-Soo</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Han-Saem</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Dolan</LastName><ForeName>Bridget M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Se-Young</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Chattarji</LastName><ForeName>Sumantra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Tonegawa</LastName><ForeName>Susumu</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 MH058880</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>PH50 MH58880</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH78821</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH078821</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C515905">Pak1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D054462">p21-Activated Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005600" MajorTopicYN="N">Fragile X Syndrome</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054462" MajorTopicYN="N">p21-Activated Kinases</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>7</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17592139</ArticleId><ArticleId IdType="pmc">PMC1899186</ArticleId><ArticleId IdType="doi">10.1073/pnas.0705003104</ArticleId><ArticleId IdType="pii">0705003104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>O'Donnell WT, Warren ST. Annu Rev Neurosci. 2002;25:315&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">12052912</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutch&#x2013;Belgian Fragile X Consortium. Cell. 1994;78:23&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">8033209</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman AW, Aldridge GM, Weiler IJ, Greenough WT. J Neurosci. 2006;26:7151&#x2013;7155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673953</ArticleId><ArticleId IdType="pubmed">16822971</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinton VJ, Brown WT, Wisniewski K, Rudelli RD. Am J Med Genet. 1991;41:289&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">1724112</ArticleId></ArticleIdList></Reference><Reference><Citation>Comery TA, Harris JB, Willems PJ, Oostra BA, Irwin SA, Weiler IJ, Greenough WT. Proc Natl Acad Sci USA. 1997;94:5401&#x2013;5404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24690</ArticleId><ArticleId IdType="pubmed">9144249</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin SA, Patel B, Idupulapati M, Harris JB, Crisostomo RA, Larsen BP, Kooy F, Willems PJ, Cras P, Kozlowski PB, et al. Am J Med Genet. 2001;98:161&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">11223852</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinney BC, Grossman AW, Elisseou NM, Greenough WT. Am J Med Genet B Neuropsychiatr Genet. 2005;136:98&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">15892134</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiler IJ, Irwin SA, Klintsova AY, Spencer CM, Brazelton AD, Miyashiro K, Comery TA, Patel B, Eberwine J, Greenough WT. Proc Natl Acad Sci USA. 1997;94:5395&#x2013;5400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24689</ArticleId><ArticleId IdType="pubmed">9144248</ArticleId></ArticleIdList></Reference><Reference><Citation>Laggerbauer B, Ostareck D, Keidel EM, Ostareck-Lederer A, Fischer U. Hum Mol Genet. 2001;10:329&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">11157796</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Zhang Y, Ku L, Wilkinson KD, Warren ST, Feng Y. Nucleic Acids Res. 2001;29:2276&#x2013;2283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC55699</ArticleId><ArticleId IdType="pubmed">11376146</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber KM, Gallagher SM, Warren ST, Bear MF. Proc Natl Acad Sci USA. 2002;99:7746&#x2013;7750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124340</ArticleId><ArticleId IdType="pubmed">12032354</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Pelletier MR, Perez Velazquez JL, Carlen PL. Mol Cell Neurosci. 2002;19:138&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">11860268</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao MG, Toyoda H, Ko SW, Ding HK, Wu LJ, Zhuo M. J Neurosci. 2005;25:7385&#x2013;7392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725289</ArticleId><ArticleId IdType="pubmed">16093389</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazroui R, Huot ME, Tremblay S, Filion C, Labelle Y, Khandjian EW. Hum Mol Genet. 2002;11:3007&#x2013;3017.</Citation><ArticleIdList><ArticleId IdType="pubmed">12417522</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A, Li W, Xu K, Bogert BA, Su K, Gao FB. Development (Cambridge, UK) 2003;130:5543&#x2013;5552.</Citation><ArticleIdList><ArticleId IdType="pubmed">14530299</ArticleId></ArticleIdList></Reference><Reference><Citation>Bokoch GM. Annu Rev Biochem. 2003;72:743&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">12676796</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen KM, Gleeson JG, Bagrodia S, Partington MW, MacMillan JC, Cerione RA, Mulley JC, Walsh CA. Nat Genet. 1998;20:25&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">9731525</ArticleId></ArticleIdList></Reference><Reference><Citation>Bienvenu T, des Portes V, McDonell N, Carrie A, Zemni R, Couvert P, Ropers HH, Moraine C, van Bokhoven H, Fryns JP, et al. Am J Med Genet. 2000;93:294&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">10946356</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi ML, Choi SY, Rao BS, Jung HY, Lee HK, Zhang D, Chattarji S, Kirkwood A, Tonegawa S. Neuron. 2004;42:773&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">15182717</ArticleId></ArticleIdList></Reference><Reference><Citation>Peier AM, McIlwain KL, Kenneson A, Warren ST, Paylor R, Nelson DL. Hum Mol Genet. 2000;9:1145&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">10767339</ArticleId></ArticleIdList></Reference><Reference><Citation>McEchron MD, Bouwmeester H, Tseng W, Weiss C, Disterhoft JF. Hippocampus. 1998;8:638&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">9882021</ArticleId></ArticleIdList></Reference><Reference><Citation>Han CJ, O'Tuathaigh CM, van Trigt L, Quinn JJ, Fanselow MS, Mongeau R, Koch C, Anderson DJ. Proc Natl Acad Sci USA. 2003;100:13087&#x2013;13092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240749</ArticleId><ArticleId IdType="pubmed">14555761</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceman S, O'Donnell WT, Reed M, Patton S, Pohl J, Warren ST. Hum Mol Genet. 2003;12:3295&#x2013;3305.</Citation><ArticleIdList><ArticleId IdType="pubmed">14570712</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Y, Absher D, Eberhart DE, Brown V, Malter HE, Warren ST. Mol Cell. 1997;1:109&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">9659908</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou L, Antion MD, Hu D, Spencer CM, Paylor R, Klann E. Neuron. 2006;51:441&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">16908410</ArticleId></ArticleIdList></Reference><Reference><Citation>Eblen ST, Slack JK, Weber MJ, Catling AD. Mol Cell Biol. 2002;22:6023&#x2013;6033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC134005</ArticleId><ArticleId IdType="pubmed">12167697</ArticleId></ArticleIdList></Reference><Reference><Citation>Selcher JC, Nekrasova T, Paylor R, Landreth GE, Sweatt JD. Learn Mem. 2001;8:11&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311358</ArticleId><ArticleId IdType="pubmed">11160759</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelleher RJ, III, Govindarajan A, Jung HY, Kang H, Tonegawa S. Cell. 2004;116:467&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">15016380</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenck A, Bardoni B, Langmann C, Harden N, Mandel JL, Giangrande A. Neuron. 2003;38:887&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">12818175</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimchinsky EA, Oberlander AM, Svoboda K. J Neurosci. 2001;21:5139&#x2013;5146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762842</ArticleId><ArticleId IdType="pubmed">11438589</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvez R, Greenough WT. Am J Med Genet A. 2005;135:155&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">15880753</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey DB, Jr, Skinner D, Sparkman KL. Pediatrics. 2003;111:407&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">12563071</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranek GT, Danko CD, Skinner ML, Bailey DB, Jr, Hatton DD, Roberts JE, Mirrett PL. J Autism Dev Disord. 2005;35:645&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">16172809</ArticleId></ArticleIdList></Reference><Reference><Citation>Nheu TV, He H, Hirokawa Y, Tamaki K, Florin L, Schmitz ML, Suzuki-Takahashi I, Jorissen RN, Burgess AW, Nishimura S, et al. Cancer J. 2002;8:328&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">12184411</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramon-Moliner E. Contemporary Research Methods in Neuroanatomy. Berlin: Springer; 1970.</Citation></Reference><Reference><Citation>Franklin KBJ, Paxinos G. The Mouse Brain in Stereotaxic Coordinates. San Diego: Academic; 1997.</Citation></Reference><Reference><Citation>Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T. Mol Cell. 2003;12:841&#x2013;849.</Citation><ArticleIdList><ArticleId IdType="pubmed">14580336</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazroui R, Huot ME, Tremblay S, Boilard N, Labelle Y, Khandjian EW. Hum Mol Genet. 2003;12:3087&#x2013;3096.</Citation><ArticleIdList><ArticleId IdType="pubmed">14532325</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17595112</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0006-2960</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>30</Issue><PubDate><Year>2007</Year><Month>Jul</Month><Day>31</Day></PubDate></JournalIssue><Title>Biochemistry</Title><ISOAbbreviation>Biochemistry</ISOAbbreviation></Journal><ArticleTitle>Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization.</ArticleTitle><Pagination><StartPage>8850</StartPage><EndPage>8860</EndPage><MedlinePgn>8850-60</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid plaques are hallmark neuropathological lesions in Alzheimer's disease, which consist of abnormally aggregated Abeta protein. Multiple Abeta aggregated species have been identified, and neurotoxicity appears to be correlated with the amount of nonfibrillar oligomers. Therefore, selective inhibition of Abeta oligomer formation has emerged as an attractive means of therapeutic intervention. To investigate whether small molecules can modulate aggregation to achieve selective inhibition of neurotoxic amyloid oligomers, Abeta aggregation was assayed in vitro in the presence of methylene blue, using immunoreactivity with the prefibrillar oligomer-specific antibody A11, transmission electron microscopy, and turbidity assays. Methylene blue inhibited oligomerization when used at substoichiometric concentrations relative to that of the Abeta monomer. Inhibition of Abeta oligomerization was achieved concomitant with promotion of fibrillization, suggesting that oligomer and fibril formation are distinct and competing pathways. Methylene blue-mediated promotion of fiber formation occurred via a dose-dependent decrease in the lag time and an increase in the fibrillization rate, consistent with promotion of both filament nucleation and elongation. Addition of methylene blue to preformed oligomers resulted in oligomer loss and promotion of fibrillization. The data show that Abeta oligomer formation is inhibited by promoting fibril formation, which suggests that the relative pathological significance of oligomers and fibrils may be tested in vivo using methylene blue. If Abeta oligomers represent the primary pathogenic species, then inhibition of this highly toxic species via promotion of formation of less toxic aggregates may be therapeutically useful.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Necula</LastName><ForeName>Mihaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Biochemistry, University of California, Irvine, California 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breydo</LastName><ForeName>Leonid</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Milton</LastName><ForeName>Saskia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kayed</LastName><ForeName>Rakez</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>van der Veer</LastName><ForeName>Wytze E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Tone</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Glabe</LastName><ForeName>Charles G</ForeName><Initials>CG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS 31230</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochemistry</MedlineTA><NlmUniqueID>0370623</NlmUniqueID><ISSNLinking>0006-2960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>T42P99266K</RegistryNumber><NameOfSubstance UI="D008751">Methylene Blue</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008751" MajorTopicYN="N">Methylene Blue</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009391" MajorTopicYN="N">Nephelometry and Turbidimetry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011489" MajorTopicYN="N">Protein Denaturation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17595112</ArticleId><ArticleId IdType="doi">10.1021/bi700411k</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17596434</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>26</Issue><PubDate><Year>2007</Year><Month>Jun</Month><Day>27</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Aneuploidy and DNA replication in the normal human brain and Alzheimer's disease.</ArticleTitle><Pagination><StartPage>6859</StartPage><EndPage>6867</EndPage><MedlinePgn>6859-67</MedlinePgn></Pagination><Abstract><AbstractText>Reactivation of the cell cycle, including DNA replication, might play a major role in Alzheimer's disease (AD). A more than diploid DNA content in differentiated neurons might alternatively result from chromosome mis-segregation during mitosis in neuronal progenitor cells. It was our objective to distinguish between these two mechanisms for aneuploidy and to provide evidence for a functional cell cycle in AD. Using slide-based cytometry, chromogenic in situ hybridization, and PCR amplification of alu-repeats, we quantified the DNA amount of identified cortical neurons in normal human brain and AD and analyzed the link between a tetraploid DNA content and expression of the early mitotic marker cyclin B1. In the normal brain, the number of neurons with a more than diploid content amounts to approximately 10%. Less than 1% of neurons contains a tetraploid DNA content. These neurons do not express cyclin B1, most likely representing constitutional tetraploidy. This population of cyclin B1-negative tetraploid neurons, at a reduced number, is also present in AD. In addition, a population of cyclin B1-positive tetraploid neurons of approximately 2% of all neurons was observed in AD. Our results indicate that at least two different mechanisms need to be distinguished giving rise to a tetraploid DNA content in the adult brain. Constitutional aneuploidy in differentiated neurons might be more frequent than previously thought. It is, however, not elevated in AD. In addition, in AD some neurons have re-entered the cell cycle and entirely passed through a functional interphase with a complete DNA replication.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mosch</LastName><ForeName>Birgit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Paul Flechsig Institute of Brain Research, Department of Neuroanatomy, University of Leipzig, D-04109 Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morawski</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mittag</LastName><ForeName>Anja</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lenz</LastName><ForeName>Dominik</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Tarnok</LastName><ForeName>Attila</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Arendt</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C534699">CCNB1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019926">Cyclin B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056744">Cyclin B1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000782" MajorTopicYN="Y">Aneuploidy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019926" MajorTopicYN="N">Cyclin B</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056744" MajorTopicYN="N">Cyclin B1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004261" MajorTopicYN="N">DNA Replication</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008938" MajorTopicYN="N">Mitosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>12</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17596434</ArticleId><ArticleId IdType="pmc">PMC6672221</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0379-07.2007</ArticleId><ArticleId IdType="pii">27/26/6859</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arendt T. Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization. Neuroscience. 2001;102:723&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">11182240</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, Rodel L, Gartner U, Holzer M. Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer's disease. NeuroReport. 1996;7:3047&#x2013;3049.</Citation><ArticleIdList><ArticleId IdType="pubmed">9116237</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, Holzer M, Gartner U. Neuronal expression of cycline dependent kinase inhibitors of the INK4 family in Alzheimer's disease. J Neural Transm. 1998;105:949&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pubmed">9869328</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, Holzer M, Stobe A, Gartner U, Luth HJ, Bruckner MK, Ueberham U. Activated mitogenic signaling induces a process of dedifferentiation in Alzheimer's disease that eventually results in cell death. Ann NY Acad Sci. 2000;920:249&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193159</ArticleId></ArticleIdList></Reference><Reference><Citation>Batzer MA, Deininger PL. Alu repeats and human genomic diversity. Nat Rev Genet. 2002;3:370&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">11988762</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeras DI, Granic A, Padmanabhan J, Crespo NC, Rojiani AM, Potter H. Alzheimer's presenilin 1 cause chromosome missegregation and aneuploidy. Neurobiol Aging. 2007 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692942</ArticleId><ArticleId IdType="pubmed">17169464</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodskij VJ, Kusc AA. Izmenenie cisla polyploidnych kletok v postembryonalom razvitiji tkanej krysy. Dokl Akad Nauk SSSR Otd Biol. 1962;162:713&#x2013;716.</Citation></Reference><Reference><Citation>Busser J, Geldmacher DS, Herrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J Neurosci. 1998;18:2801&#x2013;2807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792587</ArticleId><ArticleId IdType="pubmed">9525997</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry LM, Funk J, Lesser JM, Lesam M. Gender differences and their interpretation of genetic instability in Alzheimer's disease. Mutat Res. 1992;275:57&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">1379339</ArticleId></ArticleIdList></Reference><Reference><Citation>Darzynkiewicz Z, Smolewski P, Bedner E. Use of flow and laser scanning cytometry to study mechanisms regulating cell cycle and controlling cell death. Clin Lab Med. 2001;21:857&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pubmed">11770292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding XL, Husseman J, Tomashevski A, Nochlin D, Jin LW, Vincent I. The cell cycle Cdc25A tyrosine phosphatase is activated in degenerating postmitotic neurons in Alzheimer's disease. Am J Pathol. 2000;157:1983&#x2013;1990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1885767</ArticleId><ArticleId IdType="pubmed">11106571</ArticleId></ArticleIdList></Reference><Reference><Citation>Geller LN, Potter H. Chromosome missegregation and trisomy 21 mosaicism in Alzheimer's disease. Neurobiol Dis. 1999;6:167&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408806</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillozet-Bongaarts AL, Cahill ME, Cryns VL, Reynolds MR, Berry RW, Binder LI. Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo . J Neurochem. 2006;97:1005&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pubmed">16606369</ArticleId></ArticleIdList></Reference><Reference><Citation>Hake SB, Garcia BA, Duncan EM, Kauer M, Dellaire G, Shabanowitz J, Bazett-Jones DP, Allis CD, Hunt DF. Expression patterns and post-translational modifications associated with mammalian histone H3 variants. J Biol Chem. 2006;281:559&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pubmed">16267050</ArticleId></ArticleIdList></Reference><Reference><Citation>Heintz N. Cell death and the cell cycle: a relationship between transformation and neurodegeneration? Trends Biochem Sci. 1993;18:157&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">8328013</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrup K, Arendt T. Re-expression of cell cycle proteins induces neuronal cell death during Alzheimer's disease. J Alzheimers Dis. 2002;4:243&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">12226544</ArticleId></ArticleIdList></Reference><Reference><Citation>Houck CM, Rinehart FP, Schmid CW. A ubiquitous family of repeated DNA sequences in the human genome. J Mol Biol. 1979;132:289&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">533893</ArticleId></ArticleIdList></Reference><Reference><Citation>Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW, Lee C. Detection of large-scale variation in the human genome. Nat Genet. 2004;36:949&#x2013;951.</Citation><ArticleIdList><ArticleId IdType="pubmed">15286789</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito M. Factors controlling cyclin B expression. Plant Mol Biol. 2000;43:677&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">11089869</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriete A. Cytomics in the realm of systems biology. Cytometry A. 2005;68:19&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">16206191</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuenzle CC. Enzymology of DNA replication and repair in the brain. Brain Res. 1985;357:231&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">3006864</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapham LW, Johnstone MA. Cytologic and cytochemical studies of neuroglia. Arch Neurol. 1963;9:194&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">14048168</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz D, Mosch B, Bocsi J, Arendt T, Tarnok A. Assessment of DNA replication in central nervous system by laser scanning cytometry. Proc SPIE. 2004;5322:146&#x2013;156.</Citation></Reference><Reference><Citation>Li J, Xu M, Zhou H, Ma J, Potter H. Alzheimer presenilins in the nuclear membrane, interphase kinetochores and centrosomes suggest a role in chromosome segregation. Cell. 1997;90:917&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">9298903</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell MA, Xie C, Markesbery WR. Decreased base excision repair and increased helicase activity in Alzheimer's disease brain. Brain Res. 2000;855:116&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">10650137</ArticleId></ArticleIdList></Reference><Reference><Citation>Mares V, Lodin Z, Sacha J. A cytochemical and autoradiographic study of nuclear DNA in mouse Purkinje cells. Brain Res. 1973;53:273&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">4735887</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzarello P, Poloni M, Spadari S, Focher F. DNA repair mechanisms in neurological diseases: facts and hypotheses. J Neurol Sci. 1992;112:4&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">1469439</ArticleId></ArticleIdList></Reference><Reference><Citation>McShea A, Harris PL, Webster KR, Wahl AF, Smith MA. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol. 1997;150:1933&#x2013;1939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858317</ArticleId><ArticleId IdType="pubmed">9176387</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliore L, Testa A, Scarpato R, Pavese N, Petrozzi L, Bonuccelli U. Spontaneous and induced aneuploidy in peripheral blood lymphocytes of patients with Alzheimer's disease. Hum Genet. 1997;101:299&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">9439658</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliore L, Botto N, Scarpato R, Petrozzi L, Cipriani G, Bonuccelli U. Preferential occurrence of chromosome 21 malsegregation in peripheral blood lymphocytes of Alzheimer disease patients. Cytogenet Cell Genet. 1999;87:41&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">10640809</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliore L, Boni G, Bernardini R, Trippi F, Colognato R, Fontana I, Copped&#xe8; F, Sbrana I. Susceptibility to chromosome malsegregation in lymphocytes of women who had a Down syndrome child in young age. Neurobiol Aging. 2006;27:710&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">16005550</ArticleId></ArticleIdList></Reference><Reference><Citation>Moorhead PS, Heyman A. Chromosome studies of patients with Alzheimer's disease. Am J Med Genet. 1983;14:545&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">6859105</ArticleId></ArticleIdList></Reference><Reference><Citation>Morsch R, Simon W, Coleman PD. Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol. 1999;58:188&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">10029101</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosch B, Mittag A, Lenz D, Arendt T, Tarnok A. Laser scanning cytometry in human brain slices. Cytometry A. 2006;69:135&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">16479598</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy Z, Esiri MM, Smith AD. Expression of cell division markers in the hippocampus in Alzheimer's disease and other neurodegenerative conditions. Acta Neuropathol (Berl) 1997a;93:294&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">9083562</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy Z, Esiri MM, Cato AM, Smith AD. Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathol (Berl) 1997b;94:6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">9224524</ArticleId></ArticleIdList></Reference><Reference><Citation>Nouspikel T, Hanawalt PC. When parsimony backfires: neglecting DNA repair may doom neurons in Alzheimer's disease. Bioessays. 2003;25:168&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">12539243</ArticleId></ArticleIdList></Reference><Reference><Citation>Percy ME, Markovic VD, Dalton AJ, McLachlan DR, Berg JM, Rusk AC, Somerville MJ, Chodakowski B, Andrews DF. Age-associated chromosome 21 loss in Down syndrome: possible relevance to mosaicism and Alzheimer's disease. Am J Med Genet. 1993;45:584&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">8456829</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter H. Review and hypothesis: Alzheimer disease and Down syndrome-chromosome 21 nondisjunction may underlie both disorders. Am J Med Genet. 1991;48:1192&#x2013;1200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1683102</ArticleId><ArticleId IdType="pubmed">1827946</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter H. Cell cycle and chromosome segregation defects in Alzheimer's disease. In: Copani A, Nicoletti F, editors. Cell-cycle mechanisms and neuronal death. Georgetown, TX: Landes; 2005. pp. 55&#x2013;78.</Citation></Reference><Reference><Citation>Rehen SK, McConnell MJ, Kaushal D, Kingsbury MA, Yang AH, Chun J. Chromosomal variation in neurons of the developing and adult mammalian nervous system. Proc Natl Acad Sci USA. 2001;98:13361&#x2013;13366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC60876</ArticleId><ArticleId IdType="pubmed">11698687</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehen SK, Yung YC, McCreight MP, Kaushal D, Yang AH, Almeida BS, Kingsbury MA, Cabral KM, McConnell MJ, Anliker B, Fontanoz M, Chun J. Constitutional aneuploidy in the normal human brain. J Neurosci. 2005;25:2176&#x2013;2180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726097</ArticleId><ArticleId IdType="pubmed">15745943</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy-Engel AM, Carroll ML, Vogel E, Garber RK, Nguyen SV, Salem AH, Batzer MA, Deininger PL. Alu insertion polymorphisms for the study of human genomic diversity. Genetics. 2001;159:279&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1461783</ArticleId><ArticleId IdType="pubmed">11560904</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmetsdorf S, Gartner U, Arendt T. Expression of cell cycle-related proteins in developing and adult mouse hippocampus. Int J Dev Neurosci. 2005;23:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">15730892</ArticleId></ArticleIdList></Reference><Reference><Citation>Schupf N, Kapell D, Lee JH, Ottman R, Mayeux R. Increased risk of Alzheimer's disease in mothers of adults with Down's syndrome. Lancet. 1994;344:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">7914304</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, Maner S, Massa H, Walker M, Chi M, Navin N, Lucito R, Healy J, Hicks J, Ye K, Reiner A, Gilliam TC, Trask B, Patterson N, Zetterberg A, Wigler M. Large-scale copy number polymorphism in the human genome. Science. 2004;305:525&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">15273396</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi L, Nishioka WK, Th'ng J, Bradbury EM, Litchfield DW, Greenberg AH. Premature p34cdc2 activation required for apoptosis. Science. 1994;263:1143&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">8108732</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MZ, Nagy Z, Esiri MM. Cell cycle-related protein expression in vascular dementia and Alzheimer's disease. Neurosci Lett. 1999;271:45&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">10471210</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith TW, Lippa CF. Ki-67 immunoreactivity in Alzheimer's disease and other neurodegenerative disorders. J Neuropathol Exp Neurol. 1995;54:297&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">7745428</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaru T, Trigun SK, Okada M, Nakagawa H. Identification of cells expressing a D type G1 cyclin in matured brain: implication for its role in neuronal function. Neurosci Lett. 1993;153:169&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">8327192</ArticleId></ArticleIdList></Reference><Reference><Citation>Valet G, Leary JF, Tarnok A. Cytomics-new technologies: towards a human cytome project. Cytometry A. 2004;59:167&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">15170595</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent I, Jicha G, Rosado M, Dickson DW. Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. J Neurosci. 1997;17:3588&#x2013;3598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573674</ArticleId><ArticleId IdType="pubmed">9133382</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker JA, Kilroy GE, Xing J, Shewale J, Sinha SK, Batzer MA. Human DNA quantitation using Alu element-based polymerase chain reaction. Anal Biochem. 2003;315:122&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">12672420</ArticleId></ArticleIdList></Reference><Reference><Citation>White BJ, Crandall C, Goldsmit J, Morrow CH, Alling DW, Carleton Gajdusek DC, Tjio JH. Cytogenetic studies of familial and sporadic Alzheimer disease. Am J Med Genet. 1981;10:77&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">7294063</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AH, Kaushal D, Rehen SK, Kriedt K, Kingsbury MA, McConnell MJ, Chun J. Chromosome segregation defects contribute to aneuploidy in normal neural progenitor cells. J Neurosci. 2003;23:10454&#x2013;10462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740997</ArticleId><ArticleId IdType="pubmed">14614104</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Geldmacher DS, Herrup K. DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci. 2001;21:2661&#x2013;2668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762514</ArticleId><ArticleId IdType="pubmed">11306619</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Mufson EJ, Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci. 2003;23:2557&#x2013;2563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742098</ArticleId><ArticleId IdType="pubmed">12684440</ArticleId></ArticleIdList></Reference><Reference><Citation>Yurov YB, Iourov IY, Monakhov VV, Soloviev IV, Vostrikov VM, Vorsanova SG. The variation of aneuploidy frequency in the developing and adult human brain revealed by an interphase FISH study. J Histochem Cytochem. 2005;53:385&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">15750026</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17611268</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>27</Issue><PubDate><Year>2007</Year><Month>Jul</Month><Day>04</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Rab5 mediates an amyloid precursor protein signaling pathway that leads to apoptosis.</ArticleTitle><Pagination><StartPage>7141</StartPage><EndPage>7153</EndPage><MedlinePgn>7141-53</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) involves activation of apoptotic pathways that may be regulated through signaling cascades initiated by the amyloid precursor protein (APP). Enlarged endosomes have been observed in postmortem AD brains at very early stages of the disease. We show here that exogenous expression of a familial AD (FAD) mutant of APP or of the APP binding protein APP-BP1 in neurons causes enlargement of early endosomes, increased receptor-mediated endocytosis via a pathway dependent on APP-BP1 binding to APP, and apoptosis. Levels of both APP-BP1 and Rab5 are elevated in early endosomes in cortical embryonic neurons expressing APP(V642I) or APP-BP1, in cultured skin fibroblast cells from Down syndrome subjects, and in postmortem hippocampal tissue of individuals with AD. Indeed, Rab5 was found to bind specifically to APP-BP1, between amino acids 443 and 479. Inhibition of Rab5 or dynamin activity, but not of Eps15 (epidermal growth factor receptor pathway substrate 15) activity, rescued neurons from apoptosis induced by either APP(V642I) or APP-BP1, without affecting levels of intracellular or secreted amyloid-beta (Abeta). Induction of Rab5 activity via expression of a constitutively active mutant led to an increase in neuronal apoptosis more than twice that attributable to induction of endosome enlargement via a Rab5-independent mechanism, regardless of Abeta production. Together, these findings suggest that Rab5 activation via an APP/APP-BP1-initiated signaling pathway mediates neuronal apoptosis caused by FAD mutants of APP and that, within this pathway, Rab5 has a specific role in signaling that is distinct from, although not independent of, its role in trafficking.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laifenfeld</LastName><ForeName>Daphna</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts 02478, USA. dlaifenfeld@mclean.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patzek</LastName><ForeName>Lucas J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>McPhie</LastName><ForeName>Donna L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yuzhi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Levites</LastName><ForeName>Yona</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Cataldo</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Neve</LastName><ForeName>Rachael L</ForeName><Initials>RL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG012954</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021185</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG021185</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG12954</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D020696">rab5 GTP-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020696" MajorTopicYN="N">rab5 GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>1</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17611268</ArticleId><ArticleId IdType="pmc">PMC6794581</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4599-06.2007</ArticleId><ArticleId IdType="pii">27/27/7141</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barbieri MA, Fernandez-Pol S, Hunder C, Horazdovsky BH, Stahl PD. Role of rab5 in EGF receptor-mediated signal transduction. Eur J Cell Biol. 2004;83:305&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">15511088</ArticleId></ArticleIdList></Reference><Reference><Citation>Benmerah A, Bayrou M, Cerf-Bensussan N, Dautry-Varsat A. Inhibition of clathrin-coated pit assembly by an Eps15 mutant. J Cell Sci. 1999;112:1303&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pubmed">10194409</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertrand E, Brouillet E, Caille I, Bouillot C, Cole GM, Prochiantz A, Allinquant B. A short cytoplasmic domain of the amyloid precursor protein induces apoptosis in vitro and in vivo. Mol Cell Neurosci. 2001;18:503&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">11922141</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouillet E, Trembleau A, Galanaud D, Volovitch M, Bouillot C, Valenza C, Prochiantz A, Allinquant B. The amyloid precursor protein interacts with Go heterotrimeric protein within a cell compartment specialized in signal transduction. J Neurosci. 1999;19:1717&#x2013;1727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782156</ArticleId><ArticleId IdType="pubmed">10024358</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke WJ, Park DH, Chung HD, Marshall GL, Haring JH, Joh TH. Evidence for decreased transport of tryptophan hydroxylase in Alzheimer's disease. Brain Res. 1990;537:83&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">1707735</ArticleId></ArticleIdList></Reference><Reference><Citation>Bursztajn S, DeSouza R, McPhie DL, Berman SA, Shioi J, Robakis NK, Neve RL. Overexpression in neurons of human presenilin-1 or a presenilin-1 familial Alzheimer disease mutant does not enhance apoptosis. J Neurosci. 1998;18:9790&#x2013;9799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793279</ArticleId><ArticleId IdType="pubmed">9822738</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo A, Rebeck GW, Ghetri BG, Hulette C, Lippa C, Van Broeckhoven C, van Duijn C, Cras P, Bogdanovic N, Bird T, Peterhoff C, Nixon R. Endocytic disturbances distinguish among subtypes of Alzheimer's disease and related disorders. Ann Neurol. 2001;50:661&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pubmed">11706973</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic pathway abnormalities preceded amyloid &#x3b2; deposition in sporadic Alzheimer's disease and Down syndrome. Am J Pathol. 2000;157:277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalli V, Corti M, Gruenberg J. Endocytosis and signaling cascades: a close encounter. FEBS Lett. 2001;498:190&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">11412855</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Borinstein SC, Gillis J, Sykes VW, Bogler O. The glioma-associated protein SETA interacts with AIP1/Alix and ALG-2 and modulates apoptosis in astrocytes. J Biol Chem. 2000;275:19275&#x2013;19281.</Citation><ArticleIdList><ArticleId IdType="pubmed">10858458</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, McPhie DL, Hirschberg J, Neve RL. The amyloid precursor protein-binding protein APP&#x2013;BP1 drives the cell cycle through the S-M checkpoint and causes apoptosis in neurons. J Biol Chem. 2000;275:8929&#x2013;8935.</Citation><ArticleIdList><ArticleId IdType="pubmed">10722740</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Liu W, McPhie DL, Hassinger L, Neve RL. APP&#x2013;BP1 mediates APP-induced apoptosis and DNA synthesis and is increased in Alzheimer's disease brain. J Cell Biol. 2003;163:27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173435</ArticleId><ArticleId IdType="pubmed">14557245</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow N, Korenberg JR, Chen XN, Neve RL. APP&#x2013;BP1, a novel protein that binds to the carboxyl-terminal region of the amyloid precursor protein. J Biol Chem. 1996;271:11339&#x2013;11346.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626687</ArticleId></ArticleIdList></Reference><Reference><Citation>Chui DH, Tanahashi H Ozawa K, Ikeda S, Checler F, Ueda O, Suzuki H, Araki W, Inoue H, Shirotani K, Takahashi K, Gallyas F, Tabira T. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med. 1999;5:560&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">10229234</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper JD, Salehi A, Delcroix JD, Howe CL, Belichenko PV, Chua-Couzens J, Kilbridge JF, Carlson EJ, Epstein CJ, Mobley WC. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci USA. 2001;98:10439&#x2013;10444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC56979</ArticleId><ArticleId IdType="pubmed">11504920</ArticleId></ArticleIdList></Reference><Reference><Citation>Delcroix JD, Valletta JS, Wu C, Hunt SJ, Kowal AS, Mobley WC. NGF signaling in sensory neurons: evidence that early endosomes carry NGF retrograde signals. Neuron. 2003;39:69&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">12848933</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinneen JL, Ceresa BP. Continual expression of Rab5(Q79L) causes a ligand-independent EGFR internalization and diminishes EGFR activity. Traffic. 2004;5:606&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">15260830</ArticleId></ArticleIdList></Reference><Reference><Citation>Enouf V, Chwetzoff S, Trugnan G, Cohen J. Interactions of rotavirus VP4 spike protein with the endosomal protein Rab5 and the prenylated Rab acceptor PRA1. J Virol. 2003;77:7041&#x2013;7047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC156175</ArticleId><ArticleId IdType="pubmed">12768023</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumori A, Okochi M, Tagami S, Jiang J, Itoh N, Nakayama T, Yanagida K, Ishizuka-Katsura Y, Morihara T, Kamino K, Tanaka T, Kudo T, Tanji H, Ikuta A, Haass C, Takeda M. Presenilin-dependent &#x3b3;-secretase on plasma membrane and endosomes is functionally distinct. Biochemistry. 2006;45:4907&#x2013;4914.</Citation><ArticleIdList><ArticleId IdType="pubmed">16605258</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvan V, Gorostiza OF, Banwait S, Ataie M, Logvinova AV, Sitaraman S, Carlson E, Sagi SA, Chevallier N, Jin K, Greenberg DA, Bredesen DE. Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci USA. 2006;103:7130&#x2013;7135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1459029</ArticleId><ArticleId IdType="pubmed">16641106</ArticleId></ArticleIdList></Reference><Reference><Citation>Grbovic OM, Mathews PM, Jiang Y, Schnidt SD, Dinakar R, Summers-Terio NB, Ceresa BP, Nixon RA, Cataldo AM. Rab5-stimulated up-regulation of the endocytic pathway increases intracellular &#x3b2;-cleaved amyloid precursor protein carboxyl-terminal fragment levels and A&#x3b2; production. J Biol Chem. 2003;278:31261&#x2013;31268.</Citation><ArticleIdList><ArticleId IdType="pubmed">12761223</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa A, Kitamura N. Early endosomal localization of Hrs requires a sequence within the proline- and glutamine-rich region but not the FYVE finger. J Biol Chem. 2000;275:29636&#x2013;29642.</Citation><ArticleIdList><ArticleId IdType="pubmed">10889197</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang DY, Cho JS, Lee SH, Chae KR, Lim HJ, Min SH, Seo SJ, Song YS, Song CS, Paik SG, Sheen YY, Kim YK. Aberrant expressions of pathogenic phenotype in Alzheimer's diseased transgenic mice carrying NSE-controlled APPsw. Exp Neurol. 2004;186:20&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">14980807</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Beyreuther K, Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325:733&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">2881207</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzmann DJ, Odorizzi G, Emr SD. Receptor downregulation and multivesicular-body sorting. Nat Rev Mol Cell Biol. 2002;3:893&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">12461556</ArticleId></ArticleIdList></Reference><Reference><Citation>Komada M, Masaki R, Yamamoto A, Kitamura N. Hrs, a tyrosine kinase substrate with a conserved double zinc finger domain, is localized to the cytoplasmic surface of early endosomes. J Biol Chem. 1997;272:20538&#x2013;20544.</Citation><ArticleIdList><ArticleId IdType="pubmed">9252367</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschild CC, Jay G. The Alzheimer's A&#x3b2; peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet. 1995;9:21&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">7704018</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzetti L, Rybin V, Malabarba MG, Christoforidis S, Scita G, Zerial M, Di Fiore PP. The Eps8 protein coordinates EGF receptor signaling through Rac and trafficking through Rab5. Nature. 2000;408:374&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">11099046</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzetti L, Palamidessi A, Areces L, Scita G, Di Fiore PP. Rab5 is a signalling GTPase involved in actin remodeling by receptor tyrosine kinases. Nature. 2004;429:309&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">15152255</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBlanc AC. The role of apoptotic pathways in Alzheimer's disease neurodegeneration and cell death. Curr Alzheimer Res. 2005;2:389&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">16248844</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M-S, Kao S-C, Lemere CA, Xia W, Tseng H-C, Zhou Y, Neve R, Ahlijanian MK, Tsai L-H. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol. 2003;163:83&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173445</ArticleId><ArticleId IdType="pubmed">14557249</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu DC, Rabizadeh S, Chandra S, Shayya RF, Ellerby LM, Ye X, Salvesen GS, Koo EH, Bredesen DE. A second cytotoxic proteolytic peptide derived from amyloid &#x3b2;-protein precursor. Nat Med. 2000;6:397&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">10742146</ArticleId></ArticleIdList></Reference><Reference><Citation>McPhie DL, Lee RKK, Eckman CB, Olstein DH, Durham SP, Yager D, Younkin SG, Wurtman RJ, Neve RL. Neuronal expression of &#x3b2;-amyloid precursor protein Alzheimer mutations causes intracellular accumulation of a C-terminal fragment containing both the amyloid &#x3b2; and cytoplasmic domains. J Biol Chem. 1997;272:24743&#x2013;24746.</Citation><ArticleIdList><ArticleId IdType="pubmed">9312066</ArticleId></ArticleIdList></Reference><Reference><Citation>McPhie DL, Golde T, Eckman CB, Yager D, Younkin SG, Neve RL. The &#x3b2;-secretase cleavage product of the amyloid precursor protein mediates neuronal apoptosis caused by familial Alzheimer's disease mutations. Mol Brain Res. 2001;97:103&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">11744168</ArticleId></ArticleIdList></Reference><Reference><Citation>McPhie DL, Coopersmith R, Hines-Peralta A, Chen Y, Ivins KJ, Manly SP, Kozlowski MR, Neve KA, Neve RL. DNA synthesis and neuronal apoptosis caused by familial Alzheimer disease mutants of the amyloid precursor protein are mediated by the p21 activated kinase PAK3. J Neurosci. 2003;23:6914&#x2013;6927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740729</ArticleId><ArticleId IdType="pubmed">12890786</ArticleId></ArticleIdList></Reference><Reference><Citation>Miaczynska M, Christoforidis S, Giner A, Shevchenko A, Uttenweiler-Joseph S, Habermann B, Wilm M, Parton RG, Zerial M. APPL proteins link rab5 to nuclear signal transduction via an endosomal compartment. Cell. 2004;116:445&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">15016378</ArticleId></ArticleIdList></Reference><Reference><Citation>Missotten M, Nichols A, Rieger K, Sadoul R. Alix, a novel mouse protein undergoing calcium-dependent interaction with the apoptosis-linked-gene 2 (ALG-2) protein. Cell Death Differ. 1999;6:124&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">10200558</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy MP, Uljon SN, Fraser PE, Fauq A, Lookingbill HA, Findlay KA, Smith TE, Lewis PA, McLendon DC, Wang R, Golde TE. Presenilin 1 regulates pharmacologically distinct &#x3b3;-secretase activities. Implication for the role of presenilin in &#x3b3;-secretase cleavage. J Biol Chem. 2000;275:26277&#x2013;26284.</Citation><ArticleIdList><ArticleId IdType="pubmed">10816583</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimoto I, Okamoto T, Matsuura Y, Okamoto T, Murayama Y, Ogata E. Alzheimer amyloid protein precursor complexes with brain GTP-binding protein G(o) Nature. 1993;362:75&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446172</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases. Neurobiol Aging. 2005;26:373&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639316</ArticleId></ArticleIdList></Reference><Reference><Citation>Otomo A, Hadano S, Okada T, Mizumura H, Kunita R, Nishijima H, Showguchi-Miyata J, Yanagisawa Y, Kohiki E, Suga E, Yasuda M, Osuga H, Nishimoto T, Narumiya S, Ikeda JE. ALS2, a novel guanine nucleotide exchange factor for the small GTPase Rab5, is implicated in endosomal dynamics. Hum Mol Genet. 2003;12:1671&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pubmed">12837691</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez RG, Soriano S, Hayes JD, Ostaszewski B, Xia W, Selkoe DJ, Chen X, Stokin GB, Koo EH. Mutagenesis identifies new signals for &#x3b2;-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including A&#x3b2;42. J Biol Chem. 1999;274:18851&#x2013;18856.</Citation><ArticleIdList><ArticleId IdType="pubmed">10383380</ArticleId></ArticleIdList></Reference><Reference><Citation>Polo S, Pece S, Di Fiore PP. Endocytosis and cancer. Curr Opin Cell Biol. 2004;16:156&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">15196558</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina AK, Hochman A, Zhi X, Rottkamp CA, Nunomura A, Siedlak SL, Boux H, Castellani RJ, Perry G, Smith MA. Abortive apoptosis in Alzheimer's disease. Acta Neuropathol. 2001;101:305&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">11355301</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A, Hannequin D, Raux F, Le Meur N, Laquerriere A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, Dubas F, Frebourg T, Campion D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38:24&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369530</ArticleId></ArticleIdList></Reference><Reference><Citation>Saganich MJ, Schroeder BE, Galvan V, Bredesen DE, Koo EH, Heinemann SF. Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP. J Neurosci. 2006;26:13428&#x2013;13436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674728</ArticleId><ArticleId IdType="pubmed">17192425</ArticleId></ArticleIdList></Reference><Reference><Citation>Sager PR, Brown PA, Berlin RD. Analysis of transferrin recycling in mitotic and interphase HeLa cells by quantitative fluorescence microscopy. Cell. 1984;39:275&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">6498936</ArticleId></ArticleIdList></Reference><Reference><Citation>Seemann J, Weber K, Gerke V. Annexin I targets S100C to early endosomes. FEBS Lett. 1997;413:185&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">9287141</ArticleId></ArticleIdList></Reference><Reference><Citation>Selznick LA, Holtzman DM, Han BH, Gokden M, Srinivasan AN, Johnson EM, Jr, Roth KA. In situ immunodetection of neuronal caspase-3 activation in Alzheimer disease. J Neuropathol Exp Neurol. 1999;58:1020&#x2013;1026.</Citation><ArticleIdList><ArticleId IdType="pubmed">10499444</ArticleId></ArticleIdList></Reference><Reference><Citation>Sever S. Dynamin and endocytosis. Curr Opin Cell Biol. 2002;14:463&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">12383797</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J, Del-Favero J, Cruts M, van Duijn CM, Van Broeckhoven C. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain. 2006;129:2977&#x2013;2983.</Citation><ArticleIdList><ArticleId IdType="pubmed">16921174</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci. 2001;24:1217&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520933</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano S, Chyung AS, Chen X, Stokin GB, Lee VM, Koo EG. Expression of &#x3b2;-amyloid precursor protein-CD3&#x3b3; chimeras to demonstrate the selective generation of amyloid &#x3b2;(1&#x2013;40) and amyloid &#x3b2;(1&#x2013;42) peptides within secretory and endocytic compartments. J Biol Chem. 1999;274:32295&#x2013;32300.</Citation><ArticleIdList><ArticleId IdType="pubmed">10542269</ArticleId></ArticleIdList></Reference><Reference><Citation>Stadelmann C, Deckwerth TL, Srinivasan A, Bancher C, Bruck W, Jellinger K, Lassmann H. Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Am J Pathol. 1999;155:1459&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866960</ArticleId><ArticleId IdType="pubmed">10550301</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenmark H, Parton RG, Steele-Mortimer O, Lutcke A, Gruenberg J, Zerial M. Inhibition of rab5 GTPase activity stimulates membrane fusion in endocytosis. EMBO J. 1994;13:1287&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC394944</ArticleId><ArticleId IdType="pubmed">8137813</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, Goldstein LS. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science. 2005;307:1282&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>Tall GG, Barbieri MA, Stahl PD, Horazdovsky BF. Ras-activated endocytosis is mediated by the Rab5 guanine nucleotide exchange activity of RIN1. Dev Cell. 2001;1:73&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">11703925</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren G. Cell biology: mitosis and membranes. Nature. 1989;342:857&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pubmed">2594081</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren G, Davoust J, Cockcroft A. Recycling of transferrin receptors in A431 cells is inhibited during mitosis. EMBO J. 1984;3:2217&#x2013;2225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC557673</ArticleId><ArticleId IdType="pubmed">6209129</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilde A, Beattie EC, Lem L, Riethof DA, Liu SH, Mobley WC, Soriano P, Brodsky FM. EGF receptor signaling stimulates SRC kinase phosphorylation of clathrin, influencing clathrin redistribution and EGF uptake. Cell. 1999;96:677&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">10089883</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, Chang X, Zhang X, Guo Q. Aberrant induction of Par-4 is involved in apoptosis of hippocampal neurons in presenilin-1 M146V mutant knock-in mice. Brain Res. 2001;915:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">11578614</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17611540</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>448</Volume><Issue>7149</Issue><PubDate><Year>2007</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo.</ArticleTitle><Pagination><StartPage>73</StartPage><EndPage>77</EndPage><MedlinePgn>73-7</MedlinePgn></Pagination><Abstract><AbstractText>In Parkinson's disease, brain dopamine neurons degenerate most prominently in the substantia nigra. Neurotrophic factors promote survival, differentiation and maintenance of neurons in developing and adult vertebrate nervous system. The most potent neurotrophic factor for dopamine neurons described so far is the glial-cell-line-derived neurotrophic factor (GDNF). Here we have identified a conserved dopamine neurotrophic factor (CDNF) as a trophic factor for dopamine neurons. CDNF, together with its previously described vertebrate and invertebrate homologue the mesencephalic-astrocyte-derived neurotrophic factor, is a secreted protein with eight conserved cysteine residues, predicting a unique protein fold and defining a new, evolutionarily conserved protein family. CDNF (Armetl1) is expressed in several tissues of mouse and human, including the mouse embryonic and postnatal brain. In vivo, CDNF prevented the 6-hydroxydopamine (6-OHDA)-induced degeneration of dopaminergic neurons in a rat experimental model of Parkinson's disease. A single injection of CDNF before 6-OHDA delivery into the striatum significantly reduced amphetamine-induced ipsilateral turning behaviour and almost completely rescued dopaminergic tyrosine-hydroxylase-positive cells in the substantia nigra. When administered four weeks after 6-OHDA, intrastriatal injection of CDNF was able to restore the dopaminergic function and prevent the degeneration of dopaminergic neurons in substantia nigra. Thus, CDNF was at least as efficient as GDNF in both experimental settings. Our results suggest that CDNF might be beneficial for the treatment of Parkinson's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lindholm</LastName><ForeName>P&#xe4;ivi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voutilainen</LastName><ForeName>Merja H</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Laur&#xe9;n</LastName><ForeName>Juha</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Per&#xe4;nen</LastName><ForeName>Johan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lepp&#xe4;nen</LastName><ForeName>Veli-Matti</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Andressoo</LastName><ForeName>Jaan-Olle</ForeName><Initials>JO</Initials></Author><Author ValidYN="Y"><LastName>Lindahl</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Janhunen</LastName><ForeName>Sanna</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kalkkinen</LastName><ForeName>Nisse</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Timmusk</LastName><ForeName>T&#xf5;nis</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tuominen</LastName><ForeName>Raimo K</ForeName><Initials>RK</Initials></Author><Author ValidYN="Y"><LastName>Saarma</LastName><ForeName>Mart</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C522217">CDNF protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577430">CDNF protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C099695">MANF protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C522218">cdnf protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>8HW4YBZ748</RegistryNumber><NameOfSubstance UI="D016627">Oxidopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017124" MajorTopicYN="N">Conserved Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017403" MajorTopicYN="N">In Situ Hybridization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016627" MajorTopicYN="N">Oxidopamine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17611540</ArticleId><ArticleId IdType="doi">10.1038/nature05957</ArticleId><ArticleId IdType="pii">nature05957</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17615170</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>10</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Clinicopathological concordance and discordance in three monozygotic twin pairs with familial Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1050</StartPage><EndPage>1055</EndPage><MedlinePgn>1050-5</MedlinePgn></Pagination><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Neuropathological examination of both individuals in a monozygotic (MZ) twin pair with Alzheimer's disease (AD) is rare, especially in the molecular genetic era. We had the opportunity to assess the concordance and discordance of clinical presentation and neuropathology in three MZ twin pairs with AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The MZ twins were identified and characterised by the University of Washington Alzheimer's Disease Research Center. We reviewed the available clinical and neuropathological records for all six cases looking specifically for concordance and discordance of clinical phenotype, neuritic amyloid plaques (NP), neurofibrillary tangles (NFT) and Lewy related pathology (LRP).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Discordance in age of onset for developing AD in the MZ twins varied from 4 to 18 years. Clinical presentations also differed between twins. One twin presented with a dementia with Lewy Body clinical syndrome while the other presented with typical clinical AD. Neuropathology within the MZ twin pairs was concordant for NP and NFT, regardless of duration of disease, and was discordant for LRP. This difference was most marked in the late onset AD twin pair. One pair was found to have a mutation in presenilin-1 (PS1) (A79V) with remarkably late onset in a family member.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">MZ twins with AD can vary considerably in age of onset, presentation and disease duration. The concordance of NP and NFT pathological change and the discordance of LRP support the concept that, in AD, the former are primarily under genetic control whereas the latter (LRP) is more influenced by disease duration and environmental factors. The A79V mutation in PS1 can be associated with very late onset of dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brickell</LastName><ForeName>Kiri L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Neurological Foundation of New Zealand, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leverenz</LastName><ForeName>James B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Steinbart</LastName><ForeName>Ellen J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Rumbaugh</LastName><ForeName>Malia</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><LastName>Nochlin</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lampe</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials></Author><Author ValidYN="Y"><LastName>Holm</LastName><ForeName>Ida E</ForeName><Initials>IE</Initials></Author><Author ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Wuxing</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Bird</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG17586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG 005136-22</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D018486">Twin Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurol Neurosurg Psychiatry. 2007 Oct;78(10):1039. doi: 10.1136/jnnp.2007.118562.</RefSource><PMID Version="1">17878189</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002544" MajorTopicYN="N">Cerebral Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014430" MajorTopicYN="N">Twins, Monozygotic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17615170</ArticleId><ArticleId IdType="pmc">PMC2117553</ArticleId><ArticleId IdType="doi">10.1136/jnnp.2006.113803</ArticleId><ArticleId IdType="pii">jnnp.2006.113803</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Holmes C. Genotype and phenotype in Alzheimer's disease. Br J Psychiatry 2002180131&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">11823322</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickell K L, Steinbart E J, Rumbaugh M.et al Early onset Alzheimer's disease in families with late onset: an important subtype of Alzheimer's disease. Arch Neurol 2006631307&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pubmed">16966510</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner J C, Jarvik G P, Plassman B L.et al Risk of Alzheimer disease with the epsilon4 allele for apolipoprotein E in a population&#x2010;based study of men aged 62&#x2013;73 years. Alzheimer Dis Assoc Disord 19981240&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">9539409</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev E I, Liang Y.et al Cloning of a gene bearing missense mutations in early&#x2010;onset familial Alzheimer's disease. Nature 1995375754&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy&#x2010;Lahad E, Wasco W, Poorkaj P.et al Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995269973&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">7638622</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Chartier&#x2010;Harlin M C, Mullan M.et al Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991349704&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E A, Fafel K C, Song Y Q.et al Screening for PS1 mutations in a referral&#x2010;based series of AD cases. 21 novel mutations. Neurology 200157621&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">11524469</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Pedersen N L, Berg S.et al Heritability for Alzheimer's disease: the study of dementia in Swedish twins. J Gerontol A Biol Sci Med Sci 199752M117&#x2013;M125.</Citation><ArticleIdList><ArticleId IdType="pubmed">9060980</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds C A, Fratiglioni L.et al Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 200663168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Nee L E, Lippa C F. Alzheimer's disease in 22 twin pairs&#x2013;13 year follow&#x2010;up: hormonal, infectious and traumatic factors. Dement Geriatr Cogn Disord 199910148&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">10026389</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Mortimer J A, Fratiglioni L.et al Potentially modifiable risk factors for dementia in identical twins. Alzheimer Dement 20062110&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595867</ArticleId></ArticleIdList></Reference><Reference><Citation>Duda J E. Pathology and neurotransmitter abnormalities of dementia with Lewy bodies. Dement Geriatr Cogn Disord 2004173&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">14676464</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton R L. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha&#x2010;synuclein immunohistochemistry. Brain Pathol 200010378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098522</ArticleId><ArticleId IdType="pubmed">10885656</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharman M G, Watt D C, Janota I.et al Case report: Alzheimer's disease in a mother and identical twin sons. Psychol Med 19799771&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">574653</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook R H, Schneck S A, Clark D B. Twins with Alzheimer's disease. Arch Neurol 198138300&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">7224917</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilpatrick C, Burns R, Blumbergs P C. Identical twins with Alzheimer's disease. J Neurol Neurosurg Psychiatry 198346421&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1027390</ArticleId><ArticleId IdType="pubmed">6101177</ArticleId></ArticleIdList></Reference><Reference><Citation>Nee L E, Eldridge R, Sunderland T.et al Dementia of the Alzheimer type: clinical and family study of 22 twin pairs. Neurology 198737359&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">3822128</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M.et al Clinical diagnosis of Alzheimer's disease: report of the NINCDS&#x2010;ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 198434939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird T D, Levy&#x2010;Lahad E, Poorkaj P.et al Wide range in age of onset for chromosome 1 related familial Alzheimier's disease. Ann Neurol 199640932&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">9007102</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological staging of Alzheimer&#x2010;related changes. Acta Neuropathol 199182239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra S S, Heyman A, McKeel D.et al The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 199141479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Leverenz J B, Fishel M A, Peskind E R.et al Lewy body pathology in familial Alzheimer's disease: evidence for disease and mutation&#x2010;specific pathologic phenotype. Arch Neurol 2006631&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1892620</ArticleId><ArticleId IdType="pubmed">16533963</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith I G, Dickson D W, Lowe J.et al Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005651863&#x2013;1872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamimura K, Tanahashi H, Yamanaka H.et al Familial Alzheimer's disease genes in JNPanese. J Neurol Sci 199816076&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">9804121</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixson J E, Vernier D T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 199031545&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">2341813</ArticleId></ArticleIdList></Reference><Reference><Citation>Emi M, Wu L L, Robertson M A.et al Genotyping and sequence analysis of apolipoprotein E isoforms. Genomics 19883373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">3243553</ArticleId></ArticleIdList></Reference><Reference><Citation>Consensus recommendations for the postmortem diagnosis of Alzheimer's disease The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 199718(Suppl 4)S1&#x2013;S2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuang D W, Riekse R G, Purganan K M.et al Lewy body pathology in late&#x2010;onset familial Alzheimer's disease: a clinicopathological case series. J Alzheimer Dis 20069235&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914833</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, van Duijn C M, Backhovens H.et al Estimation of the genetic contribution of presenilin&#x2010;1 and &#x2010;2 mutations in a population&#x2010;based study of presenile Alzheimer disease. Hum Mol Genet 1998743&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">9384602</ArticleId></ArticleIdList></Reference><Reference><Citation>Finckh U, Muller&#x2010;Thomsen T, Mann U.et al High prevalence of pathogenic mutations in patients with early onset dementia detected by sequence analyses of four different genes. Am J Hum Genet 200066110&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288316</ArticleId><ArticleId IdType="pubmed">10631141</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17616482</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1474-4422</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>8</Issue><PubDate><Year>2007</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.</ArticleTitle><Pagination><StartPage>734</StartPage><EndPage>746</EndPage><MedlinePgn>734-46</MedlinePgn></Pagination><Abstract><AbstractText>The NINCDS-ADRDA and the DSM-IV-TR criteria for Alzheimer's disease (AD) are the prevailing diagnostic standards in research; however, they have now fallen behind the unprecedented growth of scientific knowledge. Distinctive and reliable biomarkers of AD are now available through structural MRI, molecular neuroimaging with PET, and cerebrospinal fluid analyses. This progress provides the impetus for our proposal of revised diagnostic criteria for AD. Our framework was developed to capture both the earliest stages, before full-blown dementia, as well as the full spectrum of the illness. These new criteria are centred on a clinical core of early and significant episodic memory impairment. They stipulate that there must also be at least one or more abnormal biomarkers among structural neuroimaging with MRI, molecular neuroimaging with PET, and cerebrospinal fluid analysis of amyloid beta or tau proteins. The timeliness of these criteria is highlighted by the many drugs in development that are directed at changing pathogenesis, particularly at the production and clearance of amyloid beta as well as at the hyperphosphorylation state of tau. Validation studies in existing and prospective cohorts are needed to advance these criteria and optimise their sensitivity, specificity, and accuracy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>INSERM U610, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris, France. bruno.dubois@psl.aphp.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard H</ForeName><Initials>HH</Initials></Author><Author ValidYN="Y"><LastName>Jacova</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Dekosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Barberger-Gateau</LastName><ForeName>Pascale</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Delacourte</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Jicha</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Meguro</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>O'brien</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Robert</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Visser</LastName><ForeName>Pieter J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2007 Aug;6(8):667-9. doi: 10.1016/S1474-4422(07)70179-5.</RefSource><PMID Version="1">17616483</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Int Psychogeriatr. 2008 Aug;20(4):853-5. doi: 10.1017/S1041610208006807.</RefSource><PMID Version="1">18416874</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2008 Aug;7(8):668-70. doi: 10.1016/S1474-4422(08)70146-7.</RefSource><PMID Version="1">18635012</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003952" MajorTopicYN="N">Diagnostic Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="Y">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009316" MajorTopicYN="N">National Institutes of Health (U.S.)</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>143</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(07)70178-3</ArticleId><ArticleId IdType="pii">S1474-4422(07)70178-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17623042</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2007</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0022-3042</ISSN><JournalIssue CitedMedium="Print"><Volume>103</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of neurochemistry</Title><ISOAbbreviation>J Neurochem</ISOAbbreviation></Journal><ArticleTitle>Sensitive ELISA detection of amyloid-beta protofibrils in biological samples.</ArticleTitle><Pagination><StartPage>334</StartPage><EndPage>345</EndPage><MedlinePgn>334-45</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid-beta (Abeta) protofibrils are known intermediates of the in vitro Abeta aggregation process and the protofibrillogenic Arctic mutation (APPE693G) provides clinical support for a pathogenic role of Abeta protofibrils in Alzheimer's disease (AD). To verify their in vivo relevance and to establish a quantitative Abeta protofibril immunoassay, Abeta conformation dependent monoclonal antibodies were generated. One of these antibodies, mAb158 (IgG2a), was used in a sandwich ELISA to specifically detect picomolar concentrations of Abeta protofibrils without interference from Abeta monomers or the amyloid precursor protein (APP). The specificity and biological significance of this ELISA was demonstrated using cell cultures and transgenic mouse models expressing human APP containing the Swedish mutation (APPKN670/671ML), or the Swedish and Arctic mutation in combination. The mAb158 sandwich ELISA analysis revealed presence of Abeta protofibrils in both cell and animal models, proving that Abeta protofibrils are formed not only in vitro, but also in vivo. Furthermore, elevated Abeta protofibril levels in the Arctic-Swedish samples emphasize the usefulness of the Arctic mutation as a model of enhanced protofibril formation. This assay provides a novel tool for investigating the role of Abeta protofibrils in AD and has the potential of becoming an important diagnostic assay.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Englund</LastName><ForeName>Hillevi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Public Health/Molecular Geriatrics, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sehlin</LastName><ForeName>Dag</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Johansson</LastName><ForeName>Ann-Sofi</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Lars N G</ForeName><Initials>LN</Initials></Author><Author ValidYN="Y"><LastName>Gellerfors</LastName><ForeName>P&#xe4;r</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Paulie</LastName><ForeName>Staffan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lannfelt</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Pettersson</LastName><ForeName>Frida Ekholm</ForeName><Initials>FE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurochem</MedlineTA><NlmUniqueID>2985190R</NlmUniqueID><ISSNLinking>0022-3042</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17623042</ArticleId><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04759.x</ArticleId><ArticleId IdType="pii">JNC4759</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17632506</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1097-6256</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>8</Issue><PubDate><Year>2007</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>A hippocampal Cdk5 pathway regulates extinction of contextual fear.</ArticleTitle><Pagination><StartPage>1012</StartPage><EndPage>1019</EndPage><MedlinePgn>1012-9</MedlinePgn></Pagination><Abstract><AbstractText>Treatment of emotional disorders involves the promotion of extinction processes, which are defined as the learned reduction of fear. The molecular mechanisms underlying extinction have only begun to be elucidated. By employing genetic and pharmacological approaches in mice, we show here that extinction requires downregulation of Rac-1 and cyclin-dependent kinase 5 (Cdk5), and upregulation of p21 activated kinase-1 (PAK-1) activity. This is physiologically achieved by a Rac-1-dependent relocation of the Cdk5 activator p35 from the membrane to the cytosol and dissociation of p35 from PAK-1. Moreover, our data suggest that Cdk5/p35 activity prevents extinction in part by inhibition of PAK-1 activity in a Rac-1-dependent manner. We propose that extinction of contextual fear is regulated by counteracting components of a molecular pathway involving Rac-1, Cdk5 and PAK-1. Our data suggest that this pathway could provide a suitable target for therapeutic treatment of emotional disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sananbenesi</LastName><ForeName>Farahnaz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Andre</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xinyu</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Schrick</LastName><ForeName>Christina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Neve</LastName><ForeName>Rachael</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Radulovic</LastName><ForeName>Jelena</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS051874</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS051874</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH073669</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH073669</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS051874</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>87414-49-1</RegistryNumber><NameOfSubstance UI="C082868">butyrolactone I</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051360">Cyclin-Dependent Kinase 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="C495906">Cdk5 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>OL659KIY4X</RegistryNumber><NameOfSubstance UI="D015107">4-Butyrolactone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015107" MajorTopicYN="N">4-Butyrolactone</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003214" MajorTopicYN="N">Conditioning, Classical</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051360" MajorTopicYN="N">Cyclin-Dependent Kinase 5</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005108" MajorTopicYN="N">Extinction, Psychological</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005239" MajorTopicYN="Y">Fear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>6</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17632506</ArticleId><ArticleId IdType="mid">NIHMS45659</ArticleId><ArticleId IdType="pmc">PMC2441763</ArticleId><ArticleId IdType="doi">10.1038/nn1943</ArticleId><ArticleId IdType="pii">nn1943</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Myers KM, Davis M. Behavioral and neural analysis of extinction. Neuron. 2002;36:567&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">12441048</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis M, Ressler K, Rothbaum BO, Richardson R. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry. 2006;60:369&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">16919524</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattal KM, Radulovic J, Lukowiak K. Extinction: does it or doesn&#x2019;t it? The requirement of altered gene activity and new protein synthesis. Biol Psychiatry. 2006;60:344&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2761679</ArticleId><ArticleId IdType="pubmed">16919523</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotres-Bayon F, Cain CK, LeDoux JE. Brain mechanisms of fear extinction: historical perspectives on the contribution of prefrontal cortex. Biol Psychiatry. 2006;60:329&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">16412988</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JJ, Fanselow MS. Modality-specific retrograde amnesia of fear. Science. 1992;256:675&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">1585183</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Sananbenesi F, Schrick C, Spiess J, Radulovic J. Distinct roles of hippocampal de novo protein synthesis and actin rearrangement in extinction of contextual fear. J Neurosci. 2004;24:1962&#x2013;1966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730386</ArticleId><ArticleId IdType="pubmed">14985438</ArticleId></ArticleIdList></Reference><Reference><Citation>Falls WA, Miserendino MJ, Davis M. Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala. J Neurosci. 1992;12:854&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576037</ArticleId><ArticleId IdType="pubmed">1347562</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhatwal JP, Stanek-Rattiner L, Davis M, Ressler KJ. Amygdala BDNF signaling is required for consolidation but not encoding of extinction. Nat Neurosci. 2006;9:870&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562628</ArticleId><ArticleId IdType="pubmed">16783370</ArticleId></ArticleIdList></Reference><Reference><Citation>Szapiro G, Vianna MR, McGaugh JL, Medina JHII. The role of NMDA glutamate receptors, PKA, MAPK and CAMKII in the hippocampus in extinction of conditioned fear. Hippocampus. 2003;13:53&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">12625457</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsicano G, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418:530&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">12152079</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukazawa Y, et al. Hippocampal LTP is accompanied by enhanced F-actin content within the dendritic spine that is essential for late LTP maintenance in vivo. Neuron. 2003;38:447&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">12741991</ArticleId></ArticleIdList></Reference><Reference><Citation>Matus A. Actin-based plasticity in dendritic spines. Science. 2000;290:754&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">11052932</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Sananbenesi F, Spiess J, Radulovic J. Cdk5 in the adult non-demented brain. Curr Drug Targets CNS Neurol Disord. 2003;2:375&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">14683465</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhavan R, Tsai LH. A decade of CDK5. Nat Rev Mol Cell Biol. 2001;2:749&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584302</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolic M. The role of Rho GTPases and associated kinases in regulating neurite outgrowth. Int J Biochem Cell Biol. 2002;34:731&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">11950591</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung ZH, Fu AK, Ip NY. Synaptic roles of Cdk5: implications in higher cognitive functions and neurodegenerative diseases. Neuron. 2006;50:13&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">16600851</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshima T, et al. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci USA. 1996;93:11173&#x2013;11178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC38303</ArticleId><ArticleId IdType="pubmed">8855328</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Sananbenesi F, Schrick C, Spiess J, Radulovic J. Cyclin-dependent kinase 5 is required for associative learning. J Neurosci. 2002;22:3700&#x2013;3707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758363</ArticleId><ArticleId IdType="pubmed">11978846</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Sananbenesi F, Pang PT, Lu B, Tsai LH. Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron. 2005;48:825&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">16337919</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelo M, Plattner F, Irvine EE, Giese KP. Improved reversal learning and altered fear conditioning in transgenic mice with regionally restricted p25 expression. Eur J Neurosci. 2003;18:423&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">12887424</ArticleId></ArticleIdList></Reference><Reference><Citation>Li BS, et al. Regulation of NMDA receptors by cyclin-dependent kinase-5. Proc Natl Acad Sci USA. 2001;98:12742&#x2013;12747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC60124</ArticleId><ArticleId IdType="pubmed">11675505</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan TC, et al. Cdk5 is essential for synaptic vesicle endocytosis. Nat Cell Biol. 2003;5:701&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">12855954</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomizawa K, et al. Cophosphorylation of amphiphysin I and dynamin I by Cdk5 regulates clathrin-mediated endocytosis of synaptic vesicles. J Cell Biol. 2003;163:813&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173686</ArticleId><ArticleId IdType="pubmed">14623869</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, et al. Phosphorylation of WAVE1 regulates actin polymerization and dendritic spine morphology. Nature. 2006;442:814&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862120</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SY, Wenk MR, Kim Y, Nairn AC, De Camilli P. Regulation of synpatojanin 1 by cyclin-dependent kinase 5 at synapses. Proc Natl Acad Sci USA. 2004;101:546&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC327184</ArticleId><ArticleId IdType="pubmed">14704270</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawasli AH, et al. Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation. Nat Neurosci. doi: 10.1038/nn1914. advance online publication 27 May 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1914</ArticleId><ArticleId IdType="pmc">PMC3910113</ArticleId><ArticleId IdType="pubmed">17529984</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama AY, Harms MB, Luo L. Small GTPases Rac and Rho in the maintenance of dendritic spines and branches in hippocampal pyramidal neurons. J Neurosci. 2000;20:5329&#x2013;5338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772334</ArticleId><ArticleId IdType="pubmed">10884317</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi ML, et al. Altered cortical synaptic morphology and impaired memory consolidation in forebrain- specific dominant-negative PAK transgenic mice. Neuron. 2004;42:773&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">15182717</ArticleId></ArticleIdList></Reference><Reference><Citation>Delamater AR. Experimental extinction in Pavlovian conditioning: behavioural and neuroscience perspectives. Q J Exp Psychol B. 2004;57:97&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15204112</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers KM, Davis M. Mechanisms of fear extinction. Mol Psychiatry. 2007;12:120&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">17160066</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitagawa M, et al. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene. 1993;8:2425&#x2013;2432.</Citation><ArticleIdList><ArticleId IdType="pubmed">8395680</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, et al. Hippocampal Mek/Erk signaling mediates extinction of contextual freezing behavior. Neurobiol Learn Mem. 2007;87:149&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1839930</ArticleId><ArticleId IdType="pubmed">16979915</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolic M, Chou MM, Lu W, Mayer BJ, Tsai LH. The p35/Cdk5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity. Nature. 1998;395:194&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">9744280</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang QG, et al. Akt inhibits MLK3/JNK3 signaling by inactivating Rac1: a protective mechanism against ischemic brain injury. J Neurochem. 2006;98:1886&#x2013;1898.</Citation><ArticleIdList><ArticleId IdType="pubmed">16831194</ArticleId></ArticleIdList></Reference><Reference><Citation>Desire L, et al. RAC1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases Abeta production in vitro and in vivo. J Biol Chem. 2005;280:37516&#x2013;37525.</Citation><ArticleIdList><ArticleId IdType="pubmed">16150730</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashid T, Banerjee M, Nikolic M. Phosphorylation of Pak1 by the p35/Cdk5 kinase affects neuronal morphology. J Biol Chem. 2001;276:49043&#x2013;49052.</Citation><ArticleIdList><ArticleId IdType="pubmed">11604394</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei M, et al. Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Cell. 2000;102:387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">10975528</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong ST, et al. Calcium-stimulated adenylyl cyclase activity is critical for hippocampus-dependent long-term memory and late phase LTP. Neuron. 1999;23:787&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">10482244</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Ferguson GD, Pineda VV, Cundiff PE, Storm DR. Overexpression of type-1 adenylyl cyclase in mouse forebrain enhances recognition memory and LTP. Nat Neurosci. 2004;7:635&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">15133516</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgos-Robles A, Vidal-Gonzalez I, Santini E, Quirk GJ. Consolidation of fear extinction requires NMDA receptor&#x2013;dependent bursting in the ventromedial prefrontal cortex. Neuron. 2007;53:871&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pubmed">17359921</ArticleId></ArticleIdList></Reference><Reference><Citation>Vianna MR, Coitinho AS, Izquierdo I. Role of the hippocampus and amygdala in the extinction of fear-motivated learning. Curr Neurovasc Res. 2004;1:55&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">16181066</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlau DJ, McGaugh JL. Enhancement of extinction memory consolidation: the role of the noradrenergic and GABAergic systems within the basolateral amygdala. Neurobiol Learn Mem. 2006;86:123&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">16458544</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CH, et al. Identification of calcineurin as a key signal in the extinction of fear memory. J Neurosci. 2003;23:1574&#x2013;1579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741970</ArticleId><ArticleId IdType="pubmed">12629159</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonhoeffer T, Yuste R. Spine motility. Phenomenology, mechanisms and function. Neuron. 2002;35:1019&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">12354393</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards DC, Sanders LC, Bokoch GM, Gill GN. Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol. 1999;1:253&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">10559936</ArticleId></ArticleIdList></Reference><Reference><Citation>Arber S, et al. Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. Nature. 1998;393:805&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">9655397</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu WY, et al. Cdk5 regulates EphA4-mediated dendritic spine retraction through an ephexin1-dependent mechanism. Nat Neurosci. 2007;10:67&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">17143272</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman DE, Dudai Y. Memory extinction, learning anew and learning the new: dissociations in the molecular machinery of learning in cortex. Science. 2001;291:2417&#x2013;2419.</Citation><ArticleIdList><ArticleId IdType="pubmed">11264539</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell DC. In: Statistical Methods for Psychology. Crokett C, editor. Duxbury Thompson Learning; Duxbury: 2002.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17634375</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>29</Issue><PubDate><Year>2007</Year><Month>Jul</Month><Day>18</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice.</ArticleTitle><Pagination><StartPage>7817</StartPage><EndPage>7826</EndPage><MedlinePgn>7817-26</MedlinePgn></Pagination><Abstract><AbstractText>It is well established that the proteolytic processing of the beta-amyloid precursor protein (APP) generates beta-amyloid (Abeta), which plays a central role in the pathogenesis of Alzheimer's disease (AD). In contrast, the physiological role of APP and of its numerous proteolytic fragments and the question of whether a loss of these functions contributes to AD are still unknown. To address this question, we replaced the endogenous APP locus by gene-targeted alleles and generated two lines of knock-in mice that exclusively express APP deletion variants corresponding either to the secreted APP ectodomain (APPs alpha) or to a C-terminal (CT) truncation lacking the YENPTY interaction motif (APPdeltaCT15). Interestingly, the deltaCT15 deletion resulted in reduced turnover of holoAPP, increased cell surface expression, and strongly reduced Abeta levels in brain, likely because of reduced processing in the endocytic pathway. Most importantly, we demonstrate that in both APP knock-in lines the expression of APP N-terminal domains either grossly attenuated or completely rescued the prominent deficits of APP knock-out mice, such as reductions in brain and body weight, grip strength deficits, alterations in circadian locomotor activity, exploratory activity, and the impairment in spatial learning and long-term potentiation. Together, our data suggest that the APP C terminus is dispensable and that APPs alpha is sufficient to mediate the physiological functions of APP assessed by these tests.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ring</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Bioinformatics and Functional Genomics, Institute for Pharmacy and Molecular Biotechnology, University of Heidelberg, D-69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weyer</LastName><ForeName>Sascha W</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>Kilian</LastName><ForeName>Susanne B</ForeName><Initials>SB</Initials></Author><Author ValidYN="Y"><LastName>Waldron</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Pietrzik</LastName><ForeName>Claus U</ForeName><Initials>CU</Initials></Author><Author ValidYN="Y"><LastName>Filippov</LastName><ForeName>Mikhail A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Herms</LastName><ForeName>Jochen</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Buchholz</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Eckman</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials></Author><Author ValidYN="Y"><LastName>Korte</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wolfer</LastName><ForeName>David P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Ulrike C</ForeName><Initials>UC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018737" MajorTopicYN="N">Hand Strength</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017384" MajorTopicYN="N">Sequence Deletion</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013037" MajorTopicYN="N">Spatial Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>1</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17634375</ArticleId><ArticleId IdType="pmc">PMC6672885</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1026-07.2007</ArticleId><ArticleId IdType="pii">27/29/7817</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Almkvist O, Basun H, Wagner SL, Rowe BA, Wahlund LO, Lannfelt L. Cerebrospinal fluid levels of alpha-secretase-cleaved soluble amyloid precursor protein mirror cognition in a Swedish family with Alzheimer disease and a gene mutation. Arch Neurol. 1997;54:641&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">9152122</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson JJ, Holtz G, Baskin PP, Wang R, Mazzarelli L, Wagner SL, Menzaghi F. Reduced cerebrospinal fluid levels of alpha-secretase-cleaved amyloid precursor protein in aged rats: correlation with spatial memory deficits. Neuroscience. 1999;93:1409&#x2013;1420.</Citation><ArticleIdList><ArticleId IdType="pubmed">10501466</ArticleId></ArticleIdList></Reference><Reference><Citation>Anliker B, M&#xfc;ller U. The functions of the mammalian amyloid precursor protein and related amyloid precursor-like proteins. Neurodegener Dis. 2006;3:239&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">17047363</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell KF, Zheng L, Fahrenholz F, Cuello AC. ADAM-10 over-expression increases cortical synaptogenesis. Neurobiol Aging. 2007 in press.</Citation><ArticleIdList><ArticleId IdType="pubmed">17187903</ArticleId></ArticleIdList></Reference><Reference><Citation>Bour A, Little S, Dodart JC, Kelche C, Mathis C. A secreted form of the beta-amyloid precursor protein (sAPP695) improves spatial recognition memory in OF1 mice. Neurobiol Learn Mem. 2004;81:27&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">14670356</ArticleId></ArticleIdList></Reference><Reference><Citation>Caill&#xe9; I, Allinquant B, Dupont E, Bouillot C, Langer A, M&#xfc;ller U, Prochiantz A. Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development. 2004;131:2173&#x2013;2181.</Citation><ArticleIdList><ArticleId IdType="pubmed">15073156</ArticleId></ArticleIdList></Reference><Reference><Citation>Chyung JH, Selkoe DJ. Inhibition of receptor-mediated endocytosis demonstrates generation of amyloid beta-protein at the cell surface. J Biol Chem. 2003;278:51035&#x2013;51043.</Citation><ArticleIdList><ArticleId IdType="pubmed">14525989</ArticleId></ArticleIdList></Reference><Reference><Citation>Colciaghi F, Borroni B, Pastorino L, Marcello E, Zimmermann M, Cattabeni F, Padovani A, Di Luca M. &#x3b1;-Secretase ADAM10 as well as &#x3b1;APPs is reduced in platelets and CSF of Alzheimer disease patients. Mol Med. 2002;8:67&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2039975</ArticleId><ArticleId IdType="pubmed">12080182</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson GR, Seabrook GR, Zheng H, Smith DW, Graham S, O'Dowd G, Bowery BJ, Boyce S, Trumbauer ME, Chen HY, van der Ploeg LH, Sirinathsinghji DJ. Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience. 1999;90:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10188929</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-Tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S. Increased amyloid-&#x3b2; 42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazeli MS, Breen K, Errington ML, Bliss TV. Increase in extracellular NCAM and amyloid precursor protein following induction of long-term potentiation in the dentate gyrus of anaesthetized rats. Neurosci Lett. 1994;169:77&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">8047297</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm MO, Grimm HS, Patzold AJ, Zinser EG, Halonen R, Duering M, Tsch&#xe4;pe JA, De Strooper B, M&#xfc;ller U, Shen J, Hartmann T. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol. 2005;7:1118&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">16227967</ArticleId></ArticleIdList></Reference><Reference><Citation>Heber S, Herms J, Gajic V, Hainfellner J, Aguzzi A, R&#xfc;licke T, von Kretzschmar H, von Koch C, Sisodia S, Tremml P, Lipp HP, Wolfer DP, M&#xfc;ller U. Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci. 2000;20:7951&#x2013;7963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772747</ArticleId><ArticleId IdType="pubmed">11050115</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert SS, Serneels L, Tolia A, Craessaerts K, Derks C, Filippov MA, M&#xfc;ller U, De Strooper B. Regulated intramembrane proteolysis of amyloid precursor protein and regulation of expression of putative target genes. EMBO Rep. 2006;7:739&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1500829</ArticleId><ArticleId IdType="pubmed">16729020</ArticleId></ArticleIdList></Reference><Reference><Citation>Herms J, Anliker B, Heber S, Ring S, Fuhrmann M, Kretzschmar H, Sisodia S, M&#xfc;ller U. Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. EMBO J. 2004;23:4106&#x2013;4115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524337</ArticleId><ArticleId IdType="pubmed">15385965</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornsten A, Lieberthal J, Fadia S, Malins R, Ha L, Xu X, Daigle I, Markowitz M, O'Connor G, Plasterk R, Li C. APL-1, a Caenorhabditis elegans protein related to the human beta-amyloid precursor protein, is essential for viability. Proc Natl Acad Sci USA. 2007;04:1971&#x2013;1976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1794273</ArticleId><ArticleId IdType="pubmed">17267616</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida A, Furukawa K, Keller JN, Mattson MP. Secreted form of beta-amyloid precursor protein shifts the frequency dependency for induction of LTD and enhances LTP in hippocampal slices. NeuroReport. 1997;8:2133&#x2013;2137.</Citation><ArticleIdList><ArticleId IdType="pubmed">9243598</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem. 1994;269:17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Lannfelt L, Basun H, Wahlund LO, Rowe BA, Wagner SL. Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. Nat Med. 1995;1:829&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pubmed">7585189</ArticleId></ArticleIdList></Reference><Reference><Citation>Li ZW, Stark G, G&#xf6;tz J, R&#xfc;licke T, Gschwind M, Huber G, M&#xfc;ller U, Weissmann C. Generation of mice with a 200-kb amyloid precursor protein gene deletion by Cre recombinase-mediated site-specific recombination in embryonic stem cells. Proc Natl Acad Sci USA. 1996;93:6158&#x2013;6162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39206</ArticleId><ArticleId IdType="pubmed">8650236</ArticleId></ArticleIdList></Reference><Reference><Citation>Madani R, Kozlov S, Akhmedov A, Cinelli P, Kinter J, Lipp HP, Sonderegger P, Wolfer DP. Impaired explorative behavior and neophobia in genetically modified mice lacking or overexpressing the extracellular serine protease inhibitor neuroserpin. Mol Cell Neurosci. 2003;23:473&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">12837630</ArticleId></ArticleIdList></Reference><Reference><Citation>Magara F, M&#xfc;ller U, Li ZW, Lipp HP, Weissmann C, Stagljar M, Wolfer DP. Genetic background changes the pattern of forebrain commissure defects in transgenic mice underexpressing the &#x3b2;-amyloid precursor protein. Proc Natl Acad Sci USA. 1999;96:4656&#x2013;4661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16388</ArticleId><ArticleId IdType="pubmed">10200318</ArticleId></ArticleIdList></Reference><Reference><Citation>Meziane H, Dodart JC, Mathis C, Little S, Clemens J, Paul SM, Ungerer A. Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. Proc Natl Acad Sci USA. 1998;95:12683&#x2013;12688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22891</ArticleId><ArticleId IdType="pubmed">9770546</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller U, Cristina N, Li ZW, Wolfer DP, Lipp HP, R&#xfc;licke T, Brandner S, Aguzzi A, Weissmann C. Behavioral and anatomical deficits in mice homozygous for a modified beta-amyloid precursor protein gene. Cell. 1994;79:755&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">8001115</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez RG, Soriano S, Hayes JD, Ostaszewski B, Xia W, Selkoe DJ, Chen X, Stokin GB, Koo EH. Mutagenesis identifies new signals for &#x3b2;-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including A&#x3b2;42. J Biol Chem. 1999;274:18851&#x2013;18856.</Citation><ArticleIdList><ArticleId IdType="pubmed">10383380</ArticleId></ArticleIdList></Reference><Reference><Citation>Phinney AL, Calhoun ME, Wolfer DP, Lipp HP, Zheng H, Jucker M. No hippocampal neuron or synaptic bouton loss in learning-impaired aged beta-amyloid precursor protein-null mice. Neuroscience. 1999;90:1207&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pubmed">10338291</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J. 2002;21:5691&#x2013;5700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC131065</ArticleId><ArticleId IdType="pubmed">12411487</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietrzik CU, Yoon IS, Jaeger S, Busse T, Weggen S, Koo EH. Fe65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. J Neurosci. 2004;24:4259&#x2013;4265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729272</ArticleId><ArticleId IdType="pubmed">15115822</ArticleId></ArticleIdList></Reference><Reference><Citation>Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J. Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci. 2006;26:7212&#x2013;7221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673945</ArticleId><ArticleId IdType="pubmed">16822978</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhard C, Hebert SS, De Strooper B. The amyloid-beta precursor protein: integrating structure with biological function. EMBO J. 2005;24:3996&#x2013;4006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1356301</ArticleId><ArticleId IdType="pubmed">16252002</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry. 1987;48(Suppl):9&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">3553166</ArticleId></ArticleIdList></Reference><Reference><Citation>Saitoh T, Sundsmo M, Roch JM, Kimura N, Cole G, Schubert D, Oltersdorf T, Schenk DB. Secreted form of amyloid beta protein precursor is involved in the growth regulation of fibroblasts. Cell. 1989;58:615&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">2475254</ArticleId></ArticleIdList></Reference><Reference><Citation>Seabrook GR, Smith DW, Bowery BJ, Easter A, Reynolds T, Fitzjohn SM, Morton RA, Zheng H, Dawson GR, Sirinathsinghji DJ, Davies CH, Collingridge GL, Hill RG. Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology. 1999;38:349&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">10219973</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol. 2004;6:1054&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">15516999</ArticleId></ArticleIdList></Reference><Reference><Citation>Sennvik K, Fastbom J, Blomberg M, Wahlund LO, Winblad B, Benedikz E. Levels of alpha- and beta-secretase-cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett. 2000;278:169&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">10653020</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinbach JP, M&#xfc;ller U, Leist M, Li ZW, Nicotera P, Aguzzi A. Hypersensitivity to seizures in beta-amyloid precursor protein-deficient mice. Cell Death Differ. 1998;5:858&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10203685</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremml P, Lipp HP, M&#xfc;ller U, Ricceri L, Wolfer DP. Neurobehavioral development, adult open field exploration and swimming navigation learning in mice with a modified beta-amyloid precursor protein gene. Behav Brain Res. 1998;95:65&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">9754878</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner PR, O'Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity, and memory. Prog Neurobiol. 2003;70:1&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">12927332</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyler SJ, Dawbarn D, Wilcock GK, Allen SJ. &#x3b1;- and &#x3b2;-secretase: profound changes in Alzheimer's disease. Biochem Biophys Res Commun. 2002;299:373&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">12445809</ArticleId></ArticleIdList></Reference><Reference><Citation>von Koch CS, Zheng H, Chen H, Trumbauer M, Thinakaran G, van der Ploeg LH, Price DL, Sisodia SS. Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice. Neurobiol Aging. 1997;18:661&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">9461064</ArticleId></ArticleIdList></Reference><Reference><Citation>White AR, Reyes R, Mercer JF, Camakaris J, Zheng H, Bush AI, Multhaup G, Beyreuther K, Masters CL, Cappai R. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res. 1999;842:439&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">10526140</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Koo EH. The amyloid precursor protein: beyond amyloid. Mol Neurodegener. 2006;1:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1538601</ArticleId><ArticleId IdType="pubmed">16930452</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW, Heavens RP, Dawson GR, Boyce S, Conner MW, Stevens KA, Slunt HH, Sisodia SS, Chen HY, van der Ploeg LH. &#x3b2;-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell. 1995;81:525&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">7758106</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17637672</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>448</Volume><Issue>7151</Issue><PubDate><Year>2007</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Delayed ageing through damage protection by the Arf/p53 pathway.</ArticleTitle><Pagination><StartPage>375</StartPage><EndPage>379</EndPage><MedlinePgn>375-9</MedlinePgn></Pagination><Abstract><AbstractText>The tumour-suppressor pathway formed by the alternative reading frame protein of the Cdkn2a locus (Arf) and by p53 (also called Trp53) plays a central part in the detection and elimination of cellular damage, and this constitutes the basis of its potent cancer protection activity. Similar to cancer, ageing also results from the accumulation of damage and, therefore, we have reasoned that Arf/p53 could have anti-ageing activity by alleviating the load of age-associated damage. Here we show that genetically manipulated mice with increased, but otherwise normally regulated, levels of Arf and p53 present strong cancer resistance and have decreased levels of ageing-associated damage. These observations extend the protective role of Arf/p53 to ageing, revealing a previously unknown anti-ageing mechanism and providing a rationale for the co-evolution of cancer resistance and longevity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matheu</LastName><ForeName>Ander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maraver</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Klatt</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Flores</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Garcia-Cao</LastName><ForeName>Isabel</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Borras</LastName><ForeName>Consuelo</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Flores</LastName><ForeName>Juana M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Vi&#xf1;a</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Blasco</LastName><ForeName>Maria A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C417743">Cdkn2a protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019941">Cyclin-Dependent Kinase Inhibitor p16</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019941" MajorTopicYN="N">Cyclin-Dependent Kinase Inhibitor p16</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17637672</ArticleId><ArticleId IdType="doi">10.1038/nature05949</ArticleId><ArticleId IdType="pii">nature05949</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17640385</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1741-7015</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><PubDate><Year>2007</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>BMC medicine</Title><ISOAbbreviation>BMC Med</ISOAbbreviation></Journal><ArticleTitle>Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease.</ArticleTitle><Pagination><StartPage>20</StartPage><MedlinePgn>20</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Statins are a class of medications that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Whether statins can benefit patients with dementia remains unclear because of conflicting results. We hypothesized that some of the confusion in the literature might arise from differences in efficacy of different statins. We used a large database to compare the action of several different statins to investigate whether some statins might be differentially associated with a reduction in the incidence of dementia and Parkinson's disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analyzed data from the decision support system of the US Veterans Affairs database, which contains diagnostic, medication and demographic information on 4.5 million subjects. The association of lovastatin, simvastatin and atorvastatin with dementia was examined with Cox proportional hazard models for subjects taking statins compared with subjects taking cardiovascular medications other than statins, after adjusting for covariates associated with dementia or Parkinson's disease.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We observed that simvastatin is associated with a significant reduction in the incidence of dementia in subjects &gt; or =65 years, using any of three models. The first model incorporated adjustment for age, the second model included adjusted for three known risk factors for dementia, hypertension, cardiovascular disease or diabetes, and the third model incorporated adjustment for the Charlson index, which is an index that provides a broad assessment of chronic disease. Data were obtained for over 700,000 subjects taking simvastatin and over 50,000 subjects taking atorvastatin who were aged &gt;64 years. Using model 3, the hazard ratio for incident dementia for simvastatin and atorvastatin are 0.46 (CI 0.44-0.48, p &lt; 0.0001) and 0.91 (CI 0.80-1.02, p = 0.11), respectively. Lovastatin was not associated with a reduction in the incidence of dementia. Simvastatin also exhibited a reduced hazard ratio for newly acquired Parkinson's disease (HR 0.51, CI 0.4-0.55, p &lt; 0.0001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Simvastatin is associated with a strong reduction in the incidence of dementia and Parkinson's disease, whereas atorvastatin is associated with a modest reduction in incident dementia and Parkinson's disease, which shows only a trend towards significance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wolozin</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Boston University School of Medicine, Boston, MA, USA. bwolozin@bu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Stanley W</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Nien-Chen</ForeName><Initials>NC</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Austin</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Todd A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Kazis</LastName><ForeName>Lewis E</ForeName><Initials>LE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med</MedlineTA><NlmUniqueID>101190723</NlmUniqueID><ISSNLinking>1741-7015</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006538">Heptanoic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance></Chemical><Chemical><RegistryNumber>9LHU78OQFD</RegistryNumber><NameOfSubstance UI="D008148">Lovastatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>A0JWA85V8F</RegistryNumber><NameOfSubstance UI="D000069059">Atorvastatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>AGG2FN16EV</RegistryNumber><NameOfSubstance UI="D019821">Simvastatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069059" MajorTopicYN="N">Atorvastatin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019992" MajorTopicYN="N">Databases as Topic</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006538" MajorTopicYN="N">Heptanoic Acids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008148" MajorTopicYN="N">Lovastatin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011758" MajorTopicYN="N">Pyrroles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019821" MajorTopicYN="N">Simvastatin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014728" MajorTopicYN="N">Veterans</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>7</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17640385</ArticleId><ArticleId IdType="pmc">PMC1955446</ArticleId><ArticleId IdType="doi">10.1186/1741-7015-5-20</ArticleId><ArticleId IdType="pii">1741-7015-5-20</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nash DT, Fillit H. Cardiovascular disease risk factors and cognitive impairment. Am J Cardiol. 2006;97:1262&#x2013;1265. doi: 10.1016/j.amjcard.2005.12.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2005.12.031</ArticleId><ArticleId IdType="pubmed">16616038</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology. 2005;65:545&#x2013;551. doi: 10.1212/01.wnl.0000172914.08967.dc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000172914.08967.dc</ArticleId><ArticleId IdType="pmc">PMC1619350</ArticleId><ArticleId IdType="pubmed">16116114</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman AB, Fitzpatrick AL, Lopez O, Jackson S, Lyketsos C, Jagust W, Ives D, Dekosky ST, Kuller LH. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc. 2005;53:1101&#x2013;1107. doi: 10.1111/j.1532-5415.2005.53360.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2005.53360.x</ArticleId><ArticleId IdType="pubmed">16108925</ArticleId></ArticleIdList></Reference><Reference><Citation>Breteler MM, Claus JJ, Grobbee DE, Hofman A. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. Bmj. 1994;308:1604&#x2013;1608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2540432</ArticleId><ArticleId IdType="pubmed">8025427</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, Tschanz JT, Mayer LS, Welsh-Bohmer KA, Breitner JC. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol. 2006;63:686&#x2013;692. doi: 10.1001/archneur.63.5.noc60013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.63.5.noc60013</ArticleId><ArticleId IdType="pubmed">16533956</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoog I, Lithell H, Hansson L, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE) Am J Hypertens. 2005;18:1052&#x2013;1059. doi: 10.1016/j.amjhyper.2005.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjhyper.2005.02.013</ArticleId><ArticleId IdType="pubmed">16109319</ArticleId></ArticleIdList></Reference><Reference><Citation>Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162:2046&#x2013;2052. doi: 10.1001/archinte.162.18.2046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.162.18.2046</ArticleId><ArticleId IdType="pubmed">12374512</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4:487&#x2013;499. doi: 10.1016/S1474-4422(05)70141-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(05)70141-1</ArticleId><ArticleId IdType="pubmed">16033691</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439&#x2013;1443. doi: 10.1001/archneur.57.10.1439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.57.10.1439</ArticleId><ArticleId IdType="pubmed">11030795</ArticleId></ArticleIdList></Reference><Reference><Citation>Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356:1627&#x2013;1631. doi: 10.1016/S0140-6736(00)03155-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(00)03155-X</ArticleId><ArticleId IdType="pubmed">11089820</ArticleId></ArticleIdList></Reference><Reference><Citation>Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, Hazzard WR, Zandi PP, Burke GL, Lyketsos CG, et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol. 2005;62:1047&#x2013;1051. doi: 10.1001/archneur.62.7.1047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.62.7.1047</ArticleId><ArticleId IdType="pubmed">16009757</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwolski C. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol. 2005;62:753&#x2013;757. doi: 10.1001/archneur.62.5.753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.62.5.753</ArticleId><ArticleId IdType="pubmed">15883262</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. 2002;59:378&#x2013;384. doi: 10.1001/archneur.59.3.378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.59.3.378</ArticleId><ArticleId IdType="pubmed">11890840</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M, Schwarzler F, Lutjohann D, Von Bergmann K, Beyreuther K, Dichgans J, Wormstall H, Hartmann T, Schulz JB. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 2002;52:346&#x2013;350. doi: 10.1002/ana.10292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10292</ArticleId><ArticleId IdType="pubmed">12205648</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59:223&#x2013;227. doi: 10.1001/archneur.59.2.223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.59.2.223</ArticleId><ArticleId IdType="pubmed">11843693</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjogren M, Mielke M, Gustafson D, Zandi P, Skoog I. Cholesterol and Alzheimer's disease &#x2013; is there a relation? Mech Ageing Dev. 2006;127:138&#x2013;147. doi: 10.1016/j.mad.2005.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2005.09.020</ArticleId><ArticleId IdType="pubmed">16332384</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandi P, Sparks L, Khachaturian A, et al. Do Statins Reduce Risk of Incident Dementia and AD? The Cache County Study. Arch Gen Psychiatry. 2004;62:217&#x2013;224. doi: 10.1001/archpsyc.62.2.217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.62.2.217</ArticleId><ArticleId IdType="pubmed">15699299</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623&#x2013;1630. doi: 10.1016/S0140-6736(02)11600-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(02)11600-X</ArticleId><ArticleId IdType="pubmed">12457784</ArticleId></ArticleIdList></Reference><Reference><Citation>Group HPSC MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7&#x2013;22. doi: 10.1016/S0140-6736(02)09327-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(02)09327-3</ArticleId><ArticleId IdType="pubmed">12114036</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MW, Joseph GJ. Pharmacy data in the VA health care system. Med Care Res Rev. 2003;60:92S&#x2013;123S. doi: 10.1177/1077558703256726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1077558703256726</ArticleId><ArticleId IdType="pubmed">15095548</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn MW, Zhang H, Arnold N, Stroupe K, Taylor BC, Wilt TJ, Hynes DM. Transition to the new race/ethnicity data collection standards in the Department of Veterans Affairs. Popul Health Metr. 2006;4:7. doi: 10.1186/1478-7954-4-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1478-7954-4-7</ArticleId><ArticleId IdType="pmc">PMC1539022</ArticleId><ArticleId IdType="pubmed">16824220</ArticleId></ArticleIdList></Reference><Reference><Citation>Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613&#x2013;619. doi: 10.1016/0895-4356(92)90133-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0895-4356(92)90133-8</ArticleId><ArticleId IdType="pubmed">1607900</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin G. Antiplatelet therapy and anticoagulation in patients with hypertension. Am Fam Physician. 2005;71:897&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pubmed">15768617</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenthal RS. Statins: effective antiatherosclerotic therapy. Am Heart J. 2000;139:577&#x2013;583. doi: 10.1016/S0002-8703(00)90033-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-8703(00)90033-4</ArticleId><ArticleId IdType="pubmed">10740137</ArticleId></ArticleIdList></Reference><Reference><Citation>Gresser U, Gathof BS. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke &#x2013; comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies. Eur J Med Res. 2004;9:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">14766335</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan LL, Petersen NJ, Snow AL, Cully JA, Schulz PE, Graham DP, Morgan RO, Braun U, Moffett ML, Yu HJ, et al. Prevalence of dementia among Veterans Affairs medical care system users. Dement Geriatr Cogn Disord. 2005;20:245&#x2013;253. doi: 10.1159/000087345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000087345</ArticleId><ArticleId IdType="pubmed">16088141</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J. 2006;151:273&#x2013;281. doi: 10.1016/j.ahj.2005.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2005.04.003</ArticleId><ArticleId IdType="pubmed">16442888</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson MH. Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome. Am J Cardiol. 2004;93:3C&#x2013;11C. doi: 10.1016/j.amjcard.2004.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2004.02.006</ArticleId><ArticleId IdType="pubmed">15178511</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunninghake DB, Ballantyne CM, Maccubbin DL, Shah AK, Gumbiner B, Mitchel YB. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clin Ther. 2003;25:1670&#x2013;1686. doi: 10.1016/S0149-2918(03)80162-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0149-2918(03)80162-5</ArticleId><ArticleId IdType="pubmed">12860491</ArticleId></ArticleIdList></Reference><Reference><Citation>Karalis DG, Ross AM, Vacari RM, Zarren H, Scott R. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol. 2002;89:667&#x2013;671. doi: 10.1016/S0002-9149(01)02337-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9149(01)02337-2</ArticleId><ArticleId IdType="pubmed">11897207</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuletic S, Riekse RG, Marcovina SM, Peskind ER, Hazzard WR, Albers JJ. Statins of Different Brain Penetrability Differentially Affect CSF PLTP Activity. Dement Geriatr Cogn Disord. 2006;22:392&#x2013;398. doi: 10.1159/000095679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000095679</ArticleId><ArticleId IdType="pubmed">16960448</ArticleId></ArticleIdList></Reference><Reference><Citation>Saheki A, Terasaki T, Tamai I, Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res. 1994;11:305&#x2013;311. doi: 10.1023/A:1018975928974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1018975928974</ArticleId><ArticleId IdType="pubmed">8165193</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57:173&#x2013;185. doi: 10.1124/pr.57.2.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.57.2.4</ArticleId><ArticleId IdType="pubmed">15914466</ArticleId></ArticleIdList></Reference><Reference><Citation>Sironi L, Gianazza E, Gelosa P, Guerrini U, Nobili E, Gianella A, Cremonesi B, Paoletti R, Tremoli E. Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects. Arterioscler Thromb Vasc Biol. 2005;25:598&#x2013;603. doi: 10.1161/01.ATV.0000157145.98200.55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.0000157145.98200.55</ArticleId><ArticleId IdType="pubmed">15681303</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108:1560&#x2013;1566. doi: 10.1161/01.CIR.0000091404.09558.AF.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000091404.09558.AF</ArticleId><ArticleId IdType="pubmed">12975259</ArticleId></ArticleIdList></Reference><Reference><Citation>Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med. 2002;162:405&#x2013;412. doi: 10.1001/archinte.162.4.405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.162.4.405</ArticleId><ArticleId IdType="pubmed">11863472</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol. 2006;97:27C&#x2013;31C. doi: 10.1016/j.amjcard.2005.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2005.12.007</ArticleId><ArticleId IdType="pubmed">16581325</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesari M, Pessina AC. Combined antihypertensive and lipid-lowering treatment. Curr Hypertens Rep. 2004;6:300&#x2013;306. doi: 10.1007/s11906-004-0025-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11906-004-0025-5</ArticleId><ArticleId IdType="pubmed">15257865</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan P, Huang TY, Tomlinson B, Lee C, Lee YS. Short-term safety and efficacy of low-dose simvastatin in elderly patients with hypertensive hypercholesterolemia and fasting hyperinsulinemia. J Clin Pharmacol. 1997;37:496&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">9208356</ArticleId></ArticleIdList></Reference><Reference><Citation>Scranton RE, Young M, Lawler E, Solomon D, Gagnon D, Gaziano JM. Statin use and fracture risk: study of a US veterans population. Arch Intern Med. 2005;165:2007&#x2013;2012. doi: 10.1001/archinte.165.17.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.165.17.2007</ArticleId><ArticleId IdType="pubmed">16186471</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. Jama. 2000;283:3211&#x2013;3216. doi: 10.1001/jama.283.24.3211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.283.24.3211</ArticleId><ArticleId IdType="pubmed">10866868</ArticleId></ArticleIdList></Reference><Reference><Citation>Marz W, Koenig W. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering? J Cardiovasc Risk. 2003;10:169&#x2013;179. doi: 10.1097/00043798-200306000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00043798-200306000-00004</ArticleId><ArticleId IdType="pubmed">12775949</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B, Mange J, Bryant R, Cordy J, Green R, McKee A. Cholesterol, Alzheimer's disease and Statins: Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neuropathol Scandanavia. 2006;185:63&#x2013;70. doi: 10.1111/j.1600-0404.2006.00687.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2006.00687.x</ArticleId><ArticleId IdType="pubmed">16866913</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17640880</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>30</Issue><PubDate><Year>2007</Year><Month>Jul</Month><Day>24</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine.</ArticleTitle><Pagination><StartPage>12506</StartPage><EndPage>12511</EndPage><MedlinePgn>12506-11</MedlinePgn></Pagination><Abstract><AbstractText>In a previous study, we found that human neural stem cells (HNSCs) exposed to high concentrations of secreted amyloid-precursor protein (sAPP) in vitro differentiated into mainly astrocytes, suggesting that pathological alterations in APP processing during neurodegenerative conditions such as Alzheimer's disease (AD) may prevent neuronal differentiation of HNSCs. Thus, successful neuroplacement therapy for AD may require regulating APP expression to favorable levels to enhance neuronal differentiation of HNSCs. Phenserine, a recently developed cholinesterase inhibitor (ChEI), has been reported to reduce APP levels in vitro and in vivo. In this study, we found reductions of APP and glial fibrillary acidic protein (GFAP) levels in the hippocampus of APP23 mice after 14 days treatment with (+)-phenserine (25 mg/kg) lacking ChEI activity. No significant change in APP gene expression was detected, suggesting that (+)-phenserine decreases APP levels and reactive astrocytes by posttranscription regulation. HNSCs transplanted into (+)-phenserine-treated APP23 mice followed by an additional 7 days of treatment with (+)-phenserine migrated and differentiated into neurons in the hippocampus and cortex after 6 weeks. Moreover, (+)-phenserine significantly increased neuronal differentiation of implanted HNSCs in hippocampal and cortical regions of APP23 mice and in the CA1 region of control mice. These results indicate that (+)-phenserine reduces APP protein in vivo and increases neuronal differentiation of HNSCs. Combination use of HNSC transplantation and treatment with drugs such as (+)-phenserine that modulate APP levels in the brain may be a useful tool for understanding mechanisms regulating stem cell migration and differentiation during neurodegenerative conditions in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marutle</LastName><ForeName>Amelia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biomolecular Sciences Center, Burnett College of Biomedical Sciences, University of Central Florida, Orlando, FL 32816, USA. amelia.marutle@ki.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohmitsu</LastName><ForeName>Masao</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Nilbratt</LastName><ForeName>Mats</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Greig</LastName><ForeName>Nigel H</ForeName><Initials>NH</Initials></Author><Author ValidYN="Y"><LastName>Nordberg</LastName><ForeName>Agneta</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sugaya</LastName><ForeName>Kiminobu</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG023472</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 23472</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005904">Glial Fibrillary Acidic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>9U1VM840SP</RegistryNumber><NameOfSubstance UI="D010830">Physostigmine</NameOfSubstance></Chemical><Chemical><RegistryNumber>SUE285UG3S</RegistryNumber><NameOfSubstance UI="C092280">phenserine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005904" MajorTopicYN="N">Glial Fibrillary Acidic Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010830" MajorTopicYN="N">Physostigmine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>1</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17640880</ArticleId><ArticleId IdType="pmc">PMC1941499</ArticleId><ArticleId IdType="doi">10.1073/pnas.0705346104</ArticleId><ArticleId IdType="pii">0705346104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sheen V, Macklis J. J Neurosci. 1995;15:8378&#x2013;8392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577948</ArticleId><ArticleId IdType="pubmed">8613770</ArticleId></ArticleIdList></Reference><Reference><Citation>Brustle O, McKay R. Curr Opin Neurobiol. 1996;6:688&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">8937835</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu T, Brannen C, Kim H, Sugaya K. NeuroReport. 2001;12:1127&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">11338178</ArticleId></ArticleIdList></Reference><Reference><Citation>Englund U, Fricker-Gates R, Lundberg C, Bjorklund A, Wictorin K. Exp Neurol. 2002;173:1&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">11771935</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Neuron. 1991;6:487&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">1673054</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller U, Cristina N, Li Z, Wolfer D, Lipp H, Rulicke T, Brandner S, Aguzzi A, Weissmann C. Cell. 1994;79:755&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">8001115</ArticleId></ArticleIdList></Reference><Reference><Citation>Salinero O, Moreno-Flores M, Wandosell F. J Neurosci Res. 2000;60:87&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">10723071</ArticleId></ArticleIdList></Reference><Reference><Citation>Caille I, Allinquant B, Dupont E, Bouillot C, Langer A, Muller U, Prochiantz A. Development (Cambridge, UK) 2004;131:2173&#x2013;2181.</Citation><ArticleIdList><ArticleId IdType="pubmed">15073156</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W. J Cell Sci. 2000;113:1857&#x2013;1870.</Citation><ArticleIdList><ArticleId IdType="pubmed">10806097</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando K, Oishi M, Takeda S, Iijima K, Isohara T, Nairn A, Kirino Y, Greengard P, Suzuki T. J Neurosci. 1999;19:4421&#x2013;4427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782598</ArticleId><ArticleId IdType="pubmed">10341243</ArticleId></ArticleIdList></Reference><Reference><Citation>Koszyca B, Blumbergs P, Manavis J, Wainwright H, James R, Gilbert J, Jones N, Reilly P. J Neurotrauma. 1998;15:675&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">9753215</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Wurtman R, Lee R. Brain Res. 2000;865:157&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">10821917</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondolfi L, Calhoun M, Ermini F, Kuhn H, Wiederhold K, Walker L, Staufenbiel M, Jucker M. J Neurosci. 2002;22:515&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758656</ArticleId><ArticleId IdType="pubmed">11784797</ArticleId></ArticleIdList></Reference><Reference><Citation>Haughey N, Nath A, Chan S, Borchard A, Rao M, Mattson M. J Neurochem. 2002;83:1509&#x2013;1524.</Citation><ArticleIdList><ArticleId IdType="pubmed">12472904</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwak YD, Brannen C, Qu T, Kim H, Dong X, Soba P, Majumdar A, Kaplan A, Beyreuther K, Sugaya K. Stem Cells Dev. 2006;15:381&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">16846375</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw K, Utsuki T, Rogers J, Yu Q, Sambamurti K, Brossi A, Ge Y, Lahiri D, Greig N. Proc Natl Acad Sci USA. 2001;98:7605&#x2013;7610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34715</ArticleId><ArticleId IdType="pubmed">11404470</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroutunian V, Greig N, Pei X, Utsuki T, Gluck R, Acevedo L, Davis KL, Wallace W. Brain Res Mol Brain Res. 1997;46:161&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">9191090</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsuki T, Yu Q, Davidson D, Chen D, Holloway H, Brossi A, Sambamurti K, Lahiri D, Greig N, Giordano T. J Pharmacol Exp Ther. 2006;318:855&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pubmed">16690718</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Staufenbiel M. Ann NY Acad Sci. 2000;920:134&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193142</ArticleId></ArticleIdList></Reference><Reference><Citation>Salbaum J, Ruddle F. J Exp Zool. 1994;269:116&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">8207383</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapp B, Hauer P. J Neurosci Res. 1994;37:538&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021975</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirazov E, Kirazov L, Bigl V, Schliebs R. Int J Dev Neurosci. 2001;19:287&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337197</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami N, Yamaki T, Iwamoto Y, Sakakibara T, Kobori N, Fushiki S, Ueda S. J Neurotrauma. 1998;15:993&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">9840772</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Hung A, Schlossmacher M, Oltersdorf T, Teplow D, Selkoe D. Ann NY Acad Sci. 1993;695:109&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">8239267</ArticleId></ArticleIdList></Reference><Reference><Citation>Bierer L, Haroutunian V, Gabriel S, Knott P, Carlin L, Purohit D, Perl D, Schmeidler J, Kanof P, Davis K. J Neurochem. 1995;64:749&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">7830069</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordberg A. Biol Psychiatry. 2001;49:200&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">11230871</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody R, Stevens J, Beck C, Dubinsky R, Kaye J, Gwyther L, Mohs RC, Thal L, Whitehouse P, DeKosky S, Cummings J. Neurology. 2001;56:1154&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">11342679</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahiri D, Farlow M, Nurnberger J, Jr, Greig N. Ann NY Acad Sci. 1997;826:416&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329715</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakaski M, Kasa P. Curr Drug Targets CNS Neurol Disord. 2003;2:163&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">12769797</ArticleId></ArticleIdList></Reference><Reference><Citation>Racchi M, Mazzucchelli M, Lenzken S, Porrello E, Lanni C, Govoni S. Chem Biol Interact. 2005;157&#x2013;158:335&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">16297899</ArticleId></ArticleIdList></Reference><Reference><Citation>Greig N, Ruckle J, Comer P, Brownell L, Holloway H, Flanagan D, Jr, Canfield C, Burford R. Curr Alzheimer Res. 2005;2:483&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">16248851</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahiri D, Lewis S, Farlow M. J Neurosci Res. 1994;37:777&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">8046778</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahiri D, Farlow M, Hintz N, Utsuki T, Greig N. Acta Neurol Scand Suppl. 2000;176:60&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">11273593</ArticleId></ArticleIdList></Reference><Reference><Citation>Gage FH. Science. 2000;287:1433&#x2013;1438.</Citation><ArticleIdList><ArticleId IdType="pubmed">10688783</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Schinder A, Christie B, Toni N, Palmer T, Gage F. Nature. 2002;415:1030&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9284568</ArticleId><ArticleId IdType="pubmed">11875571</ArticleId></ArticleIdList></Reference><Reference><Citation>Doetsch F, Alvarez-Buylla A. Proc Natl Acad Sci USA. 1996;93:14895&#x2013;14900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26233</ArticleId><ArticleId IdType="pubmed">8962152</ArticleId></ArticleIdList></Reference><Reference><Citation>Maloney B, Ge YW, Greig N, Lahiri D. FASEB J. 2004;18:1288&#x2013;1290.</Citation><ArticleIdList><ArticleId IdType="pubmed">15208260</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg S, Koo E, Selkoe D, Qiu W, Kosik K. Proc Natl Acad Sci USA. 1994;91:7104&#x2013;7108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44347</ArticleId><ArticleId IdType="pubmed">8041753</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwak YD, Choumkina E, Sugaya K. Biochem Biophys Res Commun. 2006;344:431&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">16600175</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer D, van Dijk R, Sluijs J, Nair S, Racchi M, Levelt CN, van Leeuwen F, Hol E. FASEB J. 2005;19:1451&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pubmed">16126912</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, Peel A, Mao XO, Xie L, Cottrell B, Henshall D, Greenberg D. Proc Natl Acad Sci USA. 2004;101:343&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314187</ArticleId><ArticleId IdType="pubmed">14660786</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, Galvan V, Xie L, Mao X, Gorostiza O, Bredesen D, Greenberg D. Proc Natl Acad Sci USA. 2004;101:13363&#x2013;13367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC516572</ArticleId><ArticleId IdType="pubmed">15340159</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, Xie L, Mao X, Greenberg D. Brain Res. 2006;1085:183&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">16580645</ArticleId></ArticleIdList></Reference><Reference><Citation>Atluri P, Fleck M, Shen Q, Mah S, Stadfelt D, Barnes W, Goderie S, Temple S, Schneider A. Dev Biol. 2001;240:143&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">11784052</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma W, Maric D, Li B, Hu Q, Andreadis J, Grant G, Liu Q, Shaffer K, Chang Y, Zhang L, Pancrazio J, Pant H, Stenger D, Barker J. Eur J Neurosci. 2000;12:1227&#x2013;1240.</Citation><ArticleIdList><ArticleId IdType="pubmed">10762352</ArticleId></ArticleIdList></Reference><Reference><Citation>Brannen C, Sugaya K. NeuroReport. 2000;11:1123&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">10790893</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold K, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti P, et al. Proc Natl Acad Sci USA. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun M, Burgermeister P, Phinney A, Stalder M, Tolnay M, Wiederhold K, Abramowski D, Sturchler-Pierrat C, Sommer B, Staufenbiel M, Jucker M. Proc Natl Acad Sci USA. 1999;96:14088&#x2013;14093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24195</ArticleId><ArticleId IdType="pubmed">10570203</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17646164</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>282</Volume><Issue>37</Issue><PubDate><Year>2007</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Statins reduce amyloid-beta production through inhibition of protein isoprenylation.</ArticleTitle><Pagination><StartPage>26832</StartPage><EndPage>26844</EndPage><MedlinePgn>26832-26844</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M702640200</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0021-9258(20)58754-1</ELocationID><Abstract><AbstractText>Epidemiological evidence suggests that long term treatment with hydroxymethylglutaryl-CoA reductase inhibitors, or statins, decreases the risk for developing Alzheimer disease (AD). However, statin-mediated AD protection cannot be fully explained by reduction of cholesterol levels. In addition to their cholesterol lowering effects, statins have pleiotropic actions and act to lower the concentrations of isoprenoid intermediates, such as geranylgeranyl pyrophosphate and farnesyl pyrophosphate. The Rho and Rab family small G-proteins require addition of these isoprenyl moieties at their C termini for normal GTPase function. In neuroblastoma cell lines, treatment with statins inhibits the membrane localization of Rho and Rab proteins at statin doses as low as 200 nm, without affecting cellular cholesterol levels. In addition, we show for the first time that at low, physiologically relevant, doses statins preferentially inhibit the isoprenylation of a subset of GTPases. The amyloid precursor protein (APP) is proteolytically cleaved to generate beta-amyloid (Abeta), which is the major component of senile plaques found in AD. We show that inhibition of protein isoprenylation by statins causes the accumulation of APP within the cell through inhibition of Rab family proteins involved in vesicular trafficking. Moreover, inhibition of Rho family protein function reduces levels of APP C-terminal fragments due to enhanced lysosomal dependent degradation. Statin inhibition of protein isoprenylation results in decreased Abeta secretion. In summary, we show that statins selectively inhibit GTPase isoprenylation at clinically relevant doses, leading to reduced Abeta production in an isoprenoid-dependent manner. These studies provide insight into the mechanisms by which statins may reduce AD pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ostrowski</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Case Western Reserve University, Cleveland, Ohio 44106.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilkinson</LastName><ForeName>Brandy L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Case Western Reserve University, Cleveland, Ohio 44106.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golde</LastName><ForeName>Todd E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Jacksonville, Mayo Clinic College of Medicine, Jacksonville, Florida 32224.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landreth</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Case Western Reserve University, Cleveland, Ohio 44106. Electronic address: gel2@case.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM 07250</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001427">Bacterial Toxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C029294">toxin A (Pseudomonas)</NameOfSubstance></Chemical><Chemical><RegistryNumber>9LHU78OQFD</RegistryNumber><NameOfSubstance UI="D008148">Lovastatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>AGG2FN16EV</RegistryNumber><NameOfSubstance UI="D019821">Simvastatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D020691">rab GTP-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D020741">rho GTP-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>S5UOB36OCZ</RegistryNumber><NameOfSubstance UI="D008798">Mevalonic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001427" MajorTopicYN="N">Bacterial Toxins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008148" MajorTopicYN="N">Lovastatin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008798" MajorTopicYN="N">Mevalonic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017368" MajorTopicYN="N">Protein Prenylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019821" MajorTopicYN="N">Simvastatin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020691" MajorTopicYN="N">rab GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020741" MajorTopicYN="N">rho GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17646164</ArticleId><ArticleId IdType="doi">10.1074/jbc.M702640200</ArticleId><ArticleId IdType="pii">S0021-9258(20)58754-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17664291</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0022-1007</ISSN><JournalIssue CitedMedium="Print"><Volume>204</Volume><Issue>8</Issue><PubDate><Year>2007</Year><Month>Aug</Month><Day>06</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1999</StartPage><EndPage>2008</EndPage><MedlinePgn>1999-2008</MedlinePgn></Pagination><Abstract><AbstractText>Cerebrovascular dysfunction contributes to the pathology and progression of Alzheimer's disease (AD), but the mechanisms are not completely understood. Using transgenic mouse models of AD (TgCRND8, PDAPP, and Tg2576), we evaluated blood-brain barrier damage and the role of fibrin and fibrinolysis in the progression of amyloid-beta pathology. These mouse models showed age-dependent fibrin deposition coincident with areas of blood-brain barrier permeability as demonstrated by Evans blue extravasation. Three lines of evidence suggest that fibrin contributes to the pathology. First, AD mice with only one functional plasminogen gene, and therefore with reduced fibrinolysis, have increased neurovascular damage relative to AD mice. Conversely, AD mice with only one functional fibrinogen gene have decreased blood-brain barrier damage. Second, treatment of AD mice with the plasmin inhibitor tranexamic acid aggravated pathology, whereas removal of fibrinogen from the circulation of AD mice with ancrod treatment attenuated measures of neuroinflammation and vascular pathology. Third, pretreatment with ancrod reduced the increased pathology from plasmin inhibition. These results suggest that fibrin is a mediator of inflammation and may impede the reparative process for neurovascular damage in AD. Fibrin and the mechanisms involved in its accumulation and clearance may present novel therapeutic targets in slowing the progression of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Neurobiology and Genetics, The Rockefeller University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strickland</LastName><ForeName>Sidney</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Melchor</LastName><ForeName>Jerry P</ForeName><Initials>JP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM066699</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM07739</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG020901</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM66699</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS50537</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG20901</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007739</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS050537</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>6T84R30KC1</RegistryNumber><NameOfSubstance UI="D014148">Tranexamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-31-4</RegistryNumber><NameOfSubstance UI="D005337">Fibrin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-32-5</RegistryNumber><NameOfSubstance UI="D005340">Fibrinogen</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-91-6</RegistryNumber><NameOfSubstance UI="D010958">Plasminogen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005337" MajorTopicYN="N">Fibrin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005340" MajorTopicYN="N">Fibrinogen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010539" MajorTopicYN="N">Permeability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010958" MajorTopicYN="N">Plasminogen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014148" MajorTopicYN="N">Tranexamic Acid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>2</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17664291</ArticleId><ArticleId IdType="pmc">PMC2118680</ArticleId><ArticleId IdType="doi">10.1084/jem.20070304</ArticleId><ArticleId IdType="pii">jem.20070304</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy, J., and D.J. Selkoe. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Torre, J.C. 2004. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 3:184&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">14980533</ArticleId></ArticleIdList></Reference><Reference><Citation>Farkas, E., and P.G. Luiten. 2001. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol. 64:575&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">11311463</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinters, H.V., Z.Z. Wang, and D.L. Secor. 1996. Brain parenchymal and microvascular amyloid in Alzheimer's disease. Brain Pathol. 6:179&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">8737932</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala, M., Q.N. Liu, J. Sayre, V. Pop, V. Brahmandam, M.C. Graves, and H.V. Vinters. 2002. Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. Eur. J. Clin. Invest. 32:360&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">12027877</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi, P., L. Wang, N. Seeds, J.G. McComb, S. Yamada, J.H. Griffin, P. Carmeliet, M.H. Weiss, and B.V. Zlokovic. 1999. Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler. Thromb. Vasc. Biol. 19:2801&#x2013;2806.</Citation><ArticleIdList><ArticleId IdType="pubmed">10559029</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugge, T.H., M.J. Flick, C.C. Daugherty, and J.L. Degen. 1995. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 9:794&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">7705657</ArticleId></ArticleIdList></Reference><Reference><Citation>Akassoglou, K., R.A. Adams, J. Bauer, P. Mercado, V. Tseveleki, H. Lassmann, L. Probert, and S. Strickland. 2004. Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc. Natl. Acad. Sci. USA. 101:6698&#x2013;6703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC404108</ArticleId><ArticleId IdType="pubmed">15096619</ArticleId></ArticleIdList></Reference><Reference><Citation>Busso, N., V. Peclat, K. Van Ness, E. Kolodziesczyk, J. Degen, T. Bugge, and A. So. 1998. Exacerbation of antigen-induced arthritis in urokinase-deficient mice. J. Clin. Invest. 102:41&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC509063</ArticleId><ArticleId IdType="pubmed">9649555</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledesma, M.D., J.S. Da Silva, K. Crassaerts, A. Delacourte, B. De Strooper, and C.G. Dotti. 2000. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep. 1:530&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1083779</ArticleId><ArticleId IdType="pubmed">11263499</ArticleId></ArticleIdList></Reference><Reference><Citation>Melchor, J.P., R. Pawlak, and S. Strickland. 2003. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J. Neurosci. 23:8867&#x2013;8871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740393</ArticleId><ArticleId IdType="pubmed">14523088</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudal, S., P. Krzywkowski, J. Paquette, C. Morissette, D. Lacombe, P. Tremblay, and F. Gervais. 2004. Inflammation occurs early during the Abeta deposition process in TgCRND8 mice. Neurobiol. Aging. 25:861&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">15212840</ArticleId></ArticleIdList></Reference><Reference><Citation>Yepes, M., M. Sandkvist, E.G. Moore, T.H. Bugge, D.K. Strickland, and D.A. Lawrence. 2003. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J. Clin. Invest. 112:1533&#x2013;1540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC259131</ArticleId><ArticleId IdType="pubmed">14617754</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickstein, D.L., K.E. Biron, M. Ujiie, C.G. Pfeifer, A.R. Jeffries, and W.A. Jefferies. 2006. Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease. FASEB J. 20:426&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">16507760</ArticleId></ArticleIdList></Reference><Reference><Citation>Benchenane, K., V. Berezowski, C. Ali, M. Fernandez-Monreal, J.P. Lopez-Atalaya, J. Brillault, J. Chuquet, A. Nouvelot, E.T. MacKenzie, G. Bu, et al. 2005. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation. 111:2241&#x2013;2249.</Citation><ArticleIdList><ArticleId IdType="pubmed">15851587</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldwin, H.S., H.M. Shen, H.C. Yan, H.M. DeLisser, A. Chung, C. Mickanin, T. Trask, N.E. Kirschbaum, P.J. Newman, S.M. Albelda, et al. 1994. Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31): alternatively spliced, functionally distinct isoforms expressed during mammalian cardiovascular development. Development. 120:2539&#x2013;2553.</Citation><ArticleIdList><ArticleId IdType="pubmed">7956830</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams, R.A., M. Passino, B.D. Sachs, T. Nuriel, and K. Akassoglou. 2004. Fibrin mechanisms and functions in nervous system pathology. Mol. Interv. 4:163&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">15210870</ArticleId></ArticleIdList></Reference><Reference><Citation>Akassoglou, K., K.W. Kombrinck, J.L. Degen, and S. Strickland. 2000. Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury. J. Cell Biol. 149:1157&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174825</ArticleId><ArticleId IdType="pubmed">10831618</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhart, W., G.F. Smith, J.L. Su, I. Parikh, and H. LeVine III. 1992. Amino acid sequence determination of ancrod, the thrombin-like &#x3b1;-fibrinogenase from the venom of Akistrodon rhodostoma. FEBS Lett. 297:297&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">1544412</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell, W.R., S.S. Shapiro, J. Martinez, and H.L. Nossel. 1978. The effects of ancrod, the coagulating enzyme from the venom of Malayan pit viper (A. rhodostoma) on prothrombin and fibrinogen metabolism and fibrinopeptide A release in man. J. Lab. Clin. Med. 91:592&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">641385</ArticleId></ArticleIdList></Reference><Reference><Citation>Ujiie, M., D.L. Dickstein, D.A. Carlow, and W.A. Jefferies. 2003. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation. 10:463&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">14745459</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Singh, S., D. Pirici, E. McGowan, S. Serneels, C. Ceuterick, J. Hardy, K. Duff, D. Dickson, and C. Van Broeckhoven. 2005. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am. J. Pathol. 167:527&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1603563</ArticleId><ArticleId IdType="pubmed">16049337</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, F., C. Eckman, S. Younkin, K.K. Hsiao, and C. Iadecola. 1997. Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J. Neurosci. 17:7655&#x2013;7661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793926</ArticleId><ArticleId IdType="pubmed">9315887</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouznetsova, E., M. Klingner, D. Sorger, O. Sabri, U. Grossmann, J. Steinbach, M. Scheunemann, and R. Schliebs. 2006. Developmental and amyloid plaque-related changes in cerebral cortical capillaries in transgenic Tg2576 Alzheimer mice. Int. J. Dev. Neurosci. 24:187&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">16423498</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass, C., E.H. Koo, A. Mellon, A.Y. Hung, and D.J. Selkoe. 1992. Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature. 357:500&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">1608449</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanc, E.M., M. Toborek, R.J. Mark, B. Hennig, and M.P. Mattson. 1997. Amyloid beta-peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces apoptosis in vascular endothelial cells. J. Neurochem. 68:1870&#x2013;1881.</Citation><ArticleIdList><ArticleId IdType="pubmed">9109512</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutton, E.T., G.R. Hellermann, and T. Thomas. 1997. &#x3b2;-Amyloid-induced endothelial necrosis and inhibition of nitric oxide production. Exp. Cell Res. 230:368&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">9024796</ArticleId></ArticleIdList></Reference><Reference><Citation>Hase, M., S. Araki, and H. Hayashi. 1997. Fragments of amyloid beta induce apoptosis in vascular endothelial cells. Endothelium. 5:221&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">9588814</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas, T., C. McLendon, E.T. Sutton, and G. Thomas. 1997. &#x3b2;-Amyloid-induced cerebrovascular endothelial dysfunction. Ann. N. Y. Acad. Sci. 826:447&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329721</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas, T., G. Thomas, C. McLendon, T. Sutton, and M. Mullan. 1996. &#x3b2;-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 380:168&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">8600393</ArticleId></ArticleIdList></Reference><Reference><Citation>Melchor, J.P., and W.E. Van Nostrand. 2000. Fibrillar amyloid beta-protein mediates the pathologic accumulation of its secreted precursor in human cerebrovascular smooth muscle cells. J. Biol. Chem. 275:9782&#x2013;9791.</Citation><ArticleIdList><ArticleId IdType="pubmed">10734132</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutton, R., M.E. Keohane, S.R. VanderBerg, and S.L. Gonias. 1994. Plasminogen activator inhibitor-1 in the cerebrospinal fluid as an index of neurological disease. Blood Coagul. Fibrinolysis. 5:167&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">8054448</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring, M.A., W. Farris, A.Y. Chang, D.M. Walsh, X. Wu, X. Sun, M.P. Frosch, and D.J. Selkoe. 2003. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 40:1087&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687544</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe, D.J. 2001. Clearing the brain's amyloid cobwebs. Neuron. 32:177&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">11683988</ArticleId></ArticleIdList></Reference><Reference><Citation>Ploplis, V.A., P. Carmeliet, S. Vazirzadeh, I. Van Vlaenderen, L. Moons, E.F. Plow, and D. Collen. 1995. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation. 92:2585&#x2013;2593.</Citation><ArticleIdList><ArticleId IdType="pubmed">7586361</ArticleId></ArticleIdList></Reference><Reference><Citation>Degen, J.L., A.F. Drew, J.S. Palumbo, K.W. Kombrinck, J.A. Bezerra, M.J. Danton, K. Holmback, and T.T. Suh. 2001. Genetic manipulation of fibrinogen and fibrinolysis in mice. Ann. N. Y. Acad. Sci. 936:276&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">11460484</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarova, T.P., and V.P. Yakubenko. 2001. Recognition of fibrinogen by leukocyte integrins. Ann. N. Y. Acad. Sci. 936:368&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">11460493</ArticleId></ArticleIdList></Reference><Reference><Citation>Flick, M.J., X. Du, D.P. Witte, M. Jirouskova, D.A. Soloviev, S.J. Busuttil, E.F. Plow, and J.L. Degen. 2004. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J. Clin. Invest. 113:1596&#x2013;1606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419487</ArticleId><ArticleId IdType="pubmed">15173886</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez, R.L., J.D. Ritzenthaler, and J. Roman. 1999. Transcriptional regulation of the interleukin-1beta promoter via fibrinogen engagement of the CD18 integrin receptor. Am. J. Respir. Cell Mol. Biol. 20:1059&#x2013;1066.</Citation><ArticleIdList><ArticleId IdType="pubmed">10226077</ArticleId></ArticleIdList></Reference><Reference><Citation>Koistinaho, M., and J. Koistinaho. 2005. Interactions between Alzheimer's disease and cerebral ischemia&#x2014;focus on inflammation. Brain Res. Brain Res. Rev. 48:240&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">15850663</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer, P.L., M. Schulzer, and E.G. McGeer. 1996. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 47:425&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">8757015</ArticleId></ArticleIdList></Reference><Reference><Citation>Yenari, M.A., L. Xu, X.N. Tang, Y. Qiao, and R.G. Giffard. 2006. Microglia potentiate damage to blood-brain barrier constituents: improvement by minocycline in vivo and in vitro. Stroke. 37:1087&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">16497985</ArticleId></ArticleIdList></Reference><Reference><Citation>Grammas, P., U. Reimann-Philipp, and P.H. Weigel. 2000. Cerebro vasculature-mediated neuronal cell death. Ann. N. Y. Acad. Sci. 903:55&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">10818489</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, D.Y., K.W. Park, and B.K. Jin. 2006. Thrombin induces neuro degeneration and microglial activation in the cortex in vivo and in vitro: proteolytic and non-proteolytic actions. Biochem. Biophys. Res. Commun. 346:727&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">16777064</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipser, B.D., C.E. Johanson, L. Gonzalez, T.M. Berzin, R. Tavares, C.M. Hulette, M.P. Vitek, V. Hovanesian, and E.G. Stopa. 2007. Micro vascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol. Aging. 28:977&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pubmed">16782234</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie, B., and B.C. Furie. 1988. The molecular basis of blood coagulation. Cell. 53:505&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">3286010</ArticleId></ArticleIdList></Reference><Reference><Citation>Jirouskova, M., S.S. Smyth, B. Kudryk, and B.S. Coller. 2001. A hamster antibody to the mouse fibrinogen gamma chain inhibits platelet-fibrinogen interactions and FXIIIa-mediated fibrin cross-linking, and facilitates thrombolysis. Thromb. Haemost. 86:1047&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">11686323</ArticleId></ArticleIdList></Reference><Reference><Citation>Akassoglou, K., W.M. Yu, P. Akpinar, and S. Strickland. 2002. Fibrin inhibits peripheral nerve remyelination by regulating Schwann cell differentiation. Neuron. 33:861&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pubmed">11906694</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao, K., P. Chapman, S. Nilsen, C. Eckman, Y. Harigaya, S. Younkin, F. Yang, and G. Cole. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Chishti, M.A., D.S. Yang, C. Janus, A.L. Phinney, P. Horne, J. Pearson, R. Strome, N. Zuker, J. Loukides, J. French, et al. 2001. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276:21562&#x2013;21570.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279122</ArticleId></ArticleIdList></Reference><Reference><Citation>Games, D., D. Adams, R. Alessandrini, R. Barbour, P. Berthelette, C. Blackwell, T. Carr, J. Clemens, T. Donaldson, F. Gillespie, et al. 1995. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh, T.T., K. Holmback, N.J. Jensen, C.C. Daugherty, K. Small, D.I. Simon, S. Potter, and J.L. Degen. 1995. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 9:2020&#x2013;2033.</Citation><ArticleIdList><ArticleId IdType="pubmed">7649481</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris, D.C., Z. Zhang, K. Davies, J. Fenstermacher, and M. Chopp. 1999. High resolution quantitation of microvascular plasma perfusion in non-ischemic and ischemic rat brain by laser-scanning confocal microscopy. Brain Res. Brain Res. Protoc. 4:185&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">10446413</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmued, L.C., and K.J. Hopkins. 2000. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res. 874:123&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">10960596</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17664405</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>Jul</Month><Day>31</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Donepezil preserves cognition and global function in patients with severe Alzheimer disease.</ArticleTitle><Pagination><StartPage>459</StartPage><EndPage>469</EndPage><MedlinePgn>459-69</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the efficacy and safety of donepezil for severe Alzheimer disease (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with severe AD (Mini-Mental State Examination [MMSE] scores 1 to 12 and Functional Assessment Staging [FAST] scores &gt; or =6) were enrolled in this multinational, double-blind, placebo-controlled trial at 98 sites. Patients were randomized to donepezil 10 mg daily or placebo for 24 weeks. Primary endpoints were the Severe Impairment Battery (SIB) and Clinician's Interview-Based Impression of Change-Plus caregiver input (CIBIC-Plus). Secondary endpoints included the MMSE, the Alzheimer Disease Cooperative Study-Activities of Daily Living-severe version (ADCS-ADL-sev), the Neuropsychiatric Inventory (NPI), the Caregiver Burden Questionnaire (CBQ), and the Resource Utilization for Severe Alzheimer Disease Patients (RUSP). Efficacy analyses were performed in the intent-to-treat (ITT) population using last post-baseline observation carried forward (LOCF). Safety assessments were performed for patients receiving &gt; or =1 dose of donepezil or placebo.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients were randomized to donepezil (n = 176) or placebo (n = 167). Donepezil was superior to placebo on SIB score change from baseline to endpoint (least squares mean difference 5.32; p = 0.0001). CIBIC-Plus and MMSE scores favored donepezil at endpoint (p = 0.0473 and p = 0.0267). Donepezil was not significantly different from placebo on the ADCS-ADL-sev, NPI, CBQ, or RUSP. Adverse events reported were consistent with the known cholinergic effects of donepezil and with the safety profile in patients with mild to moderate AD.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients with severe AD demonstrated greater efficacy compared to placebo on measures of cognition and global function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Black</LastName><ForeName>S E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine and Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada. sandra.black@sunnybrook.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doody</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>McRae</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Jambor</LastName><ForeName>K M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Perdomo</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17664405</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000266627.96040.5a</ArticleId><ArticleId IdType="pii">69/5/459</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17686982</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>33</Issue><PubDate><Year>2007</Year><Month>Aug</Month><Day>14</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Engineering metal ion coordination to regulate amyloid fibril assembly and toxicity.</ArticleTitle><Pagination><StartPage>13313</StartPage><EndPage>13318</EndPage><MedlinePgn>13313-8</MedlinePgn></Pagination><Abstract><AbstractText>Protein and peptide assembly into amyloid has been implicated in functions that range from beneficial epigenetic controls to pathological etiologies. However, the exact structures of the assemblies that regulate biological activity remain poorly defined. We have previously used Zn(2+) to modulate the assembly kinetics and morphology of congeners of the amyloid beta peptide (Abeta) associated with Alzheimer's disease. We now reveal a correlation among Abeta-Cu(2+) coordination, peptide self-assembly, and neuronal viability. By using the central segment of Abeta, HHQKLVFFA or Abeta(13-21), which contains residues H13 and H14 implicated in Abeta-metal ion binding, we show that Cu(2+) forms complexes with Abeta(13-21) and its K16A mutant and that the complexes, which do not self-assemble into fibrils, have structures similar to those found for the human prion protein, PrP. N-terminal acetylation and H14A substitution, Ac-Abeta(13-21)H14A, alters metal coordination, allowing Cu(2+) to accelerate assembly into neurotoxic fibrils. These results establish that the N-terminal region of Abeta can access different metal-ion-coordination environments and that different complexes can lead to profound changes in Abeta self-assembly kinetics, morphology, and toxicity. Related metal-ion coordination may be critical to the etiology of other neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Jijun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Emory University, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canfield</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Anil K</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>Shokes</LastName><ForeName>Jacob E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Bo</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Childers</LastName><ForeName>W Seth</ForeName><Initials>WS</Initials></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>James A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Zixu</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Warncke</LastName><ForeName>Kurt</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Lynn</LastName><ForeName>David G</ForeName><Initials>DG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG023695</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS048254</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM42025</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM042025</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG023695</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS048254</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>08</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008670">Metals</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004578" MajorTopicYN="N">Electron Spin Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008670" MajorTopicYN="N">Metals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018625" MajorTopicYN="N">Microscopy, Atomic Force</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013056" MajorTopicYN="N">Spectrophotometry, Ultraviolet</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>2</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17686982</ArticleId><ArticleId IdType="pmc">PMC1948904</ArticleId><ArticleId IdType="doi">10.1073/pnas.0702669104</ArticleId><ArticleId IdType="pii">0702669104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carrell RW, Lomas DA. Lancet. 1997;350:134&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">9228977</ArticleId></ArticleIdList></Reference><Reference><Citation>Patino MM, Liu JJ, Glover JR, Lindquist S. Science. 1996;273:622&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">8662547</ArticleId></ArticleIdList></Reference><Reference><Citation>Si K, Giustetto M, Etkin A, Hsu R, Janisiewicz AM, Miniaci MC, Kim JH, Zhu H, Kandel ER. Cell. 2003;115:893&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">14697206</ArticleId></ArticleIdList></Reference><Reference><Citation>Si K, Lindquist S, Kandel ER. Cell. 2003;115:879&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">14697205</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson CM. Nature. 2003;426:884&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">14685248</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheibel T, Parthasarathy R, Sawicki G, Lin XM, Jaeger H, Lindquist SL. Proc Natl Acad Sci USA. 2003;100:4527&#x2013;4532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC153589</ArticleId><ArticleId IdType="pubmed">12672964</ArticleId></ArticleIdList></Reference><Reference><Citation>Reches M, Gazit E. Science. 2003;300:625&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">12714741</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva GA, Czeisler C, Niece KL, Beniash E, Harrington DA, Kessler JA, Stupp SI. Science. 2004;303:1352&#x2013;1355.</Citation><ArticleIdList><ArticleId IdType="pubmed">14739465</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush AI, Pettingell WH, Multhaup G, Paradis MD, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE. Science. 1994;265:1464&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pubmed">8073293</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush AI, Multhaup G, Moir RD, Williamson TG, Small DH, Rumble B, Pollwein P, Beyreuther K, Masters CL. J Biol Chem. 1993;268:16109&#x2013;16112.</Citation><ArticleIdList><ArticleId IdType="pubmed">8344894</ArticleId></ArticleIdList></Reference><Reference><Citation>Syme CD, Nadal RC, Rigby SE, Viles JH. J Biol Chem. 2004;279:18169&#x2013;18177.</Citation><ArticleIdList><ArticleId IdType="pubmed">14978032</ArticleId></ArticleIdList></Reference><Reference><Citation>Atwood CS, Moir RD, Huang XD, Scarpa RC, Bacarra NME, Romano DM, Hartshorn MK, Tanzi RE, Bush AI. J Biol Chem. 1998;273:12817&#x2013;12826.</Citation><ArticleIdList><ArticleId IdType="pubmed">9582309</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtain CC, Ali F, Volitakis I, Cherny RA, Norton RS, Beyreuther K, Barrow CJ, Masters CL, Bush AI, Barnham KJ. J Biol Chem. 2001;276:20466&#x2013;20473.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274207</ArticleId></ArticleIdList></Reference><Reference><Citation>Miura T, Suzuki K, Kohata N, Takeuchi H. Biochemistry. 2000;39:7024&#x2013;7031.</Citation><ArticleIdList><ArticleId IdType="pubmed">10841784</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu ST, Howlett G, Barrow CJ. Biochemistry. 1999;38:9373&#x2013;9378.</Citation><ArticleIdList><ArticleId IdType="pubmed">10413512</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang DS, McLaurin J, Qin K, Westaway D, Fraser PE. Eur J Biochem. 2000;267:6692&#x2013;6698.</Citation><ArticleIdList><ArticleId IdType="pubmed">11054124</ArticleId></ArticleIdList></Reference><Reference><Citation>Atwood CS, Scarpa RC, Huang XD, Moir RD, Jones WD, Fairlie DP, Tanzi RE, Bush AI. J Neurochem. 2000;75:1219&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pubmed">10936205</ArticleId></ArticleIdList></Reference><Reference><Citation>Stellato F, Menestrina G, Dalla Serra M, Potrich C, Tomazzolli R, Meyer-Klaucke W, Morante S. Eur Biophys J. 2006;35:340&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">16404590</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan DM, Dong J, Jacob J, Lu K, Apkarian RP, Thiyagarajan P, Lynn DG. J Am Chem Soc. 2002;124:12644&#x2013;12645.</Citation><ArticleIdList><ArticleId IdType="pubmed">12392395</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu K, Jacob J, Thiyagarajan P, Conticello VP, Lynn DG. J Am Chem Soc. 2003;125:6391&#x2013;6393.</Citation><ArticleIdList><ArticleId IdType="pubmed">12785778</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzinger TLS, Gregory DM, Burkoth TS, Miller-Auer H, Lynn DG, Botto RE, Meredith SC. Proc Natl Acad Sci USA. 1998;95:13407&#x2013;13412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24832</ArticleId><ArticleId IdType="pubmed">9811813</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong J, Shokes JE, Scott RA, Lynn DG. J Am Chem Soc. 2006;128:3540&#x2013;3542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555692</ArticleId><ArticleId IdType="pubmed">16536526</ArticleId></ArticleIdList></Reference><Reference><Citation>Karr JW, Kaupp LJ, Szalai VA. J Am Chem Soc. 2004;126:13534&#x2013;13538.</Citation><ArticleIdList><ArticleId IdType="pubmed">15479110</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou J, Kajita K, Sugimoto N. Angew Chem Int Ed Engl. 2001;40:2274&#x2013;2277.</Citation><ArticleIdList><ArticleId IdType="pubmed">11433492</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K, Miura T, Takeuchi H. Biochem Biophys Res Commun. 2001;285:991&#x2013;996.</Citation><ArticleIdList><ArticleId IdType="pubmed">11467850</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R. Science. 2005;307:262&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653506</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigel H, Martin RB. Chem Rev. 1982;82:385&#x2013;426.</Citation></Reference><Reference><Citation>Daniele PG, Prenesti E, Ostacoli G. J Chem Soc Dalton. 1996:3269&#x2013;3275.</Citation></Reference><Reference><Citation>Peisach J, Blumberg WE. Arch Biochem Biophys. 1974;165:691&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">4374138</ArticleId></ArticleIdList></Reference><Reference><Citation>Mims WB, Peisach J. J Chem Phys. 1978;69:4921&#x2013;4930.</Citation></Reference><Reference><Citation>Flanagan HL, Singel DJ. J Chem Phys. 1987;87:5606&#x2013;5616.</Citation></Reference><Reference><Citation>Lucken EAC. Nuclear Quadrupole Coupling Constants. London: Academic; 1969.</Citation></Reference><Reference><Citation>Jiang F, McCracken J, Peisach J. J Am Chem Soc. 1990;112:9035&#x2013;9044.</Citation></Reference><Reference><Citation>Stanczak P, Valensin D, Juszczyk P, Grzonka Z, Migliorini C, Molteni E, Valensin G, Gaggelli E, Kozlowski H. Biochemistry. 2005;44:12940&#x2013;12954.</Citation><ArticleIdList><ArticleId IdType="pubmed">16185063</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowalik-Jankowska T, Ruta M, Wisniewska K, Lankiewicz L. J Inorg Biochem. 2003;95:270&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">12818797</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown DR, Guantieri V, Grasso G, Impellizzeri G, Pappalardo G, Rizzarelli E. J Inorg Biochem. 2004;98:133&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">14659642</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundberg RJ, Martin RB. Chem Rev. 1974;74:471&#x2013;517.</Citation></Reference><Reference><Citation>Nakanishi K, Nina E, Woody RW. Circular Dichroism: Principles and Applications. New York: Wiley&#x2013;VCH; 1994. p. 223.</Citation></Reference><Reference><Citation>Tsangaris JM, Martin RB. J Am Chem Soc. 1970;92:4255&#x2013;4260.</Citation><ArticleIdList><ArticleId IdType="pubmed">5428384</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabian H, Szendrei GI, Mantsch HH, Otvos L., Jr Biochem Biophys Res Commun. 1993;191:232&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">8447825</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu K. Atlanta: Emory Univ; 2005. PhD dissertation.</Citation></Reference><Reference><Citation>Paul C, Axelsen PH. J Am Chem Soc. 2005;127:5754&#x2013;5755.</Citation><ArticleIdList><ArticleId IdType="pubmed">15839650</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiramatsu H, Goto Y, Naiki H, Kitagawa T. J Am Chem Soc. 2005;127:7988&#x2013;7989.</Citation><ArticleIdList><ArticleId IdType="pubmed">15926803</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansbury PT, Jr, Costa PR, Griffiths JM, Simon EJ, Auger M, Halverson KJ, Kocisko DA, Hendsch ZS, Ashburn TT, Spencer RG, et al. Nat Struct Biol. 1995;2:990&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pubmed">7583673</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva RA, Barber-Armstrong W, Decatur SM. J Am Chem Soc. 2003;125:13674&#x2013;13675.</Citation><ArticleIdList><ArticleId IdType="pubmed">14599201</ArticleId></ArticleIdList></Reference><Reference><Citation>Brauner JW, Dugan C, Mendelsohn R. J Am Chem Soc. 2000;122:677&#x2013;683.</Citation></Reference><Reference><Citation>McCracken J, Pember S, Benkovic SJ, Villafranca JJ, Miller RJ, Peisach J. J Am Chem Soc. 1988;110:1069&#x2013;1074.</Citation></Reference><Reference><Citation>Mao Z, Bonni A, Xia F, Nadal-Vicens M, Greenberg ME. Science. 1999;286:785&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531066</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong X, Tang X, Wiedmann M, Wang X, Peng J, Zheng D, Blair LA, Marshall J, Mao Z. Neuron. 2003;38:33&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">12691662</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang X, Wang X, Gong X, Tong M, Park D, Xia Z, Mao Z. J Neurosci. 2005;25:4823&#x2013;4834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724765</ArticleId><ArticleId IdType="pubmed">15888658</ArticleId></ArticleIdList></Reference><Reference><Citation>Karr JW, Akintoye H, Kaupp LJ, Szalai VA. Biochemistry. 2005;44:5478&#x2013;5487.</Citation><ArticleIdList><ArticleId IdType="pubmed">15807541</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozin SA, Zirah S, Rebuffat S, Hoa GH, Debey P. Biochem Biophys Res Commun. 2001;285:959&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pubmed">11467845</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozlowski H, Bal W, Dyba M, Kowalik-Jankowska T. 1999;184:319&#x2013;346.</Citation></Reference><Reference><Citation>Bruni S, Cariati F, Daniele PG, Prenesti E. Spectrochim Acta A. 2000;56:815&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pubmed">10794455</ArticleId></ArticleIdList></Reference><Reference><Citation>Conato C, Gavioli R, Guerrini R, Kozlowski H, Mlynarz P, Pasti C, Pulidori F, Remelli M. Biochim Biophys Acta. 2001;1526:199&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">11325542</ArticleId></ArticleIdList></Reference><Reference><Citation>Livera CE, Pettit LD, Bataille M, Perly B, Kozlowski H, Radomska B. J Chem Soc Dalton. 1987:661&#x2013;666.</Citation></Reference><Reference><Citation>Kowalik-Jankowska T, Ruta-Dolejsz M, Wisniewska K, Lankiewicz L, Kozlowski H. J Chem Soc Dalton. 2000:4511&#x2013;4519.</Citation></Reference><Reference><Citation>Kowalik-Jankowska T, Ruta-Dolejsz M, Wisniewska K, Lankiewicz L. J Inorg Biochem. 2002;92:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">12230982</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkoth TS, Benzinger TLS, Urban V, Morgan DM, Gregory DM, Thiyagarajan P, Botto RE, Meredith SC, Lynn DG. J Am Chem Soc. 2000;122:7883&#x2013;7889.</Citation></Reference><Reference><Citation>Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R. Proc Natl Acad Sci USA. 2002;99:16742&#x2013;16747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC139214</ArticleId><ArticleId IdType="pubmed">12481027</ArticleId></ArticleIdList></Reference><Reference><Citation>Donne DG, Viles JH, Groth D, Mehlhorn I, James TL, Cohen FE, Prusiner SB, Wright PE, Dyson HJ. Proc Natl Acad Sci USA. 1997;94:13452&#x2013;13457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28326</ArticleId><ArticleId IdType="pubmed">9391046</ArticleId></ArticleIdList></Reference><Reference><Citation>James TL, Liu H, Ulyanov NB, Farr-Jones S, Zhang H, Donne DG, Kaneko K, Groth D, Mehlhorn I, Prusiner SB, et al. Proc Natl Acad Sci USA. 1997;94:10086&#x2013;10091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23313</ArticleId><ArticleId IdType="pubmed">9294167</ArticleId></ArticleIdList></Reference><Reference><Citation>Millhauser GL. Acc Chem Res. 2004;37:79&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2907897</ArticleId><ArticleId IdType="pubmed">14967054</ArticleId></ArticleIdList></Reference><Reference><Citation>Chattopadhyay M, Walter ED, Newell DJ, Jackson PJ, Aronoff-Spencer E, Peisach J, Gerfen GJ, Bennett B, Antholine WE, Millhauser GL. J Am Chem Soc. 2005;127:12647&#x2013;12656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909831</ArticleId><ArticleId IdType="pubmed">16144413</ArticleId></ArticleIdList></Reference><Reference><Citation>Morante S, Gonzalez-Iglesias R, Potrich C, Meneghini C, Meyer-Klaucke W, Menestrina G, Gasset M. J Biol Chem. 2004;279:11753&#x2013;11759.</Citation><ArticleIdList><ArticleId IdType="pubmed">14703517</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasia RM, Bertoncini CW, Marsh D, Hoyer W, Cherny D, Zweckstetter M, Griesinger C, Jovin TM, Fernandez CO. Proc Natl Acad Sci USA. 2005;102:4294&#x2013;4299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC555498</ArticleId><ArticleId IdType="pubmed">15767574</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonyuk S, Elam JS, Hough MA, Strange RW, Doucette PA, Rodriguez JA, Hayward LJ, Valentine JS, Hart PJ, Hasnain SS. Protein Sci. 2005;14:1201&#x2013;1213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2253262</ArticleId><ArticleId IdType="pubmed">15840828</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentine JS, Hart PJ. Proc Natl Acad Sci USA. 2003;100:3617&#x2013;3622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC152971</ArticleId><ArticleId IdType="pubmed">12655070</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, Li L. J Biol Chem. 2005;280:11648&#x2013;11655.</Citation><ArticleIdList><ArticleId IdType="pubmed">15659387</ArticleId></ArticleIdList></Reference><Reference><Citation>Canfield JM, Warncke K. J Phys Chem B. 2002;106:8831&#x2013;8841.</Citation></Reference><Reference><Citation>Canfield JM, Warncke K. J Phys Chem B. 2005;109:3053&#x2013;3064.</Citation><ArticleIdList><ArticleId IdType="pubmed">16851320</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17687027</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>32</Issue><PubDate><Year>2007</Year><Month>Aug</Month><Day>08</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Effects of Alzheimer's disease on different cortical layers: the role of intrinsic differences in Abeta susceptibility.</ArticleTitle><Pagination><StartPage>8496</StartPage><EndPage>8504</EndPage><MedlinePgn>8496-504</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease is late life dementia associated with significant neurodegeneration in both cortical and subcortical regions. During the approximately 10 year course of the disease, neurons are lost in a progressive pattern that is relatively consistent among individuals. One example of this is the progression of disease pathology found in both the neocortex and archicortex. In these structures, the earliest problems can be found in superficial cortical layers (II-IV), whereas later the disease advances to involve the deeper cortical layers (V-VI). It is unclear whether these apparent differences in sensitivity are intrinsic to the neurons or imposed by external factors such as the pattern of connections. We used beta-amyloid (Abeta) peptide treatment of cultured mouse neurons as our model system. We show first that, as in hippocampus, dissociated cultures of embryonic cortical neurons are biased toward the survival of cells that were finishing division in the ventricular zone at the time of harvest. Thus, embryonic day 13.5 (E13.5) cultures contain primarily deep-layer neurons whereas E16.5 cultures contain cells destined for upper layers. We use this cell-type specific segregation to our advantage and show, using both differences in gene expression profiles and Abeta survival curves, that deeper layer neurons are significantly more resistant to the toxic effects of Abeta than are cells from the more superficial strata. This suggests that an intrinsic underlying biology drives at least part of the AD progression pattern and that the time of harvest is a crucial variable in the interpretation of any cortical culture experiment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Romito-DiGiacomo</LastName><ForeName>Rita R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Alzheimer Research Laboratory, Case School of Medicine, Cleveland, Ohio 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menegay</LastName><ForeName>Harry</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Cicero</LastName><ForeName>Samantha A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Herrup</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS020591</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS20591</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>2</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17687027</ArticleId><ArticleId IdType="pmc">PMC6672937</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1008-07.2007</ArticleId><ArticleId IdType="pii">27/32/8496</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anderson S, Mione M, Yun K, Rubenstein JL. Differential origins of neocortical projection and local circuit neurons: role of Dlx genes in neocortical interneuronogenesis. Cereb Cortex. 1999;9:646&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498283</ArticleId></ArticleIdList></Reference><Reference><Citation>Banker GA, Cowan WM. Rat hippocampal neurons in dispersed cell culture. Brain Res. 1977;126:397&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">861729</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulfone A, Smiga SM, Shimamura K, Peterson A, Puelles L, Rubenstein JL. T-brain-1: a homolog of Brachyury whose expression defines molecularly distinct domains within the cerebral cortex. Neuron. 1995;15:63&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">7619531</ArticleId></ArticleIdList></Reference><Reference><Citation>Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci. 2004;24:10908&#x2013;10917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730204</ArticleId><ArticleId IdType="pubmed">15574741</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicero S, Herrup K. Cyclin-dependent kinase 5 is essential for neuronal cell cycle arrest and differentiation. J Neurosci. 2005;25:9658&#x2013;9668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725732</ArticleId><ArticleId IdType="pubmed">16237170</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs CK, Bates P, Karlo JC, Landreth GE. Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha. Neurochem Int. 2001;39:449&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11578780</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Price JL, McKeel DW, Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996;16:4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;225:1168&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">6474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavdas AA, Grigoriou M, Pachnis V, Parnavelas JG. The medial ganglionic eminence gives rise to a population of early neurons in the developing cerebral cortex. J Neurosci. 1999;19:7881&#x2013;7888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782477</ArticleId><ArticleId IdType="pubmed">10479690</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, Gabriel C, Nelson DA, White E, Mackenzie ET, Vivien D, Buisson A. Akt-dependent expression of NAIP-1 protects neurons against amyloid-beta toxicity. J Biol Chem. 2005;280:24941&#x2013;24947.</Citation><ArticleIdList><ArticleId IdType="pubmed">15797869</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippa C, Hamos J, Pulaski-Salo D. Alzheimer's disease and aging: effects on perforant pathway perikarya and synapses. Neurobiol Aging. 1992;13:405&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">1625770</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa Y, O'Leary DD. Dynamic patterned expression of orphan nuclear receptor genes RORalpha and RORbeta in developing mouse forebrain. Dev Neurosci. 2003;25:234&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">12966220</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson RC, Esiri MM, Hiorns RW, Wilcock GK, Powell TP. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc Natl Acad Sci USA. 1985;82:4531&#x2013;4534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC391136</ArticleId><ArticleId IdType="pubmed">3859874</ArticleId></ArticleIdList></Reference><Reference><Citation>Raetzman LT, Siegel RE. Immature granule neurons from cerebella of different ages exhibit distinct developmental potentials. J Neurobiol. 1999;38:559&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">10084689</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubenstein JL, Anderson S, Shi L, Miyashita-Lin E, Bulfone A, Hevner R. Genetic control of cortical regionalization and connectivity. Cereb Cortex. 1999;9:524&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498270</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T, Nowakowski RS, Caviness VS., Jr Cell cycle parameters and patterns of nuclear movement in the neocortical proliferative zone of the fetal mouse. J Neurosci. 1993;13:820&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576626</ArticleId><ArticleId IdType="pubmed">8426239</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T, Nowakowski RS, Caviness VS., Jr The cell cycle of the pseudostratified ventricular epithelium of the embryonic murine cerebral wall. J Neurosci. 1995;15:6046&#x2013;6057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577667</ArticleId><ArticleId IdType="pubmed">7666188</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T, Goto T, Miyama S, Nowakowski RS, Caviness VS., Jr Sequence of neuron origin and neocortical laminar fate: relation to cell cycle of origin in the developing murine cerebral wall. J Neurosci. 1999;19:10357&#x2013;10371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782435</ArticleId><ArticleId IdType="pubmed">10575033</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasilewska-Sampaio AP, Silveira MS, Holub O, Goecking R, Gomes FC, Neto VM, Linden R, Ferreira ST, De Felice FG. Neuritogenesis and neuronal differentiation promoted by 2,4-dinitrophenol, a novel anti-amyloidogenic compound. Faseb J. 2005;19:1627&#x2013;1636.</Citation><ArticleIdList><ArticleId IdType="pubmed">16195371</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17694066</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-8956</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>9</Issue><PubDate><Year>2007</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Clearance of amyloid-beta by circulating lipoprotein receptors.</ArticleTitle><Pagination><StartPage>1029</StartPage><EndPage>1031</EndPage><MedlinePgn>1029-31</MedlinePgn></Pagination><Abstract><AbstractText>Low-density lipoprotein receptor-related protein-1 (LRP) on brain capillaries clears amyloid beta-peptide (Abeta) from brain. Here, we show that soluble circulating LRP (sLRP) provides key endogenous peripheral 'sink' activity for Abeta in humans. Recombinant LRP cluster IV (LRP-IV) bound Abeta in plasma in mice and Alzheimer's disease-affected humans with compromised sLRP-mediated Abeta binding, and reduced Abeta-related pathology and dysfunction in a mouse model of Alzheimer disease, suggesting that LRP-IV can effectively replace native sLRP and clear Abeta.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sagare</LastName><ForeName>Abhay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Frank P. Smith Laboratory for Neuroscience and Neurosurgical Research, Department of Neurosurgery, University of Rochester Medical School, Rochester, New York 14642, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deane</LastName><ForeName>Rashid</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Bradley</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Hamm</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Pendu</LastName><ForeName>Ronan</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Marky</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lenting</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Zhenhua</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Zarcone</LastName><ForeName>Troy</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mayo</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Perlmutter</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Coma</LastName><ForeName>Mireia</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Zhihui</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Zlokovic</LastName><ForeName>Berislav V</ForeName><Initials>BV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 NS34467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG023084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026503">Low Density Lipoprotein Receptor-Related Protein-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002196" MajorTopicYN="N">Capillaries</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026503" MajorTopicYN="N">Low Density Lipoprotein Receptor-Related Protein-1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17694066</ArticleId><ArticleId IdType="mid">NIHMS208301</ArticleId><ArticleId IdType="pmc">PMC2936449</ArticleId><ArticleId IdType="doi">10.1038/nm1635</ArticleId><ArticleId IdType="pii">nm1635</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shibata M, et al. J. Clin. Invest. 2000;106:1489&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC387254</ArticleId><ArticleId IdType="pubmed">11120756</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, et al. Neuron. 2004;43:333&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294142</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Moir RD, Wagner SL. Neuron. 2004;43:605&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">15339642</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, et al. J. Cereb. Blood Flow Metab. 2007;27:909&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853021</ArticleId><ArticleId IdType="pubmed">17077814</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaki C, et al. Pharm. Res. 2006;23:1407&#x2013;1416.</Citation><ArticleIdList><ArticleId IdType="pubmed">16779710</ArticleId></ArticleIdList></Reference><Reference><Citation>von Arnim CAF, et al. J. Biol. Chem. 2005;280:17777&#x2013;17785.</Citation><ArticleIdList><ArticleId IdType="pubmed">15749709</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn KA, et al. J. Biol. Chem. 1997;272:23946&#x2013;23951.</Citation><ArticleIdList><ArticleId IdType="pubmed">9295345</ArticleId></ArticleIdList></Reference><Reference><Citation>Westein E, Denis CV, Bouma BN, Lenting PJ. J. Biol. Chem. 2002;277:2511&#x2013;2516.</Citation><ArticleIdList><ArticleId IdType="pubmed">11705989</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane Rq, et al. Nat. Med. 2003;9:907&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808450</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbinatti CV, Bu GJ. Rev. Neurosci. 2005;16:123&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">15959937</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen GA, et al. J. Mol. Biol. 2006;362:700&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">16938309</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Singh S, et al. Am. J. Pathol. 2005;167:527&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1603563</ArticleId><ArticleId IdType="pubmed">16049337</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, et al. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer JD, et al. J. Neurosci. 2005;25:2803&#x2013;2810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725147</ArticleId><ArticleId IdType="pubmed">15772340</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka Y, et al. J. Neurosci. 2003;23:29&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742136</ArticleId><ArticleId IdType="pubmed">12514198</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17698009</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>55</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Aug</Month><Day>16</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of fragile X tremor/ataxia syndrome.</ArticleTitle><Pagination><StartPage>556</StartPage><EndPage>564</EndPage><MedlinePgn>556-64</MedlinePgn></Pagination><Abstract><AbstractText>Fragile X-associated tremor/ataxia syndrome (FXTAS) is a recently recognized neurodegenerative disorder in fragile X premutation carriers with FMR1 alleles containing 55-200 CGG repeats. Previously, we developed a Drosophila model of FXTAS and demonstrated that transcribed premutation repeats alone are sufficient to cause neurodegeneration, suggesting that rCGG-repeat-binding proteins (RBPs) may be sequestered from their normal function by rCGG binding. Here, we identify Pur alpha and hnRNP A2/B1 as RBPs. We show that Pur alpha and rCGG repeats interact in a sequence-specific fashion that is conserved between mammals and Drosophila. Overexpression of Pur alpha in Drosophila could suppress rCGG-mediated neurodegeneration in a dose-dependent manner. Furthermore, Pur alpha is also present in the inclusions of FXTAS patient brains. These findings support the disease mechanism of FXTAS of rCGG repeat sequestration of specific RBPs, leading to neuronal cell death, and implicate that Pur alpha plays an important role in the pathogenesis of FXTAS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Emory University School of Medicine, Atlanta, GA 30322, USA. pjin@genetics.emory.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Ranhui</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Qurashi</LastName><ForeName>Abrar</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Yunlong</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Donghua</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Rosser</LastName><ForeName>Tracie C</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Huijie</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Yue</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Warren</LastName><ForeName>Stephen T</ForeName><Initials>ST</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 HD020521</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 HD20521</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 HD024064</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 HD24064</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS051630</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH076090</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034481">Heterogeneous-Nuclear Ribonucleoprotein Group A-B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545199">Pur-alpha protein, Drosophila</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C076035">c-MYC-associated zinc finger protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>139135-51-6</RegistryNumber><NameOfSubstance UI="D051860">Fragile X Mental Retardation Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2007 Aug 16;55(4):535-7. doi: 10.1016/j.neuron.2007.07.032.</RefSource><PMID Version="1">17698005</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005123" MajorTopicYN="N">Eye</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051860" MajorTopicYN="N">Fragile X Mental Retardation Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005600" MajorTopicYN="N">Fragile X Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018840" MajorTopicYN="N">HSP70 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034481" MajorTopicYN="N">Heterogeneous-Nuclear Ribonucleoprotein Group A-B</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008855" MajorTopicYN="N">Microscopy, Electron, Scanning</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>8</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17698009</ArticleId><ArticleId IdType="mid">NIHMS28957</ArticleId><ArticleId IdType="pmc">PMC1994817</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2007.07.020</ArticleId><ArticleId IdType="pii">S0896-6273(07)00541-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arocena DG, Iwahashi CK, Won N, Beilina A, Ludwig AL, Tassone F, Schwartz PH, Hagerman PJ. Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells. Hum Mol Genet. 2005;14:3661&#x2013;3671.</Citation><ArticleIdList><ArticleId IdType="pubmed">16239243</ArticleId></ArticleIdList></Reference><Reference><Citation>Deissler H, Behn-Krappa A, Doerfler W. Purification of nuclear proteins from human HeLa cells that bind specifically to the unstable tandem repeat (CGG)n in the human FMR1 gene. J Biol Chem. 1996;271:4327&#x2013;4334.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626781</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallia GL, Johnson EM, Khalili K. Puralpha: a multifunctional single-stranded DNA- and RNA-binding protein. Nucleic Acids Res. 2000;28:3197&#x2013;3205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110688</ArticleId><ArticleId IdType="pubmed">10954586</ArticleId></ArticleIdList></Reference><Reference><Citation>Greco CM, Berman RF, Martin RM, Tassone F, Schwartz PH, Chang A, Trapp BD, Iwahashi C, Brunberg J, Grigsby J, et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS) Brain. 2006;129:243&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">16332642</ArticleId></ArticleIdList></Reference><Reference><Citation>Greco CM, Hagerman RJ, Tassone F, Chudley AE, Del Bigio MR, Jacquemont S, Leehey M, Hagerman PJ. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain. 2002;125:1760&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pubmed">12135967</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunawardena S, Goldstein LS. Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways. Arch Neurol. 2005;62:46&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642849</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunawardena S, Her LS, Brusch RG, Laymon RA, Niesman IR, Gordesky-Gold B, Sintasath L, Bonini NM, Goldstein LS. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron. 2003;40:25&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">14527431</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagerman PJ, Hagerman RJ. The fragile-X premutation: a maturing perspective. Am J Hum Genet. 2004;74:805&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1181976</ArticleId><ArticleId IdType="pubmed">15052536</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagerman RJ, Hagerman PJ. The fragile X premutation: into the phenotypic fold. Curr Opin Genet Dev. 2002;12:278&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">12076670</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagerman RJ, Leavitt BR, Farzin F, Jacquemont S, Greco CM, Brunberg JA, Tassone F, Hessl D, Harris SW, Zhang L, et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet. 2004;74:1051&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1181968</ArticleId><ArticleId IdType="pubmed">15065016</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagerman RJ, Ono MY, Hagerman PJ. Recent advances in fragile X: a model for autism and neurodegeneration. Curr Opin Psychiatry. 2005;18:490&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">16639106</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwahashi CK, Yasui DH, An HJ, Greco CM, Tassone F, Nannen K, Babineau B, Lebrilla CB, Hagerman RJ, Hagerman PJ. Protein composition of the intranuclear inclusions of FXTAS. Brain. 2006;129:256&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246864</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, Mankodi A, Swanson MS, Moxley RT, Thornton CA. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet. 2004;13:3079&#x2013;3088.</Citation><ArticleIdList><ArticleId IdType="pubmed">15496431</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin P, Zarnescu DC, Zhang F, Pearson CE, Lucchesi JC, Moses K, Warren ST. RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in Drosophila. Neuron. 2003;39:739&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">12948442</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson EM. The Pur protein family: clues to function from recent studies on cancer and AIDS. Anticancer Res. 2003;23:2093&#x2013;2100.</Citation><ArticleIdList><ArticleId IdType="pubmed">12894583</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, Esson D, Timmers AM, Hauswirth WW, Swanson MS. A muscleblind knockout model for myotonic dystrophy. Science. 2003;302:1978&#x2013;1980.</Citation><ArticleIdList><ArticleId IdType="pubmed">14671308</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai Y, Dohmae N, Hirokawa N. Kinesin transports RNA: isolation and characterization of an RNA-transporting granule. Neuron. 2004;43:513&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">15312650</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenneson A, Zhang F, Hagedorn CH, Warren ST. Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum Mol Genet. 2001;10:1449&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pubmed">11448936</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalili K, Del Valle L, Muralidharan V, Gault WJ, Darbinian N, Otte J, Meier E, Johnson EM, Daniel DC, Kinoshita Y, et al. Puralpha is essential for postnatal brain development and developmentally coupled cellular proliferation as revealed by genetic inactivation in the mouse. Mol Cell Biol. 2003;23:6857&#x2013;6875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193944</ArticleId><ArticleId IdType="pubmed">12972605</ArticleId></ArticleIdList></Reference><Reference><Citation>Mankodi A, Urbinati CR, Yuan QP, Moxley RT, Sansone V, Krym M, Henderson D, Schalling M, Swanson MS, Thornton CA. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet. 2001;10:2165&#x2013;2170.</Citation><ArticleIdList><ArticleId IdType="pubmed">11590133</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JW, Urbinati CR, Teng-Umnuay P, Stenberg MG, Byrne BJ, Thornton CA, Swanson MS. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. Embo J. 2000;19:4439&#x2013;4448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC302046</ArticleId><ArticleId IdType="pubmed">10970838</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohashi S, Koike K, Omori A, Ichinose S, Ohara S, Kobayashi S, Sato TA, Anzai K. Identification of mRNA/protein (mRNP) complexes containing Puralpha, mStaufen, fragile X protein, and myosin Va and their association with rough endoplasmic reticulum equipped with a kinesin motor. J Biol Chem. 2002;277:37804&#x2013;37810.</Citation><ArticleIdList><ArticleId IdType="pubmed">12147688</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranum LP, Day JW. Myotonic dystrophy: RNA pathogenesis comes into focus. Am J Hum Genet. 2004;74:793&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1181975</ArticleId><ArticleId IdType="pubmed">15065017</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman S. Epidemiology. In: Hagerman RJ, editor. Fragile X Syndrome: Diagnosis, Treatment and Research. The Johns Hopkins University Press; Baltimore, MD: 2002. pp. 136&#x2013;168.</Citation></Reference><Reference><Citation>Sofola OA, Jin P, Duan R, Liu H, de Haro M, Nelson DL, Botas J. RNA binding proteins hnRNP A2/B1 and CUGBP1 supress Fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron. 2007</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2215388</ArticleId><ArticleId IdType="pubmed">17698010</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, Goldstein LS. Axonopathy and transport deficits early in the pathogenesis of Alzheimer&#x2019;s disease. Science. 2005;307:1282&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet. 2000;66:6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288349</ArticleId><ArticleId IdType="pubmed">10631132</ArticleId></ArticleIdList></Reference><Reference><Citation>Tassone F, Iwahashi C, Hagerman PJ. FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS) RNA Biology. 2004;1:103&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">17179750</ArticleId></ArticleIdList></Reference><Reference><Citation>Timchenko LT, Miller JW, Timchenko NA, DeVore DR, Datar KV, Lin L, Roberts R, Caskey CT, Swanson MS. Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Res. 1996;24:4407&#x2013;4414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC146274</ArticleId><ArticleId IdType="pubmed">8948631</ArticleId></ArticleIdList></Reference><Reference><Citation>Timchenko LT, Tapscott SJ, Cooper TA, Monckton DG. Myotonic dystrophy: discussion of molecular basis. Adv Exp Med Biol. 2002;516:27&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">12611434</ArticleId></ArticleIdList></Reference><Reference><Citation>Timchenko NA, Cai ZJ, Welm AL, Reddy S, Ashizawa T, Timchenko LT. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem. 2001;276:7820&#x2013;7826.</Citation><ArticleIdList><ArticleId IdType="pubmed">11124939</ArticleId></ArticleIdList></Reference><Reference><Citation>Timchenko NA, Patel R, Iakova P, Cai ZJ, Quan L, Timchenko LT. Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis. J Biol Chem. 2004;279:13129&#x2013;13139.</Citation><ArticleIdList><ArticleId IdType="pubmed">14722059</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan L, Dockendorff TC, Jongens TA, Dreyfuss G. Characterization of dFMR1, a drosophila melanogaster homolog of the fragile X mental retardation protein [In Process Citation] Mol Cell Biol. 2000;20:8536&#x2013;8547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC102159</ArticleId><ArticleId IdType="pubmed">11046149</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren ST, Sherman SL. The fragile X syndrome. In: Scriver CR, Beaudet AL, Valle D, Childs B, Kinzler KW, Vogelstein B, editors. The Metabolic &amp; Molecular Bases of Inherited Disease. McGraw-Hill Companies; 2001. pp. 1257&#x2013;1290.</Citation></Reference><Reference><Citation>Willemsen R, Hoogeveen-Westerveld M, Reis S, Holstege J, Severijnen LA, Nieuwenhuizen IM, Schrier M, van Unen L, Tassone F, Hoogeveen AT, et al. The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome. Hum Mol Genet. 2003;12:949&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">12700164</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, Li SH, Li XJ. Chaperone suppression of cellular toxicity of huntingtin is independent of polyglutamine aggregation. J Biol Chem. 2001;276:48417&#x2013;48424.</Citation><ArticleIdList><ArticleId IdType="pubmed">11606565</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17698010</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>55</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Aug</Month><Day>16</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS.</ArticleTitle><Pagination><StartPage>565</StartPage><EndPage>571</EndPage><MedlinePgn>565-71</MedlinePgn></Pagination><Abstract><AbstractText>Fragile X-associated tremor/ataxia syndrome (FXTAS) is a recently described neurodegenerative disorder of older adult carriers of premutation alleles (60-200 CGG repeats) in the fragile X mental retardation gene (FMR1). It has been proposed that FXTAS is an RNA-mediated neurodegenerative disease caused by the titration of RNA-binding proteins by the CGG repeats. To test this hypothesis, we utilize a transgenic Drosophila model of FXTAS that expresses a premutation-length repeat (90 CGG repeats) from the 5' UTR of the human FMR1 gene and displays neuronal degeneration. Here, we show that overexpression of RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppresses the phenotype of the CGG transgenic fly. Furthermore, we show that hnRNP A2/B1 directly interacts with riboCGG repeats and that the CUGBP1 protein interacts with the riboCGG repeats via hnRNP A2/B1.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sofola</LastName><ForeName>Oyinkan A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Peng</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Yunlong</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Ranhui</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Huijie</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>de Haro</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Botas</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 HD024064</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 HD024064</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD038038</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS042179</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS42179</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH076090</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS042179</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS051630</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067879">CELF1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102843">CELF1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034481">Heterogeneous-Nuclear Ribonucleoprotein Group A-B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>139135-51-6</RegistryNumber><NameOfSubstance UI="D051860">Fragile X Mental Retardation Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2007 Aug 16;55(4):535-7. doi: 10.1016/j.neuron.2007.07.032.</RefSource><PMID Version="1">17698005</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067879" MajorTopicYN="N">CELF1 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005123" MajorTopicYN="N">Eye</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051860" MajorTopicYN="N">Fragile X Mental Retardation Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005600" MajorTopicYN="N">Fragile X Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034481" MajorTopicYN="N">Heterogeneous-Nuclear Ribonucleoprotein Group A-B</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008855" MajorTopicYN="N">Microscopy, Electron, Scanning</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>8</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17698010</ArticleId><ArticleId IdType="mid">NIHMS28956</ArticleId><ArticleId IdType="pmc">PMC2215388</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2007.07.021</ArticleId><ArticleId IdType="pii">S0896-6273(07)00542-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arocena DG, Iwahashi CK, Won N, Beilina A, Ludwig AL, Tassone F, Schwartz PH, Hagerman PJ. Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells. Hum Mol Genet. 2005;14:3661&#x2013;3671.</Citation><ArticleIdList><ArticleId IdType="pubmed">16239243</ArticleId></ArticleIdList></Reference><Reference><Citation>de Haro M, Al-Ramahi I, De Gouyon B, Ukani L, Rosa A, Faustino NA, Ashizawa T, Cooper TA, Botas J. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1. Hum Mol Genet. 2006;15:2138&#x2013;2145.</Citation><ArticleIdList><ArticleId IdType="pubmed">16723374</ArticleId></ArticleIdList></Reference><Reference><Citation>Greco CM, Hagerman RJ, Tassone F, Chudley AE, Del Bigio MR, Jacquemont S, Leehey M, Hagerman PJ. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain. 2002;125:1760&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pubmed">12135967</ArticleId></ArticleIdList></Reference><Reference><Citation>Greco CM, Berman RF, Martin RM, Tassone F, Schwartz PH, Chang A, Trapp BD, Iwahashi C, Brunberg J, Grigsby J, et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS) Brain. 2006;129:243&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">16332642</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J, Grigsby J, Gage B, Hagerman PJ. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology. 2001;57:127&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagerman RJ, Hagerman PJ. The fragile X premutation: into the phenotypic fold. Curr Opin Genet Dev. 2002;12:278&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">12076670</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagerman PJ, Hagerman RJ. The fragile-X premutation: a maturing perspective. Am J Hum Genet. 2004;74:805&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1181976</ArticleId><ArticleId IdType="pubmed">15052536</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwahashi CK, Yasui DH, An HJ, Greco CM, Tassone F, Nannen K, Babineau B, Lebrilla CB, Hagerman RJ, Hagerman PJ. Protein composition of the intranuclear inclusions of FXTAS. Brain. 2006;129:256&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246864</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin P, Zarnescu DC, Zhang F, Pearson CE, Lucchesi JC, Moses K, Warren ST. RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in Drosophila. Neuron. 2003;39:739&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">12948442</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin P, Duan R, Qin Y, Rosser TC, Liu H, Warren ST. Pur &#x3b1; binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of Fragile X Tremor/ Ataxia Syndrome. Neuron. 2007 current issue.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1994817</ArticleId><ArticleId IdType="pubmed">17698009</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, Esson D, Timmers AM, Hauswirth WW, Swanson MS. A muscleblind knockout model for myotonic dystrophy. Science. 2003;302:1978&#x2013;1980.</Citation><ArticleIdList><ArticleId IdType="pubmed">14671308</ArticleId></ArticleIdList></Reference><Reference><Citation>Pancetti F, Bosser R, Krehan A, Pyerin W, Itarte E, Bachs O. Heterogeneous nuclear ribonucleoprotein A2 interacts with protein kinase CK2. Biochem Biophys Res Commun. 1999;260:17&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">10381337</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranum LP, Cooper TA. RNA-Mediated Neuromuscular Disorders. Annu Rev Neurosci. 2006;29:259&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">16776586</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranum LP, Day JW. Myotonic dystrophy: RNA pathogenesis comes into focus. Am J Hum Genet. 2004;74:793&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1181975</ArticleId><ArticleId IdType="pubmed">15065017</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta S, Lakhotia SC. Altered Expressions of the Noncoding hsromega Gene Enhances poly-Q-Induced Neurotoxicity in Drosophila. RNA Biol. 2006;3</Citation><ArticleIdList><ArticleId IdType="pubmed">17114940</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi N, Sasagawa N, Suzuki K, Ishiura S. The CUG-binding protein binds specifically to UG dinucleotide repeats in a yeast three-hybrid system. Biochem Biophys Res Commun. 2000;277:518&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">11032753</ArticleId></ArticleIdList></Reference><Reference><Citation>Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet. 2000;66:6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288349</ArticleId><ArticleId IdType="pubmed">10631132</ArticleId></ArticleIdList></Reference><Reference><Citation>Tassone F, Iwahashi C, Hagerman PJ. FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS) RNA Biol. 2004;1:103&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">17179750</ArticleId></ArticleIdList></Reference><Reference><Citation>Timchenko LT, Miller JW, Timchenko NA, DeVore DR, Datar KV, Lin L, Roberts R, Caskey CT, Swanson MS. Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Res. 1996;24:4407&#x2013;4414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC146274</ArticleId><ArticleId IdType="pubmed">8948631</ArticleId></ArticleIdList></Reference><Reference><Citation>Timchenko NA, Cai ZJ, Welm AL, Reddy S, Ashizawa T, Timchenko LT. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem. 2001;276:7820&#x2013;7826.</Citation><ArticleIdList><ArticleId IdType="pubmed">11124939</ArticleId></ArticleIdList></Reference><Reference><Citation>Timchenko NA, Patel R, Iakova P, Cai ZJ, Quan L, Timchenko LT. Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis. J Biol Chem. 2004;279:13129&#x2013;13139.</Citation><ArticleIdList><ArticleId IdType="pubmed">14722059</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren ST, Sherman SL. The fragile X syndrome. In: Scriver CR, Beaudet AL, Valle D, Childs B, Kinzler KW, Vogelstein B, editors. The Metabolic &amp; Molecular Bases of Inherited Disease. McGraw-Hill Companies; 2001. pp. 1257&#x2013;1290.</Citation></Reference><Reference><Citation>Willemsen R, Hoogeveen-Westerveld M, Reis S, Holstege J, Severijnen LA, Nieuwenhuizen IM, Schrier M, van Unen L, Tassone F, Hoogeveen AT, et al. The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome. Hum Mol Genet. 2003;12:949&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">12700164</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu K, Sikes ML, Haynes SR, Beyer AL. Altered levels of the Drosophila HRB87F/hrp36 hnRNP protein have limited effects on alternative splicing in vivo. Mol Biol Cell. 1996;7:1059&#x2013;1073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC275958</ArticleId><ArticleId IdType="pubmed">8862520</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17698153</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0028-3908</ISSN><JournalIssue CitedMedium="Print"><Volume>53</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Neuropharmacology</Title><ISOAbbreviation>Neuropharmacology</ISOAbbreviation></Journal><ArticleTitle>The effects of JWB1-84-1 on memory-related task performance by amyloid Abeta transgenic mice and by young and aged monkeys.</ArticleTitle><Pagination><StartPage>588</StartPage><EndPage>600</EndPage><MedlinePgn>588-600</MedlinePgn></Pagination><Abstract><AbstractText>JWB1-84-1 is one of 50 tertiary amine analogs of choline synthesized with expectation that they would be high potency compounds for cytoprotection. As one of the more potent analogs in this regard, JWB1-84-1, a piperazine derivative, was selected for testing as a cognition-enhancing agent. The compound was evaluated for efficacy in Alzheimer's disease transgenic mice (B6C3-Tg(APPswe, PSEN1dE9)85Dbo/J). A separate cohort of mice (AD Tg) were first subjected to a behavioral test battery in which the transgenic strain was compared with the wild-type strain. AD Tg mice were shown to exhibit specific deficits in the acquisition of a working memory (5-trial/session radial arm water maze, RAWM) task at a time when the animals exhibited maximal cerebral amyloid burden. JWB1-84-1 produced a dose-dependent decrease in the number of errors made by well trained AD-Tg mice the RAWM task that was maximal after the 20 microg/kg dose. Aged macaques (20-32 y) were trained to proficiency in their performance of a computer-assisted delayed matching-to-sample task. Vehicle (normal saline) or JWB1-84-1 (5-150 microg/kg, i.m.) was administered 10 min before the initiating of testing. On average, JWB1-84-1 treatment significantly improved task accuracy after all but the lowest dose. The maximal degree of improvement was attained after animals received the 100 microg/kg dose. The drug's effects were restricted primarily to Medium and Long delay trials - the most difficult portions of the task, which were improved by up to 18% above control. In young macaques JWB1-84-1 treatment also significantly reversed the decrements in task accuracy associated with the random presentation of a task distractor. Thus JWB1-84-1exhibits the potential for treating the cognitive symptoms associated with neurodegenerative diseases and attention deficit disorders. Its cytoprotective action might also work to slow the progression of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sood</LastName><ForeName>Ajay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Alzheimer's Research Center, Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta, GA 30912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warren Beach</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Webster</LastName><ForeName>Scott J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Terry</LastName><ForeName>Alvin V</ForeName><Initials>AV</Initials></Author><Author ValidYN="Y"><LastName>Buccafusco</LastName><ForeName>Jerry J</ForeName><Initials>JJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropharmacology</MedlineTA><NlmUniqueID>0236217</NlmUniqueID><ISSNLinking>0028-3908</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C525664">JWB-1-84-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003624" MajorTopicYN="N">Darkness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018737" MajorTopicYN="N">Hand Strength</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008027" MajorTopicYN="N">Light</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008254" MajorTopicYN="N">Macaca nemestrina</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004856" MajorTopicYN="N">Postural Balance</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17698153</ArticleId><ArticleId IdType="doi">10.1016/j.neuropharm.2007.06.028</ArticleId><ArticleId IdType="pii">S0028-3908(07)00200-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17698211</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0166-4328</ISSN><JournalIssue CitedMedium="Print"><Volume>184</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Dec</Month><Day>03</Day></PubDate></JournalIssue><Title>Behavioural brain research</Title><ISOAbbreviation>Behav Brain Res</ISOAbbreviation></Journal><ArticleTitle>Three weeks of running wheel exposure improves cognitive performance in the aged Tg2576 mouse.</ArticleTitle><Pagination><StartPage>124</StartPage><EndPage>132</EndPage><MedlinePgn>124-32</MedlinePgn></Pagination><Abstract><AbstractText>If begun early in life, exercise effectively reduces the development of cognitive deficits in transgenic mouse models of Alzheimer's disease (AD). However, the effectiveness of exercise, once the cognitive impairments are established, is not as clear. In terms of translating research in animal models to treatments involving exercise in Alzheimer's disease patients, it is critical to evaluate exercise intervention at time points that address not only prevention, but also treatment of cognitive decline. We provided exercise wheels to Tg2576 (TG) (n=12) and C57BL6 (WT) (n=17) mice at 16-18 months of age for three weeks. At this age animals have significant cognitive impairment and neuropathology consistent with AD. Age matched sedentary TG (n=13) and WT (n=12) mice were also included, as well as groups provided access to an immobile wheel (TG n=9, WT n=12). After three weeks, animals were evaluated in a radial arm water maze. Significant impairments were observed in the sedentary TG mice compared to WT in reference/long-term and working/short-term memory, as well as in probe trials. Exercised TG mice demonstrated improvements in memory, which made them indistinguishable from WT mice on all tasks. In addition, animals provided with an immobile wheel exhibited improvement in some, but not all cognitive measures. Our findings demonstrate that exercise can improve cognitive performance in a mouse model of AD even if applied after the development of pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nichol</LastName><ForeName>Kathryn E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Institute for Brain Aging &amp; Dementia, University of California at Irvine, Irvine, CA 92697-4540, USA. knichol@uci.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parachikova</LastName><ForeName>Anna I</ForeName><Initials>AI</Initials></Author><Author ValidYN="Y"><LastName>Cotman</LastName><ForeName>Carl W</ForeName><Initials>CW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG000538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AR047752</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Behav Brain Res</MedlineTA><NlmUniqueID>8004872</NlmUniqueID><ISSNLinking>0166-4328</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026241" MajorTopicYN="N">Exercise Movement Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012420" MajorTopicYN="N">Running</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013028" MajorTopicYN="N">Space Perception</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>12</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17698211</ArticleId><ArticleId IdType="mid">NIHMS32757</ArticleId><ArticleId IdType="pmc">PMC2215770</ArticleId><ArticleId IdType="doi">10.1016/j.bbr.2007.06.027</ArticleId><ArticleId IdType="pii">S0166-4328(07)00334-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adlard PA, Cotman CW. Voluntary exercise protects against stress-induced decreases in brain-derived neurotrophic factor protein expression. Neuroscience. 2004;124(4):985&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">15026138</ArticleId></ArticleIdList></Reference><Reference><Citation>Adlard PA, Perreau VM, Pop V, Cotman CW. Voluntary exercise decreases amyloid load in a transgenic model of alzheimer's disease. J Neurosci. 2005;25(17):4217&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725122</ArticleId><ArticleId IdType="pubmed">15858047</ArticleId></ArticleIdList></Reference><Reference><Citation>Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc. 2006;1(4):1671&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17487150</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendash GW, Garcia MF, Costa DA, Cracchiolo JR, Wefes IM, Potter H. Environmental enrichment improves cognition in aged alzheimer's transgenic mice despite stable beta-amyloid deposition. Neuroreport. 2004;15(11):1751&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">15257141</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendash GW, Gordon MN, Diamond DM, Austin LA, Hatcher JM, Jantzen P, DiCarlo G, Wilcock D, Morgan D. Behavioral assessment of alzheimer's transgenic mice following long-term abeta vaccination: Task specificity and correlations between abeta deposition and spatial memory. DNA Cell Biol. 2001;20(11):737&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">11788052</ArticleId></ArticleIdList></Reference><Reference><Citation>Ari Z, Kutlu N, Uyanik BS, Taneli F, Buyukyazi G, Tavli T. Serum testosterone, growth hormone, and insulin-like growth factor-1 levels, mental reaction time, and maximal aerobic exercise in sedentary and long-term physically trained elderly males. Int J Neurosci. 2004;114(5):623&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">15204068</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TV, Hyman BT, Younkin SG, Hsiao KK. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci. 1999;2(3):271&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen GH, Wang YJ, Wang XM, Zhou JN. Accelerated senescence prone mouse-8 shows early onset of deficits in spatial learning and memory in the radial six-arm water maze. Physiol Behav. 2004;82(5):883&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">15451654</ArticleId></ArticleIdList></Reference><Reference><Citation>Churchill JD, Galvez R, Colcombe S, Swain RA, Kramer AF, Greenough WT. Exercise, experience and the aging brain. Neurobiol Aging. 2002;23(5):941&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">12392797</ArticleId></ArticleIdList></Reference><Reference><Citation>Colcombe SJ, Kramer AF, Erickson KI, Scalf P, McAuley E, Cohen NJ, Webb A, Jerome GJ, Marquez DX, Elavsky S. Cardiovascular fitness, cortical plasticity, and aging. Proc Natl Acad Sci U S A. 2004;101(9):3316&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373255</ArticleId><ArticleId IdType="pubmed">14978288</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman CW, Berchtold NC. Exercise: A behavioral intervention to enhance brain health and plasticity. Trends Neurosci. 2002;25(6):295&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">12086747</ArticleId></ArticleIdList></Reference><Reference><Citation>Endres M, Gertz K, Lindauer U, Katchanov J, Schultze J, Schrock H, Nickenig G, Kuschinsky W, Dirnagl U, Laufs U. Mechanisms of stroke protection by physical activity. Ann Neurol. 2003;54(5):582&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">14595647</ArticleId></ArticleIdList></Reference><Reference><Citation>Engesser-Cesar C, Anderson AJ, Basso DM, Edgerton VR, Cotman CW. Voluntary wheel running improves recovery from a moderate spinal cord injury. J Neurotrauma. 2005;22(1):157&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">15665610</ArticleId></ArticleIdList></Reference><Reference><Citation>Etnier JL, Berry M. Fluid intelligence in an older copd sample after short- or long-term exercise. Med Sci Sports Exerc. 2001;33(10):1620&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11581543</ArticleId></ArticleIdList></Reference><Reference><Citation>Filteau SM, Menzies RA, Kaido TJ, O'Grady MP, Gelderd JB, Hall NR. Effects of exercise on immune functions of undernourished mice. Life Sci. 1992;51(8):565&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">1640807</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyn P, Abreu BC, Ottenbacher KJ. The effects of exercise training on elderly persons with cognitive impairment and dementia: A meta-analysis. Arch Phys Med Rehabil. 2004;85(10):1694&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">15468033</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, abeta elevation, and amyloid plaques in transgenic mice [see comments] Science. 1996;274(5284):99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyde LA, Hoplight BJ, Denenberg VH. Water version of the radial-arm maze: Learning in three inbred strains of mice. Brain Res. 1998;785(2):236&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">9518631</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Melnikova T, Fadale DJ, Xu GM, Slunt HH, Gonzales V, Younkin LH, Younkin SG, Borchelt DR, Savonenko AV. Environmental enrichment mitigates cognitive deficits in a mouse model of alzheimer's disease. J Neurosci. 2005;25(21):5217&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4440804</ArticleId><ArticleId IdType="pubmed">15917461</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Gast D, Gage FH. Neuroplasticity in old age: Sustained fivefold induction of hippocampal neurogenesis by long-term environmental enrichment. Ann Neurol. 2002;52(2):135&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">12210782</ArticleId></ArticleIdList></Reference><Reference><Citation>King DL, Arendash GW. Behavioral characterization of the tg2576 transgenic model of alzheimer's disease through 19 months. Physiol Behav. 2002;75(5):627&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">12020728</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura T, Mishina M, Sugiyama H. Enhancement of neurogenesis by running wheel exercises is suppressed in mice lacking nmda receptor epsilon 1 subunit. Neurosci Res. 2003;47(1):55&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">12941447</ArticleId></ArticleIdList></Reference><Reference><Citation>Koteja P, Garland T, Jr, Sax JK, Swallow JG, Carter PA. Behaviour of house mice artificially selected for high levels of voluntary wheel running. Anim Behav. 1999;58(6):1307&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600154</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS. Environmental enrichment reduces abeta levels and amyloid deposition in transgenic mice. Cell. 2005;120(5):701&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">15766532</ArticleId></ArticleIdList></Reference><Reference><Citation>McAuley E, Kramer AF, Colcombe SJ. Cardiovascular fitness and neurocognitive function in older adults: A brief review. Brain Behav Immun. 2004;18(3):214&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">15116743</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A beta peptide vaccination prevents memory loss in an animal model of alzheimer's disease. Nature. 2000;408(6815):982&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RGM. Spatial localization does not require the presence of local cues. Learning and Motivation. 1981;12(2):239&#x2013;260.</Citation></Reference><Reference><Citation>Pietropaolo S, Feldon J, Alleva E, Cirulli F, Yee BK. The role of voluntary exercise in enriched rearing: A behavioral analysis. Behav Neurosci. 2006;120(4):787&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">16893285</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer D. No old man ever forgot where he buried his treasure: Concepts of cognitive impairment in old age circa 1700. J Am Geriatr Soc. 2005;53(11):2023&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16274390</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu K, Laurer H, McIntosh T, Pratico D, Martinez D, Leight S, Lee VM, Trojanowski JQ. Repetitive mild brain trauma accelerates abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of alzheimer amyloidosis. J Neurosci. 2002;22(2):446&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758680</ArticleId><ArticleId IdType="pubmed">11784789</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Kempermann G, Gage FH. Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nat Neurosci. 1999;2(3):266&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195220</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Shubert T, Zhao C, Gage FH. Exercise enhances learning and hippocampal neurogenesis in aged mice. J Neurosci. 2005;25(38):8680&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1360197</ArticleId><ArticleId IdType="pubmed">16177036</ArticleId></ArticleIdList></Reference><Reference><Citation>West RL. An application of prefrontal cortex function theory to cognitive aging. Psychol Bull. 1996;120(2):272&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">8831298</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN, Morgan D. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci. 2006;26(20):5340&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675288</ArticleId><ArticleId IdType="pubmed">16707786</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17698783</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>7</Issue><PubDate><Year>2007</Year><Month>Aug</Month><Day>14</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.</ArticleTitle><Pagination><StartPage>631</StartPage><EndPage>639</EndPage><MedlinePgn>631-9</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Processes of Alzheimer disease (AD) likely begin years prior to the onset of cognitive impairment (latent AD), progress though a prodromal phase of mild cognitive impairment (MCI), and culminate in dementia. While many studies have evaluated CSF tau and Abeta(42) as biomarkers of the dementia or prodromal stages of AD, we are unaware of any study to evaluate these potential CSF biomarkers of latent AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We determined the ratio of CSF tau/Abeta(42) (T/Abeta) using Luminex reagents in 129 control individuals that spanned from 21 to 100 years of age; for comparison we included patients with MCI (n = 12), probable AD (n = 21), or other neurodegenerative diseases (n = 12).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 16% of the control group with abnormally elevated CSF T/Abeta; all were 53 years or older. Using age-matched controls with normal CSF T/Abeta we showed that the high CSF T/Abeta subgroup of controls had significantly increased frequency of the epsilon4 allele of the apolipoprotein E gene and significantly increased risk of conversion to MCI during follow-up of up to 42 months suggesting that they had latent AD at the time of lumbar puncture.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These generally applicable methods establish cutoff values to identify control individuals at increased risk of conversion to mild cognitive impairment which may be useful to people weighing the risk-benefit ratio of new preventive therapeutics and to researchers striving to enrich clinical trial populations with people with latent Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Mental Illness Research, Education, and Clinical Center and Department of Psychiatry, VA Puget Sound Health Care System, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sokal</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Leverenz</LastName><ForeName>J B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Brodey</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>G D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Raskind</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Peskind</LastName><ForeName>E R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>T J</ForeName><Initials>TJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17698783</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000267428.62582.aa</ArticleId><ArticleId IdType="pii">69/7/631</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17699670</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>33</Issue><PubDate><Year>2007</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>The brain cytoplasmic RNA BC1 regulates dopamine D2 receptor-mediated transmission in the striatum.</ArticleTitle><Pagination><StartPage>8885</StartPage><EndPage>8892</EndPage><MedlinePgn>8885-92</MedlinePgn></Pagination><Abstract><AbstractText>Dopamine D(2) receptor (D(2)DR)-mediated transmission in the striatum is remarkably flexible, and changes in its efficacy have been heavily implicated in a variety of physiological and pathological conditions. Although receptor-associated proteins are clearly involved in specific forms of synaptic plasticity, the molecular mechanisms regulating the sensitivity of D(2) receptors in this brain area are essentially obscure. We have studied the physiological responses of the D(2)DR stimulations in mice lacking the brain cytoplasmic RNA BC1, a small noncoding dendritically localized RNA that is supposed to play a role in mRNA translation. We show that the efficiency of D(2)-mediated transmission regulating striatal GABA synapses is under the control of BC1 RNA, through a negative influence on D(2) receptor protein level affecting the functional pool of receptors. Ablation of the BC1 gene did not result in widespread dysregulation of synaptic transmission, because the sensitivity of cannabinoid CB(1) receptors was intact in the striatum of BC1 knock-out (KO) mice despite D(2) and CB(1) receptors mediated similar electrophysiological actions. Interestingly, the fragile X mental retardation protein FMRP, one of the multiple BC1 partners, is not involved in the BC1 effects on the D(2)-mediated transmission. Because D(2)DR mRNA is apparently equally translated in the BC1-KO and wild-type mice, whereas the protein level is higher in BC1-KO mice, we suggest that BC1 RNA controls D(2)DR indirectly, probably regulating translation of molecules involved in D(2)DR turnover and/or stability.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Centonze</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinica Neurologica, Dipartimento di Neuroscienze, Universit&#xe0; Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Napoli</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Mercaldo</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Lacoux</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Ciotti</LastName><ForeName>Maria Teresa</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>De Chiara</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Prosperetti</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Maccarrone</LastName><ForeName>Mauro</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fezza</LastName><ForeName>Filomena</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Calabresi</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Bernardi</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bagni</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GGP05269</GrantID><Acronym>TI_</Acronym><Agency>Telethon</Agency><Country>Italy</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C076675">Bc1 long-non-coding RNA, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065127">Dopamine D2 Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007527">Isoenzymes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C079240">Mtap2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009841">Oligonucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062085">RNA, Long Noncoding</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022661">RNA, Untranslated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020736">Ribonucleoproteins, Small Cytoplasmic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Y0CM1A77L</RegistryNumber><NameOfSubstance UI="C105771">GR 103691</NameOfSubstance></Chemical><Chemical><RegistryNumber>37589-80-3</RegistryNumber><NameOfSubstance UI="D016244">Guanosine 5'-O-(3-Thiotriphosphate)</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.1.1.15</RegistryNumber><NameOfSubstance UI="D005968">Glutamate Decarboxylase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.1.1.15</RegistryNumber><NameOfSubstance UI="C401141">glutamate decarboxylase 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001713" MajorTopicYN="N">Biphenyl Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065127" MajorTopicYN="N">Dopamine D2 Receptor Antagonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005968" MajorTopicYN="N">Glutamate Decarboxylase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016244" MajorTopicYN="N">Guanosine 5'-O-(3-Thiotriphosphate)</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053444" MajorTopicYN="N">Inhibitory Postsynaptic Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007527" MajorTopicYN="N">Isoenzymes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009841" MajorTopicYN="N">Oligonucleotides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062085" MajorTopicYN="N">RNA, Long Noncoding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022661" MajorTopicYN="N">RNA, Untranslated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020736" MajorTopicYN="N">Ribonucleoproteins, Small Cytoplasmic</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>2</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17699670</ArticleId><ArticleId IdType="pmc">PMC6672174</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0548-07.2007</ArticleId><ArticleId IdType="pii">27/33/8885</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aronov S, Aranda G, Behar L, Ginzburg I. Visualization of translated tau protein in the axons of neuronal P19 cells and characterization of tau RNP granules. J Cell Sci. 2002;115:3817&#x2013;3827.</Citation><ArticleIdList><ArticleId IdType="pubmed">12235292</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker CE, Verheij C, Willemsen R, Vanderhelm R, Oerlemans F, Vermey M, Bygrave A, Hoogeveen AT, Oostra BA, Reyniers E. Fmr1 knockout mice: a model to study fragile X mental retardation. Cell. 1994;78:23&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">8033209</ArticleId></ArticleIdList></Reference><Reference><Citation>Berke JD, Hyman SE. Addiction, dopamine, and the molecular mechanisms of memory. Neuron. 2000;25:515&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">10774721</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder LI, Frankfurter A, Rebhun LI. The distribution of tau in the mammalian central nervous system. J Cell Biol. 1985;101:1371&#x2013;1378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2113928</ArticleId><ArticleId IdType="pubmed">3930508</ArticleId></ArticleIdList></Reference><Reference><Citation>Centonze D, Gubellini P, Usiello A, Rossi S, Tscherter A, Bracci E, Erbs E, Tognazzi N, Bernardi G, Pisani A, Calabresi P, Borrelli E. Differential contribution of dopamine D2S and D2L receptors in the modulation of glutamate and GABA transmission in the striatum. Neuroscience. 2004;129:157&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">15489038</ArticleId></ArticleIdList></Reference><Reference><Citation>Centonze D, Rossi S, Prosperetti C, Tscherter A, Bernardi G, Maccarrone M, Calabresi P. Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice. Biol Psychiatry. 2005;57:1583&#x2013;1589.</Citation><ArticleIdList><ArticleId IdType="pubmed">15953496</ArticleId></ArticleIdList></Reference><Reference><Citation>Charvin D, Vanhoutte P, Pages C, Borrelli E, Caboche J. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. Proc Natl Acad Sci USA. 2005;102:12218&#x2013;12223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1189314</ArticleId><ArticleId IdType="pubmed">16103364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari F, Mercaldo V, Piccoli G, Sala C, Cannata S, Achsel T, Bagni C. The fragile X mental retardation protein-RNP granules show an mGluR-dependent localization in the post-synaptic spines. Mol Cell Neurosci. 2007;34:343&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">17254795</ArticleId></ArticleIdList></Reference><Reference><Citation>Gainetdinov RR, Bohn LM, Sotnikova TD, Cyr M, Laakso A, Macrae AD, Torres GE, Kim KM, Lefkowitz RJ, Caron MG, Premont RT. Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron. 2003;38:291&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">12718862</ArticleId></ArticleIdList></Reference><Reference><Citation>Geurts M, Hermans E, Maloteaux JM. Assessment of striatal D1 and D2 dopamine receptor-G protein coupling by agonist-induced [35S]GTP gamma S binding. Life Sci. 1999;65:1633&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pubmed">10573181</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Kitada T, Costa C, Tong Y, Martella G, Tscherter A, Martins A, Bernardi G, Roth BL, Pothos EN, Calabresi P, Shen J. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron. 2005;45:489&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">15721235</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson N, Gireesh-Dharmaraj E, Czubayko U, Blackwell KT, Plenz D. A comparative voltage and current-clamp analysis of feedback and feedforward synaptic transmission in the striatal microcircuit in vitro. J Neurophysiol. 2006;95:737&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">16236782</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman JN, Hernandez A, Galarraga E, Tapia D, Laville A, Vergara R, Aceves J, Bargas J. Dopaminergic modulation of axon collaterals interconnecting spiny neurons of the rat striatum. J Neurosci. 2003;23:8931&#x2013;8940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740391</ArticleId><ArticleId IdType="pubmed">14523095</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt MJ, Kessal K, Garcia R. Ketamine induces dopamine-dependent depression of evoked hippocampal activity in the nucleus accumbens in freely moving rats. J Neurosci. 2005;25:524&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725480</ArticleId><ArticleId IdType="pubmed">15647498</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson EM, Kinoshita Y, Weinreb DB, Wortman MJ, Simon R, Khalili K, Winckler B, Gordon J. Role of Pur alpha in targeting mRNA to sites of translation in hippocampal neuronal dendrites. J Neurosci Res. 2006;83:929&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pubmed">16511857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kash SF, Tecott LH, Hodge C, Baekkeskov S. Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci USA. 1999;96:1698&#x2013;1703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15565</ArticleId><ArticleId IdType="pubmed">9990087</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman DL, Houser CR, Tobin AJ. Two forms of the gamma-aminobutyric acid synthetic enzyme glutamate decarboxylase have distinct intraneuronal distributions and cofactor interactions. J Neurochem. 1991;56:720&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8194030</ArticleId><ArticleId IdType="pubmed">1988566</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi S, Agui K, Kamo S, Li Y, Anzai K. Neural BC1 RNA associates with pur alpha, a single-stranded DNA and RNA binding protein, which is involved in the transcription of the BC1 RNA gene. Biochem Biophys Res Commun. 2000;277:341&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">11032728</ArticleId></ArticleIdList></Reference><Reference><Citation>Koos T, Tepper JM, Wilson CJ. Comparison of IPSCs evoked by spiny and fast-spiking neurons in the neostriatum. J Neurosci. 2004;24:7916&#x2013;7922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729926</ArticleId><ArticleId IdType="pubmed">15356204</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewejohann L, Skryabin BV, Sachser N, Prehn C, Heiduschka P, Thanos S, Jordan U, Dell'Omo G, Vyssotski AL, Pleskacheva MG, Lipp HP, Tiedge H, Brosius J, Prior H. Role of a neuronal small non-messenger RNA: behavioural alterations in BC1 RNA-deleted mice. Behav Brain Res. 2004;154:273&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">15302134</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallardo M, Deitinghoff A, Muller J, Goetze B, Macchi P, Peters C, Kiebler MA. Isolation and characterization of Staufen-containing ribonucleoprotein particles from rat brain. Proc Natl Acad Sci USA. 2003;100:2100&#x2013;2105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149965</ArticleId><ArticleId IdType="pubmed">12592035</ArticleId></ArticleIdList></Reference><Reference><Citation>Muddashetty R, Khanam T, Kondrashov A, Bundman M, Iacoangeli A, Kremerskothen J, Duning K, Barnekow A, Huttenhofer A, Tiedge H, Brosius J. Poly(A)-binding protein is associated with neuronal BC1 and BC200 ribonucleoprotein particles. J Mol Biol. 2002;321:433&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">12162957</ArticleId></ArticleIdList></Reference><Reference><Citation>Muramatsu T, Ohmae A, Anzai K. BC1 RNA protein particles in mouse brain contain two y-,h-element-binding proteins, translin and a 37 kDa protein. Biochem Biophys Res Commun. 1998;247:7&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">9636644</ArticleId></ArticleIdList></Reference><Reference><Citation>Muslimov IA, Santi E, Homel P, Perini S, Higgins D, Tiedge H. RNA transport in dendrites: a cis-acting targeting element is contained within neuronal BC1 RNA. J Neurosci. 1997;17:4722&#x2013;4733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850620</ArticleId><ArticleId IdType="pubmed">9169532</ArticleId></ArticleIdList></Reference><Reference><Citation>Muslimov IA, Lin Y, Heller M, Brosius J, Zakeri Z, Tiedge H. A small RNA in testis and brain: implications for male germ cell development. J Cell Sci. 2002;115:1243&#x2013;1250.</Citation><ArticleIdList><ArticleId IdType="pubmed">11884523</ArticleId></ArticleIdList></Reference><Reference><Citation>Nader MA, Morgan D, Gage HD, Nader SH, Calhoun TL, Buchheimer N, Ehrenkaufer R, Mach RH. PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat Neurosci. 2006;9:1050&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">16829955</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmrich V, Hargreaves EL, Muslimov IA, Bianchi R, Tiedge H. Dendritic BC1 RNA: modulation by kindling-induced afterdischarges. Brain Res Mol Brain Res. 2005;133:110&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">15661371</ArticleId></ArticleIdList></Reference><Reference><Citation>Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Lanciego JL, Artieda J, Gonzalo N, Olanow CW. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci. 2000;23:S8&#x2013;S19.</Citation><ArticleIdList><ArticleId IdType="pubmed">11052215</ArticleId></ArticleIdList></Reference><Reference><Citation>Plenz D. When inhibition goes incognito: feedback interaction between spiny projection neurons in striatal function. Trends Neurosci. 2003;26:436&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">12900175</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponnusamy R, Nissim HA, Barad M. Systemic blockade of D2-like dopamine receptors facilitates extinction of conditioned fear in mice. Learn Mem. 2005;12:399&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1183258</ArticleId><ArticleId IdType="pubmed">16077018</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozhdestvensky TS, Kopylov AM, Brosius J, Huttenhofer A. Neuronal BC1 RNA structure: evolutionary conversion of a tRNA(Ala) domain into an extended stem-loop structure. RNA. 2001;7:722&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1370124</ArticleId><ArticleId IdType="pubmed">11350036</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen J, Campbell DW, Leslie WD, Malisza KL, Stein MB, Paulus MP, Kravetsky LB, Kjernisted KD, Walker JR, Reiss JP. Striatal function in generalized social phobia: a functional magnetic resonance imaging study. Biol Psychiatry. 2007;61:396&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">17097072</ArticleId></ArticleIdList></Reference><Reference><Citation>Skryabin BV, Sukonina V, Jordan U, Lewejohann L, Sachser N, Muslimov I, Tiedge H, Brosius J. Neuronal untranslated BC1 RNA: targeted gene elimination in mice. Mol Cell Biol. 2003;23:6435&#x2013;6441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193692</ArticleId><ArticleId IdType="pubmed">12944471</ArticleId></ArticleIdList></Reference><Reference><Citation>Steward O, Schuman EM. Compartmentalized synthesis and degradation of proteins in neurons. Neuron. 2003;40:347&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">14556713</ArticleId></ArticleIdList></Reference><Reference><Citation>Tepper JM, Abercrombie ED, Bolam JP. Basal ganglia macrocircuits. Prog Brain Res. 2007;160:3&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17499105</ArticleId></ArticleIdList></Reference><Reference><Citation>Tunstall MJ, Oorschot DE, Kean A, Wickens JR. Inhibitory interactions between spiny projection neurons in the rat striatum. J Neurophysiol. 2002;88:1263&#x2013;1269.</Citation><ArticleIdList><ArticleId IdType="pubmed">12205147</ArticleId></ArticleIdList></Reference><Reference><Citation>Usiello A, Baik JH, Rouge-Pont F, Picetti R, Dierich A, LeMeur M, Piazza PV, Borrelli E. Distinct functions of the two isoforms of dopamine D2 receptors. Nature. 2000;408:199&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">11089973</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Iacoangeli A, Popp S, Muslimov IA, Imataka H, Sonenberg N, Lomakin IB, Tiedge H. Dendritic BC1 RNA: functional role in regulation of translation initiation. J Neurosci. 2002;22:10232&#x2013;10241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1828542</ArticleId><ArticleId IdType="pubmed">12451124</ArticleId></ArticleIdList></Reference><Reference><Citation>West N, Roy-Engel AM, Imataka H, Sonenberg N, Deininger P. Shared protein components of SINE RNPs. J Mol Biol. 2002;321:423&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">12162956</ArticleId></ArticleIdList></Reference><Reference><Citation>Zalfa F, Giorgi M, Primerano B, Moro A, Di Penta A, Reis S, Oostra B, Bagni C. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell. 2003;112:317&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">12581522</ArticleId></ArticleIdList></Reference><Reference><Citation>Zalfa F, Achsel T, Bagni C. mRNPs, polysomes or granules: FMRP in neuronal protein synthesis. Curr Opin Neurobiol. 2006;16:265&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">16707258</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17704509</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0964-6906</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>21</Issue><PubDate><Year>2007</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Human molecular genetics</Title><ISOAbbreviation>Hum Mol Genet</ISOAbbreviation></Journal><ArticleTitle>Isolation and characterization of the Drosophila ubiquilin ortholog dUbqln: in vivo interaction with early-onset Alzheimer disease genes.</ArticleTitle><Pagination><StartPage>2626</StartPage><EndPage>2639</EndPage><MedlinePgn>2626-39</MedlinePgn></Pagination><Abstract><AbstractText>UBQLN1 variants have been associated with increased risk for late-onset Alzheimer's disease (AD). We produced transgenic Drosophila models that either silence (by RNAi) or overexpress the Drosophila ortholog of human UBQLN1, dUbqln. Silencing of dUbqln in the central nervous system led to age-dependent neurodegeneration and shortened lifespan. Silencing of dUbqln in the wing led to wing vein loss that could be partially rescued by mutant rhomboid (rho), a known component of epidermal growth factor receptor signaling pathway. Conversely, overexpression of dUbqln promoted ecotopic wing veins. Overexpression of dUbqln in the eye rescued a small, rough eye phenotype induced by overexpression of Drosophila presenilin (dPsn), and also rescuing dPsn-induced malformations in bristles. In contrast, RNAi silencing of dUbqln enhanced the retinal degenerative defect induced by overexpression of dPsn. Finally, co-overexpression of dUbqln and the human amyloid precursor protein (APP) in the eye significantly reduced the levels of full-length APP and its C-terminal fragment. Collectively, these data support in vivo functional interaction between UBQLN1 and the AD-associated genes, presenilin and APP, and provide further clues regarding the potential role of UBQLN1 in AD pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Airong</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Diseases, Department of Neurology, Massachusetts General Hospital and Harvard Medical school, Charlestown, MA 02128, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Zhongcong</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Yuanlin</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>McKay</LastName><ForeName>Kenneth M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>McKee</LastName><ForeName>Mary L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 NS048140</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12AG000294</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P60 AG008812</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG014713</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH 60009</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Mol Genet</MedlineTA><NlmUniqueID>9208958</NlmUniqueID><ISSNLinking>0964-6906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053763">Presenilins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C106427">Psn protein, Drosophila</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C525176">Ubqn protein, Drosophila</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019521" MajorTopicYN="N">Body Patterning</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053763" MajorTopicYN="N">Presenilins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014921" MajorTopicYN="N">Wings, Animal</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17704509</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddm219</ArticleId><ArticleId IdType="pii">ddm219</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17715348</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>34</Issue><PubDate><Year>2007</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.</ArticleTitle><Pagination><StartPage>9115</StartPage><EndPage>9129</EndPage><MedlinePgn>9115-29</MedlinePgn></Pagination><Abstract><AbstractText>Immunotherapies for various neurodegenerative diseases have recently emerged as a promising approach for clearing pathological protein conformers in these disorders. This type of treatment has not been assessed in models that develop neuronal tau aggregates as observed in frontotemporal dementia and Alzheimer's disease. Here, we present that active immunization with a phosphorylated tau epitope, in P301L tangle model mice, reduces aggregated tau in the brain and slows progression of the tangle-related behavioral phenotype. Females had more tau pathology than males but were also more receptive to the immunotherapy. The tau antibodies generated in these animals recognized pathological tau on brain sections. Performance on behavioral assays that require extensive motor coordination correlated with tau pathology in corresponding brain areas, and antibody levels against the immunogen correlated inversely with tau pathology. Interestingly, age-dependent autoantibodies that recognized recombinant tau protein but not the immunogen were detected in the P301L mice. To confirm that anti-tau antibodies could enter the brain and bind to pathological tau, FITC-tagged antibodies purified from a P301L mouse, with a high antibody titer against the immunogen, were injected into the carotid artery of P301L mice. These antibodies were subsequently detected within the brain and colocalized with PHF1 and MC1 antibodies that recognize pathological tau. Currently, no treatment is available for clearing tau aggregates. Our present findings may lead to a novel therapy targeting one of the major hallmarks of Alzheimer's disease and frontotemporal dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Asuni</LastName><ForeName>Ayodeji A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, New York University School of Medicine, New York, New York 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boutajangout</LastName><ForeName>Allal</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Quartermain</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sigurdsson</LastName><ForeName>Einar M</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG020197</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG005891</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG20197</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG5891</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9DLQ4CIU6V</RegistryNumber><NameOfSubstance UI="D011392">Proline</NameOfSubstance></Chemical><Chemical><RegistryNumber>GMW67QNF9C</RegistryNumber><NameOfSubstance UI="D007930">Leucine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007930" MajorTopicYN="N">Leucine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011392" MajorTopicYN="N">Proline</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021641" MajorTopicYN="N">Recognition, Psychology</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>2</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17715348</ArticleId><ArticleId IdType="pmc">PMC6672191</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2361-07.2007</ArticleId><ArticleId IdType="pii">27/34/9115</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aihara N, Tanno H, Hall JJ, Pitts LH, Noble LJ. Immunocytochemical localization of immunoglobulins in the rat brain: relationship to the blood-brain barrier. J Comp Neurol. 1994;342:481&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">8040362</ArticleId></ArticleIdList></Reference><Reference><Citation>Andoh T, Kuraishi Y. Direct action of immunoglobulin G on primary sensory neurons through Fc gamma receptor I. FASEB J. 2004;18:182&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">14630707</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci. 2005;25:5446&#x2013;5454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725006</ArticleId><ArticleId IdType="pubmed">15930395</ArticleId></ArticleIdList></Reference><Reference><Citation>Asuni AA, Knudsen E, Frangione B, Wisniewski T, Sigurdsson EM. Antibody mediated modulation of A&#x3b2; induced neurotoxicity in cell culture. Neurobiol Aging. 2004;25:S581&#x2013;S582.</Citation></Reference><Reference><Citation>Asuni AA, Boutajangout A, Scholtzova H, Knudsen E, Li YS, Quartermain D, Frangione B, Wisniewski T, Sigurdsson EM. Vaccination of Alzheimer's model mice with A&#x3b2; derivative in alum adjuvant reduces A&#x3b2; burden without microhemorrhages. Eur J Neurosci. 2006;24:2530&#x2013;2542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779823</ArticleId><ArticleId IdType="pubmed">17100841</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE. Passage of amyloid-&#x3b2; protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides. 2002;23:2223&#x2013;2226.</Citation><ArticleIdList><ArticleId IdType="pubmed">12535702</ArticleId></ArticleIdList></Reference><Reference><Citation>Broadwell RD, Sofroniew MV. Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system. Exp Neurol. 1993;120:245&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">8491281</ArticleId></ArticleIdList></Reference><Reference><Citation>Carro E, Nunez A, Busiguina S, Torres-Aleman I. Circulating insulin-like growth factor I mediates effects of exercise on the brain. J Neurosci. 2000;20:2926&#x2013;2933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772191</ArticleId><ArticleId IdType="pubmed">10751445</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Barnett JL, Pieroni C, Nixon RA. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased &#x3b2;-amyloidogenesis. J Neurosci. 1997;17:6142&#x2013;6151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568334</ArticleId><ArticleId IdType="pubmed">9236226</ArticleId></ArticleIdList></Reference><Reference><Citation>Connell JW, Gibb GM, Betts JC, Blackstock WP, Gallo J, Lovestone S, Hutton M, Anderton BH. Effects of FTDP-17 mutations on the in vitro phosphorylation of tau by glycogen synthase kinase 3&#x3b2; identified by mass spectrometry demonstrate certain mutations exert long-range conformational changes. FEBS Lett. 2001;493:40&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">11278002</ArticleId></ArticleIdList></Reference><Reference><Citation>Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, Pasquier F, David JP. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology. 2002;59:398&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">12177374</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey CA, Eriksen J, Kamal A, Burrows F, Kasibhatla S, Eckman CB, Hutton M, Petrucelli L. Development of a high throughput drug screening assay for the detection of changes in tau levels&#x2014;proof of concept with HSP90 inhibitors. Curr Alzheimer Res. 2005;2:231&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">15974923</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietzschold B, Kao M, Zheng YM, Chen ZY, Maul G, Fu ZF, Rupprecht CE, Koprowski H. Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system. Proc Natl Acad Sci USA. 1992;89:7252&#x2013;7256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49684</ArticleId><ArticleId IdType="pubmed">1496020</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabian RH. Uptake of antineuronal IgM by CNS neurons: comparison with antineuronal IgG. Neurology. 1990;40:419&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">1690363</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabian RH, Petroff G. Intraneuronal IgG in the central nervous system: uptake by retrograde axonal transport. Neurology. 1987;37:1780&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pubmed">2444904</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabian RH, Ritchie TC. Intraneuronal IgG in the central nervous system. J Neurol Sci. 1986;73:257&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">3522806</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-&#x3b2; immunization in Alzheimer's disease. Brain Pathol. 2004;14:11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095815</ArticleId><ArticleId IdType="pubmed">14997933</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulga TA, Elson-Schwab I, Khurana V, Steinhilb ML, Spires TL, Hyman BT, Feany MB. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol. 2007;9:139&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">17187063</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Tau protein and neurodegeneration. Semin Cell Dev Biol. 2004;15:45&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">15036206</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonias SL, Wu LH, Salicioni AM. Low density lipoprotein receptor-related protein: regulation of the plasma membrane proteome. Thromb Haemost. 2004;91:1056&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">15175790</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Chen F, Barmettler R, Nitsch RM. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem. 2001a;276:529&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">11013246</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Chen F, Van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by A&#x3b2;42 fibrils. Science. 2001b;293:1491&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SG, Davies P, Schein JD, Binder LI. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem. 1992;267:564&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">1370450</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz J, Kowal RC, Ho YK, Brown MS, Goldstein JL. Low-density-lipoprotein receptor-related protein mediates endocytosis of monoclonal-antibodies in cultured-cells and rabbit liver. J Biol Chem. 1990;265:21355&#x2013;21362.</Citation><ArticleIdList><ArticleId IdType="pubmed">2250029</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Grundke-Iqbal I. Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer's disease and other tauopathies. Curr Drug Targets. 2004;5:495&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">15270196</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Bowser R, Kazam IG, Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res. 1997;48:128&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">9130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Berenfeld B, Davies P. Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease. J Neurosci Res. 1999;55:713&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">10220112</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopf PM, Harling-Berg CJ, Cserr HF, Basu D, Sirulnick EJ, Nolan SC, Park JT, Keir G, Thompson EJ, Hickey WF. Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. J Immunol. 1998;161:692&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">9670944</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted &#x3b2;-amyloid precursor protein and mediates its degradation. Cell. 1995;82:331&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">7543026</ArticleId></ArticleIdList></Reference><Reference><Citation>LaRue B, Hogg E, Sagare A, Jovanovic S, Maness L, Maurer C, Deane R, Zlokovic BV. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-&#x3b2; peptide in wild type and Alzheimer's Tg2576 mice. J Neurosci Methods. 2004;138:233&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">15325132</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul MM, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu HM, Atack JR, Rapoport SI. Immunohistochemical localization of intracellular plasma proteins in the human central nervous system. Acta Neuropathol (Berl) 1989;78:16&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">2735186</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645&#x2013;2668.</Citation><ArticleIdList><ArticleId IdType="pubmed">15389672</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D. A&#x3b2; vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005a;64:129&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642916</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D. Effects of &#x3b1;-synuclein immunization in a mouse model of Parkinson's disease. Neuron. 2005b;46:857&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">15953415</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaelis ML, Ansar S, Chen Y, Reiff ER, Seyb KI, Himes RH, Audus KL, Georg GI. &#x3b2;-Amyloid-induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents. J Pharmacol Exp Ther. 2005;312:659&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pubmed">15375176</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed HA, Mosier DR, Zou LL, Siklos L, Alexianu ME, Engelhardt JI, Beers DR, Le WD, Appel SH. Immunoglobulin Fc gamma receptor promotes immunoglobulin uptake, immunoglobulin-mediated calcium increase, and neurotransmitter release in motor neurons. J Neurosci Res. 2002;69:110&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111822</ArticleId></ArticleIdList></Reference><Reference><Citation>Nerenberg ST, Prasad R. Radioimmunoassays for Ig classes G, A, M, D, and E in spinal fluids: normal values of different age groups. J Lab Clin Med. 1975;86:887&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">1185045</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-&#x3b2; peptide: a case report. Nat Med. 2003;9:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640446</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA. 2005;102:6990&#x2013;6995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1088065</ArticleId><ArticleId IdType="pubmed">15867159</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. A&#x3b2; immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294141</ArticleId></ArticleIdList></Reference><Reference><Citation>Otvos L, Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res. 1994;39:669&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">7534834</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris D, Town T, Parker TA, Tan J, Humphrey J, Crawford F, Mullan M. Inhibition of Alzheimer's &#x3b2;-amyloid induced vasoactivity and proinflammatory response in microglia by a cGMP-dependent mechanism. Exp Neurol. 1999;157:211&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">10222124</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickhardt M, Gazova Z, von Bergen M, Khlistunova I, Wang Y, Hascher A, Mandelkow EM, Biernat J, Mandelkow E. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J Biol Chem. 2005;280:3628&#x2013;3635.</Citation><ArticleIdList><ArticleId IdType="pubmed">15525637</ArticleId></ArticleIdList></Reference><Reference><Citation>Poduslo JF, Curran GL, Wengenack TM, Malester B, Duff K. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001;8:555&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">11493021</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis A, Wiederholt WC, Raskind M, Schellenberg GD. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998;43:815&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport SI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol. 2000;20:217&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11537517</ArticleId><ArticleId IdType="pubmed">10696511</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribe EM, Perez M, Puig B, Gich I, Lim F, Cuadrado M, Sesma T, Catena S, Sanchez B, Nieto M, Gomez-Ramos P, Moran MA, Cabodevilla F, Samaranch L, Ortiz L, Perez A, Ferrer I, Avila J, Gomez-Isla T. Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis. 2005;20:814&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">16125396</ArticleId></ArticleIdList></Reference><Reference><Citation>Rye DB, Leverenz J, Greenberg SG, Davies P, Saper CB. The distribution of Alz-50 immunoreactivity in the normal human brain. Neuroscience. 1993;56:109&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232910</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahara N, Lewis J, McGowan E, Dickson DW, Hutton M, Yen SHC, Lee G. Temporal expression and phosphorylation of tau in P301L mutant tau transgenic mice. Neurobiol Aging. 2002;23:S552&#x2013;S553.</Citation></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D. Amyloid-&#x3b2; immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci. 2002;3:824&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">12360327</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmittgen TD, Zakrajsek BA. Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. J Biochem Biophys Methods. 2000;46:69&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">11086195</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM. Histological staining of amyloid-&#x3b2; in mouse brains. Methods Mol Biol. 2005;299:299&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980613</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM. Immunotherapy for conformational diseases. Curr Pharm Des. 2006;12:2569&#x2013;2585.</Citation><ArticleIdList><ArticleId IdType="pubmed">16842179</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM, Lorens SA, Hejna MJ, Dong XW, Lee JM. Local and distant histopathological effects of unilateral amyloid-&#x3b2; 25&#x2013;35 injections into the amygdala of young F344 rats. Neurobiol Aging. 1996;17:893&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">9363801</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM, Lee JM, Dong XW, Hejna MJ, Lorens SA. Bilateral injections of amyloid-&#x3b2; 25&#x2013;35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects. Neurobiol Aging. 1997;18:591&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">9461057</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T. Immunization with a non-toxic/non-fibrillar amyloid-&#x3b2; homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am J Pathol. 2001;159:439&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850561</ArticleId><ArticleId IdType="pubmed">11485902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, Goni F, Frangione B, Wisniewski T. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-&#x3b2; derivatives. J Neurosci. 2004;24:6277&#x2013;6282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729550</ArticleId><ArticleId IdType="pubmed">15254082</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM, Wadghiri YZ, Mosconi L, Blind JA, Knudsen E, Asuni A, Scholtzova H, Tsui WH, Li Y, Sadowski M, Turnbull DH, deLeon M, Wisniewski T. A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol Aging. 2007 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408732</ArticleId><ArticleId IdType="pubmed">17291630</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Bird TD, Ghetti B. Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathol. 1998;8:387&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098460</ArticleId><ArticleId IdType="pubmed">9546295</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Orne JD, Santacruz K, Pitstick R, Carlson GA, Ashe KH, Hyman BT. Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol. 2006;168:1598&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1606598</ArticleId><ArticleId IdType="pubmed">16651626</ArticleId></ArticleIdList></Reference><Reference><Citation>Tampellini D, Magran&#xe9; J, Takahashi RH, Li F, Lin MT, Almeida CG, Gouras GK. Internalized antibodies to the A&#x3b2; domain of APP reduce neuronal A&#x3b2; and protect against synaptic alterations. J Biol Chem. 2007;282:18895&#x2013;18906.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468102</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD. Neuropathological changes in Alzheimer disease. Prog Brain Res. 1994;101:383&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">8029466</ArticleId></ArticleIdList></Reference><Reference><Citation>The TH, Feltkamp TE. Conjugation of fluorescein isothiocyanate to antibodies II. A reproducible method. Immunology. 1970;18:875&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1455722</ArticleId><ArticleId IdType="pubmed">4913804</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres EM, Perry TA, Blockland A, Wilkinson LS, Wiley RG, Lappi DA, Dunnet SB. Behavioural, histochemical and biochemical consequences of selective immunolesions in discrete regions of the basal forebrain cholinergic system. Neuroscience. 1994;63:95&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">7898665</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadghiri YZ, Sigurdsson EM, Sadowski M, Elliott JI, Li Y, Scholtzova H, Tang CY, Aguinaldo G, Pappolla M, Duff K, Wisniewski T, Turnbull DH. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med. 2003;50:293&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">12876705</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver CL, Espinoza M, Kress Y, Davies P. Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging. 2000;21:719&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">11016541</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, Lee EB, Xie SX, Joyce S, Li C, Toleikis PM, Lee VM, Trojanowski JQ. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA. 2005;102:227&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC544048</ArticleId><ArticleId IdType="pubmed">15615853</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Skundric DS, Segal MB, Lipovac MN, Mackic JB, Davson H. A saturable mechanism for transport of immunoglobulin G across the blood-brain barrier of the guinea pig. Exp Neurol. 1990;107:263&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">1689666</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17716969</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>282</Volume><Issue>43</Issue><PubDate><Year>2007</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy.</ArticleTitle><Pagination><StartPage>31755</StartPage><EndPage>31765</EndPage><MedlinePgn>31755-65</MedlinePgn></Pagination><Abstract><AbstractText>Neurofibrillary lesions are characteristic for a group of human diseases, named tauopathies, which are characterized by prominent intracellular accumulations of abnormal filaments formed by the microtubule-associated protein Tau. The tauopathies are accompanied by abnormal changes in Tau protein, including pathological conformation, somatodendritic mislocalization, hyperphosphorylation, and aggregation, whose interdependence is not well understood. To address these issues we have created transgenic mouse lines in which different variants of full-length Tau are expressed in a regulatable fashion, allowing one to switch the expression on and off at defined time points. The Tau variants differ by small mutations in the hexapeptide motifs that control the ability of Tau to adopt a beta-structure conformation and hence to aggregate. The "pro-aggregation" mutant DeltaK280, derived from one of the mutations observed in frontotemporal dementias, aggregates avidly in vitro, whereas the "anti-aggregation" mutant DeltaK280/PP cannot aggregate because of two beta-breaking prolines. In the transgenic mice, the pro-aggregation Tau induces a pathological conformation and pre-tangle aggregation, even at low expression levels, the anti-aggregation mutant does not. This illustrates that abnormal aggregation is primarily controlled by the molecular structure of Tau in vitro and in the organism. Both variants of Tau become mislocalized and hyperphosphorylated independently of aggregation, suggesting that localization and phosphorylation are mainly a consequence of increased concentration. These pathological changes are reversible when the expression of Tau is switched off. The pro-aggregation Tau causes a strong reduction in spine synapses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eckermann</LastName><ForeName>Katrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Max-Planck Unit for Structural Molecular Biology, Notkestrasse 85, 22607 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mocanu</LastName><ForeName>Maria-Magdalena</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Khlistunova</LastName><ForeName>Inna</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Biernat</LastName><ForeName>Jacek</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Nissen</LastName><ForeName>Astrid</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hofmann</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sch&#xf6;nig</LastName><ForeName>Kai</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Bujard</LastName><ForeName>Hermann</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Haemisch</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eckhard</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Lepu</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Rune</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17716969</ArticleId><ArticleId IdType="doi">10.1074/jbc.M705282200</ArticleId><ArticleId IdType="pii">S0021-9258(20)68700-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17717139</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0002-9440</ISSN><JournalIssue CitedMedium="Print"><Volume>171</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The American journal of pathology</Title><ISOAbbreviation>Am J Pathol</ISOAbbreviation></Journal><ArticleTitle>Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model.</ArticleTitle><Pagination><StartPage>1304</StartPage><EndPage>1311</EndPage><MedlinePgn>1304-11</MedlinePgn></Pagination><Abstract><AbstractText>Dendritic spines, the site of most excitatory synapses in the brain, are lost in Alzheimer's disease and in related mouse models, undoubtedly contributing to cognitive dysfunction. We hypothesized that spine loss results from plaque-associated alterations of spine stability, causing an imbalance in spine formation and elimination. To investigate effects of plaques on spine stability in vivo, we observed cortical neurons using multiphoton microscopy in a mouse model of amyloid pathology before and after extensive plaque deposition. We also observed age-matched nontransgenic mice to study normal effects of aging on spine plasticity. We found that spine density and structural plasticity are maintained during normal aging. Tg2576 mice had normal spine density and plasticity before plaques appeared, but after amyloid pathology is established, severe disruptions were observed. In control animals, spine formation and elimination were equivalent over 1 hour of observation ( approximately 5% of observed spines), resulting in stable spine density. However, in aged Tg2576 mice spine elimination increased, specifically in the immediate vicinity of plaques. Spine formation was unchanged, resulting in spine loss. These data show a small population of rapidly changing spines in adult and even elderly mouse cortex; further, in the vicinity of amyloid plaques, spine stability is markedly impaired leading to loss of synaptic structural integrity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spires-Jones</LastName><ForeName>Tara L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital/ Harvard Medical School, Charlestown, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer-Luehmann</LastName><ForeName>Melanie</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Osetek</LastName><ForeName>Jennifer D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Phillip B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Edward A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Bacskai</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG008487</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000277</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB000768</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG00277</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08487</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Pathol</MedlineTA><NlmUniqueID>0370502</NlmUniqueID><ISSNLinking>0002-9440</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17717139</ArticleId><ArticleId IdType="pmc">PMC1988879</ArticleId><ArticleId IdType="doi">10.2353/ajpath.2007.070055</ArticleId><ArticleId IdType="pii">S0002-9440(10)62393-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hyman BT, Van Horsen GW, Damasio AR, Barnes CL. Alzheimer&#x2019;s disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;225:1168&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">6474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Hyman BT. Neuronal structure is altered by amyloid plaques. Rev Neurosci. 2004;15:267&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">15526551</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW, Styren SD. Structural correlates of cognition in dementia: quantification and assessment of synapse change. Neurodegeneration. 1996;5:417&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">9117556</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Hansen L, DeTeresa R, Alford M, Terry R. Synaptic and neuritic alterations during the progression of Alzheimer&#x2019;s disease. Neurosci Lett. 1994;174:67&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">7970158</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman PD, Yao PJ. Synaptic slaughter in Alzheimer&#x2019;s disease. Neurobiol Aging. 2003;24:1023&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643374</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris KM. Structure, development, and plasticity of dendritic spines. Curr Opin Neurobiol. 1999;9:343&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">10395574</ArticleId></ArticleIdList></Reference><Reference><Citation>Matus A. Growth of dendritic spines: a continuing story. Curr Opin Neurobiol. 2005;15:67&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">15721746</ArticleId></ArticleIdList></Reference><Reference><Citation>Majewska A, Sur M. Motility of dendritic spines in visual cortex in vivo: changes during the critical period and effects of visual deprivation. Proc Natl Acad Sci USA. 2003;100:16024&#x2013;16029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC307686</ArticleId><ArticleId IdType="pubmed">14663137</ArticleId></ArticleIdList></Reference><Reference><Citation>Matus A. Actin-based plasticity in dendritic spines. Science. 2000;290:754&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">11052932</ArticleId></ArticleIdList></Reference><Reference><Citation>Lendvai B, Stern EA, Chen B, Svoboda K. Experience-dependent plasticity of dendritic spines in the developing rat barrel cortex in vivo. Nature. 2000;404:876&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">10786794</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern EA, Maravall M, Svoboda K. Rapid development and plasticity of layer 2/3 maps in rat barrel cortex in vivo. Neuron. 2001;31:305&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">11502260</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmaat AJ, Trachtenberg JT, Wilbrecht L, Shepherd GM, Zhang X, Knott GW, Svoboda K. Transient and persistent dendritic spines in the neocortex in vivo. Neuron. 2005;45:279&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">15664179</ArticleId></ArticleIdList></Reference><Reference><Citation>Trachtenberg JT, Chen BE, Knott GW, Feng G, Sanes JR, Welker E, Svoboda K. Long-term in vivo imaging of experience-dependent synaptic plasticity in adult cortex. Nature. 2002;420:788&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">12490942</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala JC, Spacek J, Harris KM. Dendritic spine pathology: cause or consequence of neurological disorders? Brain Res Brain Res Rev. 2002;39:29&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12086707</ArticleId></ArticleIdList></Reference><Reference><Citation>Catala I, Ferrer I, Galofre E, Fabregues I. Decreased numbers of dendritic spines on cortical pyramidal neurons in dementia. A quantitative Golgi study on biopsy samples. Hum Neurobiol. 1988;6:255&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">3350705</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies CA, Mann DM, Sumpter PQ, Yates PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer&#x2019;s disease. J Neurol Sci. 1987;78:151&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">3572454</ArticleId></ArticleIdList></Reference><Reference><Citation>de Ruiter JP, Uylings HB. Morphometric and dendritic analysis of fascia dentata granule cells in human aging and senile dementia. Brain Res. 1987;402:217&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">3828794</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Toward a comprehensive theory for Alzheimer&#x2019;s disease. Hypothesis: Alzheimer&#x2019;s disease is caused by the cerebral accumulation and cytotoxicity of amyloid &#x3b2;-protein. Ann NY Acad Sci. 2000;924:17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193794</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz TA, Carter DB, Merchant KM. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol Dis. 2003;13:246&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">12901839</ArticleId></ArticleIdList></Reference><Reference><Citation>Moolman DL, Vitolo OV, Vonsattel JP, Shelanski ML. Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol. 2004;33:377&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">15475691</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci. 2004;7:1181&#x2013;1183.</Citation><ArticleIdList><ArticleId IdType="pubmed">15475950</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005;25:7278&#x2013;7287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, A&#x3b2; elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, Debnath ML, Holt DP, Wang Y, Hyman BT. Imaging A&#x3b2; plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol. 2002;61:797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">12230326</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT. Non-Fc-mediated mechanisms are involved in clearance of amyloid-&#x3b2; in vivo by immunotherapy. J Neurosci. 2002;22:7873&#x2013;7878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758112</ArticleId><ArticleId IdType="pubmed">12223540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardo JA, Stern EA, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ, Hyman BT. Amyloid-&#x3b2; antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci. 2003;23:10879&#x2013;10883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740984</ArticleId><ArticleId IdType="pubmed">14645482</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoch J, Hickey GA, Kajdasz ST, Hyman BT, Bacskai BJ. In vivo imaging of amyloid-&#x3b2; deposits in mouse brain with multiphoton microscopy. Sigurdsson EM, editor. Totowa: Humana Press,; Amyloid proteinsmethods and protocols. 2004:pp 349&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Molnar Z, Kind PC, Cordery PM, Upton AL, Blakemore C, Hannan AJ. Activity-dependent regulation of synapse and dendritic spine morphology in developing barrel cortex requires phospholipase C-&#x3b2;1 signalling. Cereb Cortex. 2005;15:385&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">15749982</ArticleId></ArticleIdList></Reference><Reference><Citation>Majewska A, Tashiro A, Yuste R. Regulation of spine calcium dynamics by rapid spine motility. J Neurosci. 2000;20:8262&#x2013;8268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773195</ArticleId><ArticleId IdType="pubmed">11069932</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert V, Da Silva JS, Dotti CG. Localized recruitment and activation of RhoA underlies dendritic spine morphology in a glutamate receptor-dependent manner. J Cell Biol. 2006;172:453&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2063654</ArticleId><ArticleId IdType="pubmed">16449195</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke SN, Barnes CA. Neural plasticity in the ageing brain. Nat Rev Neurosci. 2006;7:30&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">16371948</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, Lin A, Chang P, Gan WB. Development of long-term dendritic spine stability in diverse regions of cerebral cortex. Neuron. 2005;46:181&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">15848798</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of the amyloid-&#x3b2; protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM, Gouras GK. &#x3b2;-Amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis. 2005;20:187&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">16242627</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2006;103:5161&#x2013;5166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1405622</ArticleId><ArticleId IdType="pubmed">16549764</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern EA, Bacskai BJ, Hickey GA, Attenello FJ, Lombardo JA, Hyman BT. Cortical synaptic integration in vivo is disrupted by amyloid-&#x3b2; plaques. J Neurosci. 2004;24:4535&#x2013;4540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729398</ArticleId><ArticleId IdType="pubmed">15140924</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles RB, Wyart C, Buldyrev SV, Cruz L, Urbanc B, Hasselmo ME, Stanley HE, Hyman BT. Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 1999;96:5274&#x2013;5279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21854</ArticleId><ArticleId IdType="pubmed">10220456</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles RB, Gomez-Isla T, Hyman BT. A&#x3b2; associated neuropil changes: correlation with neuronal loss and dementia. J Neuropathol Exp Neurol. 1998;57:1122&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862634</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amore JD, Kajdasz ST, McLellan ME, Bacskai BJ, Stern EA, Hyman BT. In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories. J Neuropathol Exp Neurol. 2003;62:137&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">12578223</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson TC, Vickers JC. The morphological phenotype of &#x3b2;-amyloid plaques and associated neuritic changes in Alzheimer&#x2019;s disease. Neuroscience. 2001;105:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">11483304</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL. Synaptic targeting by Alzheimer&#x2019;s-related amyloid &#x3b2; oligomers. J Neurosci. 2004;24:10191&#x2013;10200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730194</ArticleId><ArticleId IdType="pubmed">15537891</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. Regulation of NMDA receptor trafficking by amyloid-&#x3b2;. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P, Morabito M, Almeida OF. Soluble &#x3b2;-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci. 2005;25:11061&#x2013;11070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725651</ArticleId><ArticleId IdType="pubmed">16319306</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, Khan K, Seubert P, Freedman S, Schenk D, Games D. &#x3b2;-Amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer&#x2019;s disease. J Neurosci. 2005;25:9096&#x2013;9101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725749</ArticleId><ArticleId IdType="pubmed">16207868</ArticleId></ArticleIdList></Reference><Reference><Citation>McLellan ME, Kajdasz ST, Hyman BT, Bacskai BJ. In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J Neurosci. 2003;23:2212&#x2013;2217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742052</ArticleId><ArticleId IdType="pubmed">12657680</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC. Contribution of glial cells to the development of amyloid plaques in Alzheimer&#x2019;s disease. Neurobiol Aging. 2004;25:663&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172746</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2000;97:2892&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, Gimbel DA, GrandPre T, Lee J-K, Kim J-E, Li W, Lee DH, Strittmatter SM. Alzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-&#x3b2; plaque deposition. J Neurosci. 2006;26:1386&#x2013;1395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2846286</ArticleId><ArticleId IdType="pubmed">16452662</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert V, Dotti CG. Transmitting on actin: synaptic control of dendritic architecture. J Cell Sci. 2007;120:205&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">17215449</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu HT, Pan F, Yang G, Gan WB. Choice of cranial window type for in vivo imaging affects dendritic spine turnover in the cortex. Nat Neurosci. 2007;10:549&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">17417634</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17721511</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1087-0156</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>9</Issue><PubDate><Year>2007</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature biotechnology</Title><ISOAbbreviation>Nat Biotechnol</ISOAbbreviation></Journal><ArticleTitle>Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.</ArticleTitle><Pagination><StartPage>1035</StartPage><EndPage>1044</EndPage><MedlinePgn>1035-44</MedlinePgn></Pagination><Abstract><AbstractText>We describe a chemical proteomics approach to profile the interaction of small molecules with hundreds of endogenously expressed protein kinases and purine-binding proteins. This subproteome is captured by immobilized nonselective kinase inhibitors (kinobeads), and the bound proteins are quantified in parallel by mass spectrometry using isobaric tags for relative and absolute quantification (iTRAQ). By measuring the competition with the affinity matrix, we assess the binding of drugs to their targets in cell lysates and in cells. By mapping drug-induced changes in the phosphorylation state of the captured proteome, we also analyze signaling pathways downstream of target kinases. Quantitative profiling of the drugs imatinib (Gleevec), dasatinib (Sprycel) and bosutinib in K562 cells confirms known targets including ABL and SRC family kinases and identifies the receptor tyrosine kinase DDR1 and the oxidoreductase NQO2 as novel targets of imatinib. The data suggest that our approach is a valuable tool for drug discovery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bantscheff</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cellzome AG, Meyerhofstrasse 1, D-69117 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eberhard</LastName><ForeName>Dirk</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>Yann</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Bastuck</LastName><ForeName>Sonja</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Boesche</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hobson</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mathieson</LastName><ForeName>Toby</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Perrin</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Raida</LastName><ForeName>Manfred</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rau</LastName><ForeName>Christina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Reader</LastName><ForeName>Val&#xe9;rie</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Sweetman</LastName><ForeName>Gavain</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bouwmeester</LastName><ForeName>Tewis</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hopf</LastName><ForeName>Carsten</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kruse</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Neubauer</LastName><ForeName>Gitte</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Ramsden</LastName><ForeName>Nigel</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Rick</LastName><ForeName>Jens</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kuster</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Drewes</LastName><ForeName>Gerard</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Biotechnol</MedlineTA><NlmUniqueID>9604648</NlmUniqueID><ISSNLinking>1087-0156</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001549">Benzamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002457">Cell Extracts</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004800">Enzymes, Immobilized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>8A1O1M485B</RegistryNumber><NameOfSubstance UI="D000068877">Imatinib Mesylate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.99.-</RegistryNumber><NameOfSubstance UI="C419642">NRH - quinone oxidoreductase2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.99.-</RegistryNumber><NameOfSubstance UI="D011808">Quinone Reductases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C092030">DDR1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D000070819">Discoidin Domain Receptor 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D020794">Receptor Protein-Tyrosine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="D016315">Proto-Oncogene Proteins c-abl</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Biotechnol. 2007 Sep;25(9):994-6. doi: 10.1038/nbt0907-994.</RefSource><PMID Version="1">17846628</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002457" MajorTopicYN="N">Cell Extracts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002846" MajorTopicYN="N">Chromatography, Affinity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070819" MajorTopicYN="N">Discoidin Domain Receptor 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004800" MajorTopicYN="N">Enzymes, Immobilized</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068877" MajorTopicYN="N">Imatinib Mesylate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020014" MajorTopicYN="N">K562 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016315" MajorTopicYN="N">Proto-Oncogene Proteins c-abl</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011808" MajorTopicYN="N">Quinone Reductases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020794" MajorTopicYN="N">Receptor Protein-Tyrosine Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17721511</ArticleId><ArticleId IdType="doi">10.1038/nbt1328</ArticleId><ArticleId IdType="pii">nbt1328</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17724122</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9525</ISSN><JournalIssue CitedMedium="Print"><Volume>178</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>Aug</Month><Day>27</Day></PubDate></JournalIssue><Title>The Journal of cell biology</Title><ISOAbbreviation>J Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice.</ArticleTitle><Pagination><StartPage>829</StartPage><EndPage>841</EndPage><MedlinePgn>829-41</MedlinePgn></Pagination><Abstract><AbstractText>The tumor necrosis factor type 1 death receptor (TNFR1) contributes to apoptosis. TNFR1, a subgroup of the TNFR superfamily, contains a cytoplasmic death domain. We recently demonstrated that the TNFR1 cascade is required for amyloid beta protein (Abeta)-induced neuronal death. However, the function of TNFR1 in Abeta plaque pathology and amyloid precursor protein (APP) processing in Alzheimer's disease (AD) remains unclear. We report that the deletion of the TNFR1 gene in APP23 transgenic mice (APP23/TNFR1(-/-)) inhibits Abeta generation and diminishes Abeta plaque formation in the brain. Genetic deletion of TNFR1 leads to reduced beta-secretase 1 (BACE1) levels and activity. TNFR1 regulates BACE1 promoter activity via the nuclear factor-kappaB pathway, and the deletion of TNFR1 in APP23 transgenic mice prevents learning and memory deficits. These findings suggest that TNFR1 not only contributes to neurodegeneration but also that it is involved in APP processing and Abeta plaque formation. Thus, TNFR1 is a novel therapeutic target for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Haldeman Laboratory of Molecular and Cellular Neurobiology, Sun Health Research Institute, Sun City, AZ 85351, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Zhenyu</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Lindholm</LastName><ForeName>Kristina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Berning</LastName><ForeName>Lilian</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Lemere</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Rena</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG025888</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025888</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cell Biol</MedlineTA><NlmUniqueID>0375356</NlmUniqueID><ISSNLinking>0021-9525</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047888">Receptors, Tumor Necrosis Factor, Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.11</RegistryNumber><NameOfSubstance UI="D015260">Neprilysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.56</RegistryNumber><NameOfSubstance UI="D007339">Insulysin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="Y">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007339" MajorTopicYN="N">Insulysin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="Y">Memory Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015260" MajorTopicYN="N">Neprilysin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047888" MajorTopicYN="N">Receptors, Tumor Necrosis Factor, Type I</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>2</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17724122</ArticleId><ArticleId IdType="pmc">PMC2064547</ArticleId><ArticleId IdType="doi">10.1083/jcb.200705042</ArticleId><ArticleId IdType="pii">jcb.200705042</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ashkenazi, A., and V.M. Dixit. 1998. Death receptors: signaling and modulation. Science. 281:1305&#x2013;1308.</Citation><ArticleIdList><ArticleId IdType="pubmed">9721089</ArticleId></ArticleIdList></Reference><Reference><Citation>Atwood, C.S., G. Perry, and M.A. Smith. 2003. Cerebral hemorrhage and amyloid-beta. Science. 299:1014.</Citation><ArticleIdList><ArticleId IdType="pubmed">12586924</ArticleId></ArticleIdList></Reference><Reference><Citation>Barger, S.W., D. Horster, K. Furukawa, Y. Goodman, J. Krieglstein, and M.P. Mattson. 1995. Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc. Natl. Acad. Sci. USA. 92:9328&#x2013;9332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40978</ArticleId><ArticleId IdType="pubmed">7568127</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldin, M.P., I.L. Mett, E.E. Varfolomeev, I. Chumakov, Y. Shemer-Avni, J.H. Camonis, and D. Wallach. 1995. Self-association of the &#x201c;death domains&#x201d; of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J. Biol. Chem. 270:387&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">7529234</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourtchouladze, R., R. Lidge, R. Catapano, J. Stanley, S. Gossweiler, D. Romashko, R. Scott, and T. Tully. 2003. A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc. Natl. Acad. Sci. USA. 100:10518&#x2013;10522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193593</ArticleId><ArticleId IdType="pubmed">12930888</ArticleId></ArticleIdList></Reference><Reference><Citation>Brosnan-Watters, G., and D.F. Wozniak. 1997. A rotating holeboard procedure for testing drug effects on spatial learning and memory in mice. Brain Res. Brain Res. Protoc. 1:331&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">9384812</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce, A.J., W. Boling, M.S. Kindy, J. Peschon, P.J. Kraemer, M.K. Carpenter, F.W. Holtsberg, and M.P. Mattson. 1996. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat. Med. 2:788&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">8673925</ArticleId></ArticleIdList></Reference><Reference><Citation>Cagnin, A., D.J. Brooks, A.M. Kennedy, R.N. Gunn, R. Myers, F.E. Turkheimer, T. Jones, and R.B. Banati. 2001. In-vivo measurement of activated microglia in dementia. Lancet. 358:461&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">11513911</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun, M.E., K.H. Wiederhold, D. Abramowski, A.L. Phinney, A. Probst, C. Sturchler-Pierrat, M. Staufenbiel, B. Sommer, and M. Jucker. 1998. Neuron loss in APP transgenic mice. Nature. 395:755&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">9796810</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun, M.E., P. Burgermeister, A.L. Phinney, M. Stalder, M. Tolnay, K.H. Wiederhold, D. Abramowski, C. Sturchler-Pierrat, B. Sommer, M. Staufenbiel, and M. Jucker. 1999. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc. Natl. Acad. Sci. USA. 96:14088&#x2013;14093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24195</ArticleId><ArticleId IdType="pubmed">10570203</ArticleId></ArticleIdList></Reference><Reference><Citation>Casas, C., N. Sergeant, J.M. Itier, V. Blanchard, O. Wirths, N. van der Kolk, V. Vingtdeux, E. van de Steeg, G. Ret, T. Canton, et al. 2004. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am. J. Pathol. 165:1289&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618627</ArticleId><ArticleId IdType="pubmed">15466394</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen, M.A., W. Zhou, H. Qing, A. Lehman, S. Philipsen, and W. Song. 2004. Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Mol. Cell. Biol. 24:865&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC343820</ArticleId><ArticleId IdType="pubmed">14701757</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen, D.L., P. Hedera, D.R. Premkumar, R.P. Friedland, and R.N. Kalaria. 1997. Amyloid-beta protein angiopathies masquerading as Alzheimer's disease? Ann. NY Acad. Sci. 826:390&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329710</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart, J.C., K.R. Bales, K.S. Gannon, S.J. Greene, R.B. DeMattos, C. Mathis, C.A. DeLong, S. Wu, X. Wu, D.M. Holtzman, and S.M. Paul. 2002. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5:452&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941374</ArticleId></ArticleIdList></Reference><Reference><Citation>Farris, W., S. Mansourian, Y. Chang, L. Lindsley, E.A. Eckman, M.P. Frosch, C.B. Eckman, R.E. Tanzi, D.J. Selkoe, and S. Guenette. 2003. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. USA. 100:4162&#x2013;4167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC153065</ArticleId><ArticleId IdType="pubmed">12634421</ArticleId></ArticleIdList></Reference><Reference><Citation>Frid, P., S.V. Anisimov, and N. Popovic. 2007. Congo red and protein aggregation in neurodegenerative diseases. Brain Res. Rev. 53:135&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">16959325</ArticleId></ArticleIdList></Reference><Reference><Citation>Galimberti, D., N. Schoonenboom, P. Scheltens, C. Fenoglio, F. Bouwman, E. Venturelli, I. Guidi, M.A. Blankenstein, N. Bresolin, and E. Scarpini. 2006. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch. Neurol. 63:538&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pubmed">16606766</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia, J. 1987. Sharing research results with patients: the views of care-givers involved in a randomized controlled trial. J. Reprod. Infant Psychol. 5:9&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">11659937</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert, L.E., P.A. Scherr, J.L. Bienias, D.A. Bennett, and D.A. Evans. 2003. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60:1119&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925369</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong, H.S., E.M. Hwang, H.J. Sim, H.J. Cho, J.H. Boo, S.S. Oh, S.U. Kim, and I. Mook-Jung. 2003. Interferon gamma stimulates beta-secretase expression and sAPPbeta production in astrocytes. Biochem. Biophys. Res. Commun. 307:922&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">12878199</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao, K.K., D.R. Borchelt, K. Olson, R. Johannsdottir, C. Kitt, W. Yunis, S. Xu, C. Eckman, S. Younkin, D. Price, et al. 1995. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron. 15:1203&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">7576662</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu, H., J. Xiong, and D.V. Goeddel. 1995. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell. 81:495&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">7758105</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry, M.C., M. McNamara, K. Fedorchak, K. Hsiao, and B.T. Hyman. 1997. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 56:965&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291938</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh, Y., M. Yamada, M. Hayakawa, E. Otomo, and T. Miyatake. 1993. Cerebral amyloid angiopathy: a significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly. J. Neurol. Sci. 116:135&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">8336159</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, C., and L.B. Hersh. 1995. Neprilysin: assay methods, purification, and characterization. Methods Enzymol. 248:253&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">7674925</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, R., K. Lindholm, L.B. Yang, X. Yue, M. Citron, R. Yan, T. Beach, L. Sue, M. Sabbagh, H. Cai, et al. 2004. a. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc. Natl. Acad. Sci. USA. 101:3632&#x2013;3637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373514</ArticleId><ArticleId IdType="pubmed">14978286</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, R., L. Yang, K. Lindholm, Y. Konishi, X. Yue, H. Hampel, D. Zhang, and Y. Shen. 2004. b. Tumor necrosis factor death receptor signaling cascade is required for amyloid-beta protein-induced neuron death. J. Neurosci. 24:1760&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730458</ArticleId><ArticleId IdType="pubmed">14973251</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka, Y., M. Picciano, B. Malester, J. LaFrancois, C. Zehr, J.M. Daeschner, J.A. Olschowka, M.I. Fonseca, M.K. O'Banion, A.J. Tenner, et al. 2001. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 158:1345&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891893</ArticleId><ArticleId IdType="pubmed">11290552</ArticleId></ArticleIdList></Reference><Reference><Citation>Pak, T., P. Cadet, K.J. Mantione, and G.B. Stefano. 2005. Morphine via nitric oxide modulates beta-amyloid metabolism: a novel protective mechanism for Alzheimer's disease. Med. Sci. Monit. 11:BR357&#x2013;BR366.</Citation><ArticleIdList><ArticleId IdType="pubmed">16192893</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel, N.S., D. Paris, V. Mathura, A.N. Quadros, F.C. Crawford, and M.J. Mullan. 2005. Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J. Neuroinflammation. 2:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC555557</ArticleId><ArticleId IdType="pubmed">15762998</ArticleId></ArticleIdList></Reference><Reference><Citation>Peschon, J.J., D.S. Torrance, K.L. Stocking, M.B. Glaccum, C. Otten, C.R. Willis, K. Charrier, P.J. Morrissey, C.B. Ware, and K.M. Mohler. 1998. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J. Immunol. 160:943&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pubmed">9551933</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittenger, C., Y.Y. Huang, R.F. Paletzki, R. Bourtchouladze, H. Scanlin, S. Vronskaya, and E.R. Kandel. 2002. Reversible inhibition of CREB/ATF transcription factors in region CA1 of the dorsal hippocampus disrupts hippocampus-dependent spatial memory. Neuron. 34:447&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">11988175</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambamurti, K., R. Kinsey, B. Maloney, Y.W. Ge, and D.K. Lahiri. 2004. Gene structure and organization of the human beta-secretase (BACE) promoter. FASEB J. 18:1034&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pubmed">15059975</ArticleId></ArticleIdList></Reference><Reference><Citation>Sastre, M., I. Dewachter, S. Rossner, N. Bogdanovic, E. Rosen, P. Borghgraef, B.O. Evert, L. Dumitrescu-Ozimek, D.R. Thal, G. Landreth, et al. 2006. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl. Acad. Sci. USA. 103:443&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1326151</ArticleId><ArticleId IdType="pubmed">16407166</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura, C.A., G. Chen, S. Malkani, S.Y. Choi, R.H. Takahashi, D. Zhang, G.K. Gouras, A. Kirkwood, R.G. Morris, and J. Shen. 2005. Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J. Neurosci. 25:6755&#x2013;6764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725351</ArticleId><ArticleId IdType="pubmed">16033885</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz, C., B.P. Rutten, A. Pielen, S. Schafer, O. Wirths, G. Tremp, C. Czech, V. Blanchard, G. Multhaup, P. Rezaie, et al. 2004. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 164:1495&#x2013;1502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1615337</ArticleId><ArticleId IdType="pubmed">15039236</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe, D.J. 2003. Aging, amyloid, and Alzheimer's disease: a perspective in honor of Carl Cotman. Neurochem. Res. 28:1705&#x2013;1713.</Citation><ArticleIdList><ArticleId IdType="pubmed">14584824</ArticleId></ArticleIdList></Reference><Reference><Citation>Shyu, W.C., S.Z. Lin, M.F. Chiang, C.Y. Su, and H. Li. 2006. Intracerebral peripheral blood stem cell (CD34+) implantation induces neuroplasticity by enhancing beta1 integrin-mediated angiogenesis in chronic stroke rats. J. Neurosci. 26:3444&#x2013;3453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673856</ArticleId><ArticleId IdType="pubmed">16571751</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard, A.R., D. Soulet, G. Gowing, J.P. Julien, and S. Rivest. 2006. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron. 49:489&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476660</ArticleId></ArticleIdList></Reference><Reference><Citation>Skalli, O., P. Ropraz, A. Trzeciak, G. Benzonana, D. Gillessen, and G. Gabbiani. 1986. A monoclonal antibody against &#x3b1;-smooth muscle actin: a new probe for smooth muscle differentiation. J. Cell Biol. 103:2787&#x2013;2796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2114627</ArticleId><ArticleId IdType="pubmed">3539945</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommer, B., and M. Staufenbiel. 1998. A beta peptide deposition in the brains of transgenic mice: evidence for a key event in Alzheimer's disease pathogenesis. Mol. Psychiatry. 3:284&#x2013;286, 282&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">9702731</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, E.S., M.A. Juliano, L. Juliano, and L.B. Hersh. 2003. Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development. J. Biol. Chem. 278:49789&#x2013;49794.</Citation><ArticleIdList><ArticleId IdType="pubmed">14527953</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat, C., D. Abramowski, M. Duke, K.H. Wiederhold, C. Mistl, S. Rothacher, B. Ledermann, K. Burki, P. Frey, P.A. Paganetti, et al. 1997. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA. 94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamagno, E., P. Bardini, A. Obbili, A. Vitali, R. Borghi, D. Zaccheo, M.A. Pronzato, O. Danni, M.A. Smith, G. Perry, and M. Tabaton. 2002. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol. Dis. 10:279&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">12270690</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamagno, E., M. Parola, P. Bardini, A. Piccini, R. Borghi, M. Guglielmotto, G. Santoro, A. Davit, O. Danni, M.A. Smith, et al. 2005. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J. Neurochem. 92:628&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">15659232</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi, R.E., and L. Bertram. 2005. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarkowski, E., N. Andreasen, A. Tarkowski, and K. Blennow. 2003. Intrathecal inflammation precedes development of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 74:1200&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738668</ArticleId><ArticleId IdType="pubmed">12933918</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartaglia, L.A., M. Rothe, Y.F. Hu, and D.V. Goeddel. 1993. Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor. Cell. 73:213&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">8386591</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry, R.D., L.A. Hansen, R. DeTeresa, P. Davies, H. Tobias, and R. Katzman. 1987. Senile dementia of the Alzheimer type without neocortical neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 46:262&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">2881985</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal, D.R., E. Ghebremedhin, M. Orantes, and O.D. Wiestler. 2003. Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J. Neuropathol. Exp. Neurol. 62:1287&#x2013;1301.</Citation><ArticleIdList><ArticleId IdType="pubmed">14692704</ArticleId></ArticleIdList></Reference><Reference><Citation>Thifault, S., R. Lalonde, N. Sanon, and P. Hamet. 2002. Comparisons between C57BL/6J and A/J mice in motor activity and coordination, hole-poking, and spatial learning. Brain Res. Bull. 58:213&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">12127020</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian, J., J. Shi, K. Bailey, and D.M. Mann. 2003. Negative association between amyloid plaques and cerebral amyloid angiopathy in Alzheimer's disease. Neurosci. Lett. 352:137&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">14625042</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiraboschi, P., M.N. Sabbagh, L.A. Hansen, D.P. Salmon, A. Merdes, A. Gamst, E. Masliah, M. Alford, L.J. Thal, and J. Corey-Bloom. 2004. Alzheimer disease without neocortical neurofibrillary tangles: &#x201c;a second look.&#x201d; Neurology. 62:1141&#x2013;1147.</Citation><ArticleIdList><ArticleId IdType="pubmed">15079014</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobe, M., Y. Isobe, H. Tomizawa, T. Nagasaki, H. Takahashi, T. Fukazawa, and H. Hayashi. 2003. Discovery of quinazolines as a novel structural class of potent inhibitors of NF-kappa B activation. Bioorg. Med. Chem. 11:383&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">12517433</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dam, D., R. D'Hooge, M. Staufenbiel, C. Van Ginneken, F. Van Meir, and P.P. De Deyn. 2003. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur. J. Neurosci. 17:388&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">12542676</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dooren, T., D. Muyllaert, P. Borghgraef, A. Cresens, H. Devijver, I. Van der Auwera, S. Wera, I. Dewachter, and F. Van Leuven. 2006. Neuronal or glial expression of human apolipoprotein e4 affects parenchymal and vascular amyloid pathology differentially in different brain regions of double- and triple-transgenic mice. Am. J. Pathol. 168:245&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1592662</ArticleId><ArticleId IdType="pubmed">16400027</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar, R., B.D. Bennett, S. Babu-Khan, S. Kahn, E.A. Mendiaz, P. Denis, D.B. Teplow, S. Ross, P. Amarante, R. Loeloff, et al. 1999. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinters, H.V. 1987. Cerebral amyloid angiopathy. A critical review. Stroke. 18:311&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">3551211</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, H., G.D. Ferguson, V.V. Pineda, P.E. Cundiff, and D.R. Storm. 2004. Overexpression of type-1 adenylyl cyclase in mouse forebrain enhances recognition memory and LTP. Nat. Neurosci. 7:635&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">15133516</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner, H.L., and D.J. Selkoe. 2002. Inflammation and therapeutic vaccination in CNS diseases. Nature. 420:879&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">12490962</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock, D.M., G. DiCarlo, D. Henderson, J. Jackson, K. Clarke, K.E. Ugen, M.N. Gordon, and D. Morgan. 2003. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 23:3745&#x2013;3751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742181</ArticleId><ArticleId IdType="pubmed">12736345</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock, D.M., A. Rojiani, A. Rosenthal, G. Levkowitz, S. Subbarao, J. Alamed, D. Wilson, N. Wilson, M.J. Freeman, M.N. Gordon, and D. Morgan. 2004. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 24:6144&#x2013;6151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729674</ArticleId><ArticleId IdType="pubmed">15240806</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiltfang, J., A. Smirnov, B. Schnierstein, G. Kelemen, U. Matthies, H.W. Klafki, M. Staufenbiel, G. Huther, E. Ruther, and J. Kornhuber. 1997. Improved electrophoretic separation and immunoblotting of beta-amyloid (A beta) peptides 1-40, 1-42, and 1-43. Electrophoresis. 18:527&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">9150936</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler, D.T., L. Bondolfi, M.C. Herzig, L. Jann, M.E. Calhoun, K.H. Wiederhold, M. Tolnay, M. Staufenbiel, and M. Jucker. 2001. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J. Neurosci. 21:1619&#x2013;1627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762950</ArticleId><ArticleId IdType="pubmed">11222652</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, Q., J. Zhang, H. Liu, S. Babu-Khan, R. Vassar, A.L. Biere, M. Citron, and G. Landreth. 2003. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 23:7504&#x2013;7509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740758</ArticleId><ArticleId IdType="pubmed">12930788</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, L., K. Lindholm, Y. Konishi, R. Li, and Y. Shen. 2002. Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J. Neurosci. 22:3025&#x2013;3032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757531</ArticleId><ArticleId IdType="pubmed">11943805</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, L.B., K. Lindholm, R. Yan, M. Citron, W. Xia, X.L. Yang, T. Beach, L. Sue, P. Wong, D. Price, et al. 2003. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med. 9:3&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">12514700</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, J., M.I. Fonseca, R. Kayed, I. Hernandez, S.D. Webster, O. Yazan, D.H. Cribbs, C.G. Glabe, and A.J. Tenner. 2005. Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J. Neuroinflammation. 2:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1326209</ArticleId><ArticleId IdType="pubmed">16332263</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17727639</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0022-3042</ISSN><JournalIssue CitedMedium="Print"><Volume>103</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of neurochemistry</Title><ISOAbbreviation>J Neurochem</ISOAbbreviation></Journal><ArticleTitle>Soluble oligomers from a non-disease related protein mimic Abeta-induced tau hyperphosphorylation and neurodegeneration.</ArticleTitle><Pagination><StartPage>736</StartPage><EndPage>748</EndPage><MedlinePgn>736-48</MedlinePgn></Pagination><Abstract><AbstractText>Protein aggregation and amyloid accumulation in different tissues are associated with cellular dysfunction and toxicity in important human pathologies, including Alzheimer's disease and various forms of systemic amyloidosis. Soluble oligomers formed at the early stages of protein aggregation have been increasingly recognized as the main toxic species in amyloid diseases. To gain insight into the mechanisms of toxicity instigated by soluble protein oligomers, we have investigated the aggregation of hen egg white lysozyme (HEWL), a normally harmless protein. HEWL initially aggregates into beta-sheet rich, roughly spherical oligomers which appear to convert with time into protofibrils and mature amyloid fibrils. HEWL oligomers are potently neurotoxic to rat cortical neurons in culture, while mature amyloid fibrils are little or non-toxic. Interestingly, when added to cortical neuronal cultures HEWL oligomers induce tau hyperphosphorylation at epitopes that are characteristically phosphorylated in neurons exposed to soluble oligomers of the amyloid-beta peptide. Furthermore, injection of HEWL oligomers in the cerebral cortices of adult rats induces extensive neurodegeneration in different brain areas. These results show that soluble oligomers from a non-disease related protein can mimic specific neuronal pathologies thought to be induced by soluble amyloid-beta peptide oligomers in Alzheimer's disease and support the notion that amyloid oligomers from different proteins may share common structural determinants that would explain their generic cytotoxicities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vieira</LastName><ForeName>Marcelo N N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Programa de Bioqu&#xed;mica e Biof&#xed;sica Celular, Instituto de Bioqu&#xed;mica M&#xe9;dica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forny-Germano</LastName><ForeName>Let&#xed;cia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Saraiva</LastName><ForeName>Leonardo M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Sebollela</LastName><ForeName>Adriano</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Ana M Blanco</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Houzel</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>De Felice</LastName><ForeName>Fernanda G</ForeName><Initials>FG</Initials></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>S&#xe9;rgio T</ForeName><Initials>ST</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurochem</MedlineTA><NlmUniqueID>2985190R</NlmUniqueID><ISSNLinking>0022-3042</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>2390-54-7</RegistryNumber><NameOfSubstance UI="C009462">thioflavin T</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.17</RegistryNumber><NameOfSubstance UI="D009113">Muramidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002645" MajorTopicYN="N">Chickens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002850" MajorTopicYN="N">Chromatography, Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002942" MajorTopicYN="N">Circular Dichroism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004591" MajorTopicYN="N">Electrophoresis, Polyacrylamide Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005456" MajorTopicYN="N">Fluorescent Dyes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009113" MajorTopicYN="N">Muramidase</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009391" MajorTopicYN="N">Nephelometry and Turbidimetry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17727639</ArticleId><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04809.x</ArticleId><ArticleId IdType="pii">JNC4809</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17727636</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0022-3042</ISSN><JournalIssue CitedMedium="Print"><Volume>103</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of neurochemistry</Title><ISOAbbreviation>J Neurochem</ISOAbbreviation></Journal><ArticleTitle>Single molecule profiling of tau gene expression in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1228</StartPage><EndPage>1236</EndPage><MedlinePgn>1228-36</MedlinePgn></Pagination><Abstract><AbstractText>Tau is a microtubule-associated protein that is important for establishing and maintaining neuronal morphology. In addition to its role in normal cells, tau protein is involved in many neurodegenerative diseases, e.g. Alzheimer's disease (AD) and frontotemporal dementia, as the main component of intraneuronal aggregates. Alternative splicing of tau gene in the brain can give rise to at least six protein variants. A causative role of skewed tau exon 10 inclusion has been defined in frontotemporal dementia; however, no link was established between the aberrant splicing of tau and AD. Here, we applied a single-molecule-based technology, polymerase colony or polony, to simultaneously monitor tau splicing variant and haplotype profile in sporadic AD and normal brains. We found that the coordinated expression of tau exons 2 and 10 is altered in AD. Additional investigations of cis and trans mechanisms of this observation revealed a decreased protein expression of a known tau splicing factor, htra2-beta-1 in AD, thereby implicating a trans mechanism. Our results demonstrate that dysregulation of combinatorial splicing might serve as a signature for aging-related diseases, and the polony assay could be widely adapted for the study of other tauopathies. Furthermore, splicing-based therapeutics is an emerging area of drug development, and a well-defined and quantitative assay for monitoring single-gene transcriptome will be relevant for such development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Conrad</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, MassGeneral Institute for Neurodegenerative Disease (MIND), Charlestown, Massachusetts, USA. cgc2105@columbia.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Conrad</LastName><ForeName>Cintia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Schoenfeld</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Zhide</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Ingelsson</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Stamm</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Church</LastName><ForeName>George</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurochem</MedlineTA><NlmUniqueID>2985190R</NlmUniqueID><ISSNLinking>0022-3042</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.108</RegistryNumber><NameOfSubstance UI="C000615914">HTRA2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.108</RegistryNumber><NameOfSubstance UI="D000074923">High-Temperature Requirement A Serine Peptidase 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017398" MajorTopicYN="N">Alternative Splicing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001681" MajorTopicYN="N">Biological Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074923" MajorTopicYN="N">High-Temperature Requirement A Serine Peptidase 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008967" MajorTopicYN="N">Molecular Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012697" MajorTopicYN="N">Serine Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17727636</ArticleId><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04857.x</ArticleId><ArticleId IdType="pii">JNC4857</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17761549</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Increased risk of parkinsonism in women who underwent oophorectomy before menopause.</ArticleTitle><Pagination><StartPage>200</StartPage><EndPage>209</EndPage><MedlinePgn>200-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">There is increasing laboratory evidence for a neuroprotective effect of estrogen on the nigrostriatal pathway; however, the epidemiologic evidence remains limited and conflicting. We studied the association of oophorectomy performed before the onset of menopause with the risk of subsequent parkinsonism.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We included all women who underwent either unilateral or bilateral oophorectomy before the onset of menopause for a noncancer indication from 1950 through 1987 while residing in Olmsted County, MN. Each member of the oophorectomy cohort was matched by age to a referent woman in the same population who had not undergone oophorectomy. In total, we studied 1,252 women with unilateral oophorectomy, 1,075 women with bilateral oophorectomy, and 2,368 referent women. Women were followed through death or end of study using a combination of direct or proxy interviews, neurologic examinations, medical records in a records-linkage system, and death certificates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Women who underwent either unilateral or bilateral oophorectomy before the onset of menopause had an increased risk of parkinsonism compared with referent women (HR 1.68; 95% CI 1.06 to 2.67; p = 0.03), and the risk increased with younger age at oophorectomy (test for linear trend; p = 0.01). The findings were similar regardless of the indication for the oophorectomy, and for unilateral or bilateral oophorectomy considered separately. The findings were also consistent for Parkinson disease alone, but did not reach significance.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Both unilateral and bilateral oophorectomy performed prior to menopause may be associated with an increased risk of parkinsonism and the effect may be age-dependent. However, our findings await independent replication.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rocca</LastName><ForeName>W A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. rocca@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bower</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Maraganore</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Ahlskog</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Grossardt</LastName><ForeName>B R</ForeName><Initials>BR</Initials></Author><Author ValidYN="Y"><LastName>de Andrade</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Melton</LastName><ForeName>L J</ForeName><Initials>LJ</Initials><Suffix>3rd</Suffix></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AR30582</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS33978</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004967">Estrogens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019610" MajorTopicYN="N">Cytoprotection</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004967" MajorTopicYN="N">Estrogens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008594" MajorTopicYN="N">Menopause, Premature</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008910" MajorTopicYN="N" Type="Geographic">Minnesota</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017072" MajorTopicYN="N">Neostriatum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010052" MajorTopicYN="N">Ovariectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17761549</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000280573.30975.6a</ArticleId><ArticleId IdType="pii">01.wnl.0000280573.30975.6a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17761551</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>11</Issue><PubDate><Year>2007</Year><Month>Sep</Month><Day>11</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause.</ArticleTitle><Pagination><StartPage>1074</StartPage><EndPage>1083</EndPage><MedlinePgn>1074-83</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">There is increasing laboratory evidence for a neuroprotective effect of estrogen; however, the clinical and epidemiologic evidence remains limited and conflicting. We studied the association of oophorectomy performed before the onset of menopause with the risk of subsequent cognitive impairment or dementia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We included all women who underwent unilateral or bilateral oophorectomy before the onset of menopause for a non-cancer indication while residing in Olmsted County, MN, from 1950 through 1987. Each member of the oophorectomy cohort was matched by age to a referent woman from the same population who had not undergone oophorectomy. In total, we studied 813 women with unilateral oophorectomy, 676 women with bilateral oophorectomy, and 1,472 referent women. Women were followed through death or end of study using either direct or proxy interviews.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Women who underwent either unilateral or bilateral oophorectomy before the onset of menopause had an increased risk of cognitive impairment or dementia compared to referent women (hazard ratio [HR] = 1.46; 95% CI 1.13 to 1.90; adjusted for education, type of interview, and history of depression). The risk increased with younger age at oophorectomy (test for linear trend; adjusted p &lt; 0.0001). These associations were similar regardless of the indication for the oophorectomy, and for women who underwent unilateral or bilateral oophorectomy considered separately.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Both unilateral and bilateral oophorectomy preceding the onset of menopause are associated with an increased risk of cognitive impairment or dementia. The effect is age-dependent and suggests a critical age window for neuroprotection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rocca</LastName><ForeName>W A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA. rocca@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bower</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Maraganore</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Ahlskog</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Grossardt</LastName><ForeName>B R</ForeName><Initials>BR</Initials></Author><Author ValidYN="Y"><LastName>de Andrade</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Melton</LastName><ForeName>L J</ForeName><Initials>LJ</Initials><Suffix>3rd</Suffix></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AR30582</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS33978</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004967">Estrogens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2007 Sep 11;69(11):1070-1. doi: 10.1212/01.wnl.0000279584.03800.3d.</RefSource><PMID Version="1">17846406</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004967" MajorTopicYN="N">Estrogens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007407" MajorTopicYN="N">Interviews as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008594" MajorTopicYN="N">Menopause, Premature</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010052" MajorTopicYN="N">Ovariectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17761551</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000276984.19542.e6</ArticleId><ArticleId IdType="pii">01.wnl.0000276984.19542.e6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17761882</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>317</Volume><Issue>5842</Issue><PubDate><Year>2007</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>A MicroRNA feedback circuit in midbrain dopamine neurons.</ArticleTitle><Pagination><StartPage>1220</StartPage><EndPage>1224</EndPage><MedlinePgn>1220-4</MedlinePgn></Pagination><Abstract><AbstractText>MicroRNAs (miRNAs) are evolutionarily conserved, 18- to 25-nucleotide, non-protein coding transcripts that posttranscriptionally regulate gene expression during development. miRNAs also occur in postmitotic cells, such as neurons in the mammalian central nervous system, but their function is less well characterized. We investigated the role of miRNAs in mammalian midbrain dopaminergic neurons (DNs). We identified a miRNA, miR-133b, that is specifically expressed in midbrain DNs and is deficient in midbrain tissue from patients with Parkinson's disease. miR-133b regulates the maturation and function of midbrain DNs within a negative feedback circuit that includes the paired-like homeodomain transcription factor Pitx3. We propose a role for this feedback circuit in the fine-tuning of dopaminergic behaviors such as locomotion.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jongpil</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departments of Pathology and Neurology, Center for Neurobiology and Behavior, and Taub Institute, Columbia University, College of Physicians and Surgeons 15-403, 630 West 168th Street, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Keiichi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ishii</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Vanti</LastName><ForeName>William B</ForeName><Initials>WB</Initials></Author><Author ValidYN="Y"><LastName>Voronov</LastName><ForeName>Sergey V</ForeName><Initials>SV</Initials></Author><Author ValidYN="Y"><LastName>Murchison</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Hannon</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Abeliovich</LastName><ForeName>Asa</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS064433</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020413">3' Untranslated Regions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C433629">homeobox protein PITX3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.26.3</RegistryNumber><NameOfSubstance UI="D043244">Ribonuclease III</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2007 Aug 31;317(5842):1179-80. doi: 10.1126/science.1148530.</RefSource><PMID Version="1">17761871</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D020413" MajorTopicYN="N">3' Untranslated Regions</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053595" MajorTopicYN="N">Embryonic Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025461" MajorTopicYN="Y">Feedback, Physiological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018398" MajorTopicYN="N">Homeodomain Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008124" MajorTopicYN="N">Locomotion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008636" MajorTopicYN="N">Mesencephalon</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043244" MajorTopicYN="N">Ribonuclease III</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>11</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17761882</ArticleId><ArticleId IdType="mid">NIHMS153190</ArticleId><ArticleId IdType="pmc">PMC2782470</ArticleId><ArticleId IdType="doi">10.1126/science.1140481</ArticleId><ArticleId IdType="pii">317/5842/1220</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>He L, Hannon GJ. Nat Rev Genet. 2004 Jul;5:522.</Citation><ArticleIdList><ArticleId IdType="pubmed">15211354</ArticleId></ArticleIdList></Reference><Reference><Citation>Meister G, Tuschl T. Nature. 2004 Sep 16;431:343.</Citation><ArticleIdList><ArticleId IdType="pubmed">15372041</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambros V. Nature. 2004 Sep 16;431:350.</Citation><ArticleIdList><ArticleId IdType="pubmed">15372042</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel DP. Cell. 2004 Jan 23;116:281.</Citation><ArticleIdList><ArticleId IdType="pubmed">14744438</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, et al. Nature. 2003 Sep 25;425:415.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Grishok A, et al. Cell. 2001 Jul 13;106:23.</Citation><ArticleIdList><ArticleId IdType="pubmed">11461699</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S, Johnston RJ, Jr, Frokjaer-Jensen C, Lockery S, Hobert O. Nature. 2004 Aug 12;430:785.</Citation><ArticleIdList><ArticleId IdType="pubmed">15306811</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston RJ, Hobert O. Nature. 2003 Dec 18;426:845.</Citation><ArticleIdList><ArticleId IdType="pubmed">14685240</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambros V. Cell. 2003 Jun 13;113:673.</Citation><ArticleIdList><ArticleId IdType="pubmed">12809598</ArticleId></ArticleIdList></Reference><Reference><Citation>Giraldez AJ, et al. Science. 2005 May 6;308:833.</Citation><ArticleIdList><ArticleId IdType="pubmed">15774722</ArticleId></ArticleIdList></Reference><Reference><Citation>Giraldez AJ, et al. Science. 2006 Apr 7;312:75.</Citation><ArticleIdList><ArticleId IdType="pubmed">16484454</ArticleId></ArticleIdList></Reference><Reference><Citation>Krichevsky AM, King KS, Donahue CP, Khrapko K, Kosik KS. Rna. 2003 Oct;9:1274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1370491</ArticleId><ArticleId IdType="pubmed">13130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Krichevsky AM. Neuron. 2005 Sep 15;47:779.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157272</ArticleId></ArticleIdList></Reference><Reference><Citation>Krichevsky AM, Sonntag KC, Isacson O, Kosik KS. Stem Cells. 2006 Apr;24:857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605651</ArticleId><ArticleId IdType="pubmed">16357340</ArticleId></ArticleIdList></Reference><Reference><Citation>Schratt GM, et al. Nature. 2006 Jan 19;439:283.</Citation><ArticleIdList><ArticleId IdType="pubmed">16421561</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallen A, Perlmann T. Ann N Y Acad Sci. 2003 Jun;991:48.</Citation><ArticleIdList><ArticleId IdType="pubmed">12846973</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, et al. Nature. 2002 Jul 4;418:50.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinat C, et al. Proc Natl Acad Sci U S A. 2006 Feb 21;103:2874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413837</ArticleId><ArticleId IdType="pubmed">16477036</ArticleId></ArticleIdList></Reference><Reference><Citation>Murchison EP, Partridge JF, Tam OH, Cheloufi S, Hannon GJ. Proc Natl Acad Sci U S A. 2005 Aug 23;102:12135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1185572</ArticleId><ArticleId IdType="pubmed">16099834</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuhma N, et al. J Neurosci. 2004 Jan 28;24:972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729804</ArticleId><ArticleId IdType="pubmed">14749442</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang DY, Ardayfio P, Kang UJ, Semina EV, Kim KS. Brain Res Mol Brain Res. 2003 Jun 10;114:123.</Citation><ArticleIdList><ArticleId IdType="pubmed">12829322</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes I, Tovmasian LT, Silva RM, Burke RE, Goff SP. Proc Natl Acad Sci U S A. 2003 Apr 1;100:4245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC153078</ArticleId><ArticleId IdType="pubmed">12655058</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Munckhof P, et al. Development. 2003 Jun;130:2535.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702666</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson TJ, et al. J Neurosci. 2004 Nov 10;24:10040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730191</ArticleId><ArticleId IdType="pubmed">15537872</ArticleId></ArticleIdList></Reference><Reference><Citation>John B, et al. PLoS Biol. 2004 Nov;2:e363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC521178</ArticleId><ArticleId IdType="pubmed">15502875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Cell. 2003 Dec 26;115:787.</Citation><ArticleIdList><ArticleId IdType="pubmed">14697198</ArticleId></ArticleIdList></Reference><Reference><Citation>Smidt MP, Smits SM, Burbach JP. Cell Tissue Res. 2004 Oct;318:35.</Citation><ArticleIdList><ArticleId IdType="pubmed">15300495</ArticleId></ArticleIdList></Reference><Reference><Citation>Sylvestre Y, et al. J Biol Chem. 2007 Jan 26;282:2135.</Citation><ArticleIdList><ArticleId IdType="pubmed">17135249</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumer SC, Vrana KE. J Neurochem. 1996 Aug;67:443.</Citation><ArticleIdList><ArticleId IdType="pubmed">8764568</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebel M, Gauthier Y, Moreau A, Drouin J. J Neurochem. 2001 Apr;77:558.</Citation><ArticleIdList><ArticleId IdType="pubmed">11299318</ArticleId></ArticleIdList></Reference><Reference><Citation>Becskei A, Serrano L. Nature. 2000 Jun 1;405:590.</Citation><ArticleIdList><ArticleId IdType="pubmed">10850721</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobo MK, Karsten SL, Gray M, Geschwind DH, Yang XW. Nat Neurosci. 2006 Mar;9:443.</Citation><ArticleIdList><ArticleId IdType="pubmed">16491081</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17764635</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1528-4042</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Current neurology and neuroscience reports</Title><ISOAbbreviation>Curr Neurol Neurosci Rep</ISOAbbreviation></Journal><ArticleTitle>The genetics of frontotemporal lobar degeneration.</ArticleTitle><Pagination><StartPage>434</StartPage><EndPage>442</EndPage><MedlinePgn>434-42</MedlinePgn></Pagination><Abstract><AbstractText>The clinical disorders associated with frontotemporal lobar degeneration (FTLD) are increasingly recognized as an important cause of early-onset dementia. Patients usually present with progressive changes in personality, behavior, or language, progressing to general cognitive impairment and ultimately death. In the past decade, improved clinical and histopathologic characterization uncovered extensive heterogeneity, and multiple clinical and pathologic FTLD subtypes were defined. Simultaneously, the discovery of four causal FTLD genes emphasized the genetic complexity associated with FTLD. More recently, the field of FTLD has gained increased attention as a result of two major findings. First, mutations in the progranulin gene (PGRN) were recognized as a major cause of FTLD with ubiquitin-positive and tau-negative inclusions (FTLD-U), and subsequently the TAR DNA-binding protein-43 (TDP-43) was identified as a key protein within the ubiquitinated inclusions in FTLD-U and amyotrophic lateral sclerosis (ALS). In this report, we outline the progress made in the study of the genetic etiologies and neuropathologic substrates in FTLD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, FL 32224, USA. rademakers.rosa@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hutton</LastName><ForeName>Mike</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026251</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Neurol Neurosci Rep</MedlineTA><NlmUniqueID>100931790</NlmUniqueID><ISSNLinking>1528-4042</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C503812">CHMP2B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056827">Endosomal Sorting Complexes Required for Transport</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492314">GRN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D000251">Adenosine Triphosphatases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.6</RegistryNumber><NameOfSubstance UI="D000074405">Valosin Containing Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000251" MajorTopicYN="N">Adenosine Triphosphatases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056827" MajorTopicYN="N">Endosomal Sorting Complexes Required for Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074405" MajorTopicYN="N">Valosin Containing Protein</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>73</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17764635</ArticleId><ArticleId IdType="doi">10.1007/s11910-007-0067-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mol Genet Metab. 2001 Dec;74(4):458-75</Citation><ArticleIdList><ArticleId IdType="pubmed">11749051</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Cell Biol. 1994 Feb;6(1):74-81</Citation><ArticleIdList><ArticleId IdType="pubmed">8167029</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Neurol. 2006 Dec 13;6:44</Citation><ArticleIdList><ArticleId IdType="pubmed">17166276</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2002 Oct 8;59(7):1077-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12370467</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 1995 Sep;4(9):1625-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8541850</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1989 Feb;8(2):393-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2498079</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Biol Cell. 1997 Feb;8(2):353-65</Citation><ArticleIdList><ArticleId IdType="pubmed">9190213</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Med (Berl). 2003 Oct;81(10):600-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12928786</ArticleId></ArticleIdList></Reference><Reference><Citation>J Endocrinol. 1998 Aug;158(2):145-51</Citation><ArticleIdList><ArticleId IdType="pubmed">9771457</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 2006 Jun;65(6):571-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16783167</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2006 Apr;129(Pt 4):868-76</Citation><ArticleIdList><ArticleId IdType="pubmed">16495328</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2007 Mar;25(3):561-70</Citation><ArticleIdList><ArticleId IdType="pubmed">17174556</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2007 May;130(Pt 5):1360-74</Citation><ArticleIdList><ArticleId IdType="pubmed">17439980</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathol Appl Neurobiol. 2004 Aug;30(4):369-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15305982</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Struct Funct. 1996 Oct;21(5):283-95</Citation><ArticleIdList><ArticleId IdType="pubmed">9118234</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2005 Jul 1;14(13):1753-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15888485</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Aug 24;442(7105):920-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1989 Apr;2(4):1389-97</Citation><ArticleIdList><ArticleId IdType="pubmed">2560640</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2002 Dec 13;111(6):867-78</Citation><ArticleIdList><ArticleId IdType="pubmed">12526812</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2006 Oct;169(4):1343-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17003490</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurodegener Dis. 2006;3(3):129-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16954699</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2005 Oct 25;65(8):1304-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16247064</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1998 Dec 4;282(5395):1914-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9836646</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2004 Apr;36(4):377-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15034582</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2005 Aug;37(8):806-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16041373</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2005 Mar;57(3):457-61</Citation><ArticleIdList><ArticleId IdType="pubmed">15732117</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2006 Sep 26;67(6):1074-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16807408</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2006 Nov;129(Pt 11):3081-90</Citation><ArticleIdList><ArticleId IdType="pubmed">17071926</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 1994 Aug 16;33(32):9511-22</Citation><ArticleIdList><ArticleId IdType="pubmed">8068626</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2006 Oct 6;314(5796):130-3</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Sci. 2003 Nov 1;116(Pt 21):4283-90</Citation><ArticleIdList><ArticleId IdType="pubmed">14514884</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 2007 Feb;66(2):152-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17279000</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2007 Feb;64(2):240-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17296840</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 2005 Aug;64(8):730-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16106222</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2006 Sep;60(3):374-80</Citation><ArticleIdList><ArticleId IdType="pubmed">16983677</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mutat. 2007 Apr;28(4):416</Citation><ArticleIdList><ArticleId IdType="pubmed">17345602</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2006 Aug 22;67(4):644-51</Citation><ArticleIdList><ArticleId IdType="pubmed">16790606</ArticleId></ArticleIdList></Reference><Reference><Citation>J Histochem Cytochem. 2000 Jul;48(7):999-1009</Citation><ArticleIdList><ArticleId IdType="pubmed">10858277</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2000 Apr;74(4):1749-57</Citation><ArticleIdList><ArticleId IdType="pubmed">10737634</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2001 Nov;58(11):1813-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11708988</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1997 Jul 25;74(4):380-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9259373</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2006 Oct 15;15(20):2988-3001</Citation><ArticleIdList><ArticleId IdType="pubmed">16950801</ArticleId></ArticleIdList></Reference><Reference><Citation>Orphanet J Rare Dis. 2006 Aug 09;1:30</Citation><ArticleIdList><ArticleId IdType="pubmed">16899117</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):87-92</Citation><ArticleIdList><ArticleId IdType="pubmed">17190808</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1998 Jun 18;393(6686):702-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Mol Med. 2002 Dec;8(12):555-62</Citation><ArticleIdList><ArticleId IdType="pubmed">12470988</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2007 Mar 13;68(11):820-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17202431</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 1999 May 7;450(3):306-11</Citation><ArticleIdList><ArticleId IdType="pubmed">10359094</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Hum Genet. 2007 Mar;15(3):369-74</Citation><ArticleIdList><ArticleId IdType="pubmed">17228326</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2007 May;130(Pt 5):1375-85</Citation><ArticleIdList><ArticleId IdType="pubmed">17360763</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2007 Jul;171(1):227-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17591968</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1998 Dec;51(6):1546-54</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1997 Jun;41(6):706-15</Citation><ArticleIdList><ArticleId IdType="pubmed">9189031</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mutat. 2007 Sep;28(9):846-55</Citation><ArticleIdList><ArticleId IdType="pubmed">17436289</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2006 May 1;398(1-2):83-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16431024</ArticleId></ArticleIdList></Reference><Reference><Citation>Traffic. 2005 Jan;6(1):2-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15569240</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2003 Feb;9(2):225-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12524533</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Aug 24;442(7105):916-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Hum Genet. 2002 Jul;10(7):399-405</Citation><ArticleIdList><ArticleId IdType="pubmed">12107813</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2001 Jun;56(11 Suppl 4):S21-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11402146</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2000 Apr 12;9(6):979-86</Citation><ArticleIdList><ArticleId IdType="pubmed">10767321</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2006 Dec 5;141B(8):944-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16941655</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1994 Dec;55(6):1159-65</Citation><ArticleIdList><ArticleId IdType="pubmed">7977375</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mutat. 2004 Oct;24(4):277-95</Citation><ArticleIdList><ArticleId IdType="pubmed">15365985</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Neurol. 2007 Feb;27(1):48-57</Citation><ArticleIdList><ArticleId IdType="pubmed">17226741</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2006 Sep;60(3):314-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16983685</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2006 Nov;129(Pt 11):3124-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17071927</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2006 Dec 15;15(24):3529-37</Citation><ArticleIdList><ArticleId IdType="pubmed">17085483</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2006 Mar 28;66(6):839-44</Citation><ArticleIdList><ArticleId IdType="pubmed">16421333</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1990 Dec;9(13):4225-30</Citation><ArticleIdList><ArticleId IdType="pubmed">2124967</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17784787</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1553-7374</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>8</Issue><PubDate><Year>2007</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>PLoS pathogens</Title><ISOAbbreviation>PLoS Pathog</ISOAbbreviation></Journal><ArticleTitle>In vitro and in vivo neurotoxicity of prion protein oligomers.</ArticleTitle><Pagination><StartPage>e125</StartPage><MedlinePgn>e125</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e125</ELocationID><Abstract><AbstractText>The mechanisms underlying prion-linked neurodegeneration remain to be elucidated, despite several recent advances in this field. Herein, we show that soluble, low molecular weight oligomers of the full-length prion protein (PrP), which possess characteristics of PrP to PrPsc conversion intermediates such as partial protease resistance, are neurotoxic in vitro on primary cultures of neurons and in vivo after subcortical stereotaxic injection. Monomeric PrP was not toxic. Insoluble, fibrillar forms of PrP exhibited no toxicity in vitro and were less toxic than their oligomeric counterparts in vivo. The toxicity was independent of PrP expression in the neurons both in vitro and in vivo for the PrP oligomers and in vivo for the PrP fibrils. Rescue experiments with antibodies showed that the exposure of the hydrophobic stretch of PrP at the oligomeric surface was necessary for toxicity. This study identifies toxic PrP species in vivo. It shows that PrP-induced neurodegeneration shares common mechanisms with other brain amyloidoses like Alzheimer disease and opens new avenues for neuroprotective intervention strategies of prion diseases targeting PrP oligomers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simoneau</LastName><ForeName>Steve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Commissariat &#xe0; l'Energie Atomique, Fontenay-aux-Roses, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezaei</LastName><ForeName>Human</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Sal&#xe8;s</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Kaiser-Schulz</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Lefebvre-Roque</LastName><ForeName>Maxime</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Fournier</LastName><ForeName>Jean-Guy</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Comte</LastName><ForeName>Julien</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wopfner</LastName><ForeName>Franziska</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Grosclaude</LastName><ForeName>Jeanne</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sch&#xe4;tzl</LastName><ForeName>Hermann</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lasm&#xe9;zas</LastName><ForeName>Corinne Ida</ForeName><Initials>CI</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Pathog</MedlineTA><NlmUniqueID>101238921</NlmUniqueID><ISSNLinking>1553-7366</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019138">Antibodies, Blocking</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019138" MajorTopicYN="N">Antibodies, Blocking</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007425" MajorTopicYN="N">Intracellular Membranes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017096" MajorTopicYN="N">Prion Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Competing interests.</b> The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>8</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17784787</ArticleId><ArticleId IdType="pmc">PMC1959381</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.0030125</ArticleId><ArticleId IdType="pii">07-PLPA-RA-0188</ArticleId><ArticleId IdType="sici">plpa-03-08-15</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216:136&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">6801762</ArticleId></ArticleIdList></Reference><Reference><Citation>Doi S, Ito M, Shinagawa M, Sato G, Isomura M, et al. Western blot detection of scrapie-associated fibril protein in tissues outside the central nervous system from preclinical scrapie-infected mice. J Gen Virol. 1988;69:955&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pubmed">2895800</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, et al. Conversion of a-helices into &#xdf;-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA. 1993;90:10962&#x2013;10966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47901</ArticleId><ArticleId IdType="pubmed">7902575</ArticleId></ArticleIdList></Reference><Reference><Citation>Legname G, Baskakov IV, Nguyen HO, Riesner D, Cohen FE, et al. Synthetic mammalian prions. Science. 2004;305:673&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">15286374</ArticleId></ArticleIdList></Reference><Reference><Citation>Couzin J. Biomedicine. An end to the prion debate? Don't count on it. Science. 2004;305:589.</Citation><ArticleIdList><ArticleId IdType="pubmed">15286333</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissmann C. A &#x2018;unified theory' of prion propagation. Nature. 1991;352:679&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">1876183</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003;26:267&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">12704221</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagliavini F, Forloni G, D'Ursi P, Bugiani O, Salmona M. Studies on peptide fragments of prion proteins. Adv Protein Chem. 2001;57:171&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">11447690</ArticleId></ArticleIdList></Reference><Reference><Citation>Gambetti P, Parchi P, Petersen RB, Chen SG, Lugaresi E. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: Clinical, pathological and molecular features. Brain Pathol. 1995;5:43&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">7767490</ArticleId></ArticleIdList></Reference><Reference><Citation>Telling GC, Haga T, Torchia M, Tremblay P, DeArmond SJ, et al. Interactions between wild-type and mutant prion proteins modulate neurodegeneration in transgenic mice. Genes Dev. 1996;10:1736&#x2013;1750.</Citation><ArticleIdList><ArticleId IdType="pubmed">8698234</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasm&#xe9;zas CI, Deslys JP, Robain O, Jaegly A, Beringue V, et al. Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science. 1997;275:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">8994041</ArticleId></ArticleIdList></Reference><Reference><Citation>Manuelidis L, Fritch W, Xi YG. Evolution of a strain of CJD that induces BSE-like plaques. Science. 1997;277:94&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">9204907</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J, Palmer MS, Sidle KCL, Gowland I, Medori R, et al. Transmission of fatal familial insomnia to laboratory animals. Lancet. 1995;346:569&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">7658786</ArticleId></ArticleIdList></Reference><Reference><Citation>Manson J, Jamieson E, Baybutt H, Tuzi N, Barron R, et al. A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy. EMBO J. 1999;18:6855&#x2013;6864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1171748</ArticleId><ArticleId IdType="pubmed">10581259</ArticleId></ArticleIdList></Reference><Reference><Citation>Flechsig E, Shmerling D, Hegyi I, Raeber AJ, Fischer M, et al. Prion protein devoid of the octapeptide repeat region restores susceptibility to scrapie in PrP knockout mice. Neuron. 2000;27:399&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">10985358</ArticleId></ArticleIdList></Reference><Reference><Citation>Forloni G, Angeretti N, Chiesa R, Monzani E, Salmona M, et al. Neurotoxicity of a prion protein fragment. Nature. 1993;362:543&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">8464494</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown DR, Schmidt B, Kretzschmar HA. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature. 1996;380:345&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">8598929</ArticleId></ArticleIdList></Reference><Reference><Citation>Haik S, Peyrin JM, Lins L, Rosseneu MY, Brasseur R, et al. Neurotoxicity of the putative transmembrane domain of the prion protein. Neurobiol Dis. 2000;7:644&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">11114262</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahadi R, Farrelly PV, Kenna BL, Kourie JI, Tagliavini F, et al. Channels formed with a mutant prion protein PrP(82&#x2013;146) homologous to a 7-kDa fragment in diseased brain of GSS patients. Am J Physiol Cell Physiol. 2003;285:C862&#x2013;C872.</Citation><ArticleIdList><ArticleId IdType="pubmed">12814912</ArticleId></ArticleIdList></Reference><Reference><Citation>Shmerling D, Hegyi I, Fischer M, Blattler T, Brandner S, et al. Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell. 1998;93:203&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">9568713</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefani M, Dobson CM. Protein aggregation and aggregate toxicity: New insights into protein folding, misfolding diseases and biological evolution. J Mol Med. 2003;81:678&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">12942175</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science. 2002;296:1991&#x2013;1995.</Citation><ArticleIdList><ArticleId IdType="pubmed">12065827</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissmann C, Enari M, Klohn PC, Rossi D, Flechsig E. Molecular biology of prions. Acta Neurobiol Exp (Wars) 2002;62:153&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">12416393</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer NW, Broadley SA, Hirschberger T, Tavan P, Kretzschmar HA, et al. Identification of anti-prion compounds as efficient inhibitors of polyglutamine protein aggregation in a zebrafish model. J Biol Chem. 2007;282:9195&#x2013;9203.</Citation><ArticleIdList><ArticleId IdType="pubmed">17170113</ArticleId></ArticleIdList></Reference><Reference><Citation>Baskakov IV, Legname G, Baldwin MA, Prusiner SB, Cohen FE. Pathway complexity of prion protein assembly into amyloid. J Biol Chem. 2002;277:21140&#x2013;21148.</Citation><ArticleIdList><ArticleId IdType="pubmed">11912192</ArticleId></ArticleIdList></Reference><Reference><Citation>Baskakov IV, Legname G, Prusiner SB, Cohen FE. Folding of prion protein to its native alpha-helical conformation is under kinetic control. J Biol Chem. 2001;276:19687&#x2013;19690.</Citation><ArticleIdList><ArticleId IdType="pubmed">11306559</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokolowski F, Modler AJ, Masuch R, Zirwer D, Baier M, et al. Formation of critical oligomers is a key event during conformational transition of recombinant syrian hamster prion protein. J Biol Chem. 2003;278:40481&#x2013;40492.</Citation><ArticleIdList><ArticleId IdType="pubmed">12917432</ArticleId></ArticleIdList></Reference><Reference><Citation>Govaerts C, Wille H, Prusiner SB, Cohen FE. Evidence for assembly of prions with left-handed beta-helices into trimers. Proc Natl Acad Sci U S A. 2004;101:8342&#x2013;8347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC420396</ArticleId><ArticleId IdType="pubmed">15155909</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazlauskaite J, Young A, Gardner CE, Macpherson JV, Venien-Bryan C, et al. An unusual soluble beta-turn-rich conformation of prion is involved in fibril formation and toxic to neuronal cells. Biochem Biophys Res Commun. 2005;328:292&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">15670783</ArticleId></ArticleIdList></Reference><Reference><Citation>Novitskaya V, Bocharova OV, Bronstein I, Baskakov IV. Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J Biol Chem. 2006;281:13828&#x2013;13836.</Citation><ArticleIdList><ArticleId IdType="pubmed">16554307</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaei H, Choiset Y, Eghiaian F, Treguer E, Mentre P, et al. Amyloidogenic unfolding intermediates differentiate sheep prion protein variants. J Mol Biol. 2002;322:799&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pubmed">12270715</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen K, Schafer O, Birkmann E, Post K, Serban H, et al. Structural intermediates in the putative pathway from the cellular prion protein to the pathogenic form. Biol Chem. 2001;382:683&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">11405232</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaei H, Eghiaian F, Perez J, Doublet B, Choiset Y, et al. Sequential generation of two structurally distinct ovine prion protein soluble oligomers displaying different biochemical reactivities. J Mol Biol. 2005;347:665&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">15755458</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerber R, Tahiri-Alaoui A, Hore PJ, James W. Oligomerization of the human prion protein proceeds via a molten globule intermediate. J Biol Chem. 2007;282:6300&#x2013;6307.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210575</ArticleId></ArticleIdList></Reference><Reference><Citation>Spielhaupter C, Sch&#xe4;tzl HM. PrPC directly interacts with proteins involved in signaling pathways. J Biol Chem. 2001;276:44604&#x2013;44612.</Citation><ArticleIdList><ArticleId IdType="pubmed">11571277</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilch S, Wopfner F, Renner-Muller I, Kremmer E, Bauer C, et al. Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J Biol Chem. 2003;278:18524&#x2013;18531.</Citation><ArticleIdList><ArticleId IdType="pubmed">12637572</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson CM. Protein folding and misfolding. Nature. 2003;426:884&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">14685248</ArticleId></ArticleIdList></Reference><Reference><Citation>Eghiaian F, Daubenfeld T, Quenet Y, van Audenhaege M, Bouin AP, et al. Diversity in prion protein oligomerization pathways results from domain expansion as revealed by hydrogen/deuterium exchange and disulfide linkage. Proc Natl Acad Sci U S A. 2007;104:7414&#x2013;7419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1863451</ArticleId><ArticleId IdType="pubmed">17442756</ArticleId></ArticleIdList></Reference><Reference><Citation>Forloni G, Bugiani O, Tagliavini F, Salmona M. Apoptosis-mediated neurotoxicity induced by beta-amyloid and PrP fragments. Mol Chem Neuropathol. 1996;28:163&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">8871955</ArticleId></ArticleIdList></Reference><Reference><Citation>Chabry J, Ratsimanohatra C, Sponne I, Elena PP, Vincent JP, et al. In vivo and in vitro neurotoxicity of the human prion protein (PrP) fragment P118&#x2013;135 independently of PrP expression. J Neurosci. 2003;23:462&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741883</ArticleId><ArticleId IdType="pubmed">12533606</ArticleId></ArticleIdList></Reference><Reference><Citation>Fioriti L, Quaglio E, Massignan T, Colombo L, Stewart RS, et al. The neurotoxicity of prion protein (PrP) peptide 106&#x2013;126 is independent of the expression level of PrP and is not mediated by abnormal PrP species. Mol Cell Neurosci. 2005;28:165&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">15607951</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, et al. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature. 1996;379:339&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">8552188</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffrey M, Goodsir CM, Race RE, Chesebro B. Scrapie-specific neuronal lesions are independent of neuronal PrP expression. Ann Neurol. 2004;55:781&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pubmed">15174012</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, et al. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science. 2003;302:871&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593181</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallucci GR, White MD, Farmer M, Dickinson A, Khatun H, et al. Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron. 2007;53:325&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270731</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell JE, Ironside JW. Neuropathology of spongiform encephalopathies in humans. Br Med Bull. 1993;49:738&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">8137127</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez L, Martin S, Jeffrey M. Distinct profiles of PrP(d) immunoreactivity in the brain of scrapie- and BSE-infected sheep: Implications for differential cell targeting and PrP processing. J Gen Virol. 2003;84:1339&#x2013;1350.</Citation><ArticleIdList><ArticleId IdType="pubmed">12692301</ArticleId></ArticleIdList></Reference><Reference><Citation>Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science. 2005;308:1435&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pubmed">15933194</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccardo P, Manson JC, King D, Ghetti B, Barron RM. Accumulation of prion protein in the brain that is not associated with transmissable disease. Proc Natl Acad Sci. 2007;104:4712&#x2013;4217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1838665</ArticleId><ArticleId IdType="pubmed">17360589</ArticleId></ArticleIdList></Reference><Reference><Citation>Relini A, Torrassa S, Rolandi R, Gliozzi A, Rosano C, et al. Monitoring the process of HypF fibrillization and liposome permeabilization by protofibrils. J Mol Biol. 2004;338:943&#x2013;957.</Citation><ArticleIdList><ArticleId IdType="pubmed">15111058</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer SJ, Dewji NN. Evidence that Perutz's double-beta-stranded subunit structure for beta-amyloids also applies to their channel-forming structures in membranes. Proc Natl Acad Sci U S A. 2006;103:1546&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1345708</ArticleId><ArticleId IdType="pubmed">16432204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hundt C, Peyrin J-M, Haik S, Gauczynski S, Leucht C, et al. Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor. EMBO J. 2001;20:5876&#x2013;5886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125289</ArticleId><ArticleId IdType="pubmed">11689428</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann F, Tolnay M, Brabeck C, Pahnke J, Kloz U, et al. Lethal recessive myelin toxicity of prion protein lacking its central domain. EMBO J. 2007;26:538&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1783444</ArticleId><ArticleId IdType="pubmed">17245436</ArticleId></ArticleIdList></Reference><Reference><Citation>Li A, Christensen HM, Stewart LR, Roth KA, Chiesa R, et al. Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105&#x2013;125. EMBO J. 2007;26:548&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1783448</ArticleId><ArticleId IdType="pubmed">17245437</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto M, Rockenstein E, Crews L, Masliah E. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med. 2003;4:21&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">14528050</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Wollmann R, Lindquist S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science. 2002;298:1781&#x2013;1785.</Citation><ArticleIdList><ArticleId IdType="pubmed">12386337</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristiansen M, Messenger MJ, Klohn PC, Brandner S, Wadsworth JD, et al. Disease-related prion protein forms aggresomes in neuronal cells leading to caspase activation and apoptosis. J Biol Chem. 2005;280:38851&#x2013;38861.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157591</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardai G, Csermely P, Soti C. Chaperone function and chaperone overload in the aged. A preliminary analysis. Exp Gerontol. 2002;37:1257&#x2013;1262.</Citation><ArticleIdList><ArticleId IdType="pubmed">12470839</ArticleId></ArticleIdList></Reference><Reference><Citation>Csermely P. Chaperone overload is a possible contributor to &#x2018;civilization diseases'. Trends Genet. 2001;17:701&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">11718923</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaei H, Marc D, Choiset Y, Takahashi M, Hui Bon Hoa G, et al. High yield purification and physico-chemical properties of full-length recombinant allelic variants of sheep prion protein linked to scrapie susceptibility. Eur J Biochem. 2000;267:2833&#x2013;2839.</Citation><ArticleIdList><ArticleId IdType="pubmed">10806380</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xfc;eler H, Fischer M, Lang Y, Bluethmann H, Lipp H-P, et al. Normal development and behaviour of mice lacking the neuronal cell surface PrP protein. Nature. 1992;356:577&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">1373228</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore RC, Mastrangelo P, Bouzamondo E, Heinrich C, Legname G, et al. Doppel-induced cerebellar degeneration in transgenic mice. Proc Natl Acad Sci U S A. 2001;98:15288&#x2013;15293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC65022</ArticleId><ArticleId IdType="pubmed">11734625</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Donovan CN, Tobin D, Cotter TG. Prion protein fragment PrP-(106&#x2013;126) induces apoptosis via mitochondrial disruption in human neuronal SH-SY5Y cells. J Biol Chem. 2001;276:43516&#x2013;43523.</Citation><ArticleIdList><ArticleId IdType="pubmed">11533027</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17784957</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1742-2094</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><PubDate><Year>2007</Year><Month>Sep</Month><Day>04</Day></PubDate></JournalIssue><Title>Journal of neuroinflammation</Title><ISOAbbreviation>J Neuroinflammation</ISOAbbreviation></Journal><ArticleTitle>A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.</ArticleTitle><Pagination><StartPage>21</StartPage><MedlinePgn>21</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">An accumulating body of evidence is consistent with the hypothesis that excessive or prolonged increases in proinflammatory cytokine production by activated glia is a contributor to the progression of pathophysiology that is causally linked to synaptic dysfunction and hippocampal behavior deficits in neurodegenerative diseases such as Alzheimer's disease (AD). This raises the opportunity for the development of new classes of potentially disease-modifying therapeutics. A logical candidate CNS target is p38 alpha MAPK, a well-established drug discovery molecular target for altering proinflammatory cytokine cascades in peripheral tissue disorders. Activated p38 MAPK is seen in human AD brain tissue and in AD-relevant animal models, and cell culture studies strongly implicate p38 MAPK in the increased production of proinflammatory cytokines by glia activated with human amyloid-beta (A beta) and other disease-relevant stressors. However, the vast majority of small molecule drugs do not have sufficient penetrance of the blood-brain barrier to allow their use as in vivo research tools or as therapeutics for neurodegenerative disorders. The goal of this study was to test the hypothesis that brain p38 alpha MAPK is a potential in vivo target for orally bioavailable, small molecules capable of suppressing excessive cytokine production by activated glia back towards homeostasis, allowing an improvement in neurologic outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A novel synthetic small molecule based on a molecular scaffold used previously was designed, synthesized, and subjected to analyses to demonstrate its potential in vivo bioavailability, metabolic stability, safety and brain uptake. Testing for in vivo efficacy used an AD-relevant mouse model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A novel, CNS-penetrant, non-toxic, orally bioavailable, small molecule inhibitor of p38 alpha MAPK (MW01-2-069A-SRM) was developed. Oral administration of the compound at a low dose (2.5 mg/kg) resulted in attenuation of excessive proinflammatory cytokine production in the hippocampus back towards normal in the animal model. Animals with attenuated cytokine production had reductions in synaptic dysfunction and hippocampus-dependent behavioral deficits.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The p38 alpha MAPK pathway is quantitatively important in the A beta-induced production of proinflammatory cytokines in hippocampus, and brain p38 alpha MAPK is a viable molecular target for future development of potential disease-modifying therapeutics in AD and related neurodegenerative disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Munoz</LastName><ForeName>Lenka</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Drug Discovery and Chemical Biology, Northwestern University, 303 E Chicago Ave, Mailcode W896, Chicago, IL 60611, USA. lmunoz@pharm.usyd.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ralay Ranaivo</LastName><ForeName>Hantamalala</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Roy</LastName><ForeName>Saktimayee M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Wenhui</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Craft</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>McNamara</LastName><ForeName>Laurie K</ForeName><Initials>LK</Initials></Author><Author ValidYN="Y"><LastName>Chico</LastName><ForeName>Laura Wing</ForeName><Initials>LW</Initials></Author><Author ValidYN="Y"><LastName>Van Eldik</LastName><ForeName>Linda J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Watterson</LastName><ForeName>D Martin</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG031311</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuroinflammation</MedlineTA><NlmUniqueID>101222974</NlmUniqueID><ISSNLinking>1742-2094</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015507">Drugs, Investigational</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C524807">MW01-2-069A-SRM</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011724">Pyridazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048308">Mitogen-Activated Protein Kinase 14</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015507" MajorTopicYN="N">Drugs, Investigational</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048308" MajorTopicYN="N">Mitogen-Activated Protein Kinase 14</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011724" MajorTopicYN="N">Pyridazines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17784957</ArticleId><ArticleId IdType="pmc">PMC2014744</ArticleId><ArticleId IdType="doi">10.1186/1742-2094-4-21</ArticleId><ArticleId IdType="pii">1742-2094-4-21</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Craft JM, Watterson DM, Van Eldik LJ. Neuroinflammation: a potential therapeutic target. Expert Opin Ther Targets. 2005;9:887&#x2013;900. doi: 10.1517/14728222.9.5.887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728222.9.5.887</ArticleId><ArticleId IdType="pubmed">16185146</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW, Mrak RE. Glial-neuronal interactions in Alzheimer's disease: the potential role of a "cytokine cycle" in disease progression. Brain Pathol. 1998;8:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098321</ArticleId><ArticleId IdType="pubmed">9458167</ArticleId></ArticleIdList></Reference><Reference><Citation>Minagar A, Shapshak P, Fujimura R, Ownby R, Heyes M, Eisdorfer C. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci. 2002;202:13&#x2013;23. doi: 10.1016/S0022-510X(02)00207-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(02)00207-1</ArticleId><ArticleId IdType="pubmed">12220687</ArticleId></ArticleIdList></Reference><Reference><Citation>Moisse K, Strong MJ. Innate immunity in amyotrophic lateral sclerosis. Biochim Biophys Acta. 2006;1762:1083&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">16624536</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak RE, Griffin WST. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging. 2005;26:349&#x2013;354. doi: 10.1016/j.neurobiolaging.2004.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.05.010</ArticleId><ArticleId IdType="pubmed">15639313</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagatsu T, Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Pharm Des. 2005;11:999&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">15777250</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr CF, Rowe DB, Halliday GM. An inflammatory review of Parkinson's disease. Prog Neurobiol. 2002;68:325&#x2013;340. doi: 10.1016/S0301-0082(02)00127-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0301-0082(02)00127-2</ArticleId><ArticleId IdType="pubmed">12531233</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringheim GE, Conant K. Neurodegenerative disease and the neuroimmune axis (Alzheimer's and Parkinson's disease, and viral infections) J Neuroimmunol. 2004;147:43&#x2013;49. doi: 10.1016/j.jneuroim.2003.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2003.10.013</ArticleId><ArticleId IdType="pubmed">14741426</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothwell NJ, Luheshi GN. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci. 2000;23:618&#x2013;625. doi: 10.1016/S0166-2236(00)01661-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-2236(00)01661-1</ArticleId><ArticleId IdType="pubmed">11137152</ArticleId></ArticleIdList></Reference><Reference><Citation>Sargsyan SA, Monk PN, Shaw PJ. Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia. 2005;51:241&#x2013;253. doi: 10.1002/glia.20210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20210</ArticleId><ArticleId IdType="pubmed">15846792</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft JM, Watterson DM, Van Eldik LJ. Human amyloid &#x3b2;-induced neuroinflammation is an early event in neurodegeneration. Glia. 2006;53:484&#x2013;490. doi: 10.1002/glia.20306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20306</ArticleId><ArticleId IdType="pubmed">16369931</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WST, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA. 1989;86:7611&#x2013;7615. doi: 10.1073/pnas.86.19.7611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.86.19.7611</ArticleId><ArticleId IdType="pmc">PMC298116</ArticleId><ArticleId IdType="pubmed">2529544</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft JM, Watterson DM, Marks A, Van Eldik LJ. Enhanced susceptibility of S100B transgenic mice to neuroinflammation and neuronal dysfunction induced by intracerebroventricular infusion of human &#x3b2;-amyloid. Glia. 2005;51:209&#x2013;216. doi: 10.1002/glia.20194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20194</ArticleId><ArticleId IdType="pubmed">15810011</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft JM, Watterson DM, Hirsch E, Van Eldik LJ. Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human beta-amyloid. J Neuroinflammation. 2005;2:15&#x2013;23. doi: 10.1186/1742-2094-2-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-2-15</ArticleId><ArticleId IdType="pmc">PMC1190207</ArticleId><ArticleId IdType="pubmed">15967035</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Liu L, Kang J, Sheng JG, Barger SW, Mrak RE, Griffin WST. Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci. 2000;20:149&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6774108</ArticleId><ArticleId IdType="pubmed">10627591</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WST, Liu L, Li Y, Mrak RE, Barger SW. Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammation. 2006;3:5&#x2013;13. doi: 10.1186/1742-2094-3-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-3-5</ArticleId><ArticleId IdType="pmc">PMC1435743</ArticleId><ArticleId IdType="pubmed">16542445</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldik LJ, Griffin WST. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging. 1996;17:761&#x2013;766. doi: 10.1016/0197-4580(96)00104-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(96)00104-2</ArticleId><ArticleId IdType="pmc">PMC3886636</ArticleId><ArticleId IdType="pubmed">8892349</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Zhu SG, Jones RA, Griffin WST, Mrak RE. Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exp Neurol. 2000;163:388&#x2013;391. doi: 10.1006/exnr.2000.7393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.2000.7393</ArticleId><ArticleId IdType="pmc">PMC3886634</ArticleId><ArticleId IdType="pubmed">10833312</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Jones RA, Zhou XQ, McGinness JM, Van Eldik LJ, Mrak RE, Griffin WS. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation. Neurochem Int. 2001;39:341&#x2013;348. doi: 10.1016/S0197-0186(01)00041-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-0186(01)00041-9</ArticleId><ArticleId IdType="pmc">PMC3833633</ArticleId><ArticleId IdType="pubmed">11578769</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft JM, Watterson DM, Frautschy SA, Van Eldik LJ. Aminopyridazines inhibit &#x3b2;-amyloid induced glial activation and neuronal damage in vivo. Neurobiol Aging. 2004;25:1283&#x2013;1292. doi: 10.1016/j.neurobiolaging.2004.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.01.006</ArticleId><ArticleId IdType="pubmed">15465624</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft JM, Van Eldik LJ, Zasadzki M, Hu W, Watterson DM. Aminopyridazines attenuate hippocampus dependent behavioral deficits induced by human A&#x3b2; in a murine model of neuroinflammation. J Mol Neurosci. 2004;24:115&#x2013;122. doi: 10.1385/JMN:24:1:115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/JMN:24:1:115</ArticleId><ArticleId IdType="pubmed">15314259</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W, Ralay Ranaivo H, Roy SM, Behanna HA, Wing LK, Munoz L, Guo L, Van Eldik LJ, Watterson DM. Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorg Med Chem Lett. 2007;17:414&#x2013;418. doi: 10.1016/j.bmcl.2006.10.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2006.10.028</ArticleId><ArticleId IdType="pmc">PMC1868432</ArticleId><ArticleId IdType="pubmed">17079143</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralay Ranaivo H, Craft JM, Hu W, Guo L, Wing LK, Van Eldik LJ, Watterson DM. Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci. 2006;26:662&#x2013;670. doi: 10.1523/JNEUROSCI.4652-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4652-05.2006</ArticleId><ArticleId IdType="pmc">PMC6674428</ArticleId><ArticleId IdType="pubmed">16407564</ArticleId></ArticleIdList></Reference><Reference><Citation>Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov. 2004;3:330&#x2013;339. doi: 10.1038/nrd1342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd1342</ArticleId><ArticleId IdType="pubmed">15060528</ArticleId></ArticleIdList></Reference><Reference><Citation>Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL. Anti-TNF-alpha therapies: the next generation. Nat Rev Drug Discov. 2003;2:736&#x2013;746. doi: 10.1038/nrd1175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd1175</ArticleId><ArticleId IdType="pubmed">12951580</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed. 2006;8:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1785182</ArticleId><ArticleId IdType="pubmed">16926764</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids&#x2013;new mechanisms for old drugs. N Engl J Med. 2005;353:1711&#x2013;1723. doi: 10.1056/NEJMra050541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra050541</ArticleId><ArticleId IdType="pubmed">16236742</ArticleId></ArticleIdList></Reference><Reference><Citation>Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96:23&#x2013;43. doi: 10.1016/S0163-7258(02)00297-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0163-7258(02)00297-8</ArticleId><ArticleId IdType="pubmed">12441176</ArticleId></ArticleIdList></Reference><Reference><Citation>Wing LK, Behanna HA, Van Eldik LJ, Watterson DM, Ralay Ranaivo H. De novo and molecular target-independent discovery of orally bioavailable lead compounds for neurological disorders. Curr Alzheimer Res. 2006;3:205&#x2013;214. doi: 10.2174/156720506777632844.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720506777632844</ArticleId><ArticleId IdType="pubmed">16842097</ArticleId></ArticleIdList></Reference><Reference><Citation>Somera-Molena KC, Robin B, Somera CA, Anderson C, Koh S, Behanna HA, Van Eldik LJ, Watterson DM, Wainwright MS. Glial activation links early-life seizures and long-term neurologic dysfunction: evidence using a small molecule inhibitor of pro-inflammatory cytokine upregulation. Epilepsia. 2007. online May 23, 2007. doi:10.1111/j.1528-1167.2007.01135.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">17521344</ArticleId></ArticleIdList></Reference><Reference><Citation>Sams-Dodd F. Drug discovery: selecting the optimal approach. Drug Discov Today. 2006;11:465&#x2013;472. doi: 10.1016/j.drudis.2006.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2006.03.015</ArticleId><ArticleId IdType="pubmed">16635811</ArticleId></ArticleIdList></Reference><Reference><Citation>Sams-Dodd F. Research and market strategy: how choice of drug discovery approach can affect market position. Drug Discov Today. 2007;12:314&#x2013;318. doi: 10.1016/j.drudis.2007.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2007.02.014</ArticleId><ArticleId IdType="pubmed">17395091</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams JL, Badger AM, Kumar S, Lee JC. p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines. Prog Med Chem. 2001;38:1&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">11774793</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy&#x2013;from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta. 2005;1754:253&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">16198162</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov. 2003;2:717&#x2013;726. doi: 10.1038/nrd1177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd1177</ArticleId><ArticleId IdType="pubmed">12951578</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001;81:807&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274345</ArticleId></ArticleIdList></Reference><Reference><Citation>Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol. 2004;4:372&#x2013;377. doi: 10.1016/j.coph.2004.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2004.03.009</ArticleId><ArticleId IdType="pubmed">15251131</ArticleId></ArticleIdList></Reference><Reference><Citation>Schieven GL. The biology of p38 kinase: a central role in inflammation. Curr Top Med Chem. 2005;5:921&#x2013;928. doi: 10.2174/1568026054985902.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026054985902</ArticleId><ArticleId IdType="pubmed">16178737</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalrymple SA. p38 mitogen activated protein kinase as a therapeutic target for Alzheimer's disease. J Mol Neurosci. 2002;19:295&#x2013;299. doi: 10.1385/JMN:19:3:295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/JMN:19:3:295</ArticleId><ArticleId IdType="pubmed">12540055</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson GV, Bailey CD. The p38 MAP kinase signaling pathway in Alzheimer's disease. Exp Neurol. 2003;183:263&#x2013;268. doi: 10.1016/S0014-4886(03)00268-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-4886(03)00268-1</ArticleId><ArticleId IdType="pubmed">14552867</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfo E, Avila J. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res. 2005;2:3&#x2013;18. doi: 10.2174/1567205052772713.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205052772713</ArticleId><ArticleId IdType="pubmed">15977985</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K, Floyd RA, Zheng NY, Nael R, Robinson KA, Nguyen X, Pye QN, Stewart CA, Geddes J, Markesbery WR, et al. p38 kinase is activated in the Alzheimer's disease brain. J Neurochem. 1999;72:2053&#x2013;2058. doi: 10.1046/j.1471-4159.1999.0722053.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1999.0722053.x</ArticleId><ArticleId IdType="pubmed">10217284</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF. Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J Alzheimers Dis. 2001;3:41&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214071</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun A, Liu M, Nguyen XV, Bing G. P38 MAP kinase is activated at early stages in Alzheimer's disease brain. Exp Neurol. 2003;183:394&#x2013;405. doi: 10.1016/S0014-4886(03)00180-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-4886(03)00180-8</ArticleId><ArticleId IdType="pubmed">14552880</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol. 2000;59:880&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">11079778</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Rottkamp CA, Hartzler A, Sun Z, Takeda A, Boux H, Shimohama S, Perry G, Smith MA. Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. J Neurochem. 2001;79:311&#x2013;318. doi: 10.1046/j.1471-4159.2001.00597.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2001.00597.x</ArticleId><ArticleId IdType="pubmed">11677259</ArticleId></ArticleIdList></Reference><Reference><Citation>Culbert AA, Skaper SD, Howlett DR, Evans NA, Facci L, Soden PE, Seymour ZM, Guillot F, Gaestel M, Richardson JC. MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease. J Biol Chem. 2006;281:23658&#x2013;23667. doi: 10.1074/jbc.M513646200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M513646200</ArticleId><ArticleId IdType="pubmed">16774924</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I. Stress kinases involved in tau phosphorylation in Alzheimer's disease, tauopathies and APP transgenic mice. Neurotox Res. 2004;6:469&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">15658002</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S, Pepeu G, Casamenti F. Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis. 2002;11:257&#x2013;274. doi: 10.1006/nbdi.2002.0538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2002.0538</ArticleId><ArticleId IdType="pubmed">12505419</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y, Yan EZ, Fan Y, Zong ZH, Qi ZM, Li Z. Sodium ferulate prevents amyloid-beta-induced neurotoxicity through suppression of p38 MAPK and upregulation of ERK-1/2 and Akt/protein kinase B in rat hippocampus. Acta Pharmacol. 2005;26:943&#x2013;951. doi: 10.1111/j.1745-7254.2005.00158.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1745-7254.2005.00158.x</ArticleId><ArticleId IdType="pubmed">16038626</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage MJ, Lin YG, Ciallella JR, Flood DG, Scott RW. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J Neurosci. 2002;22:3376&#x2013;3385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758401</ArticleId><ArticleId IdType="pubmed">11978814</ArticleId></ArticleIdList></Reference><Reference><Citation>Franciosi S, Ryu JK, Choi HB, Radov L, Kim SU, McLarnon JG. Broad-spectrum effects of 4-aminopyridine to modulate amyloid &#x3b2; 1&#x2013;42 -induced cell signaling and functional responses in human microglia. J Neurosci. 2006;26:11652&#x2013;11664. doi: 10.1523/JNEUROSCI.2490-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2490-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674791</ArticleId><ArticleId IdType="pubmed">17093087</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Smith CJ, Van Eldik LJ. Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production. Neurobiol Aging. 2004;25:431&#x2013;439. doi: 10.1016/S0197-4580(03)00126-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(03)00126-X</ArticleId><ArticleId IdType="pubmed">15013563</ArticleId></ArticleIdList></Reference><Reference><Citation>Koistinaho M, Koistinaho J. Role of p38 and p44/42 mitogen-activated protein kinases in microglia. Glia. 2002;40:175&#x2013;183. doi: 10.1002/glia.10151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.10151</ArticleId><ArticleId IdType="pubmed">12379905</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald DR, Bamberger ME, Combs CK, Landreth GE. beta-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes. J Neurosci. 1998;18:4451&#x2013;4460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792680</ArticleId><ArticleId IdType="pubmed">9614222</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyo H, Jou I, Jung S, Hong S, Joe E-h. Mitogen-activated protein kinases activated by lipopolysaccharide and &#x3b2;-amyloid in cultured rat microglia. Neuroreport. 1998;9:871&#x2013;874. doi: 10.1097/00001756-199803300-00020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-199803300-00020</ArticleId><ArticleId IdType="pubmed">9579682</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat NR, Zhang P, Lee JC, Hogan EL. Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-&#x3b1; gene expression in endotoxin-stimulated primary glial cultures. J Neurosci. 1998;18:1633&#x2013;1641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792636</ArticleId><ArticleId IdType="pubmed">9464988</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YB, Schrader JW, Kim SU. p38 MAP kinase regulates TNF-&#x3b1; production in human astrocytes and microglia by multiple mechanisms. Cytokine. 2000;12:874&#x2013;880. doi: 10.1006/cyto.2000.0688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cyto.2000.0688</ArticleId><ArticleId IdType="pubmed">10880231</ArticleId></ArticleIdList></Reference><Reference><Citation>Wermuth CG. Similarity in drugs: reflections on analogue design. Drug Discov Today. 2006;11:348&#x2013;354. doi: 10.1016/j.drudis.2006.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2006.02.006</ArticleId><ArticleId IdType="pubmed">16580977</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardridge WM. Blood-brain barrier delivery. Drug Discov Today. 2007;12:54&#x2013;61. doi: 10.1016/j.drudis.2006.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2006.10.013</ArticleId><ArticleId IdType="pubmed">17198973</ArticleId></ArticleIdList></Reference><Reference><Citation>Dury K. New methods in the chemistry of pyridazinones. Angew Chem Int Ed. 1965;4:292&#x2013;300. doi: 10.1002/anie.196502921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.196502921</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravi&#xf1;a E, Teran C, Santana L, Garcia N, Estevez I. Pyridazine derivatives, IX. Synthesis of 2H-pyridazin-3-ones with aroylpiperazinyl group. Heterocycles. 1990;31:1967&#x2013;1974.</Citation></Reference><Reference><Citation>Sotelo E, Fraiz N, Yanez M, Laguna R, Cano E, Ravina E. Pyridazines. Part 31: synthesis and antiplatelet activity of 4,5-disubstituted-6-phenyl-3(2H)-pyridazinones. Chem Pharm Bull (Tokyo) 2002;50:1574&#x2013;1577. doi: 10.1248/cpb.50.1574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/cpb.50.1574</ArticleId><ArticleId IdType="pubmed">12499593</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Shen H. Solubility and Lipophilicity: Assessing physicochemical properties of lead compounds. In: Yan Z, Caldwell GW, editor. Methods in Pharmacology and Toxicology Optimization in Drug Discovery: In Vitro Methods. Totowa, New Jersey: Humana Press; 2004. pp. 1&#x2013;17.</Citation></Reference><Reference><Citation>Nasal A, Siluk D, Kaliszan R. Chromatographic retention parameters in medicinal chemistry and molecular pharmacology. Curr Med Chem. 2003;10:381&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">12570698</ArticleId></ArticleIdList></Reference><Reference><Citation>Streng WH. Physical chemical characterization of drug substances. Drug Discovery Today. 1997;2:415&#x2013;426. doi: 10.1016/S1359-6446(97)01077-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1359-6446(97)01077-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Takacs-Novak K, Avdeef A. Interlaboratory study of log P determination by shake-flask and potentiometric methods. J Pharm Biomed Anal. 1996;14:1405&#x2013;1413. doi: 10.1016/0731-7085(96)01773-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0731-7085(96)01773-6</ArticleId><ArticleId IdType="pubmed">8877846</ArticleId></ArticleIdList></Reference><Reference><Citation>Behanna HA, Watterson DM, Ranaivo HR. Development of a novel bioavailable inhibitor of the calmodulin-regulated protein kinase MLCK: a lead compound that attenuates vascular leak. Biochim Biophys Acta. 2006;1763:1266&#x2013;1274. doi: 10.1016/j.bbamcr.2006.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2006.08.007</ArticleId><ArticleId IdType="pubmed">16996151</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher AM, Schavocky JP, Velentza AV, Mirzoeva S, Watterson DM. A calmodulin-regulated protein kinase linked to neuron survival is a substrate for the calmodulin-regulated death-associated protein kinase. Biochemistry. 2004;43:8116&#x2013;8124. doi: 10.1021/bi049589v.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi049589v</ArticleId><ArticleId IdType="pubmed">15209507</ArticleId></ArticleIdList></Reference><Reference><Citation>Velentza AV, Wainwright MS, Zasadzki M, Mirzoeva S, Schumacher AM, Haiech J, Focia PJ, Egli M, Watterson DM. An aminopyridazine-based inhibitor of a pro-apoptotic protein kinase attenuates hypoxia-ischemia induced acute brain injury. Bioorg Med Chem Lett. 2003;13:3465&#x2013;3470. doi: 10.1016/S0960-894X(03)00733-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-894X(03)00733-9</ArticleId><ArticleId IdType="pubmed">14505650</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackley DC, Rockich KT, Baker TR. Metabolic stability assessed by liver microsomes and hepatocytes. In: Yan Z, Caldwell GW, editor. Methods in Pharmacology and Toxicology Optimization in Drug Discovery: In Vitro Methods. Totowa, New Jersey: Humana Press; 2004. pp. 151&#x2013;162.</Citation></Reference><Reference><Citation>Hynes J, Leftheris K. Small molecule p38 inhibitors: novel structural features and advances from 2002 &#x2013; 2005. Curr Topics Med Chem. 2005;5:967&#x2013;985. doi: 10.2174/1568026054985920.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026054985920</ArticleId><ArticleId IdType="pubmed">16178741</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem. 2005;12:2979&#x2013;2994. doi: 10.2174/092986705774462914.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/092986705774462914</ArticleId><ArticleId IdType="pubmed">16378500</ArticleId></ArticleIdList></Reference><Reference><Citation>Peifer C, Wagner G, Laufer S. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. Curr Top Med Chem. 2006;6:113&#x2013;149. doi: 10.2174/156802606775270323.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156802606775270323</ArticleId><ArticleId IdType="pubmed">16454763</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, Cole GM. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging. 2001;22:993&#x2013;1005. doi: 10.1016/S0197-4580(01)00300-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(01)00300-1</ArticleId><ArticleId IdType="pubmed">11755008</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhagwat SS, Manning AM, Hoekstra MF, Lewis A. Gene-regulating protein kinases as important anti-inflammatory targets. Drug Discov Today. 1999;4:472&#x2013;479. doi: 10.1016/S1359-6446(99)01402-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1359-6446(99)01402-6</ArticleId><ArticleId IdType="pubmed">10481143</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov. 2002;1:727&#x2013;730. doi: 10.1038/nrd892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd892</ArticleId><ArticleId IdType="pubmed">12209152</ArticleId></ArticleIdList></Reference><Reference><Citation>Russ AP, Lampel S. The druggable genome: an update. Drug Discov Today. 2005;10:1607&#x2013;1610. doi: 10.1016/S1359-6446(05)03666-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1359-6446(05)03666-4</ArticleId><ArticleId IdType="pubmed">16376820</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Liu L, Barger SW, Griffin WS. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci. 2003;23:1605&#x2013;1611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833596</ArticleId><ArticleId IdType="pubmed">12629164</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17826768</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0014-4886</ISSN><JournalIssue CitedMedium="Print"><Volume>208</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Experimental neurology</Title><ISOAbbreviation>Exp Neurol</ISOAbbreviation></Journal><ArticleTitle>Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans.</ArticleTitle><Pagination><StartPage>185</StartPage><EndPage>192</EndPage><MedlinePgn>185-92</MedlinePgn></Pagination><Abstract><AbstractText>Studies in animal models have shown that traumatic brain injury (TBI) induces the rapid accumulation of many of the same key proteins that form pathologic aggregates in neurodegenerative diseases. Here, we examined whether this rapid process also occurs in humans after TBI. Brain tissue from 18 cases who died after TBI and from 6 control cases was examined using immunohistochemistry. Following TBI, widespread axonal injury was persistently identified by the accumulation of neurofilament protein and amyloid precursor protein (APP) in axonal bulbs and varicosities. Axonal APP was found to co-accumulate with its cleavage enzymes, beta-site APP cleaving enzyme (BACE), presenilin-1 (PS1) and their product, amyloid-beta (Abeta). In addition, extensive accumulation of alpha-synuclein (alpha-syn) was found in swollen axons and tau protein was found to accumulate in both axons and neuronal cell bodies. These data show rapid axonal accumulation of proteins implicated in neurodegenerative diseases including Alzheimer's disease and the synucleinopathies. The cause of axonal pathology can be attributed to disruption of axons due to trauma, or as a secondary effect of raised intracranial pressure or hypoxia. Such axonal pathology in humans may provide a unique environment whereby co-accumulation of APP, BACE, and PS1 leads to intra-axonal production of Abeta as well as accumulation of alpha-syn and tau. This process may have important implications for survivors of TBI who have been shown to be at greater risk of developing neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uryu</LastName><ForeName>Kunihiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Center for Neurodegenerative Disease Research, Pathology and Laboratory Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiao-Han</ForeName><Initials>XH</Initials></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Browne</LastName><ForeName>Kevin D</ForeName><Initials>KD</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Victoria E</ForeName><Initials>VE</Initials></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>David I</ForeName><Initials>DI</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Douglas H</ForeName><Initials>DH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS08803</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS38104</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG011542</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS038104</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG012527</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG12527</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG11542</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS008803</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Exp Neurol</MedlineTA><NlmUniqueID>0370712</NlmUniqueID><ISSNLinking>0014-4886</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002102" MajorTopicYN="N">Cadaver</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>4</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17826768</ArticleId><ArticleId IdType="mid">NIHMS36204</ArticleId><ArticleId IdType="pmc">PMC3979356</ArticleId><ArticleId IdType="doi">10.1016/j.expneurol.2007.06.018</ArticleId><ArticleId IdType="pii">S0014-4886(07)00242-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abrahamson EE, Ikonomovic MD, Ciallella JR, Hope CE, Paljug WR, Isanski BA, Flood DG, Clark RS, DeKosky ST. Caspase inhibition therapy abolishes brain trauma-induced increases in Abeta peptide: implications for clinical outcome. Exp Neurol. 2006;197(2):437&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">16300758</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams JH, Doyle D, Ford I, Gennarelli TA, Graham DI, McLellan DR. Diffuse axonal injury in head injury: definition, diagnosis and grading. Histopathology. 1989;15(1):49&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">2767623</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams JH, Graham DI. The relationship between ventricular fluid pressure and the neuropathology of raised intracranial pressure. Neuropath Appl Neurobiol. 1976;2:323&#x2013;332.</Citation></Reference><Reference><Citation>Adams JH, Graham DI, Gennarelli TA, Maxwell WL. Diffuse axonal injury in non-missile head injury. J Neurol Neurosurg Psychiatry. 1991;54(6):481&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC488581</ArticleId><ArticleId IdType="pubmed">1880506</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams JH, Graham DI, Murray LS, Scott G. Diffuse axonal injury due to nonmissile head injury in humans: an analysis of 45 cases. Ann Neurol. 1982;12(6):557&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">7159059</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams JH, Graham DI, Scott G, Parker LS, Doyle D. Brain damage in fatal non-missile head injury. J Clin Pathol. 1980;33(12):1132&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1146364</ArticleId><ArticleId IdType="pubmed">7451661</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Shlomo Y. The epidemiology of Parkinson&#x2019;s disease. Baillieres Clin Neurol. 1997;6(1):55&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">9426868</ArticleId></ArticleIdList></Reference><Reference><Citation>Black M, Graham DI. Sudden unexplained death in adults caused by intracranial pathology. J Clin Pathol. 2002;55(1):44&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1769576</ArticleId><ArticleId IdType="pubmed">11825924</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82(4):239&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE, Mathis CA, Bales KR, Paul SM, Hyman BT, Holtzman DM. Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest. 2005;115(2):428&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC544607</ArticleId><ArticleId IdType="pubmed">15668737</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen XH, Siman R, Iwata A, Meaney DF, Trojanowski JQ, Smith DH. Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma. Am J Pathol. 2004;165(2):357&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618579</ArticleId><ArticleId IdType="pubmed">15277212</ArticleId></ArticleIdList></Reference><Reference><Citation>Christman CW, Grady MS, Walker SA, Holloway KL, Povlishock JT. Ultrastructural studies of diffuse axonal injury in humans. J Neurotrauma. 1994;11(2):173&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">7523685</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391(6665):387&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol. 2002;52(2):205&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">12210791</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler WP, Wolfe MS. A portrait of Alzheimer secretases--new features and familiar faces. Science. 2001;293(5534):1449&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520976</ArticleId></ArticleIdList></Reference><Reference><Citation>Factor SA, Weiner WJ. Prior history of head trauma in Parkinson&#x2019;s disease. Mov Disord. 1991;6(3):225&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">1922127</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med. 2004;10(10):1055&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">15459709</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4(2):160&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Geddes JF, Whitwell HL, Graham DI. Traumatic axonal injury: practical issues for diagnosis in medicolegal cases. Neuropathol Appl Neurobiol. 2000;26(2):105&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">10840273</ArticleId></ArticleIdList></Reference><Reference><Citation>Gennarelli TA. Mechanisms of brain injury. J Emerg Med. 1993;11(Suppl 1):5&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">8445204</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 2000;290(5493):985&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11062131</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW. Head injury and Parkinson&#x2019;s disease risk in twins. Ann Neurol. 2006;60(1):65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">16718702</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorrie C, Oakes S, Duflou J, Blumbergs P, Waite PM. Axonal injury in children after motor vehicle crashes: extent, distribution, and size of axonal swellings using beta-APP immunohistochemistry. J Neurotrauma. 2002;19(10):1171&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">12427326</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady MS, McLaughlin MR, Christman CW, Valadka AB, Fligner CL, Povlishock JT. The use of antibodies targeted against the neurofilament subunits for the detection of diffuse axonal injury in humans. J Neuropathol Exp Neurol. 1993;52(2):143&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">8440996</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham DI, Ford I, Adams JH, Doyle D, Teasdale GM, Lawrence AE, McLellan DR. Ischaemic brain damage is still common in fatal non-missile head injury. J Neurol Neurosurg Psychiatry. 1989;52(3):346&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1032409</ArticleId><ArticleId IdType="pubmed">2926419</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham DI, Gentleman SM, Lynch A, Roberts GW. Distribution of beta-amyloid protein in the brain following severe head injury. Neuropathol Appl Neurobiol. 1995;21(1):27&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">7770117</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z, Cupples LA, Kurz A, Auerbach SH, Volicer L, Chui H, Green RC, Sadovnick AD, Duara R, DeCarli C, Johnson K, Go RC, Growdon JH, Haines JL, Kukull WA, Farrer LA. Head injury and the risk of AD in the MIRAGE study. Neurology. 2000;54(6):1316&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">10746604</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Uryu K, Abrahamson EE, Ciallella JR, Trojanowski JQ, Lee VM, Clark RS, Marion DW, Wisniewski SR, DeKosky ST. Alzheimer&#x2019;s pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol. 2004;190(1):192&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">15473992</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata A, Chen XH, McIntosh TK, Browne KD, Smith DH. Long-term accumulation of amyloid-beta in axons following brain trauma without persistent upregulation of amyloid precursor protein genes. J Neuropathol Exp Neurol. 2002;61(12):1056&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">12484568</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LS. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature. 2001;414(6864):643&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11740561</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A, Stokin GB, Yang Z, Xia CH, Goldstein LS. Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron. 2000;28(2):449&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">11144355</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambri M, Djurovic V, Kibble M, Cairns N, Al-Sarraj S. Specificity and sensitivity of betaAPP in head injury. Clin Neuropathol. 2001;20(6):263&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">11758782</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Morfini GA, Lee EB, Farah MH, Szodorai A, DeBoer SR, Koliatsos VE, Kins S, Lee VM, Wong PC, Price DL, Brady ST, Sisodia SS. Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revisited. J Neurosci. 2005;25(9):2386&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726084</ArticleId><ArticleId IdType="pubmed">15745965</ArticleId></ArticleIdList></Reference><Reference><Citation>Lees AJ. Trauma and Parkinson disease. Rev Neurol (Paris) 1997;153(10):541&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9684017</ArticleId></ArticleIdList></Reference><Reference><Citation>Lye TC, Shores EA. Traumatic brain injury as a risk factor for Alzheimer&#x2019;s disease: a review. Neuropsychol Rev. 2000;10(2):115&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">10937919</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxwell WL, Povlishock JT, Graham DL. A mechanistic analysis of nondisruptive axonal injury: a review. J Neurotrauma. 1997;14(7):419&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">9257661</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Hart MN, Terry RD. Making the diagnosis of Alzheimer&#x2019;s disease. A primer for practicing pathologists. Arch Pathol Lab Med. 1993;117(2):132&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">8427562</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortimer JA, French LR, Hutton JT, Schuman LM. Head injury as a risk factor for Alzheimer&#x2019;s disease. Neurology. 1985;35(2):264&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">3969219</ArticleId></ArticleIdList></Reference><Reference><Citation>Nashef L. Unexpected death in epilepsy: terminology and definitions. Epilepsia. 1997;38(Suppl.11):S6&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19909329</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayernouri T. Posttraumatic parkinsonism. Surg Neurol. 1985;24(3):263&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">4023906</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemetz PN, Leibson C, Naessens JM, Beard M, Kokmen E, Annegers JF, Kurland LT. Traumatic brain injury and time to onset of Alzheimer&#x2019;s disease: a population-based study. Am J Epidemiol. 1999;149(1):32&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">9883791</ArticleId></ArticleIdList></Reference><Reference><Citation>Newell KL, Boyer P, Gomez-Tortosa E, Hobbs W, Hedley-Whyte ET, Vonsattel JP, Hyman BT. Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury. J Neuropathol Exp Neurol. 1999;58(12):1263&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10604751</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman SJ, G S, Graham DI, Brown F, Roberts GW. Tissue distribution and cellular localisation of hyperphosphorylated tau in human head injury and agematched controls. Chichester: Wiley; 1995.</Citation></Reference><Reference><Citation>Norris EH, Giasson BI, Lee VM. Alpha-synuclein: normal function and role in neurodegenerative diseases. Curr Top Dev Biol. 2004;60:17&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">15094295</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunan J, Small DH. Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Lett. 2000;483(1):6&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">11033346</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsuka N, Tomonaga M, Ikeda K. Rapid appearance of beta-amyloid precursor protein immunoreactivity in damaged axons and reactive glial cells in rat brain following needle stab injury. Brain Res. 1991;568(1-2):335&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1814579</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilz P. Axonal injury in head injury. Acta Neurochir Suppl (Wien) 1983;32:119&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">6581700</ArticleId></ArticleIdList></Reference><Reference><Citation>Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D, Phillips C, Gau BA, Welsh-Bohmer KA, Burke JR, Guralnik JM, Breitner JC. Documented head injury in early adulthood and risk of Alzheimer&#x2019;s disease and other dementias. Neurology. 2000;55(8):1158&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">11071494</ArticleId></ArticleIdList></Reference><Reference><Citation>Povlishock JT, Becker DP. Fate of reactive axonal swellings induced by head injury. Lab Invest. 1985;52(5):540&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">2581065</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmusson DX, Brandt J, Martin DB, Folstein MF. Head injury as a risk factor in Alzheimer&#x2019;s disease. Brain Inj. 1995;9(3):213&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7606235</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichard RR, White CL, 3rd, Hladik CL, Dolinak D. Beta-amyloid precursor protein staining of nonaccidental central nervous system injury in pediatric autopsies. J Neurotrauma. 2003;20(4):347&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">12866814</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI. Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 1994;57(4):419&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1072869</ArticleId><ArticleId IdType="pubmed">8163989</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt ML, Zhukareva V, Newell KL, Lee VM, Trojanowski JQ. Tau isoform profile and phosphorylation state in dementia pugilistica recapitulate Alzheimer&#x2019;s disease. Acta Neuropathol (Berl) 2001;101(5):518&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">11484824</ArticleId></ArticleIdList></Reference><Reference><Citation>Schofield PW, Tang M, Marder K, Bell K, Dooneief G, Chun M, Sano M, Stern Y, Mayeux R. Alzheimer&#x2019;s disease after remote head injury: an incidence study. J Neurol Neurosurg Psychiatry. 1997;62(2):119&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC486721</ArticleId><ArticleId IdType="pubmed">9048710</ArticleId></ArticleIdList></Reference><Reference><Citation>Schonheit B, Zarski R, Ohm TG. Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology. Neurobiol Aging. 2004;25(6):697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">15165691</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Wolfe MS. In search of gamma-secretase: presenilin at the cutting edge. Proc Natl Acad Sci U S A. 2000;97(11):5690&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33989</ArticleId><ArticleId IdType="pubmed">10823929</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherriff FE, Bridges LR, Sivaloganathan S. Early detection of axonal injury after human head trauma using immunocytochemistry for beta-amyloid precursor protein. Acta Neuropathol (Berl) 1994;87(1):55&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8140894</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith C, Graham DI, Murray LS, Nicoll JA. Tau immunohistochemistry in acute brain injury. Neuropathol Appl Neurobiol. 2003;29(5):496&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">14507341</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DH, Chen XH, Iwata A, Graham DI. Amyloid beta accumulation in axons after traumatic brain injury in humans. J Neurosurg. 2003;98(5):1072&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12744368</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DH, Chen XH, Nonaka M, Trojanowski JQ, Lee VM, Saatman KE, Leoni MJ, Xu BN, Wolf JA, Meaney DF. Accumulation of amyloid beta and tau and the formation of neurofilament inclusions following diffuse brain injury in the pig. J Neuropathol Exp Neurol. 1999;58(9):982&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">10499440</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DH, M D. Axonal damage in traumatic brain injury. The neuroscientist. 2000;6:483&#x2013;495.</Citation></Reference><Reference><Citation>Smith DH, Uryu K, Saatman KE, Trojanowski JQ, McIntosh TK. Protein accumulation in traumatic brain injury. Neuromolecular Med. 2003;4(1-2):59&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">14528053</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern MB. Head trauma as a risk factor for Parkinson&#x2019;s disease. Mov Disord. 1991;6(2):95&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">2057017</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, Goldstein LS. Axonopathy and transport deficits early in the pathogenesis of Alzheimer&#x2019;s disease. Science. 2005;307(5713):1282&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone JR, Okonkwo DO, Singleton RH, Mutlu LK, Helm GA, Povlishock JT. Caspase-3-mediated cleavage of amyloid precursor protein and formation of amyloid Beta peptide in traumatic axonal injury. J Neurotrauma. 2002;19(5):601&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">12042095</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ, Lee VM. Parkinson&#x2019;s disease and related synucleinopathies are a new class of nervous system amyloidoses. Neurotoxicology. 2002;23(4-5):457&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">12428717</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu K, Giasson BI, Longhi L, Martinez D, Murray I, Conte V, Nakamura M, Saatman K, Talbot K, Horiguchi T, McIntosh T, Lee VM, Trojanowski JQ. Age-dependent synuclein pathology following traumatic brain injury in mice. Exp Neurol. 2003;184(1):214&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">14637093</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoesen GW, Hyman BT. Hippocampal formation: anatomy and the patterns of pathology in Alzheimer&#x2019;s disease. Prog Brain Res. 1990;83:445&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">2392569</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M. Beta-secretase cleavage of Alzheimer&#x2019;s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286(5440):735&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Zemlan FP, Rosenberg WS, Luebbe PA, Campbell TA, Dean GE, Weiner NE, Cohen JA, Rudick RA, Woo D. Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J Neurochem. 1999;72(2):741&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">9930748</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17855343</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>282</Volume><Issue>46</Issue><PubDate><Year>2007</Year><Month>Nov</Month><Day>16</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway.</ArticleTitle><Pagination><StartPage>33305</StartPage><EndPage>33312</EndPage><MedlinePgn>33305-33312</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M610390200</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0021-9258(20)71664-9</ELocationID><Abstract><AbstractText>Numerous studies have now shown that the amyloid beta-protein (Abeta), the principal component of cerebral plaques in Alzheimer disease, rapidly and potently inhibits certain forms of synaptic plasticity. The amyloid (or Abeta) hypothesis proposes that the continuous disruption of normal synaptic physiology by Abeta contributes to the development of Alzheimer disease. However, there is little consensus about how Abeta mediates this inhibition at the molecular level. Using mouse primary hippocampal neurons, we observed that a brief treatment with cell-derived, soluble, human Abeta disrupted the activation of three kinases (Erk/MAPK, CaMKII, and the phosphatidylinositol 3-kinase-activated protein Akt/protein kinase B) that are required for long term potentiation, whereas two other kinases (protein kinase A and protein kinase C) were stimulated normally. An antagonist of the insulin receptor family of tyrosine kinases was found to mimic the pattern of Abeta-mediated kinase inhibition. We then found that soluble Abeta binds to the insulin receptor and interferes with its insulin-induced autophosphorylation. Taken together, these data demonstrate that physiologically relevant levels of naturally secreted Abeta interfere with insulin receptor function in hippocampal neurons and prevent the rapid activation of specific kinases required for long term potentiation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Townsend</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School and Center for Neurologic Diseases, Brigham and Women&#x149;s Hospital, Boston, Massachusetts 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Tapan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School and Center for Neurologic Diseases, Brigham and Women&#x149;s Hospital, Boston, Massachusetts 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School and Center for Neurologic Diseases, Brigham and Women&#x149;s Hospital, Boston, Massachusetts 02115. Electronic address: dselkoe@rics.bwh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG027443</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS07484-04</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D011972">Receptor, Insulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011972" MajorTopicYN="N">Receptor, Insulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17855343</ArticleId><ArticleId IdType="doi">10.1074/jbc.M610390200</ArticleId><ArticleId IdType="pii">S0021-9258(20)71664-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17855360</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>282</Volume><Issue>45</Issue><PubDate><Year>2007</Year><Month>Nov</Month><Day>09</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>SorLA/LR11 regulates processing of amyloid precursor protein via interaction with adaptors GGA and PACS-1.</ArticleTitle><Pagination><StartPage>32956</StartPage><EndPage>32964</EndPage><MedlinePgn>32956-64</MedlinePgn></Pagination><Abstract><AbstractText>SorLA has been recognized as a novel sorting receptor that regulates trafficking and processing of the amyloid precursor protein (APP) and that represents a significant risk factor for sporadic Alzheimer disease. Here, we investigated the cellular mechanisms that control intracellular trafficking of sorLA and their relevance for APP processing. We demonstrate that sorLA acts as a retention factor for APP in trans-Golgi compartments/trans-Golgi network, preventing release of the precursor into regular processing pathways. Proper localization and activity of sorLA are dependent on functional interaction with GGA and PACS-1, adaptor proteins involved in protein transport to and from the trans-Golgi network. Aberrant targeting of sorLA to the recycling compartment or the plasma membrane causes faulty APP trafficking and imbalance in non-amyloidogenic and amyloidogenic processing fates. Thus, our findings identified altered routing of sorLA as a major cellular mechanism contributing to abnormal APP processing and enhanced amyloid beta-peptide formation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Max-Delbrueck Center for Molecular Medicine, Robert-Roessle-Strasse 10, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sporbert</LastName><ForeName>Anje</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rohe</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Reimer</LastName><ForeName>Tatjana</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Rehm</LastName><ForeName>Armin</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Olav M</ForeName><Initials>OM</Initials></Author><Author ValidYN="Y"><LastName>Willnow</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033942">Adaptor Proteins, Vesicular Transport</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C407306">GGA adaptor proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026502">LDL-Receptor Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491914">PACS1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102582">SORL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033921">Vesicular Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D020727">ADP-Ribosylation Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020727" MajorTopicYN="N">ADP-Ribosylation Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033942" MajorTopicYN="N">Adaptor Proteins, Vesicular Transport</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006031" MajorTopicYN="N">Glycosylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026502" MajorTopicYN="N">LDL-Receptor Related Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033921" MajorTopicYN="N">Vesicular Transport Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17855360</ArticleId><ArticleId IdType="doi">10.1074/jbc.M705073200</ArticleId><ArticleId IdType="pii">S0021-9258(20)61305-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">1786532</PMID><DateCompleted><Year>1992</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-8993</ISSN><JournalIssue CitedMedium="Print"><Volume>563</Volume><Issue>1-2</Issue><PubDate><Year>1991</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Brain research</Title><ISOAbbreviation>Brain Res</ISOAbbreviation></Journal><ArticleTitle>Localization of Alzheimer beta A4 amyloid precursor protein at central and peripheral synaptic sites.</ArticleTitle><Pagination><StartPage>184</StartPage><EndPage>194</EndPage><MedlinePgn>184-94</MedlinePgn></Pagination><Abstract><AbstractText>We have recently shown that the amyloid beta A4 precursor protein (APP) is synthesized in neurons and undergoes fast axonal transport to synaptic sites [Koo et al., Proc. Natl. Acad. Sci. U.S.A., 87 (1990) 1561-1565]. Using immunofluorescence, laser confocal microscopy and immunoelectron microscopy with simultaneous detection of APP and synaptophysin, we now report a preferential localization of APP at synaptic sites of human and rat brain and at neuromuscular junctions. APP is further found on vesicular elements of neuronal perikarya, dendrites and axons. The synaptic localization of APP implies (1) a role of APP in physiological synaptic activity and (2) a potential and early impairment of central synapses when synaptic APP is converted to beta A4 amyloid during the pathological evolution of Alzheimer's disease and Down's syndrome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schubert</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center for Molecular Biology, University of Heidelberg, F.R.G.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prior</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Weidemann</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Dircksen</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Multhaup</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>C L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Beyreuther</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Brain Res</MedlineTA><NlmUniqueID>0045503</NlmUniqueID><ISSNLinking>0006-8993</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016708">Synaptophysin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005453" MajorTopicYN="N">Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007834" MajorTopicYN="N">Lasers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016253" MajorTopicYN="N">Microscopy, Immunoelectron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009132" MajorTopicYN="N">Muscles</DescriptorName><QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010525" MajorTopicYN="N">Peripheral Nerves</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011919" MajorTopicYN="N">Rats, Inbred Strains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016708" MajorTopicYN="N">Synaptophysin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1786532</ArticleId><ArticleId IdType="doi">10.1016/0006-8993(91)91532-6</ArticleId><ArticleId IdType="pii">0006-8993(91)91532-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17875915</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>12</Issue><PubDate><Year>2007</Year><Month>Sep</Month><Day>18</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease.</ArticleTitle><Pagination><StartPage>1270</StartPage><EndPage>1277</EndPage><MedlinePgn>1270-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the frequency of glucocerebrosidase (GBA) mutations in cases and controls enrolled in the Genetic Epidemiology of Parkinson's Disease (GEPD) study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We sequenced all exons of the GBA gene in 278 Parkinson disease (PD) cases and 179 controls enrolled in GEPD, with a wide range of age at onset (AAO), and that included a subset of 178 Jewish cases and 85 Jewish controls. Cases and controls were recruited without knowledge of family history of PD, and cases were oversampled in the AAO &lt; 50 years category.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">13.7% of PD cases (38/278) carried GBA mutations, compared with 4.5% of controls (8/179) (odds ratio [OR] 3.4, 95% CI 1.5 to 7.4). The frequency of GBA mutations was 22.2% in 90 cases with AAO &lt; or = 50 years, compared with 9.7% in 185 cases with AAO &gt; 50 years (OR 2.7, 95% CI 1.3 to 5.3). Adjusting for age at the time of evaluation, sex, family history of PD, and Jewish ancestry, GBA carriers had a 1.7-year-earlier AAO of PD (95% CI 0.5 to 3.3, p &lt; 0.04) than noncarriers. The average AAO of PD was 2.5 years earlier in carriers with an AAO &lt; or = 50 years compared with noncarriers (95% CI 0.6 to 4.5, p &lt; 0.01) and this was not seen in the AAO &gt; 50 years group. The frequency of GBA mutations was higher in a subset of 178 cases that reported four Jewish grandparents (16.9%) than in cases who did not report Jewish ancestry (8.0%) (p &lt; 0.01). Nine different GBA mutations were identified in PD cases, including 84insGG, E326K, T369M, N370S, D409H, R496H, L444P, RecNciI, and a novel mutation, P175P.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study suggests that the Glucocerebrosidase gene may be a susceptibility gene for Parkinson disease and that Glucocerebrosidase mutations may modify age at onset.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>L N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA. lc654@columbia.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>B M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Mejia-Santana</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Louis</LastName><ForeName>E D</ForeName><Initials>ED</Initials></Author><Author ValidYN="Y"><LastName>Cote</LastName><ForeName>L J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Fahn</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Waters</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Frucht</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ottman</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Marder</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>M01 RR000645</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS36630</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR00645</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS050487</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS50487</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS036630</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS036630</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.2.1.45</RegistryNumber><NameOfSubstance UI="D005962">Glucosylceramidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005962" MajorTopicYN="N">Glucosylceramidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040582" MajorTopicYN="N">Inheritance Patterns</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007585" MajorTopicYN="N">Jews</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><i>Disclosure:</i> The authors report no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>4</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17875915</ArticleId><ArticleId IdType="mid">NIHMS449725</ArticleId><ArticleId IdType="pmc">PMC3624967</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000276989.17578.02</ArticleId><ArticleId IdType="pii">69/12/1270</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sidransky E. Gaucher disease: complexity in a &#x201c;simple&#x201d; disorder. Mol Genet Metab. 2004;83:6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">15464415</ArticleId></ArticleIdList></Reference><Reference><Citation>Neudorfer O, Giladi N, Elstein D, et al. Occurrence of Parkinson&#x2019;s syndrome in type I Gaucher disease. QJM. 1996;89:691&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">8917744</ArticleId></ArticleIdList></Reference><Reference><Citation>Tayebi N, Callahan M, Madike V, et al. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab. 2001;73:313&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">11509013</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimaraes J, Amaral O, Sa Miranda MC. Adult-onset neuronopathic form of Gaucher&#x2019;s disease: a case report. Parkinsonism Relat Disord. 2003;9:261&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">12781591</ArticleId></ArticleIdList></Reference><Reference><Citation>Cormand B, Grinberg D, Gort L, et al. Molecular analysis and clinical findings in the Spanish Gaucher disease population: putative haplotype of the N370S ancestral chromosome. Hum Mutat. 1998;11:295&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">9554746</ArticleId></ArticleIdList></Reference><Reference><Citation>Machaczka M, Rucinska M, Skotnicki AB, Jurczak W. Parkinson&#x2019;s syndrome preceding clinical manifestation of Gaucher&#x2019;s disease. Am J Hematol. 1999;61:216&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">10398575</ArticleId></ArticleIdList></Reference><Reference><Citation>Tayebi N, Walker J, Stubblefield B, et al. Gaucher disease with parkinsonian manifestations: does glucocere-brosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab. 2003;79:104&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">12809640</ArticleId></ArticleIdList></Reference><Reference><Citation>Varkonyi J, Rosenbaum H, Baumann N, et al. Gaucher disease associated with parkinsonism: four further case reports. Am J Med Genet. 2003;116A:348&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">12522789</ArticleId></ArticleIdList></Reference><Reference><Citation>Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocere-brosidase gene and Parkinson&#x2019;s disease in Ashkenazi Jews. N Engl J Med. 2004;351:1972&#x2013;1977.</Citation><ArticleIdList><ArticleId IdType="pubmed">15525722</ArticleId></ArticleIdList></Reference><Reference><Citation>Lwin A, Orvisky E, Goker-Alpan O, et al. Glucocere-brosidase mutations in subjects with parkinsonism. Mol Genet Metab. 2004;81:70&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">14728994</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Morgan AJ, Lang AE, et al. Analysis of the glucocerebrosidase gene in Parkinson&#x2019;s disease. Mov Disord. 2005;20:367&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">15517592</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark LN, Nicolai A, Afridi S, et al. Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson&#x2019;s disease in subjects of Jewish ethnicity. Mov Disord. 2005;20:100&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">15517591</ArticleId></ArticleIdList></Reference><Reference><Citation>Eblan MJ, Nguyen J, Ziegler SG, et al. Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela. Mov Disord. 2006;21:282&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">16261622</ArticleId></ArticleIdList></Reference><Reference><Citation>Goker-Alpan O, Giasson BI, Eblan MJ, et al. Glucocere-brosidase mutations are an important risk factor for Lewy body disorders. Neurology. 2006;67:908&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">16790605</ArticleId></ArticleIdList></Reference><Reference><Citation>Toft M, Pielsticker L, Ross OA, et al. Glucocere-brosidase gene mutations and Parkinson disease in the Norwegian population. Neurology. 2006;66:415&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476943</ArticleId></ArticleIdList></Reference><Reference><Citation>Marder K, Levy G, Louis ED, et al. Familial aggregation of early- and late-onset Parkinson&#x2019;s disease. Ann Neurol. 2003;54:507&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pubmed">14520664</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark LN, Afridi S, Karlins E, et al. Case-control study of the parkin gene in early-onset Parkinson disease. Arch Neurol. 2006;63:548&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">16606767</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson&#x2019;s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psych. 1992;55:181&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1014720</ArticleId><ArticleId IdType="pubmed">1564476</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahn S, Marsden CD, Calne D. Recent developments in Parkinson&#x2019;s disease. Florham Park, NJ: Macmillan Healthcare Information; 1987.</Citation></Reference><Reference><Citation>Stern Y, Sano M, Paulson JRM. Modified mini-mental state examination: validity and reliability. Neurology. 1987;37(suppl 1):179.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Marder K, Levy G, Louis ED, et al. Accuracy of family history data on Parkinson&#x2019;s disease. Neurology. 2003;61:18&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrer H. A genetic profile of contemporary Jewish populations. Nat Rev Genet. 2001;2:891&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">11715044</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone DL, Tayebi N, Orvisky E, et al. Glucocere-brosidase gene mutations in patients with type 2 Gaucher disease. Hum Mutat. 2000;15:181&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">10649495</ArticleId></ArticleIdList></Reference><Reference><Citation>Beutler E, Nguyen NJ, Henneberger MW, et al. Gaucher disease: gene frequencies in the Ashkenazi Jewish population. Am J Hum Genet. 1993;52:85&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1682129</ArticleId><ArticleId IdType="pubmed">8434610</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas N, Lucking CB, Ricard S, et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson&#x2019;s Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson&#x2019;s Disease. Hum Mol Genet. 1999;8:567&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072423</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedrich K, Marder K, Harris J, et al. Evaluation of 50 probands with early-onset Parkinson&#x2019;s disease for Parkin mutations. Neurology. 2002;58:1239&#x2013;1246.</Citation><ArticleIdList><ArticleId IdType="pubmed">11971093</ArticleId></ArticleIdList></Reference><Reference><Citation>West A, Periquet M, Lincoln S, et al. Complex relationship between Parkin mutations and Parkinson disease. Am J Med Genet. 2002;114:584&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">12116199</ArticleId></ArticleIdList></Reference><Reference><Citation>Foroud T, Uniacke SK, Liu L, et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology. 2003;60:796&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">12629236</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira SA, Scott WK, Martin ER, et al. Parkin mutations and susceptibility alleles in late-onset Parkinson&#x2019;s disease. Ann Neurol. 2003;53:624&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730996</ArticleId></ArticleIdList></Reference><Reference><Citation>Lincoln SJ, Maraganore DM, Lesnick TG, et al. Parkin variants in North American Parkinson&#x2019;s disease: cases and controls. Mov Disord. 2003;18:1306&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pubmed">14639672</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedrich K, Djarmati A, Schafer N, et al. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. Neurology. 2004;62:389&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">14872018</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, Nutt JG, James D, et al. Parkin mutation analysis in clinic patients with early-onset Parkinson&#x2019;s disease. Am J Med Genet. 2004;129A:44&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">15266615</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoli-Avella AM, Giroud-Benitez JL, Akyol A, et al. Novel parkin mutations detected in patients with early-onset Parkinson&#x2019;s disease. Mov Disord. 2005;20:424&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">15584030</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan NL, Horta W, Eunson L, et al. Parkin disease in a Brazilian kindred: manifesting heterozygotes and clinical follow-up over 10 years. Mov Disord. 2005;20:479&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">15641013</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu RM, Bounds R, Lincoln S, et al. Parkin mutations and early-onset parkinsonism in a Taiwanese cohort. Arch Neurol. 2005;62:82&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642853</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M, Latourelle JC, Wooten GF, et al. Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol. 2006;63:826&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pubmed">16769863</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark LN, Afridi S, Mejia-Santana H, et al. Analysis of an early-onset Parkinson&#x2019;s disease cohort for DJ-1 mutations. Mov Disord. 2004;19:796&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">15254937</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou-Sleiman PM, Muqit MM, McDonald NQ, et al. A heterozygous effect for PINK1 mutations in Parkinson&#x2019;s disease? Ann Neurol. 2006;60:414&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">16969854</ArticleId></ArticleIdList></Reference><Reference><Citation>Djarmati A, Hedrich K, Svetel M, et al. Heterozygous PINK1 mutations: a susceptibility factor for Parkinson disease? Mov Disord. 2006;21:1526&#x2013;1530.</Citation><ArticleIdList><ArticleId IdType="pubmed">16755580</ArticleId></ArticleIdList></Reference><Reference><Citation>Toft M, Myhre R, Pielsticker L, et al. PINK1 mutation heterozygosity and the risk of Parkinson&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2007;78:82&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117782</ArticleId><ArticleId IdType="pubmed">17172567</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedrich K, Eskelson C, Wilmot B, et al. Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord. 2004;19:1146&#x2013;1157.</Citation><ArticleIdList><ArticleId IdType="pubmed">15390068</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilker R, Klein C, Ghaemi M, et al. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol. 2001;49:367&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">11261512</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilker R, Klein C, Hedrich K, et al. The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans. Neurosci Lett. 2002;323:50&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">11911988</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohmann E, Periquet M, Bonifati V, et al. How much phenotypic variation can be attributed to parkin genotype? Ann Neurol. 2003;54:176&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">12891670</ArticleId></ArticleIdList></Reference><Reference><Citation>Munhoz RP, Sa DS, Rogaeva E, et al. Clinical findings in a large family with a parkin ex3delta40 mutation. Arch Neurol. 2004;61:701&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">15148147</ArticleId></ArticleIdList></Reference><Reference><Citation>Kono S, Shirakawa K, Ouchi Y, et al. Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier. J Neurol Sci. 2007;252:181&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">17182061</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17878420</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>298</Volume><Issue>11</Issue><PubDate><Year>2007</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases.</ArticleTitle><Pagination><StartPage>1281</StartPage><EndPage>1290</EndPage><MedlinePgn>1281-90</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">The aim of carrier screening is to prevent severe, untreatable genetic disease by identifying couples at risk before the birth of an affected child, and providing such couples with options for reproductive outcomes for affected pregnancies. Gaucher disease (GD) is an autosomal recessive storage disorder, relatively frequent in Ashkenazi Jews. Carrier screening for GD is controversial because common type 1 GD is often asymptomatic and effective treatment exists. However, screening is offered to Ashkenazi Jews worldwide and has been offered in Israel since 1995.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the scope and outcomes of nationwide GD screening.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">All Israeli genetic centers provided data on the number of individuals screened for GD, the number of carriers identified, the number of carrier couples identified, and the mutations identified in these couples between January 1, 1995, and March 31, 2003. Carrier couples were interviewed via telephone between January 21, 2003, and August 31, 2004, using a structured questionnaire for relevant outcome measures.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Screening scope (number of testing centers, tested individuals, and carrier couples), screening process (type of pretest and posttest consultations), and screening outcomes (utilization of prenatal diagnosis and pregnancy terminations).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Between January 1, 1995, and March 31, 2003, 10 of 12 Israeli genetic centers (83.3%) offered carrier screening. Carrier frequency was 5.7%, and 83 carrier couples were identified among an estimated 28,893 individuals screened. There were 82 couples at risk for offspring with type 1 GD. Seventy of 82 couples (85%) were at risk for asymptomatic or mildly affected offspring and 12 of 82 couples (15%) were at risk for moderately affected offspring. At postscreening, 65 interviewed couples had 90 pregnancies, and prenatal diagnosis was performed in 68 pregnancies (76%), detecting 16 fetuses with GD (24%). Pregnancies were terminated in 2 of 13 fetuses (15%) predicted to be asymptomatic or mildly affected and 2 of 3 fetuses (67%) with predicted moderate disease. There were significantly fewer pregnancy terminations in couples who in addition to genetic counseling had medical counseling with a GD expert (1 of 13 [8%] vs 3 of 3 with no medical counseling [100%], P = .007).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this study of GD screening among Ashkenazi Jewish couples in Israel, most couples did not terminate affected pregnancies, although screening was associated with a few pregnancy terminations. The main possible benefit was providing couples with knowledge and control. The divergence of these outcomes from stated goals of screening programs is likely to confront carrier screening programs for low-penetrance diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zuckerman</LastName><ForeName>Shachar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hebrew University-Hadassah Medical School, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lahad</LastName><ForeName>Amnon</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Shmueli</LastName><ForeName>Amir</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Zimran</LastName><ForeName>Ari</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Peleg</LastName><ForeName>Leah</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Orr-Urtreger</LastName><ForeName>Avi</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Levy-Lahad</LastName><ForeName>Ephrat</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Sagi</LastName><ForeName>Michal</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2007 Sep 19;298(11):1329-31. doi: 10.1001/jama.298.11.1329.</RefSource><PMID Version="1">17878426</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000028" MajorTopicYN="N">Abortion, Induced</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005776" MajorTopicYN="N">Gaucher Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005817" MajorTopicYN="N">Genetic Counseling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007557" MajorTopicYN="N">Israel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007585" MajorTopicYN="N">Jews</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011296" MajorTopicYN="N">Prenatal Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17878420</ArticleId><ArticleId IdType="doi">10.1001/jama.298.11.1281</ArticleId><ArticleId IdType="pii">298/11/1281</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17880003</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1615-9853</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>20</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Proteomics</Title><ISOAbbreviation>Proteomics</ISOAbbreviation></Journal><ArticleTitle>8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>3651</StartPage><EndPage>3660</EndPage><MedlinePgn>3651-60</MedlinePgn></Pagination><Abstract><AbstractText>An 8-plex version of an isobaric reagent for the quantitation of proteins using shotgun methods is presented. The 8-plex version of the reagent relies on amine-labeling chemistry of peptides similar to 4-plex reagents. MS/MS reporter ions at 113, 114, 115, 116, 117, 118, 119, and 121 m/z are used to quantify protein expression. This technology which was first applied to a test mixture consisting of eight proteins and resulted in accurate quantitation, has the potential to increase throughput of analysis for quantitative shotgun proteomics experiments when compared to 2- and 4-plex methods. The technology was subsequently applied to a longitudinal study of cerebrospinal fluid (CSF) proteins from subjects undergoing intravenous Ig treatment for Alzheimer's disease. Results from this study identify a number of protein expression changes that occur in CSF after 3 and 6 months of treatment compared to a baseline and compared to a drug washout period. A visualization tool was developed for this dataset and is presented. The tool can aid in the identification of key peptides and measurements. One conclusion aided by the visualization tool is that there are differences in considering peptide-based observations versus protein-based observations from quantitative shotgun proteomics studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choe</LastName><ForeName>Leila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Ascenzo</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Relkin</LastName><ForeName>Norman R</ForeName><Initials>NR</Initials></Author><Author ValidYN="Y"><LastName>Pappin</LastName><ForeName>Darryl</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Williamson</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Guertin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Pribil</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kelvin H</ForeName><Initials>KH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH059926</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Proteomics</MedlineTA><NlmUniqueID>101092707</NlmUniqueID><ISSNLinking>1615-9853</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002556">Cerebrospinal Fluid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007202">Indicators and Reagents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.2.1.1</RegistryNumber><NameOfSubstance UI="D002256">Carbonic Anhydrases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002256" MajorTopicYN="N">Carbonic Anhydrases</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002556" MajorTopicYN="N">Cerebrospinal Fluid Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007202" MajorTopicYN="N">Indicators and Reagents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="Y">Proteomics</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>3</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17880003</ArticleId><ArticleId IdType="mid">NIHMS440940</ArticleId><ArticleId IdType="pmc">PMC3594777</ArticleId><ArticleId IdType="doi">10.1002/pmic.200700316</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tonge R, Shaw J, Middleton B, Rowlinson R, et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics. 2001;1:377&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">11680884</ArticleId></ArticleIdList></Reference><Reference><Citation>Choe LH, Lee KH. Quantitative and qualitative measure of intralaboratory two-dimensional protein gel reproducibility and the effects of sample preparation, sample load, and image analysis. Electrophoresis. 2003;24:3500&#x2013;3507.</Citation><ArticleIdList><ArticleId IdType="pubmed">14595697</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KH. Proteomics: a technology-driven and technology-limited discovery science. Trends Biotechnol. 2001;19:217&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">11356283</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald WH, Yates JR. Shotgun proteomics: integrating technologies to answer biological questions. Curr Opin Mol Ther. 2003;5:302&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">12870441</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross PL, Huang YN, Marchese JN, Williamson B, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics. 2004;3:1154&#x2013;1169.</Citation><ArticleIdList><ArticleId IdType="pubmed">15385600</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodel RC, Du Y, Depboylu C, Hampel H, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer&#x2019;s disease. J Neurol Neurosurg Psych. 2004;75:1472&#x2013;1474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738770</ArticleId><ArticleId IdType="pubmed">15377700</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Weksler ME, Relkin N, Turkenich R, LaRusse S, et al. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol. 2002;37:943&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pubmed">12086704</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal K, Choe LH, Lee KH. Quantitative analysis of protein expression using amine-specific isobaric tags in Escherichia coli cells expressing rhsA elements. Proteomics. 2005;5:2297&#x2013;2308.</Citation><ArticleIdList><ArticleId IdType="pubmed">15887184</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttlin EL, Hegemen AD, Harms AC, Sussman MR. Prediction of error associated with false-positive rate determination for peptide identification in large-scale proteomics experiments using a combined reverse and forward peptide sequence database strategy. J Proteome Res. 2007;6:392&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572755</ArticleId><ArticleId IdType="pubmed">17203984</ArticleId></ArticleIdList></Reference><Reference><Citation>Castano EM, Roher AE, Esh CL, Kokjohn TA, et al. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer&#x2019;s disease and non-demented elderly subjects. Neurol Res. 2006;28:155&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">16551433</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D, Wilcox MA, Laird NM, Rodes L, et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet. 1998;19:357&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">9697696</ArticleId></ArticleIdList></Reference><Reference><Citation>Puchades M, Hansson SF, Nilsson CL, Andreasen N, et al. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer&#x2019;s disease. Brain Res Mol Brain Res. 2003;118:140&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">14559363</ArticleId></ArticleIdList></Reference><Reference><Citation>Eder U, Leitner B, Kirchmair R, Pohl P, et al. Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases. J Neural Transm. 1998;105:39&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">9588759</ArticleId></ArticleIdList></Reference><Reference><Citation>Finehout EJ, Franck Z, Choe LH, Relkin N, et al. Cerebrospinal fluid proteomic biomarkers for Alzheimer&#x2019;s disease. Ann Neurol. 2007;61:120&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">17167789</ArticleId></ArticleIdList></Reference><Reference><Citation>Nesvizhskii AI, Aebersold R. Interpretation of shotgun proteomic data: the protein inference problem. Mol Cell Proteomics. 2005;4:1419&#x2013;1440.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009968</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman RA. Cerebrospinal Fluid in Diseases of the Nervous System. 2. W. B. Saunders Company; Philadelphia: 1992.</Citation></Reference><Reference><Citation>Nilselid AM, Davidsson P, Nagga K, Andreasen N, et al. Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int. 2006;48:718&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">16490286</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17880892</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>55</Volume><Issue>6</Issue><PubDate><Year>2007</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Postsynaptic positioning of endocytic zones and AMPA receptor cycling by physical coupling of dynamin-3 to Homer.</ArticleTitle><Pagination><StartPage>874</StartPage><EndPage>889</EndPage><MedlinePgn>874-89</MedlinePgn></Pagination><Abstract><AbstractText>Endocytosis of AMPA receptors and other postsynaptic cargo occurs at endocytic zones (EZs), stably positioned sites of clathrin adjacent to the postsynaptic density (PSD). The tight localization of postsynaptic endocytosis is thought to control spine composition and regulate synaptic transmission. However, the mechanisms that situate the EZ near the PSD and the role of spine endocytosis in synaptic transmission are unknown. Here, we report that a physical link between dynamin-3 and the postsynaptic adaptor Homer positions the EZ near the PSD. Disruption of dynamin-3 or its interaction with Homer uncouples the PSD from the EZ, resulting in synapses lacking postsynaptic clathrin. Loss of the EZ leads to a loss of synaptic AMPA receptors and reduced excitatory synaptic transmission that corresponds with impaired synaptic recycling. Thus, a physical link between the PSD and the EZ ensures localized endocytosis and recycling by recapturing and maintaining a proximate pool of cycling AMPA receptors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jiuyi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Duke University Medical Center, Durham, NC 27710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helton</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials></Author><Author ValidYN="Y"><LastName>Blanpied</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>R&#xe1;cz</LastName><ForeName>Bence</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Newpher</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Weinberg</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Ehlers</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG024492</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS039402</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS047574</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002966">Clathrin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000072233">Homer Scaffolding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D020558">GTP Phosphohydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.5</RegistryNumber><NameOfSubstance UI="D034286">Dynamin III</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2007 Sep 20;55(6):825-7. doi: 10.1016/j.neuron.2007.09.004.</RefSource><PMID Version="1">17880887</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002966" MajorTopicYN="N">Clathrin</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034286" MajorTopicYN="N">Dynamin III</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020558" MajorTopicYN="N">GTP Phosphohydrolases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072233" MajorTopicYN="N">Homer Scaffolding Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022161" MajorTopicYN="N">Transport Vesicles</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>12</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17880892</ArticleId><ArticleId IdType="mid">NIHMS65159</ArticleId><ArticleId IdType="pmc">PMC2597538</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2007.06.041</ArticleId><ArticleId IdType="pii">S0896-6273(07)00586-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ashby MC, De La Rue SA, Ralph GS, Uney J, Collingridge GL, Henley JM. Removal of AMPA receptors (AMPARs) from synapses is preceded by transient endocytosis of extrasynaptic AMPARs. J Neurosci. 2004;24:5172&#x2013;5176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3309030</ArticleId><ArticleId IdType="pubmed">15175386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashby MC, Maier SR, Nishimune A, Henley JM. Lateral diffusion drives constitutive exchange of AMPA receptors at dendritic spines and is regulated by spine morphology. J Neurosci. 2006;26:7046&#x2013;7055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673929</ArticleId><ArticleId IdType="pubmed">16807334</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron MK, Boeckers TM, Vaida B, Faham S, Gingery M, Sawaya MR, Salyer D, Gundelfinger ED, Bowie JU. An architectural framework that may lie at the core of the postsynaptic density. Science. 2006;311:531&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">16439662</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanpied TA, Scott DB, Ehlers MD. Dynamics and regulation of clathrin coats at specialized endocytic zones of dendrites and spines. Neuron. 2002;36:435&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">12408846</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown TC, Tran IC, Backos DS, Esteban JA. NMDA receptor-dependent activation of the small GTPase Rab5 drives the removal of synaptic AMPA receptors during hippocampal LTD. Neuron. 2005;45:81&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">15629704</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao H, Garcia F, McNiven MA. Differential distribution of dynamin isoforms in mammalian cells. Mol Biol Cell. 1998;9:2595&#x2013;2609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25532</ArticleId><ArticleId IdType="pubmed">9725914</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll RC, Beattie EC, Xia H, Luscher C, Altschuler Y, Nicoll RA, Malenka RC, von Zastrow M. Dynamin-dependent endocytosis of ionotropic glutamate receptors. Proc Natl Acad Sci U S A. 1999;96:14112&#x2013;14117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24199</ArticleId><ArticleId IdType="pubmed">10570207</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury S, Shepherd JD, Okuno H, Lyford G, Petralia RS, Plath N, Kuhl D, Huganir RL, Worley PF. Arc/Arg3.1 interacts with the endocytic machinery to regulate AMPA receptor trafficking. Neuron. 2006;52:445&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1784006</ArticleId><ArticleId IdType="pubmed">17088211</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook TA, Urrutia R, McNiven MA. Identification of dynamin 2, an isoform ubiquitously expressed in rat tissues. Proc Natl Acad Sci U S A. 1994;91:644&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43005</ArticleId><ArticleId IdType="pubmed">8290576</ArticleId></ArticleIdList></Reference><Reference><Citation>Cottrell JR, Borok E, Horvath TL, Nedivi E. CPG2: a brain- and synapse-specific protein that regulates the endocytosis of glutamate receptors. Neuron. 2004;44:677&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065105</ArticleId><ArticleId IdType="pubmed">15541315</ArticleId></ArticleIdList></Reference><Reference><Citation>Derkach VA, Oh MC, Guire ES, Soderling TR. Regulatory mechanisms of AMPA receptors in synaptic plasticity. Nat Rev Neurosci. 2007;8:101&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">17237803</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers MD. Reinsertion or degradation of AMPA receptors determined by activity-dependent endocytic sorting. Neuron. 2000;28:511&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">11144360</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers MD, Heine M, Groc L, Lee MC, Choquet D. Diffusional Trapping of GluR1 AMPA Receptors by Input-Specific Synaptic Activity. Neuron. 2007;54:447&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1993808</ArticleId><ArticleId IdType="pubmed">17481397</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson SM, Brasnjo G, Hayashi M, Wolfel M, Collesi C, Giovedi S, Raimondi A, Gong LW, Ariel P, Paradise S, et al. A selective activity-dependent requirement for dynamin 1 in synaptic vesicle endocytosis. Science. 2007;316:570&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">17463283</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaidarov I, Santini F, Warren RA, Keen JH. Spatial control of coated-pit dynamics in living cells. Nat Cell Biol. 1999;1:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10559856</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner SM, Takamiya K, Xia J, Suh JG, Johnson R, Yu S, Huganir RL. Calcium-permeable AMPA receptor plasticity is mediated by subunit-specific interactions with PICK1 and NSF. Neuron. 2005;45:903&#x2013;915.</Citation><ArticleIdList><ArticleId IdType="pubmed">15797551</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerrow K, Romorini S, Nabi SM, Colicos MA, Sala C, El-Husseini A. A preformed complex of postsynaptic proteins is involved in excitatory synapse development. Neuron. 2006;49:547&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476664</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray NW, Fourgeaud L, Huang B, Chen J, Cao H, Oswald BJ, Hemar A, McNiven MA. Dynamin 3 is a component of the postsynapse, where it interacts with mGluR5 and Homer. Curr Biol. 2003;13:510&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pubmed">12646135</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray NW, Kruchten AE, Chen J, McNiven MA. A dynamin-3 spliced variant modulates the actin/cortactin-dependent morphogenesis of dendritic spines. J Cell Sci. 2005;118:1279&#x2013;1290.</Citation><ArticleIdList><ArticleId IdType="pubmed">15741233</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi MK, Ames HM, Hayashi Y. Tetrameric hub structure of postsynaptic scaffolding protein homer. J Neurosci. 2006;26:8492&#x2013;8501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674353</ArticleId><ArticleId IdType="pubmed">16914674</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaksonen M, Toret CP, Drubin DG. Harnessing actin dynamics for clathrin-mediated endocytosis. Nat Rev Mol Cell Biol. 2006;7:404&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">16723976</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy MJ, Ehlers MD. Organelles and trafficking machinery for postsynaptic plasticity. Annu Rev Neurosci. 2006;29:325&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1876664</ArticleId><ArticleId IdType="pubmed">16776589</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh TW, Korolchuk VI, Wairkar YP, Jiao W, Evergren E, Pan H, Zhou Y, Venken KJ, Shupliakov O, Robinson IM, et al. Eps15 and Dap160 control synaptic vesicle membrane retrieval and synapse development. J Cell Biol. 2007;178:309&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064449</ArticleId><ArticleId IdType="pubmed">17620409</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruchten AE, McNiven MA. Dynamin as a mover and pincher during cell migration and invasion. J Cell Sci. 2006;119:1683&#x2013;1690.</Citation><ArticleIdList><ArticleId IdType="pubmed">16636070</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao D, Hessler NA, Malinow R. Activation of postsynaptically silent synapses during pairing-induced LTP in CA1 region of hippocampal slice. Nature. 1995;375:400&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">7760933</ArticleId></ArticleIdList></Reference><Reference><Citation>Luscher C, Xia H, Beattie EC, Carroll RC, von Zastrow M, Malenka RC, Nicoll RA. Role of AMPA receptor cycling in synaptic transmission and plasticity. Neuron. 1999;24:649&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pubmed">10595516</ArticleId></ArticleIdList></Reference><Reference><Citation>Marco E, Wedlich-Soldner R, Li R, Altschuler SJ, Wu LF. Endocytosis optimizes the dynamic localization of membrane proteins that regulate cortical polarity. Cell. 2007;129:411&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2000346</ArticleId><ArticleId IdType="pubmed">17448998</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks B, McMahon HT. Calcium triggers calcineurin-dependent synaptic vesicle recycling in mammalian nerve terminals. Curr Biol. 1998;8:740&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">9651678</ArticleId></ArticleIdList></Reference><Reference><Citation>Naisbitt S, Kim E, Tu JC, Xiao B, Sala C, Valtschanoff J, Weinberg RJ, Worley PF, Sheng M. Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin. Neuron. 1999;23:569&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">10433268</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakata T, Iwamoto A, Noda Y, Takemura R, Yoshikura H, Hirokawa N. Predominant and developmentally regulated expression of dynamin in neurons. Neuron. 1991;7:461&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">1832879</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto PM, Gamby C, Wells D, Fallon J, Vallee RB. Dynamin isoform-specific interaction with the shank/ProSAP scaffolding proteins of the postsynaptic density and actin cytoskeleton. J Biol Chem. 2001;276:48458&#x2013;48465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715172</ArticleId><ArticleId IdType="pubmed">11583995</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto PM, Tripet B, Litowski J, Hodges RS, Vallee RB. Multiple distinct coiled-coils are involved in dynamin self-assembly. J Biol Chem. 1999;274:10277&#x2013;10286.</Citation><ArticleIdList><ArticleId IdType="pubmed">10187814</ArticleId></ArticleIdList></Reference><Reference><Citation>Park M, Penick EC, Edwards JG, Kauer JA, Ehlers MD. Recycling endosomes supply AMPA receptors for LTP. Science. 2004;305:1972&#x2013;1975.</Citation><ArticleIdList><ArticleId IdType="pubmed">15448273</ArticleId></ArticleIdList></Reference><Reference><Citation>Park M, Salgado JM, Ostroff L, Helton TD, Robinson CG, Harris KM, Ehlers MD. Plasticity-induced growth of dendritic spines by exocytic trafficking from recycling endosomes. Neuron. 2006;52:817&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1899130</ArticleId><ArticleId IdType="pubmed">17145503</ArticleId></ArticleIdList></Reference><Reference><Citation>Praefcke GJ, McMahon HT. The dynamin superfamily: universal membrane tubulation and fission molecules? Nat Rev Mol Cell Biol. 2004;5:133&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">15040446</ArticleId></ArticleIdList></Reference><Reference><Citation>Racz B, Blanpied TA, Ehlers MD, Weinberg RJ. Lateral organization of endocytic machinery in dendritic spines. Nat Neurosci. 2004;7:917&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">15322548</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala C, Futai K, Yamamoto K, Worley PF, Hayashi Y, Sheng M. Inhibition of dendritic spine morphogenesis and synaptic transmission by activity-inducible protein Homer1a. J Neurosci. 2003;23:6327&#x2013;6337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740555</ArticleId><ArticleId IdType="pubmed">12867517</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala C, Piech V, Wilson NR, Passafaro M, Liu G, Sheng M. Regulation of dendritic spine morphology and synaptic function by Shank and Homer. Neuron. 2001;31:115&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">11498055</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DA. Regulating actin dynamics at membranes: a focus on dynamin. Traffic. 2004;5:463&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">15180823</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott DB, Michailidis I, Mu Y, Logothetis D, Ehlers MD. Endocytosis and degradative sorting of NMDA receptors by conserved membrane-proximal signals. J Neurosci. 2004;24:7096&#x2013;7109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729175</ArticleId><ArticleId IdType="pubmed">15306643</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng M, Hoogenraad CC. The Postsynaptic Architecture of Excitatory Synapses: A More Quantitative View. Annu Rev Biochem. 2007;76:823&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pubmed">17243894</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd JD, Rumbaugh G, Wu J, Chowdhury S, Plath N, Kuhl D, Huganir RL, Worley PF. Arc/Arg3.1 Mediates Homeostatic Synaptic Scaling of AMPA Receptors. Neuron. 2006;52:475&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1764219</ArticleId><ArticleId IdType="pubmed">17088213</ArticleId></ArticleIdList></Reference><Reference><Citation>Slepnev VI, Ochoa GC, Butler MH, Grabs D, De Camilli P. Role of phosphorylation in regulation of the assembly of endocytic coat complexes. Science. 1998;281:821&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pubmed">9694653</ArticleId></ArticleIdList></Reference><Reference><Citation>Tardin C, Cognet L, Bats C, Lounis B, Choquet D. Direct imaging of lateral movements of AMPA receptors inside synapses. Embo J. 2003;22:4656&#x2013;4665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC212729</ArticleId><ArticleId IdType="pubmed">12970178</ArticleId></ArticleIdList></Reference><Reference><Citation>Triller A, Choquet D. Surface trafficking of receptors between synaptic and extrasynaptic membranes: and yet they do move! Trends Neurosci. 2005;28:133&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">15749166</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakeman P, Doan A, Aakalu VK, Lanahan AA, Sheng M, Worley PF. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron. 1999;23:583&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">10433269</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu JC, Xiao B, Yuan JP, Lanahan AA, Leoffert K, Li M, Linden DJ, Worley PF. Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors. Neuron. 1998;21:717&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">9808459</ArticleId></ArticleIdList></Reference><Reference><Citation>Valtschanoff JG, Weinberg RJ. Laminar organization of the NMDA receptor complex within the postsynaptic density. J Neurosci. 2001;21:1211&#x2013;1217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762240</ArticleId><ArticleId IdType="pubmed">11160391</ArticleId></ArticleIdList></Reference><Reference><Citation>Washbourne P, Liu XB, Jones EG, McAllister AK. Cycling of NMDA receptors during trafficking in neurons before synapse formation. J Neurosci. 2004;24:8253&#x2013;8264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729693</ArticleId><ArticleId IdType="pubmed">15385609</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17881561</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>39</Issue><PubDate><Year>2007</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors.</ArticleTitle><Pagination><StartPage>15537</StartPage><EndPage>15542</EndPage><MedlinePgn>15537-42</MedlinePgn></Pagination><Abstract><AbstractText>Fragile X syndrome (FXS), a common inherited form of mental retardation, is caused by the functional absence of the fragile X mental retardation protein (FMRP), an RNA-binding protein that regulates the translation of specific mRNAs at synapses. Altered synaptic plasticity has been described in a mouse FXS model. However, the mechanism by which the loss of FMRP alters synaptic function, and subsequently causes the mental impairment, is unknown. Here, in cultured hippocampal neurons, we used siRNAs against Fmr1 to demonstrate that a reduction of FMRP in dendrites leads to an increase in internalization of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) subunit, GluR1, in dendrites. This abnormal AMPAR trafficking was caused by spontaneous action potential-driven network activity without synaptic stimulation by an exogenous agonist and was rescued by 2-methyl-6-phenylethynyl-pyridine (MPEP), an mGluR5-specific inverse agonist. Because AMPAR internalization depends on local protein synthesis after mGluR5 stimulation, FMRP, a negative regulator of translation, may be viewed as a counterbalancing signal, wherein the absence of FMRP leads to an apparent excess of mGluR5 signaling in dendrites. Because AMPAR trafficking is a driving process for synaptic plasticity underlying learning and memory, our data suggest that hypersensitive AMPAR internalization in response to excess mGluR signaling may represent a principal cellular defect in FXS, which may be corrected by using mGluR antagonists.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakamoto</LastName><ForeName>Mika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Emory University School of Medicine, 615 Michael Street, Whitehead Biomedical Research Building, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nalavadi</LastName><ForeName>Vijayalaxmi</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Epstein</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Narayanan</LastName><ForeName>Usha</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Bassell</LastName><ForeName>Gary J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Warren</LastName><ForeName>Stephen T</ForeName><Initials>ST</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 HD020521</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD20521</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS051127</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 HD024064</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS051127</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD020521</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD24064</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578935">GRM5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578936">Grm5 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578937">Grm5 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064529">Receptor, Metabotropic Glutamate 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018094">Receptors, Metabotropic Glutamate</NameOfSubstance></Chemical><Chemical><RegistryNumber>139135-51-6</RegistryNumber><NameOfSubstance UI="D051860">Fragile X Mental Retardation Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051860" MajorTopicYN="N">Fragile X Mental Retardation Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005600" MajorTopicYN="N">Fragile X Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008607" MajorTopicYN="N">Intellectual Disability</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064529" MajorTopicYN="N">Receptor, Metabotropic Glutamate 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018094" MajorTopicYN="N">Receptors, Metabotropic Glutamate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>3</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17881561</ArticleId><ArticleId IdType="pmc">PMC2000537</ArticleId><ArticleId IdType="doi">10.1073/pnas.0707484104</ArticleId><ArticleId IdType="pii">0707484104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Malenka RC, Bear MF. Neuron. 2004;44:5&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450156</ArticleId></ArticleIdList></Reference><Reference><Citation>Bredt DS, Nicoll RA. Neuron. 2003;40:361&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">14556714</ArticleId></ArticleIdList></Reference><Reference><Citation>Malenka RC. Ann NY Acad Sci. 2003;1003:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">14684431</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll RC, Beattie EC, von Zastrow M, Malenka RC. Nat Rev Neurosci. 2001;2:315&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">11331915</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang EH, Savage MJ, Flood DG, Thomas JM, Levy RB, Mahadomrongkul V, Shirao T, Aoki C, Huerta PT. Proc Natl Acad Sci USA. 2006;103:3410&#x2013;3415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413872</ArticleId><ArticleId IdType="pubmed">16492745</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison PJ, McLaughlin D, Kerwin RW. Lancet. 1991;337:450&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671470</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Pelletier MR, Perez Velazquez JL, Carlen PL. Mol Cell Neurosci. 2002;19:138&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">11860268</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Donnell WT, Warren ST. Annu Rev Neurosci. 2002;25:315&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">12052912</ArticleId></ArticleIdList></Reference><Reference><Citation>Antar LN, Bassell GJ. Neuron. 2003;37:555&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">12597853</ArticleId></ArticleIdList></Reference><Reference><Citation>Bear MF, Huber KM, Warren ST. Trends Neurosci. 2004;27:370&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">15219735</ArticleId></ArticleIdList></Reference><Reference><Citation>Garber K, Smith KT, Reines D, Warren ST. Curr Opin Genet Dev. 2006;16:270&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">16647847</ArticleId></ArticleIdList></Reference><Reference><Citation>Antar LN, Dictenberg JB, Plociniak M, Afroz R, Bassell GJ. Genes Brain Behav. 2005;4:350&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">16098134</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber KM, Kayser MS, Bear MF. Science. 2000;288:1254&#x2013;1257.</Citation><ArticleIdList><ArticleId IdType="pubmed">10818003</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber KM, Gallagher SM, Warren ST, Bear MF. Proc Natl Acad Sci USA. 2002;99:7746&#x2013;7750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124340</ArticleId><ArticleId IdType="pubmed">12032354</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou L, Antion MD, Hu D, Spencer CM, Paylor R, Klann E. Neuron. 2006;17:441&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">16908410</ArticleId></ArticleIdList></Reference><Reference><Citation>Koekkoek SK, Yamaguchi K, Milojkovic BA, Dortland BR, Ruigrok TJ, Maex R, De Graaf W, Smit AE, VanderWerf F, Bakker CE, et al. Neuron. 2005;47:339&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">16055059</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao MY, Zhou Q, Nicoll RA. Neuropharmacology. 2001;41:664&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">11640920</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Philpot BD, Huber KM, Dong X, Fallon JR, Bear MF. Nat Neurosci. 2001;4:1079&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">11687813</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll RC, Beattie EC, Xia H, Luscher C, Altschuler Y, Nicoll RA, Malenka RC, von Zastrow M. Proc Natl Acad Sci USA. 1999;96:14112&#x2013;14117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24199</ArticleId><ArticleId IdType="pubmed">10570207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JW, Ju W, Foster K, Lee SH, Ahmadian G, Wyszynski M, Wang YT, Sheng M. Nat Neurosci. 2000;3:1282&#x2013;1290.</Citation><ArticleIdList><ArticleId IdType="pubmed">11100149</ArticleId></ArticleIdList></Reference><Reference><Citation>Beattie EC, Carroll RC, Yu X, Morishita W, Yasuda H, von Zastrow M, Malenka RC. Nat Neurosci. 2000;3:1291&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pubmed">11100150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers MD. Neuron. 2000;28:511&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">11144360</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Cell. 2003;115:199&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">14567917</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosyreva ED, Huber KM. J Neurophysiol. 2006;95:3291&#x2013;3295.</Citation><ArticleIdList><ArticleId IdType="pubmed">16452252</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll FY, Stolle A, Beart PM, Voerste A, Brabet I, Mauler F, Joly C, Antonicek H, Bockaert J, Muller T, et al. Mol Pharmacol. 2001;59:965&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573968</ArticleId><ArticleId IdType="pubmed">11306677</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang SC, Zhao W, Bauchwitz R, Yan Q, Bianchi R, Wong RK. J Neurosci. 2005;25:8048&#x2013;8055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725444</ArticleId><ArticleId IdType="pubmed">16135762</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer BE, Huber KM. J Neurosci. 2007;27:3120&#x2013;3130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672463</ArticleId><ArticleId IdType="pubmed">17376973</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuffrida R, Musumeci S, D'Antoni S, Bonaccorso CM, Giuffrida-Stella AM, Oostra BA, Catania MV. J Neurosci. 2005;25:8908&#x2013;8916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725593</ArticleId><ArticleId IdType="pubmed">16192381</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenough WT, Klintsova AY, Irwin SA, Galvez R, Bates KE, Weiler IJ. Proc Natl Acad Sci USA. 2001;98:7101&#x2013;7106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34629</ArticleId><ArticleId IdType="pubmed">11416194</ArticleId></ArticleIdList></Reference><Reference><Citation>Antar LN, Afroz R, Dictenberg JB, Carroll RC, Bassell GJ. J Neurosci. 2004;24:2648&#x2013;2655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729525</ArticleId><ArticleId IdType="pubmed">15028757</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Neuropharmacology. 2005;49:1053&#x2013;1066.</Citation><ArticleIdList><ArticleId IdType="pubmed">16054174</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride SM, Choi CH, Wang Y, Liebelt D, Braunstein E, Ferreiro D, Sehgal A, Siwicki KK, Dockendorff TC, Nguyen HT, et al. Neuron. 2005;45:753&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748850</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker B, Richards RI, Lardelli M. Hum Mol Genet. 2006;15:3446&#x2013;3458.</Citation><ArticleIdList><ArticleId IdType="pubmed">17065172</ArticleId></ArticleIdList></Reference><Reference><Citation>Volk LJ, Daly CA, Huber KM. J Neurophysiol. 2006;95:2427&#x2013;2438.</Citation><ArticleIdList><ArticleId IdType="pubmed">16421200</ArticleId></ArticleIdList></Reference><Reference><Citation>Goslin K, Asmussen H, Banker G. In: Culturing Nerve Cells. Banker G, Goslin K, editors. Cambridge, MA: MIT Press; 1998. pp. 339&#x2013;370.</Citation></Reference><Reference><Citation>Craig AM. In: Culturing Nerve Cells. Banker G, Goslin K, editors. Cambridge, MA: MIT Press; 1998. pp. 79&#x2013;111.</Citation></Reference><Reference><Citation>Abramoff MD, Magelhaes PJ, Ram SJ. Biophot Internat. 2004;11:36&#x2013;42.</Citation></Reference><Reference><Citation>Ruppert D, Wand MP, Carroll RJ. Semiparametric Regression. Cambridge, UK: Cambridge Univ Press; 2003.</Citation></Reference><Reference><Citation>Akaike H. In: A Celebration of Statistics. Atkinson AC, Fienberg SE, editors. New York: Springer; 1985. pp. 1&#x2013;24.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17884188</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0166-4328</ISSN><JournalIssue CitedMedium="Print"><Volume>186</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Jan</Month><Day>10</Day></PubDate></JournalIssue><Title>Behavioural brain research</Title><ISOAbbreviation>Behav Brain Res</ISOAbbreviation></Journal><ArticleTitle>Amyloid precursor protein knockout mice show age-dependent deficits in passive avoidance learning.</ArticleTitle><Pagination><StartPage>126</StartPage><EndPage>132</EndPage><MedlinePgn>126-32</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid precursor protein (APP) is involved in the pathogenesis of Alzheimer's disease (AD), but its role in cognition has been relatively little studied. APP knockout (KO) animals have been described previously and show deficits in grip strength, reduced locomotor activity and impaired learning and memory in a conditioned avoidance test and the Morris water-maze. In order to further investigate the in vivo function of APP and its proteolytic derivatives, we tested APP KO mice and age-matched wild type controls at two different ages, 3 and 8 months, in a range of behavioural tests measuring neuromuscular, locomotor and cognitive functions. These tests included the acquisition of a passive avoidance response as a measure of long-term memory of an aversive experience, and spontaneous alternation in a Y-maze, regarded as a measure of spatial short-term memory. The absence of APP expression in APP KO mice was confirmed at the protein level using hippocampal tissue in Western blotting. APP KO mice displayed deficits in forelimb grip strength and locomotor activity in agreement with previous studies. In the Y-maze test used for spontaneous alternation behaviour, APP KO animals did not exhibit reduced alternation rates. On the other hand, in the passive avoidance test, APP KO mice showed an age-related deficit in retention of memory for an aversive experience. The results suggest that APP and/or its proteolytic derivatives may play a role in long-term memory in adult brain and/or may be required during the development and maintenance of neuronal networks involved in this type of memory.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Senechal</LastName><ForeName>Yann</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neuroscience Research, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Lichtstrasse 35, CH-4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials></Author><Author ValidYN="Y"><LastName>Dev</LastName><ForeName>Kumlesh K</ForeName><Initials>KK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Behav Brain Res</MedlineTA><NlmUniqueID>8004872</NlmUniqueID><ISSNLinking>0166-4328</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001362" MajorTopicYN="N">Avoidance Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016555" MajorTopicYN="N">Matched-Pair Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053580" MajorTopicYN="N">Muscle Strength</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013037" MajorTopicYN="N">Spatial Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17884188</ArticleId><ArticleId IdType="doi">10.1016/j.bbr.2007.08.003</ArticleId><ArticleId IdType="pii">S0166-4328(07)00401-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17894374</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Beta-amyloid burden is not associated with rates of brain atrophy.</ArticleTitle><Pagination><StartPage>204</StartPage><EndPage>212</EndPage><MedlinePgn>204-12</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To test the hypothesis that beta-amyloid (Abeta) burden is associated with rates of brain atrophy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Forty-five subjects who had been prospectively studied, died, and had an autopsy diagnosis of low, intermediate, or high probability of Alzheimer's disease who had two volumetric head magnetic resonance imaging scans were identified. Compact and total (compact + diffuse) Abeta burden was measured using a computerized image analyzer with software program to detect the proportion of gray matter occupied by Abeta. Visual ratings of Abeta burden were also performed. The boundary shift integral was used to calculate change over time in whole-brain and ventricular volume. All boundary shift integral results were annualized by adjusting for scan interval. Demographics, cognitive measures, clinical diagnoses, apolipoprotein E genotype, neurofibrillary tangle (NFT) pathology, and vascular lesion burden were determined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There was no correlation between compact or total Abeta burden, or visual Abeta ratings, and rates of brain loss or ventricular expansion in all subjects. However, significant correlations were observed between rates of brain loss and age, Braak NFT stage, and change over time in cognitive measures. These features also correlated with rates of ventricular expansion. The rates of brain loss and ventricular expansion were greater in demented compared with nondemented subjects.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">These findings suggest that rate of brain volume loss is not determined by the amount of insoluble Abeta in the gray matter.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Josephs</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA. josephs.keith@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitwell</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Zeshan</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Shiung</LastName><ForeName>Maria M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Weigand</LastName><ForeName>Stephen D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials></Author><Author ValidYN="Y"><LastName>Parisi</LastName><ForeName>Joseph E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG11378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 HD49078</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 HD049078</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020547" MajorTopicYN="N">Lateral Ventricles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: There is no conflict of interest</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>8</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17894374</ArticleId><ArticleId IdType="mid">NIHMS137272</ArticleId><ArticleId IdType="pmc">PMC2735194</ArticleId><ArticleId IdType="doi">10.1002/ana.21223</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Masters CL, Simms G, Weinman NA, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82:4245&#x2013;4249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimo A, Winblad B, Jonsson L. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimer's and Dementia. 2007;3:81&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595921</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256:184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Koller M, Black RS, et al. Clinical effects of A{beta} immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005</Citation><ArticleIdList><ArticleId IdType="pubmed">15883316</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004;62:591&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730165</ArticleId><ArticleId IdType="pubmed">14981176</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Black RS, Gilman S, et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64:1563&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883317</ArticleId></ArticleIdList></Reference><Reference><Citation>Archer HA, Edison P, Brooks DJ, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol. 2006;60:145&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">16802294</ArticleId></ArticleIdList></Reference><Reference><Citation>Silbert LC, Quinn JF, Moore MM, et al. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology. 2003;61:487&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">12939422</ArticleId></ArticleIdList></Reference><Reference><Citation>American Pyschiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th Ed) (DSM IV) Washington DC: American Psychiatric Association; 1994.</Citation></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer' disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging. 1997;18:S1&#x2013;S2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook R, Hardy J, Duff K. Single-day apolipoprotein E genotyping. J Neurosci Methods. 1994;53:125&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">7823614</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Tsuboi Y, Cookson N, et al. Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration. Arch Neurol. 2004;61:1579&#x2013;1584.</Citation><ArticleIdList><ArticleId IdType="pubmed">15477512</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl. 1996;165:3&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8740983</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 2001;23:291&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11531144</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunter JL, Shiung MM, Manduca A, et al. Methodological considerations for measuring rates of brain atrophy. J Magn Reson Imaging. 2003;18:16&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740859</ArticleId><ArticleId IdType="pubmed">12815635</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging. 1997;16:623&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">9368118</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryan RN, Manolio TA, Schertz LD, et al. A method for using MR to evaluate the effects of cardiovascular disease on the brain: the cardiovascular health study. AJNR Am J Neuroradiol. 1994;15:1625&#x2013;1633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8333726</ArticleId><ArticleId IdType="pubmed">7847205</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, Barkhof F, Leys D, et al. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci. 1993;114:7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8433101</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318&#x2013;1322.</Citation><ArticleIdList><ArticleId IdType="pubmed">11387493</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, O'Brien PC, Rettman DW, et al. FLAIR histogram segmentation for measurement of leukoaraiosis volume. J Magn Reson Imaging. 2001;14:668&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2755497</ArticleId><ArticleId IdType="pubmed">11747022</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien PC. The appropriateness of analysis of variance and multiple-comparison procedures. Biometrics. 1983;39:787&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">6652209</ArticleId></ArticleIdList></Reference><Reference><Citation>Perneger TV. What's wrong with Bonferroni adjustments. Bmj. 1998;316:1236&#x2013;1238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1112991</ArticleId><ArticleId IdType="pubmed">9553006</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Gearing M, McKeel DW, Jr, et al. Interlaboratory comparison of neuropathology assessments in Alzheimer's disease: a study of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) J Neuropathol Exp Neurol. 1994;53:303&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">8176413</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi H, Hirai S, Morimatsu M, et al. Diffuse type of senile plaques in the brains of Alzheimer-type dementia. Acta Neuropathol (Berl) 1988;77:113&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">2465658</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Crystal HA, Mattiace LA, et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging. 1992;13:179&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">1311804</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62:1087&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656067</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64:431&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353389</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis DG, Schmitt FA, Wekstein DR, et al. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol. 1999;58:376&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">10218633</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings BJ, Pike CJ, Shankle R, et al. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging. 1996;17:921&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pubmed">9363804</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussiere T, Friend PD, Sadeghi N, et al. Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer's disease. Neuroscience. 2002;112:75&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">12044473</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Herrmann FR, Bussiere T, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology. 2003;60:1495&#x2013;1500.</Citation><ArticleIdList><ArticleId IdType="pubmed">12743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992;42:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, et al. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61:378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>Gertz HJ, Xuereb J, Huppert F, et al. Examination of the validity of the hierarchical model of neuropathological staging in normal aging and Alzheimer's disease. Acta Neuropathol (Berl) 1998;95:154&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">9498050</ArticleId></ArticleIdList></Reference><Reference><Citation>Brion JP, Flament-Durand J, Dustin P. Alzheimer's disease and tau proteins. Lancet. 1986;2:1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">2877247</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy Z, Jobst KA, Esiri MM, et al. Hippocampal pathology reflects memory deficit and brain imaging measurements in Alzheimer's disease: clinicopathologic correlations using three sets of pathologic diagnostic criteria. Dementia. 1996;7:76&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">8866679</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology. 2002;58:750&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745935</ArticleId><ArticleId IdType="pubmed">11889239</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosche KM, Mortimer JA, Smith CD, et al. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology. 2002;58:1476&#x2013;1482.</Citation><ArticleIdList><ArticleId IdType="pubmed">12034782</ArticleId></ArticleIdList></Reference><Reference><Citation>Enzinger C, Fazekas F, Matthews PM, et al. Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology. 2005;64:1704&#x2013;1711.</Citation><ArticleIdList><ArticleId IdType="pubmed">15911795</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii K, Kawachi T, Sasaki H, et al. Voxel-based morphometric comparison between early- and late-onset mild Alzheimer's disease and assessment of diagnostic performance of z score images. AJNR Am J Neuroradiol. 2005;26:333&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7974092</ArticleId><ArticleId IdType="pubmed">15709131</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlund LO, Julin P, Lannfelt L, et al. Inheritance of the ApoE epsilon4 allele increases the rate of brain atrophy in dementia patients. Dement Geriatr Cogn Disord. 1999;10:262&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">10364643</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Jack CR, Jr, Parisi JE, et al. Rates of cerebral atrophy differ in different degenerative pathologies. Brain. 2007;130:1148&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752409</ArticleId><ArticleId IdType="pubmed">17347250</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17895400</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-0103</ISSN><JournalIssue CitedMedium="Internet"><Volume>323</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of pharmacology and experimental therapeutics</Title><ISOAbbreviation>J Pharmacol Exp Ther</ISOAbbreviation></Journal><ArticleTitle>1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.</ArticleTitle><Pagination><StartPage>822</StartPage><EndPage>830</EndPage><MedlinePgn>822-30</MedlinePgn></Pagination><Abstract><AbstractText>Some nonsteroidal anti-inflammatory drugs has been shown to allosterically modulate the activity of gamma-secretase, the enzymatic complex responsible for the formation of beta-amyloid (Abeta). 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074) is a new gamma-secretase modulator, devoid of anticyclooxygenase (COX) and Notch-interfering activities in vitro. We evaluated the effects of chronic CHF5074 treatment on brain Abeta pathology in Tg2576 transgenic mice. Twenty-eight animals of 9.5 to 10.5 months of age received CHF5074-medicated diet (375 ppm) or standard diet for 17 weeks. Compared with controls, CHF5074 treatment significantly reduced the area occupied by plaques and the number of plaques in cortex (-52.2 +/- 5.6%, p = 0.0003 and -48.9 +/- 6.6%, p = 0.0004, respectively) and hippocampus (-76.7 +/- 6.4%, p = 0.004 and -66.2 +/- 10.3%, p = 0.037, respectively). Biochemical analysis confirmed the histopathological measures, with CHF5074-treated animals showing reduced total brain Abeta40 (-49.2 +/- 9.2%, p = 0.017) and Abeta42 (-43.5 +/- 9.7%, p = 0.027) levels. In a human neuroglioma cell line expressing Swedish mutated form of amyloid precursor protein (H4swe), CHF5074 reduced Abeta42 and Abeta40 secretion, with an IC50 of 3.6 and 18.4 microM, respectively, values consistent with those measured in the brain of the CHF5074-treated Tg2576 mice (6.4 +/- 0.4 microM). At 5 microM, no effects were observed on Notch intracellular cleavage in human embryonic kidney 293swe cells. CHF5074 was well tolerated by Tg2576 mice. No abnormal findings were observed upon histopathological examination of the gastrointestinal tract, indicating the absence of COX-related toxicity. Semiquantitative histochemical evaluation of goblet cells in the ileum of vehicle- and CHF5074-treated animals yielded similar results, suggesting no effects on Notch pathway. CHF5074 is therefore a promising therapeutic agent for Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Imbimbo</LastName><ForeName>Bruno P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Research &amp; Development, Chiesi Farmaceutici, via Palermo 26/A, 43100 Parma, Italy. b.imbimbo@chiesigroup.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Giudice</LastName><ForeName>Elda</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Colavito</LastName><ForeName>Davide</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>D'Arrigo</LastName><ForeName>Antonello</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Dalle Carbonare</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Villetti</LastName><ForeName>Gino</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Facchinetti</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Volta</LastName><ForeName>Roberta</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Pietrini</LastName><ForeName>Vladimiro</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Baroc</LastName><ForeName>Maria F</ForeName><Initials>MF</Initials></Author><Author ValidYN="Y"><LastName>Serneels</LastName><ForeName>Lutgarde</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Leon</LastName><ForeName>Alberta</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Pharmacol Exp Ther</MedlineTA><NlmUniqueID>0376362</NlmUniqueID><ISSNLinking>0022-3565</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C522246">1-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)cyclopropanecarboxylic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003521">Cyclopropanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>5GRO578KLP</RegistryNumber><NameOfSubstance UI="D005480">Flurbiprofen</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003521" MajorTopicYN="N">Cyclopropanes</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005480" MajorTopicYN="N">Flurbiprofen</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17895400</ArticleId><ArticleId IdType="doi">10.1124/jpet.107.129007</ArticleId><ArticleId IdType="pii">S0022-3565(24)34177-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17895381</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>40</Issue><PubDate><Year>2007</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Molecular basis for passive immunotherapy of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>15659</StartPage><EndPage>15664</EndPage><MedlinePgn>15659-64</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid aggregates of the amyloid-beta (Abeta) peptide are implicated in the pathology of Alzheimer's disease. Anti-Abeta monoclonal antibodies (mAbs) have been shown to reduce amyloid plaques in vitro and in animal studies. Consequently, passive immunization is being considered for treating Alzheimer's, and anti-Abeta mAbs are now in phase II trials. We report the isolation of two mAbs (PFA1 and PFA2) that recognize Abeta monomers, protofibrils, and fibrils and the structures of their antigen binding fragments (Fabs) in complex with the Abeta(1-8) peptide DAEFRHDS. The immunodominant EFRHD sequence forms salt bridges, hydrogen bonds, and hydrophobic contacts, including interactions with a striking WWDDD motif of the antigen binding fragments. We also show that a similar sequence (AKFRHD) derived from the human protein GRIP1 is able to cross-react with both PFA1 and PFA2 and, when cocrystallized with PFA1, binds in an identical conformation to Abeta(1-8). Because such cross-reactivity has implications for potential side effects of immunotherapy, our structures provide a template for designing derivative mAbs that target Abeta with improved specificity and higher affinity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gardberg</LastName><ForeName>Anna S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, TN 37996, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dice</LastName><ForeName>Lezlee T</ForeName><Initials>LT</Initials></Author><Author ValidYN="Y"><LastName>Ou</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Rich</LastName><ForeName>Rebecca L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Helmbrecht</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wetzel</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Myszka</LastName><ForeName>David G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Paul H</ForeName><Initials>PH</Initials></Author><Author ValidYN="Y"><LastName>Dealwis</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>2IPT</AccessionNumber><AccessionNumber>2IPU</AccessionNumber><AccessionNumber>2IQ</AccessionNumber><AccessionNumber>2IQ9</AccessionNumber><AccessionNumber>2ROW</AccessionNumber><AccessionNumber>2ROZ</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG018416</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS046356</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS46356</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001666" MajorTopicYN="N">Binding Sites, Antibody</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020349" MajorTopicYN="N">Surface Plasmon Resonance</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17895381</ArticleId><ArticleId IdType="pmc">PMC1994138</ArticleId><ArticleId IdType="doi">10.1073/pnas.0705888104</ArticleId><ArticleId IdType="pii">0705888104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dobson CM. Nature. 2002;418:729&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">12181546</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner HL, Frenkel D. Nat Rev Immunol. 2006;6:404&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">16639431</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Proc Natl Acad Sci USA. 2001;98:8850&#x2013;8855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37524</ArticleId><ArticleId IdType="pubmed">11438712</ArticleId></ArticleIdList></Reference><Reference><Citation>Gevorkian G, Petrushina I, Manoutcharian K, Ghochikyan A, Acero G, Vasilevko V, Cribbs DH, Agadjanyan MG. J Neuroimmunol. 2004;156:10&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">15465592</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon B. Curr Alzheimer Res. 2004;1:149&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">15975063</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenkel D, Dewachter I, Van Leuven F, Solomon B. Vaccine. 2003;21:1060&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pubmed">12559780</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavie V, Becker M, Cohen-Kupiec R, Yacoby I, Koppel R, Wedenig M, Hutter-Paier B, Solomon B. J Mol Neurosci. 2004;24:105&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">15314258</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, et al. Nat Med. 2000;6:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Proc Natl Acad Sci USA. 1997;94:4109&#x2013;4112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20576</ArticleId><ArticleId IdType="pubmed">9108113</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Tanzi RE, Marzloff K, Barbour R, Schenk D. J Neuropathol Exp Neurol. 1992;51:76&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">1740675</ArticleId></ArticleIdList></Reference><Reference><Citation>Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, et al. Nature. 1992;359:325&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">1406936</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, Lee VM. J Biol Chem. 2006;281:4292&#x2013;4299.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361260</ArticleId></ArticleIdList></Reference><Reference><Citation>Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE. J Clin Invest. 2006;116:193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1307561</ArticleId><ArticleId IdType="pubmed">16341263</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenkel D, Solomon B, Benhar I. J Neuroimmunol. 2000;106:23&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">10814779</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Nuallain B, Wetzel R. Proc Natl Acad Sci USA. 2002;99:1485&#x2013;1490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122217</ArticleId><ArticleId IdType="pubmed">11818542</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodali R, Wetzel R. Curr Opin Struct Biol. 2007;17:48&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">17251001</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Protein Pept Lett. 2004;11:213&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">15182223</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper JD, Wong SS, Lieber CM, Lansbury PT. Chem Biol. 1997;4:119&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">9190286</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams AD, Sega M, Chen M, Kheterpal I, Geva M, Berthelier V, Kaleta DT, Cook KD, Wetzel R. Proc Natl Acad Sci USA. 2005;102:7115&#x2013;7120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1091746</ArticleId><ArticleId IdType="pubmed">15883377</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruckner K, Pablo Labrador J, Scheiffele P, Herb A, Seeburg PH, Klein R. Neuron. 1999;22:511&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">10197531</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark LA, Boriack-Sjodin PA, Eldredge J, Fitch C, Friedman B, Hanf KJ, Jarpe M, Liparoto SF, Li Y, Lugovskoy A, et al. Protein Sci. 2006;15:949&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2242497</ArticleId><ArticleId IdType="pubmed">16597831</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Beuerlein G, Nie Y, Smith H, Lee BA, Hensler M, Huse WD, Watkins JD. Proc Natl Acad Sci USA. 1998;95:6037&#x2013;6042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27581</ArticleId><ArticleId IdType="pubmed">9600913</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, et al. Proc Natl Acad Sci USA. 2003;100:2023&#x2013;2028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149952</ArticleId><ArticleId IdType="pubmed">12566568</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams AD, Shivaprasad S, Wetzel R. J Mol Biol. 2006;357:1283&#x2013;1294.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476445</ArticleId></ArticleIdList></Reference><Reference><Citation>Wetzel R, Shivaprasad S, Williams AD. Biochemistry. 2007;46:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2526019</ArticleId><ArticleId IdType="pubmed">17198370</ArticleId></ArticleIdList></Reference><Reference><Citation>Giudicelli V, Chaume D, Lefranc MP. Nucleic Acids Res. 2004;32:W435&#x2013;W440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC441550</ArticleId><ArticleId IdType="pubmed">15215425</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, Bohm G, Demuth HU. Biochemistry. 2006;45:12393&#x2013;12399.</Citation><ArticleIdList><ArticleId IdType="pubmed">17029395</ArticleId></ArticleIdList></Reference><Reference><Citation>Kheterpal I, Williams A, Murphy C, Bledsoe B, Wetzel R. Biochemistry. 2001;40:11757&#x2013;11767.</Citation><ArticleIdList><ArticleId IdType="pubmed">11570876</ArticleId></ArticleIdList></Reference><Reference><Citation>Kheterpal I, Chen M, Cook KD, Wetzel R. J Mol Biol. 2006;361:785&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">16875699</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Nuallain B, Thakur AK, Williams AD, Bhattacharyya AM, Chen S, Thiagarajan G, Wetzel R. Methods Enzymol. 2006;413:34&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046390</ArticleId></ArticleIdList></Reference><Reference><Citation>Goding JW. Monoclonal Antibodies: Principles and Practice. San Diego: Academic; 1996.</Citation></Reference><Reference><Citation>Harris LJ, Skaletsky E, McPherson A. Proteins. 1995;23:285&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592710</ArticleId></ArticleIdList></Reference><Reference><Citation>Otwinowski Z, Minor W. In: Macromolecular Crystallography, Part A. Carter CW, Sweet RM, editors. Vol 276. New York: Academic; 1997. pp. 307&#x2013;326.</Citation></Reference><Reference><Citation>Zhu X, Heine A, Monnat F, Houk KN, Janda KD, Wilson IA. J Mol Biol. 2003;329:69&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">12742019</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Cowtan K. Acta Crystallogr D. 2004;60:2126&#x2013;2132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Murshudov GN, Vagin AA, Dodson EJ. Acta Crystallogr D. 1997;53:240&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">15299926</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaguine AA, Richelle J, Wodak SJ. Acta Crystallogr D. 1999;55:191&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">10089410</ArticleId></ArticleIdList></Reference><Reference><Citation>Laskowski RA, MacArthur MW, Moss DS, Thornton JM. J Appl Cryst. 1993;26:283&#x2013;291.</Citation></Reference><Reference><Citation>Davis IW, Murray LW, Richardson JS, Richardson DC. Nucleic Acids Res. 2004;32:W615&#x2013;W619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC441536</ArticleId><ArticleId IdType="pubmed">15215462</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">1789684</PMID><DateCompleted><Year>1992</Year><Month>03</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>30</Volume><Issue>4</Issue><PubDate><Year>1991</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.</ArticleTitle><Pagination><StartPage>572</StartPage><EndPage>580</EndPage><MedlinePgn>572-80</MedlinePgn></Pagination><Abstract><AbstractText>We present here both linear regressions and multivariate analyses correlating three global neuropsychological tests with a number of structural and neurochemical measurements performed on a prospective series of 15 patients with Alzheimer's disease and 9 neuropathologically normal subjects. The statistical data show only weak correlations between psychometric indices and plaques and tangles, but the density of neocortical synapses measured by a new immunocytochemical/densitometric technique reveals very powerful correlations with all three psychological assays. Multivariate analysis by stepwise regression produced a model including midfrontal and inferior parietal synapse density, plus inferior parietal plaque counts with a correlation coefficient of 0.96 for Mattis's Dementia Rating Scale. Plaque density contributed only 26% of that strength.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Terry</LastName><ForeName>R D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California-San Diego, La Jolla 92093-0624.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>D P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Butters</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>DeTeresa</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>L A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Katzman</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08201</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId><ArticleId IdType="doi">10.1002/ana.410300410</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17898208</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>39</Issue><PubDate><Year>2007</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.</ArticleTitle><Pagination><StartPage>10365</StartPage><EndPage>10371</EndPage><MedlinePgn>10365-71</MedlinePgn></Pagination><Abstract><AbstractText>Dementia with Lewy bodies (DLB) is pathologically characterized by the presence of alpha-synuclein-containing Lewy bodies within the neocortical, limbic, and paralimbic regions. Like Alzheimer's disease (AD), Abeta plaques are also present in most DLB cases. The contribution of Abeta to the development of DLB is unclear. [11C]-Pittsburgh compound B ([11C]-PIB) is a thioflavin-T derivative that has allowed in vivo Abeta burden to be quantified using positron emission tomography (PET). [11C]-PIB PET studies have shown similar high cortical [11C]-PIB binding in AD and DLB subjects. To establish the potential binding of PIB to alpha-synuclein in DLB patients, we characterized the in vitro binding of PIB to recombinant human alpha-synuclein and DLB brain homogenates. Analysis of the in vitro binding studies indicated that [3H]-PIB binds to alpha-synuclein fibrils but with lower affinity than that demonstrated/reported for Abeta(1-42) fibrils. Furthermore, [3H]-PIB was observed to bind to Abeta plaque-containing DLB brain homogenates but failed to bind to DLB homogenates that were Abeta plaque-free ("pure DLB"). Positive PIB fluorescence staining of DLB brain sections colocalized with immunoreactive Abeta plaques but failed to stain Lewy bodies. Moreover, image quantification analysis suggested that given the small size and low density of Lewy bodies within the brains of DLB subjects, any contribution of Lewy bodies to the [11C]-PIB PET signal would be negligible. These studies indicate that PIB retention observed within the cortical gray matter regions of DLB subjects in [11C]-PIB PET studies is largely attributable to PIB binding to Abeta plaques and not Lewy bodies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fodero-Tavoletti</LastName><ForeName>Michelle T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Pathology, The University of Melbourne, Melbourne, Victoria 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>David P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>McLean</LastName><ForeName>Catriona A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Adlard</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Barnham</LastName><ForeName>Kevin J</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Foster</LastName><ForeName>Lisa E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Leone</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Perez</LastName><ForeName>Keyla</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Cort&#xe9;s</LastName><ForeName>Mikhalina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Culvenor</LastName><ForeName>Janetta G</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qiao-Xin</ForeName><Initials>QX</Initials></Author><Author ValidYN="Y"><LastName>Laughton</LastName><ForeName>Katrina M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Cappai</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor L</ForeName><Initials>VL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>WT069851MA</GrantID><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>3</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17898208</ArticleId><ArticleId IdType="pmc">PMC6673163</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0630-07.2007</ArticleId><ArticleId IdType="pii">27/39/10365</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol. 1998;152:879&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858234</ArticleId><ArticleId IdType="pubmed">9546347</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappai R, Leck SL, Tew DJ, Williamson NA, Smith DP, Galatis D, Sharples RA, Curtain CC, Ali FE, Cherny RA, Culvenor JG, Bottomley SP, Masters CL, Barnham KJ, Hill AF. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J. 2005;19:1377&#x2013;1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">15946991</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan A, Chauhan VP, Rubenstein R, Wegiel J, Wisniewski HM. Media from rhabdomyosarcoma and neuroblastoma cell cultures stimulate in vitro aggregation and fibrillization of amyloid beta-protein. Neurochem Res. 1997;22:227&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">9016850</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI. Treatment with a copper-zinc chelator markedly and rapidly inhibits &#x3b2;-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 2001;30:665&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">11430801</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway KA, Harper JD, Lansbury PT., Jr Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry. 2000;39:2552&#x2013;2563.</Citation><ArticleIdList><ArticleId IdType="pubmed">10704204</ArticleId></ArticleIdList></Reference><Reference><Citation>Culvenor JG, McLean CA, Cutt S, Campbell BC, Maher F, Jakala P, Hartmann T, Beyreuther K, Masters CL, Li QX. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am J Pathol. 1999;155:1173&#x2013;1181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1867017</ArticleId><ArticleId IdType="pubmed">10514400</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Ser T, Hachinski V, Merskey H, Munoz DG. Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load. Alzheimer Dis Assoc Disord. 2001;15:31&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">11236823</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A&#x3b2; antibody alters CNS and plasma A&#x3b2; clearance and decreases brain A&#x3b2; burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2001;98:8850&#x2013;8855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37524</ArticleId><ArticleId IdType="pubmed">11438712</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Crystal H, Mattiace LA, Kress Y, Schwagerl A, Ksiezak-Reding H, Davies P, Yen SH. Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques. Acta Neuropathol (Berl) 1989;78:572&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">2683563</ArticleId></ArticleIdList></Reference><Reference><Citation>Doubleday EK, Snowden JS, Varma AR, Neary D. Qualitative performance characteristics differentiate dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002;72:602&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737879</ArticleId><ArticleId IdType="pubmed">11971046</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64:1563&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883317</ArticleId></ArticleIdList></Reference><Reference><Citation>George AJ, Holsinger RM, McLean CA, Laughton KM, Beyreuther K, Evin G, Masters CL, Li QX. APP intracellular domain is increased and soluble Abeta is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. Neurobiol Dis. 2004;16:124&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15207269</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Growdon WB, McNamara M, Newell K, Gomez-Tortosa E, Hedley-Whyte ET, Hyman BT. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology. 1999;53:2003&#x2013;2009.</Citation><ArticleIdList><ArticleId IdType="pubmed">10599772</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Tortosa E, Irizarry MC, Gomez-Isla T, Hyman BT. Clinical and neuropathological correlates of dementia with Lewy bodies. Ann NY Acad Sci. 2000;920:9&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193181</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000;10:378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098522</ArticleId><ArticleId IdType="pubmed">10885656</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125:391&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">11844739</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper JD, Wong SS, Lieber CM, Lansbury PT. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol. 1997;4:119&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">9190286</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzman R, Saitoh T. Advances in Alzheimer's disease. FASEB J. 1991;5:278&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">2001787</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr ML, Small DH. Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: function, regulation of proteolysis, and implications for drug development. J Neurosci Res. 2005;80:151&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">15672415</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Debnath ML, Pettegrew JW. Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Neurobiol Aging. 1995;16:541&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">8544903</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Mathis CA. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 2001;69:1471&#x2013;1484.</Citation><ArticleIdList><ArticleId IdType="pubmed">11554609</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, Hamilton RL, Ikonomovic MD, DeKosky ST, Mathis CA. The binding of 2-(4&#x2032;-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci. 2003;23:2086&#x2013;2092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741999</ArticleId><ArticleId IdType="pubmed">12657667</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-&#x3b2; in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci. 2005;25:10598&#x2013;10606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725842</ArticleId><ArticleId IdType="pubmed">16291932</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine H., III Soluble multimeric Alzheimer beta(1&#x2013;40) pre-amyloid complexes in dilute solution. Neurobiol Aging. 1995;16:755&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">8532108</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine H., III Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 1999;309:274&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">10507030</ArticleId></ArticleIdList></Reference><Reference><Citation>Li QX, Mok SS, Laughton KM, McLean CA, Volitakis I, Cherny RA, Cheung NS, White AR, Masters CL. Overexpression of Abeta is associated with acceleration of onset of motor impairment and superoxide dismutase 1 aggregation in an amyotrophic lateral sclerosis mouse model. Aging Cell. 2006;5:153&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">16626394</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippa CF, Smith TW, Swearer JM. Alzheimer's disease and Lewy body disease: a comparative clinicopathological study. Ann Neurol. 1994;35:81&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">8285597</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, Nee LE, O'Connell B, Pollen DA, St. George-Hyslop P, Ghetti B, Nochlin D, Bird TD, Cairns NJ, Lee VM, Iwatsubo T, Trojanowski JQ. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol. 1998;153:1365&#x2013;1370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853391</ArticleId><ArticleId IdType="pubmed">9811326</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Cappai R, Barnham KJ, Villemagne VL. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem. 2006;97:1700&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">16805778</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT, Holt DP, Wang Y, Huang GF, Debnath ML, Klunk WE. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett. 2002;12:295&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">11814781</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740&#x2013;2754.</Citation><ArticleIdList><ArticleId IdType="pubmed">12801237</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Klunk WE, Price JC, DeKosky ST. Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch Neurol. 2005;62:196&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">15710847</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>Minger SL, Esiri MM, McDonald B, Keene J, Carter J, Hope T, Francis PT. Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology. 2000;55:1460&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pubmed">11094098</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol. 2003;60:1685&#x2013;1691.</Citation><ArticleIdList><ArticleId IdType="pubmed">14676042</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JT, Randall JD, Eder PS, Huang X, Bush AI, Tanzi RE, Venti A, Payton SM, Giordano T, Nagano S, Cahill CM, Moir R, Lahiri DK, Greig N, Sarang SS, Gullans SR. Alzheimer's disease drug discovery targeted to the APP mRNA 5'untranslated region. J Mol Neurosci. 2002;19:77&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">12212798</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TE, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL. Imaging &#x3b2;-amyloid burden in aging and dementia. Neurology. 2007;68:1718&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Hagen M, Seubert P. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol. 2004;16:599&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">15342006</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DP, Radford SE. Role of the single disulphide bond of beta(2)-microglobulin in amyloidosis in vitro. Protein Sci. 2001;10:1775&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2253195</ArticleId><ArticleId IdType="pubmed">11514668</ArticleId></ArticleIdList></Reference><Reference><Citation>The National Institute on Aging Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging. 1997;18:S1&#x2013;S2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ. Emerging Alzheimer's disease therapies: focusing on the future. Neurobiol Aging. 2002;23:985&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pubmed">12470793</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Rowe CC, Macfarlane S, Novakovic K, Masters CL. Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease. J Clin Neurosci. 2005a;12:221&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">15851069</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Ackermann U, Gong SJ, Pike K, Novakovic KE, Dickinson K, Savage G, Tochon-Danguy H, O'Keefe G, Woodward M, Masters CL, Price JC, Klunk WE, Mathis CA, Rowe CC. Abeta amyloid imaging in dementia with Lewy bodies and Alzheimer's disease with 11C-PIB PET. J Nucl Med. 2005b:46&#x2013;124.</Citation></Reference><Reference><Citation>Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem. 1997;272:22364&#x2013;22372.</Citation><ArticleIdList><ArticleId IdType="pubmed">9268388</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W. Amyloid inhibitors and Alzheimer's disease. Curr Opin Investig Drugs. 2003;4:55&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">12625030</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong W, Lomakin A, Kirkitadze MD, Teplow DB, Chen SH, Benedek GB. Structure determination of micelle-like intermediates in amyloid beta-protein fibril assembly by using small angle neutron scattering. Proc Natl Acad Sci USA. 2002;99:150&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC117530</ArticleId><ArticleId IdType="pubmed">11756677</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17898224</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>39</Issue><PubDate><Year>2007</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43.</ArticleTitle><Pagination><StartPage>10530</StartPage><EndPage>10534</EndPage><MedlinePgn>10530-4</MedlinePgn></Pagination><Abstract><AbstractText>TAR DNA binding protein-43 (TDP-43) is the pathologic substrate of neuronal and glial inclusions in frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTDL-U) and in amyotrophic lateral sclerosis (ALS). Mutations in the progranulin gene (PGRN) have been shown to cause familial FTLD-U. The relationship between progranulin and TDP-43 and their respective roles in neurodegeneration is unknown. We report that progranulin mediates proteolytic cleavage of TDP-43 to generate approximately 35 and approximately 25 kDa species. Suppression of PGRN expression with small interfering RNA leads to caspase-dependent accumulation of TDP-43 fragments that can be inhibited with caspase inhibitor treatment. Cells treated with staurosporine also induced caspase-dependent cleavage and redistribution of TDP-43 from its nuclear localization to cytoplasm. Altered cleavage and redistribution of TDP-43 in cell culture models are similar to findings in FTLD-U and ALS. The results suggest that abnormal metabolism of TDP-43 mediated by progranulin may play a pivotal role in neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yong-Jie</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Ya-fei</ForeName><Initials>YF</Initials></Author><Author ValidYN="Y"><LastName>Dickey</LastName><ForeName>Chad A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Buratti</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Baralle</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Bailey</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Pickering-Brown</LastName><ForeName>Stuart</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0400356</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01-AG-026251-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492314">GRN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053179">Caspase 7</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053179" MajorTopicYN="N">Caspase 7</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006868" MajorTopicYN="N">Hydrolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>3</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17898224</ArticleId><ArticleId IdType="pmc">PMC6673167</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3421-07.2007</ArticleId><ArticleId IdType="pii">27/39/10530</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary D, Melquist S, Richardson A, Dickson D, Berger Z, Eriksen J, Robinson T, Zehr C, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem. 2001;276:36337&#x2013;36343.</Citation><ArticleIdList><ArticleId IdType="pubmed">11470789</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Dork T, Zuccato E, Pagani F, Romano M, Baralle FE. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 2001;20:1774&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC145463</ArticleId><ArticleId IdType="pubmed">11285240</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Brindisi A, Giombi M, Tisminetzky S, Ayala YM, Baralle FE. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem. 2005;280:37572&#x2013;37584.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157593</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ, van Duijn C, Peeters K, Sciot R, Santens P, De Pooter T, Mattheijssens M, Van den Broeck M, Cuijt I, Vennekens K, De Deyn PP, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006;442:920&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel R, He Z, Carmichael KP, Halper J, Bateman A. Cellular localization of gene expression for progranulin. J Histochem Cytochem. 2000;48:999&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">10858277</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW. Required techniques and useful molecular markers in the neuropathologic diagnosis of neurodegenerative diseases. Acta Neuropathol (Berl) 2005;109:14&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">15645265</ArticleId></ArticleIdList></Reference><Reference><Citation>Gass J, Cannon A, Mackenzie IR, Boeve B, Baker M, Adamson J, Crook R, Melquist S, Kuntz K, Petersen R, Josephs K, Pickering-Brown SM, Graff-Radford N, Uitti R, Dickson D, Wszolek Z, Gonzalez J, Beach TG, Bigio E, Johnson N, et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet. 2006;15:2988&#x2013;3001.</Citation><ArticleIdList><ArticleId IdType="pubmed">16950801</ArticleId></ArticleIdList></Reference><Reference><Citation>Liau LM, Lallone RL, Seitz RS, Buznikov A, Gregg JP, Kornblum HI, Nelson SF, Bronstein JM. Identification of a human glioma-associated growth factor gene, granulin, using differential immuno-absorption. Cancer Res. 2000;60:1353&#x2013;1360.</Citation><ArticleIdList><ArticleId IdType="pubmed">10728698</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Baker M, Pickering-Brown S, Hsiung GY, Lindholm C, Dwosh E, Gass J, Cannon A, Rademakers R, Hutton M, Feldman HH. The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain. 2006;129:3081&#x2013;3090.</Citation><ArticleIdList><ArticleId IdType="pubmed">17071926</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol. 1999;58:459&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">10331434</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Truax AC, Vanmassenhove B, Kretzschmar HA, Van Deerlin VM, Clark CM, Grossman M, Miller BL, Trojanowski JQ, Lee VM. TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. J Neuropathol Exp Neurol. 2007;66:177&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">17356379</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou SH, Wu F, Harrich D, Garcia-Martinez LF, Gaynor RB. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol. 1995;69:3584&#x2013;3596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189073</ArticleId><ArticleId IdType="pubmed">7745706</ArticleId></ArticleIdList></Reference><Reference><Citation>Su JH, Nichol KE, Sitch T, Sheu P, Chubb C, Miller BL, Tomaselli KJ, Kim RC, Cotman CW. DNA damage and activated caspase-3 expression in neurons and astrocytes: evidence for apoptosis in frontotemporal dementia. Exp Neurol. 2000;163:9&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">10785439</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998;281:1312&#x2013;1316.</Citation><ArticleIdList><ArticleId IdType="pubmed">9721091</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, Lacomis L, Erdjument-Bromage H, Tempst P, Wright CD, Ding A. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell. 2002;111:867&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">12526812</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17909128</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>10</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Effect of Alzheimer disease risk on brain function during self-appraisal in healthy middle-aged adults.</ArticleTitle><Pagination><StartPage>1163</StartPage><EndPage>1171</EndPage><MedlinePgn>1163-71</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Asymptomatic middle-aged adult children of patients with Alzheimer disease (AD) recently were found to exhibit functional magnetic resonance imaging (fMRI) deficits in the mesial temporal lobe during an encoding task. Whether this effect will be observed on other fMRI tasks is yet unknown. This study examines the neural substrates of self-appraisal (SA) in persons at risk for AD. Accurate appraisal of deficits is a problem for many patients with AD, and prior fMRI studies of healthy young adults indicate that brain areas vulnerable to AD such as the anterior mesial temporal lobe and posterior cingulate are involved during SA tasks.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether parental family history of AD (hereafter referred to as FH) or presence of the epsilon4 allele of the apolipoprotein E gene (APOE4) exerts independent effects on brain function during SA.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional factorial design in which APOE4 status (present vs absent) was one factor and FH was the other. All participants received cognitive testing, genotyping, and an fMRI task that required subjective SA decisions regarding trait adjective words in comparison with semantic decisions about the same words.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">An academic medical center with a research-dedicated 3.0-T MR imaging facility.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Cognitively normal middle-aged adults (n = 110), 51 with an FH and 59 without an FH.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Blood oxygen-dependent contrast measured using T2*-weighted echo-planar imaging.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Parental family history of AD and APOE4 status interacted in the posterior cingulate and left superior and medial frontal regions. There were main effects of FH (FH negative &gt; FH positive) in the left hippocampus and ventral posterior cingulate. There were no main effects of APOE genotype.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results suggest that FH may affect brain function during subjective SA in regions commonly affected by AD. Although the participants in this study were asymptomatic and middle-aged, the findings suggest that there may be subtle alterations in brain function attributable to AD risk factors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, 2500 Overlook Terrace, Madison, WI 53705, USA. scj@medicine.wisc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ries</LastName><ForeName>Michele L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Hess</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Gleason</LastName><ForeName>Carey E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Andrew L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Rowley</LastName><ForeName>Howard A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sager</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG021155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG 21155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001364" MajorTopicYN="N">Awareness</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016241" MajorTopicYN="N">Child of Impaired Parents</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003657" MajorTopicYN="N">Decision Making</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="Y">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>3</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17909128</ArticleId><ArticleId IdType="mid">NIHMS70365</ArticleId><ArticleId IdType="pmc">PMC2650497</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.64.10.1163</ArticleId><ArticleId IdType="pii">64/10/1163</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Corder EH, Ghebremedhin E, Taylor MG, Thal DR, Ohm TG, Braak H. The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Ann N Y Acad Sci. 2004 Jun;1019:24&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">15246987</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak E, Griffing K, Arai K, Bohl J, Bratzke H, Braak H. Neuropathology of Alzheimer's disease: what is new since A. Alzheimer? Eur Arch Psychiatry Clin Neurosci. 1999;249 Suppl 3:14&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">10654095</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohm TG, Muller H, Braak H, Bohl J. Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's disease-related neurofibrillary changes. Neuroscience. 1995 Jan;64(1):209&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">7708206</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):284&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratiglioni L, Ahlbom A, Viitanen M, Winblad B. Risk factors for late-onset Alzheimer's disease: a population-based, case-control study. Ann Neurol. 1993 Mar;33(3):258&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">8498809</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, Cupples LA, Go R, et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. Jama. 2002 Jan 16;287(3):329&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790212</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassett SS, Yousem DM, Cristinzio C, et al. Familial risk for Alzheimer's disease alters fMRI activation patterns. Brain. 2006 May;129(Pt 5):1229&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744898</ArticleId><ArticleId IdType="pubmed">16627465</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondi MW, Houston WS, Eyler LT, Brown GG. fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology. 2005 Feb 8;64(3):501&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1761695</ArticleId><ArticleId IdType="pubmed">15699382</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Houston WS, Eyler LT, et al. Identification of Alzheimer disease risk by functional magnetic resonance imaging. Arch Neurol. 2005 Dec;62(12):1881&#x2013;1888.</Citation><ArticleIdList><ArticleId IdType="pubmed">16344346</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Greve DN, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005 Aug 9;65(3):404&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335677</ArticleId><ArticleId IdType="pubmed">16087905</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Baxter L, Susskind-Wilder L, Connor DJ, Sabbagh MN, Caselli RJ. Hippocampal adaptation to face repetition in healthy elderly and mild cognitive impairment. Neuropsychologia. 2004;42(7):980&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">14998712</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Schmitz TW, Trivedi MA, et al. The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. J Neurosci. 2006 May 31;26(22):6069&#x2013;6076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684824</ArticleId><ArticleId IdType="pubmed">16738250</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Schmitz TW, Moritz CH, et al. Activation of brain regions vulnerable to Alzheimer's disease: The effect of mild cognitive impairment. Neurobiol Aging. 2006;27(11):1604&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2627778</ArticleId><ArticleId IdType="pubmed">16226349</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind J, Persson J, Ingvar M, et al. Reduced functional brain activity response in cognitively intact apolipoprotein E {varepsilon}4 carriers. Brain. 2006 Mar 14;</Citation><ArticleIdList><ArticleId IdType="pubmed">16537568</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi MA, Schmitz TW, Ries ML, et al. Reduced hippocampal activation during episodic encoding in middle-aged individuals at genetic risk of Alzheimer's disease: a cross-sectional study. BMC Med. 2006;4:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1373642</ArticleId><ArticleId IdType="pubmed">16412236</ArticleId></ArticleIdList></Reference><Reference><Citation>Royall DR, Lauterbach EC, Cummings JL, et al. Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci. 2002 Fall;14(4):377&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">12426407</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz TW, Johnson SC. Relevance to self: a brief review and framework of neural systems underlying appraisal. Neuroscience and Biobehavioral Reviews. in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1973156</ArticleId><ArticleId IdType="pubmed">17418416</ArticleId></ArticleIdList></Reference><Reference><Citation>Northoff G, Bermpohl F. Cortical midline structures and the self. Trends Cogn Sci. 2004 Mar;8(3):102&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">15301749</ArticleId></ArticleIdList></Reference><Reference><Citation>Northoff G, Heinzel A, de Greck M, Bermpohl F, Dobrowolny H, Panksepp J. Self-referential processing in our brain-A meta-analysis of imaging studies on the self. Neuroimage. 2006 Feb 5;</Citation><ArticleIdList><ArticleId IdType="pubmed">16466680</ArticleId></ArticleIdList></Reference><Reference><Citation>Amodio DM, Frith CD. Meeting of minds: the medial frontal cortex and social cognition. Nat Rev Neurosci. 2006 Apr;7(4):268&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">16552413</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception I: The neural basis of normal emotion perception. Biol Psychiatry. 2003 Sep 1;54(5):504&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">12946879</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005 Aug 24;25(34):7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Am J Psychiatry. 2002 Jun;159(5):738&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">11986126</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334(12):752&#x2013;758. Eng.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4703&#x2013;4707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123711</ArticleId><ArticleId IdType="pubmed">11930016</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005 Jun 8;25(11):1528&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig C, Snyder AZ, Bhakta M, et al. Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14504&#x2013;14509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC283621</ArticleId><ArticleId IdType="pubmed">14608034</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett AM, Eslinger PJ, Ballentine NH, Heilman KM. Unawareness of cognitive deficit (cognitive anosognosia) in probable AD and control subjects. Neurology. 2005 Feb 22;64(4):693&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">15728294</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz TW, Johnson SC. Self-appraisal decisions evoke dissociated dorsal-ventral aMPFC networks. NeuroImage. 2006 Dec 1;30:1050&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2627777</ArticleId><ArticleId IdType="pubmed">16326117</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Baxter LC, Wilder LS, Pipe JG, Heiserman JE, Prigatano GP. Neural correlates of self-reflection. Brain. 2002 Aug;125(Pt 8):1808&#x2013;1814.</Citation><ArticleIdList><ArticleId IdType="pubmed">12135971</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz TW, Kawahara-Baccus TN, Johnson SC. Metacognitive evaluation, self-relevance, and the right prefrontal cortex. Neuroimage. 2004 Jun;22(2):941&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pubmed">15193625</ArticleId></ArticleIdList></Reference><Reference><Citation>Sager MA, Hermann B, La Rue A. Middle-Aged Children of Persons With Alzheimer's Disease: APOE Genotypes and Cognitive Function in the Wisconsin Registry for Alzheimer's Prevention. J Geriatr Psychiatry Neurol. 2005 Dec;18(4):245&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">16306248</ArticleId></ArticleIdList></Reference><Reference><Citation>Ries ML, Jabbar B, Schmitz TW, et al. Anosognosia in mild cognitive impairment: relationship to activation of cortical midline structures involved in self-appraisal. Journal of the International Neuropsychological Society. in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2654607</ArticleId><ArticleId IdType="pubmed">17445294</ArticleId></ArticleIdList></Reference><Reference><Citation>Jezzard P, Balaban RS. Correction for geometric distortion in echo planar images from B0 field variations. Magn Reson Med. 1995 Jul;34(1):65&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">7674900</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson M. Fast, automated, N-dimensional phase-unwrapping algorithm. Magn Reson Med. 2003 Jan;49(1):193&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">12509838</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston KJ. Commentary and opinion: II. Statistical parametric mapping: ontology and current issues. Journal of Cerebral Blood Flow &amp; Metabolism. 1995;15(3):361&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">7713993</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi M, Wichmann A, Jabbar B, et al. Structural MRI discriminates individuals with mild cognitive impairment from age-matched controls: a combined neuropsychological and voxel based morphometry study. Alzheimer&#x2019;s and Dementia: The Journal of the Alzheimer&#x2019;s Association. 2007;2:296&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2584359</ArticleId><ArticleId IdType="pubmed">19020671</ArticleId></ArticleIdList></Reference><Reference><Citation>Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage. 2001;14(1 Pt 1):21&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">11525331</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt BA, Vogt L, Laureys S. Cytology and functionally correlated circuits of human posterior cingulate areas. Neuroimage. 2006 Jan 15;29(2):452&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2649771</ArticleId><ArticleId IdType="pubmed">16140550</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenstein E, Bowers D, Verfaellie M, Heilman KM, Day A, Watson RT. Retrosplenial amnesia. Brain. 1987 Dec;110(Pt 6):1631&#x2013;1646.</Citation><ArticleIdList><ArticleId IdType="pubmed">3427404</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner AD, Shannon BJ, Kahn I, Buckner RL. Parietal lobe contributions to episodic memory retrieval. Trends Cogn Sci. 2005 Sep;9(9):445&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">16054861</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Schmitz TW, Kawahara-Baccus TN, et al. The Cerebral Response during Subjective Choice with and without Self-reference. J Cogn Neurosci. 2005 Dec;17(12):1897&#x2013;1906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2629049</ArticleId><ArticleId IdType="pubmed">16356327</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley WM, Macrae CN, Wyland CL, Caglar S, Inati S, Heatherton TF. Finding the self? An event-related fMRI study. J Cogn Neurosci. 2002 Jul 1;14(5):785&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">12167262</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane RD, Fink GR, Chau PM, Dolan RJ. Neural activation during selective attention to subjective emotional responses. Neuroreport. 1997;8(18):3969&#x2013;3972.</Citation><ArticleIdList><ArticleId IdType="pubmed">9462476</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusnard DA, Akbudak E, Shulman GL, Raichle ME. Medial prefrontal cortex and self-referential mental activity: Relation to a default mode of brain function. Proc Natl Acad Sci U S A. 2001;20:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC31213</ArticleId><ArticleId IdType="pubmed">11259662</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestor PJ, Fryer TD, Ikeda M, Hodges JR. Retrosplenial cortex (BA 29/30) hypometabolism in mild cognitive impairment (prodromal Alzheimer's disease) Eur J Neurosci. 2003 Nov;18(9):2663&#x2013;2667.</Citation><ArticleIdList><ArticleId IdType="pubmed">14622168</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson NA, Jahng GH, Weiner MW, et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology. 2005 Mar;234(3):851&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851934</ArticleId><ArticleId IdType="pubmed">15734937</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology. 2003 Apr 22;60(8):1374&#x2013;1377.</Citation><ArticleIdList><ArticleId IdType="pubmed">12707450</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wahlund LO, Svensson L, Winblad B, Julin P. Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment. BMC Neurol. 2002 Sep 12;2(1):9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC128832</ArticleId><ArticleId IdType="pubmed">12227833</ArticleId></ArticleIdList></Reference><Reference><Citation>Kogure D, Matsuda H, Ohnishi T, et al. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J Nucl Med. 2000 Jul;41(7):1155&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">10914904</ArticleId></ArticleIdList></Reference><Reference><Citation>Arikuni T, Sako H, Murata A. Ipsilateral connections of the anterior cingulate cortex with the frontal and medial temporal cortices in the macaque monkey. Neurosci Res. 1994 Nov;21(1):19&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">7535904</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavada C, Company T, Tejedor J, Cruz-Rizzolo RJ, Reinoso-Suarez F. The anatomical connections of the macaque monkey orbitofrontal cortex. A review. Cereb Cortex. 2000 Mar;10(3):220&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">10731218</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall GA, Kaufer DI, Lopez OL, Rao GR, Hamilton RL, DeKosky ST. Right prosubiculum amyloid plaque density correlates with anosognosia in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004 Oct;75(10):1396&#x2013;1400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738763</ArticleId><ArticleId IdType="pubmed">15377684</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondadori CR, de Quervain DJ, Buchmann A, et al. Better Memory and Neural Efficiency in Young Apolipoprotein E {varepsilon}4 Carriers. Cereb Cortex. 2006 Oct 31;</Citation><ArticleIdList><ArticleId IdType="pubmed">17077159</ArticleId></ArticleIdList></Reference><Reference><Citation>Handley OJ, Morrison CM, Miles C, Bayer AJ. ApoE gene and familial risk of Alzheimer's disease as predictors of odour identification in older adults. Neurobiol Aging. 2006 Oct;27(10):1425&#x2013;1430.</Citation><ArticleIdList><ArticleId IdType="pubmed">16202482</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondadori CR, Buchmann A, Mustovic H, et al. Enhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years. Brain. 2006 Nov;129(Pt 11):2908&#x2013;2922.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012294</ArticleId></ArticleIdList></Reference><Reference><Citation>Han SD, Houston WS, Jak AJ, et al. Verbal paired-associate learning by APOE genotype in non-demented older adults: fMRI evidence of a right hemispheric compensatory response. Neurobiol Aging. 2007 Feb;28(2):238&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1705815</ArticleId><ArticleId IdType="pubmed">16434125</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med. 2000;343(7):450&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831477</ArticleId><ArticleId IdType="pubmed">10944562</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Bates JF, et al. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol. 2004 Jul;56(1):27&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335689</ArticleId><ArticleId IdType="pubmed">15236399</ArticleId></ArticleIdList></Reference><Reference><Citation>Celone KA, Calhoun VD, Dickerson BC, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci. 2006 Oct 4;26(40):10222&#x2013;10231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674636</ArticleId><ArticleId IdType="pubmed">17021177</ArticleId></ArticleIdList></Reference><Reference><Citation>Small S, Perera GM, DeLaPaz R, Mayeux R, Stern Y. Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Ann Neurol. 1999;45(4):466&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">10211471</ArticleId></ArticleIdList></Reference><Reference><Citation>Machulda MM, Ward HA, Borowski B, et al. Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients. Neurology. 2003 Aug 26;61(4):500&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744465</ArticleId><ArticleId IdType="pubmed">12939424</ArticleId></ArticleIdList></Reference><Reference><Citation>Demb JB, Desmond JE, Wagner AD, Vaidya CJ, Glover GH, Gabrieli JD. Semantic encoding and retrieval in the left inferior prefrontal cortex: A functional MRI study of task difficulty and process specificity. Journal of Neuroscience. 1995;15(9):5870&#x2013;5878. Eng.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577672</ArticleId><ArticleId IdType="pubmed">7666172</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao SM, Bandettini PA, Binder JR, et al. Relationship between finger movement rate and functional magnetic resonance signal change in human primary motor cortex. J Cereb Blood Flow Metab. 1996;16(6):1250&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pubmed">8898698</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark CE, Squire LR. When zero is not zero: the problem of ambiguous baseline conditions in fMRI. Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12760&#x2013;12766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC60127</ArticleId><ArticleId IdType="pubmed">11592989</ArticleId></ArticleIdList></Reference><Reference><Citation>Morcom AM, Fletcher PC. Does the brain have a baseline? Why we should be resisting a rest. Neuroimage. 2006 Oct 16;</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandstrom CK, Krishnan S, Slavin MJ, Tran TT, Doraiswamy PM, Petrella JR. Hippocampal atrophy confounds template-based functional MR imaging measures of hippocampal activation in patients with mild cognitive impairment. AJNR Am J Neuroradiol. 2006 Sep;27(8):1622&#x2013;1627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8139763</ArticleId><ArticleId IdType="pubmed">16971599</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17911105</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>282</Volume><Issue>47</Issue><PubDate><Year>2007</Year><Month>Nov</Month><Day>23</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Active gamma-secretase complexes contain only one of each component.</ArticleTitle><Pagination><StartPage>33985</StartPage><EndPage>33993</EndPage><MedlinePgn>33985-93</MedlinePgn></Pagination><Abstract><AbstractText>Gamma-secretase is an intramembrane aspartyl protease complex that cleaves type I integral membrane proteins, including the amyloid beta-protein precursor and the Notch receptor, and is composed of presenilin, Pen-2, nicastrin, and Aph-1. Although all four of these membrane proteins are essential for assembly and activity, the stoichiometry of the complex is unknown, with the number of presenilin molecules present being especially controversial. Here we analyze functional gamma-secretase complexes, isolated by immunoprecipitation from solubilized membrane fractions and able to produce amyloid beta-peptides and amyloid beta-protein precursor intracellular domain. We show that the active isolated protease contains only one presenilin per complex, which excludes certain models of the active site that require aspartate dyads formed between two presenilin molecules. We also quantified components in the isolated complexes by Western blot using protein standards and found that the amounts of Pen-2 and nicastrin were the same as that of presenilin. Moreover, we found that one Aph-1 was not co-immunoprecipitated with another in active complexes, evidence that Aph-1 is likewise present as a monomer. Taken together, these results demonstrate that the stoichiometry of gamma-components presenilin:Pen-2:nicastrin:Aph-1 is 1:1:1:1.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Toru</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diehl</LastName><ForeName>Thekla S</ForeName><Initials>TS</Initials></Author><Author ValidYN="Y"><LastName>Narayanan</LastName><ForeName>Saravanakumar</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Funamoto</LastName><ForeName>Satoru</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ihara</LastName><ForeName>Yasuo</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 17574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D046912">Multiprotein Complexes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C469349">PSENEN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053763">Presenilins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C413604">nicastrin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="C475154">APH1A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046912" MajorTopicYN="N">Multiprotein Complexes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010447" MajorTopicYN="N">Peptide Hydrolases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053763" MajorTopicYN="N">Presenilins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051880" MajorTopicYN="N">Receptors, Notch</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17911105</ArticleId><ArticleId IdType="doi">10.1074/jbc.M705248200</ArticleId><ArticleId IdType="pii">S0021-9258(20)54450-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17911251</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>41</Issue><PubDate><Year>2007</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death.</ArticleTitle><Pagination><StartPage>16329</StartPage><EndPage>16334</EndPage><MedlinePgn>16329-34</MedlinePgn></Pagination><Abstract><AbstractText>Nerve growth factor (NGF) binds to TrkA receptor and triggers activation of numerous signaling cascades, which play critical roles in neuronal plasticity, survival, and neurite outgrowth. To mimic NGF functions pharmacologically, we developed a high-throughput screening assay to identify small-molecule agonists for TrkA receptor. The most potent compound, gambogic amide, selectively binds to TrkA, but not TrkB or TrkC, and robustly induces its tyrosine phosphorylation and downstream signaling activation, including Akt and MAPKs. Further, it strongly prevents glutamate-induced neuronal cell death and provokes prominent neurite outgrowth in PC12 cells. Gambogic amide specifically interacts with the cytoplasmic juxtamembrane domain of TrkA receptor and triggers its dimerization. Administration of this molecule in mice substantially diminishes kainic acid-triggered neuronal cell death and decreases infarct volume in the transient middle cerebral artery occlusion model of stroke. Thus, gambogic amide might not only establish a powerful platform for dissection of the physiological roles of NGF and TrkA receptor but also provide effective treatments for neurodegenerative diseases and stroke.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Sung-Wuk</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okada</LastName><ForeName>Masashi</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sayeed</LastName><ForeName>Iqbal</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Ge</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Peng</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Keqiang</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS045627</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS04851</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000577">Amides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044004">Xanthones</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N585K83U2</RegistryNumber><NameOfSubstance UI="C052659">gambogic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D020917">Receptor, trkA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000577" MajorTopicYN="N">Amides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002544" MajorTopicYN="N">Cerebral Infarction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020917" MajorTopicYN="N">Receptor, trkA</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044004" MajorTopicYN="N">Xanthones</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>4</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17911251</ArticleId><ArticleId IdType="pmc">PMC2042206</ArticleId><ArticleId IdType="doi">10.1073/pnas.0706662104</ArticleId><ArticleId IdType="pii">0706662104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kaplan DR, Stephens RM. J Neurobiol. 1994;25:1404&#x2013;1417.</Citation><ArticleIdList><ArticleId IdType="pubmed">7852994</ArticleId></ArticleIdList></Reference><Reference><Citation>Mufson EJ, Lavine N, Jaffar S, Kordower JH, Quirion R, Saragovi HU. Exp Neurol. 1997;146:91&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225742</ArticleId></ArticleIdList></Reference><Reference><Citation>Counts SE, Nadeem M, Wuu J, Ginsberg SD, Saragovi HU, Mufson EJ. Ann Neurol. 2004;56:520&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">15455399</ArticleId></ArticleIdList></Reference><Reference><Citation>Backman C, Rose GM, Bartus RT, Hoffer BJ, Mufson EJ, Granholm AC. J Comp Neurol. 1997;387:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">9331167</ArticleId></ArticleIdList></Reference><Reference><Citation>Barinaga M. Science. 1994;266:973.</Citation><ArticleIdList><ArticleId IdType="pubmed">7973680</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay RM. Philos Trans R Soc Lond B Biol Sci. 1996;351:365&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">8730773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebadi M, Bashir RM, Heidrick ML, Hamada FM, Refaey HE, Hamed A, Helal G, Baxi MD, Cerutis DR, Lassi NK. Neurochem Int. 1997;30:347&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">9106250</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor B, Dragunow M. Brain Res Brain Res Rev. 1998;27:1&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9639663</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon SB, Priestley JV. Curr Opin Neurobiol. 1995;5:616&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">8580713</ArticleId></ArticleIdList></Reference><Reference><Citation>McArthur JC, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra C, Rubin M, Cohen BA, Tucker T, et al. Neurology. 2000;54:1080&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pubmed">10720278</ArticleId></ArticleIdList></Reference><Reference><Citation>Verrall M. Nature. 1994;370:6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8015607</ArticleId></ArticleIdList></Reference><Reference><Citation>Saragovi HU, Greene MI, Chrusciel RA, Kahn M. Biotechnology (NY) 1992;10:773&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pubmed">1368266</ArticleId></ArticleIdList></Reference><Reference><Citation>Saragovi HU, Fitzpatrick D, Raktabutr A, Nakanishi H, Kahn M, Greene MI. Science. 1991;253:792&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">1876837</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee FS, Chao MV. Proc Natl Acad Sci USA. 2001;98:3555&#x2013;3560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30691</ArticleId><ArticleId IdType="pubmed">11248116</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano J, Chiba K, Tada M, Yoshii T. Phytochemistry. 1996;41:815&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">8835458</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo QL, You QD, Wu ZQ, Yuan ST, Zhao L. Acta Pharmacol Sin/I. 2004;25:769&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">15169630</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu ZQ, Guo QL, You QD, Zhao L, Gu HY. Biol Pharm Bull. 2004;27:1769&#x2013;1774.</Citation><ArticleIdList><ArticleId IdType="pubmed">15516720</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Guo QL, You QD, Wu ZQ, Gu HY. Biol Pharm Bull. 2004;27:998&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">15256729</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Guo QL, You QD, Zhao L, Gu HY, Yang Y, Zhang HW, Tan Z, Wang X. Carcinogenesis. 2007;28:632&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012222</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasibhatla S, Jessen KA, Maliartchouk S, Wang JY, English NM, Drewe J, Qiu L, Archer SP, Ponce AE, Sirisoma N, et al. Proc Natl Acad Sci USA. 2005;102:12095&#x2013;12100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1189297</ArticleId><ArticleId IdType="pubmed">16103367</ArticleId></ArticleIdList></Reference><Reference><Citation>Urfer R, Tsoulfas P, O'Connell L, Shelton DL, Parada LF, Presta LG. EMBO J. 1995;14:2795&#x2013;2805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC398398</ArticleId><ArticleId IdType="pubmed">7796806</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Tatsuno T, Carney JM, Mattson MP. J Cereb Blood Flow Metab. 1993;13:378&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">8478396</ArticleId></ArticleIdList></Reference><Reference><Citation>Kume T, Nishikawa H, Tomioka H, Katsuki H, Akaike A, Kaneko S, Maeda T, Kihara T, Shimohama S. Brain Res. 2000;852:279&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">10678754</ArticleId></ArticleIdList></Reference><Reference><Citation>Culmsee C, Gerling N, Lehmann M, Nikolova-Karakashian M, Prehn JH, Mattson MP, Krieglstein J. Neuroscience. 2002;115:1089&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pubmed">12453482</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokaia Z, Andsberg G, Martinez-Serrano A, Lindvall O. Neuroscience. 1998;84:1113&#x2013;1125.</Citation><ArticleIdList><ArticleId IdType="pubmed">9578399</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TH, Kato H, Chen ST, Kogure K, Itoyama Y. Stroke. 1998;29:1687&#x2013;1696.</Citation><ArticleIdList><ArticleId IdType="pubmed">9707213</ArticleId></ArticleIdList></Reference><Reference><Citation>Culmsee C, Stumm RK, Schafer MK, Weihe E, Krieglstein J. Eur J Pharmacol. 1999;379:33&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">10499369</ArticleId></ArticleIdList></Reference><Reference><Citation>Guegan C, Onteniente B, Makiura Y, Merad-Boudia M, Ceballos-Picot I, Sola B. Brain Res Mol Brain Res. 1998;55:133&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">9645968</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk YO, Chen WY, Wong WJ, Hu HH, Hsu LC, Chern CM, Huang KJ, Law SL. Drug Deliv. 2004;11:319&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">15742557</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabakman R, Jiang H, Shahar I, Arien-Zakay H, Levine RA, Lazarovici P. Ann NY Acad Sci. 2005;1053:84&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">16179511</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadler JV, Perry BW, Gentry C, Cotman CW. J Comp Neurol. 1980;192:333&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">7400401</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperk G, Lassmann H, Baran H, Kish SJ, Seitelberger F, Hornykiewicz O. Neuroscience. 1983;10:1301&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">6141539</ArticleId></ArticleIdList></Reference><Reference><Citation>Schauwecker PE, Steward O. Proc Natl Acad Sci USA. 1997;94:4103&#x2013;4108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20575</ArticleId><ArticleId IdType="pubmed">9108112</ArticleId></ArticleIdList></Reference><Reference><Citation>Faherty CJ, Xanthoudakis S, Smeyne RJ. Brain Res Mol Brain Res. 1999;70:159&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">10381555</ArticleId></ArticleIdList></Reference><Reference><Citation>Glassford A, Lee JE, Xu L, Giffard RG. Neurol Res. 2002;24:796&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12500703</ArticleId></ArticleIdList></Reference><Reference><Citation>Arevalo JC, Conde B, Hempstead BL, Chao MV, Martin-Zanca D, Perez P. Mol Cell Biol. 2000;20:5908&#x2013;5916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC86068</ArticleId><ArticleId IdType="pubmed">10913174</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding L, Huang D, Wang J, Li S. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;846:112&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">16962395</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson L. Exp Neurol. 1993;124:5&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">8282080</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17913918</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>40</Issue><PubDate><Year>2007</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities.</ArticleTitle><Pagination><StartPage>10849</StartPage><EndPage>10859</EndPage><MedlinePgn>10849-59</MedlinePgn></Pagination><Abstract><AbstractText>Although gamma-secretase is recognized as a therapeutic target for Alzheimer's disease, side effects associated with strong inhibition of this aspartyl protease raised serious concerns regarding this therapeutic strategy. However, it is not known whether moderate inhibition of this enzyme will allow dissociation of beneficial effects in the CNS from mechanism-based toxicities in the periphery. We tested this possibility by using a series of mice with genetic reduction of gamma-secretase (levels ranging from 25 to 64% of control mice). Here, we document that even 30% reduction of gamma-secretase can effectively ameliorate amyloid burden in the CNS. However, global reduction of this enzyme below a threshold level increased the risk of developing squamous cell carcinoma as well as abnormal proliferation of granulocytes in a gamma-secretase dosage-dependent manner. Importantly, we demonstrate that there exists a critical gamma-secretase level that reduces the risk of amyloidosis in the CNS and limits tumorigenesis in epithelia. Our findings suggest that moderate inhibition of gamma-secretase represents an attractive anti-amyloid therapy for Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Tong</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, The Johns Hopkins University, School of Medicine, Baltimore, Maryland 21205, USA. tli1@jhmi.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Hongjin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Brayton</LastName><ForeName>Cory</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Laird</LastName><ForeName>Fiona M</ForeName><Initials>FM</Initials></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Guojun</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Shiwen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Placanica</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>T C</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Crain</LastName><ForeName>Barbara J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Donald L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Eberhart</LastName><ForeName>Charles G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Philip C</ForeName><Initials>PC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 NS047308</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS045150</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS45150</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C413604">nicastrin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurosci. 2007 Dec 12;27(50):13579-80. doi: 10.1523/JNEUROSCI.4821-07.2007.</RefSource><PMID Version="1">18077669</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>4</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17913918</ArticleId><ArticleId IdType="pmc">PMC6672827</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2152-07.2007</ArticleId><ArticleId IdType="pii">27/40/10849</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allman D, Punt JA, Izon DJ, Aster JC, Pear WS. An invitation to T and more: Notch signaling in lymphopoiesis. Cell. 2002;109:S1&#x2013;S11.</Citation><ArticleIdList><ArticleId IdType="pubmed">11983148</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasson KI, Savonenko AV, Vidensky S, Goellner JJ, Zhang Y, Shaffer A, Kaufmann WI, Worley PF, Isakson P, Markowska AL. Age-dependent cognitive deficits and neuronal loss cyclooxygenase-2 transgenic mice. J Neurosci. 2001;21:8198&#x2013;8209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763862</ArticleId><ArticleId IdType="pubmed">11588192</ArticleId></ArticleIdList></Reference><Reference><Citation>Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">10221902</ArticleId></ArticleIdList></Reference><Reference><Citation>Barten DM, Guss VL, Corsa JA, Loo A, Hansel SB, Zheng M, Munoz B, Srinivasan K, Wang B, Robertson BJ, Polson CT, Wang J, Roberts SB, Hendrick JP, Anderson JJ, Loy JK, Denton R, Verdoorn TA, Smith DW, Felsenstein KM. Dynamics of &#x3b2;-amyloid reductions in brain, cerebrospinal fluid, and plasma of &#x3b2;-amyloid precursor protein transgenic mice treated with a &#x3b3;-secretase inhibitor. J Pharmacol Exp Ther. 2005;312:635&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">15452193</ArticleId></ArticleIdList></Reference><Reference><Citation>Birchler JA, Riddle NC, Auger DL, Veitia RA. Dosage balance in gene regulation: biological implications. Trends Genet. 2005;21:219&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">15797617</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299:256&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">12446870</ArticleId></ArticleIdList></Reference><Reference><Citation>Brayton C, Justice M, Montgomery CA. Evaluating mutant mice: anatomic pathology. Vet Pathol. 2001;38:1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">11199155</ArticleId></ArticleIdList></Reference><Reference><Citation>Brittan M, Wright N. Gastrointestinal stem cells. J Pathol. 2002;197:492&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">12115865</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci. 2001;4:233&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron. 2003;38:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>Elchuri S, Oberley TD, Qi W, Eisenstein RS, Jackson Roberts L, Van Remmen H, Epstein CJ, Huang TT. CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. 2004;24:367&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">15531919</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Xu G, Fromholt D, Gonzales V, Borchelt DR. Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Neuropathol Exp Neurol. 2003;62:1220&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pubmed">14692698</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher GC, DeLuca C, Liepa J, Zhou L, Snow B. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell. 2005;7:263&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">15766664</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Fici GJ, Mao CA, Myers RL, Shuang R, Donoho GP, Pauley AM, Himes CS, Qin W, Kola I, Merchant KM, Nye JS. Positive and negative regulation of the gamma-secretase activity by nicastrin in a murine model. J Biol Chem. 2003a;278:33445&#x2013;33449.</Citation><ArticleIdList><ArticleId IdType="pubmed">12815056</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Ma G, Cai H, Price DL, Wong PC. Nicastrin is required for assembly of presenilin/&#x3b3;-secretase complexes to mediate notch signaling and for processing and trafficking of &#x3b2;-amyloid precursor protein in mammals. J Neurosci. 2003b;23:3272&#x2013;3277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742329</ArticleId><ArticleId IdType="pubmed">12716934</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YM, Lai MT, Xu M, Huang Q, DiMuzio-Mower J, Sardana MK, Shi XP, Yin KC, Shafer JA, Gardell SJ. Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl Acad Sci USA. 2000;97:6138&#x2013;6143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18571</ArticleId><ArticleId IdType="pubmed">10801983</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo WJ, Wang H, Li H, Kim BS, Shah S, Lee HJ, Thinakaran G, Kim TW, Yu G, Xu H. PEN-2 and APH-1 coordinately regulate proteolytic processing of presenilin 1. J Biol Chem. 2003;278:7850&#x2013;7854.</Citation><ArticleIdList><ArticleId IdType="pubmed">12522139</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma G, Li T, Price DL, Wong PC. APH-1a is the principal mammalian APH-1 isoform present in &#x3b3;-secretase complexes during embryonic development. J Neurosci. 2005;25:192&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725209</ArticleId><ArticleId IdType="pubmed">15634781</ArticleId></ArticleIdList></Reference><Reference><Citation>Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, Jacobs RT, Zacco A, Greenberg B, Ciaccio PJ. Modulation of notch processing by &#x3b3;-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci. 2004;82:341&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">15319485</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, Hui CC, Clevers H, Dotto GP, Radtke F. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet. 2003;33:416&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12590261</ArticleId></ArticleIdList></Reference><Reference><Citation>Proweller A, Tu L, Lepore JJ, Cheng L, Lu MM, Seykora J, Millar SE, Pear WS, Parmacek MS. Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Res. 2006;66:7438&#x2013;7444.</Citation><ArticleIdList><ArticleId IdType="pubmed">16885339</ArticleId></ArticleIdList></Reference><Reference><Citation>Qyang Y, Chambers SM, Wang P, Xia X, Chen X, Goodell MA, Zheng H. Myeloproliferative disease in mice with reduced presenilin gene dosage: effect of gamma-secretase blockage. Biochemistry. 2004;43:5352&#x2013;5359.</Citation><ArticleIdList><ArticleId IdType="pubmed">15122901</ArticleId></ArticleIdList></Reference><Reference><Citation>Radtke F, Wilson A, Stark G, Bauer M, van Meerwijk J, MacDonald HR, Aguet M. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity. 1999;10:547&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">10367900</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Behrens MI, Xiong C, Miller JP, Morris JC. Alzheimer disease and cancer. Neurology. 2005;64:895&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">15753432</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng H-X, Rahmani Z, Krizus A, McKenna-Yasek D, Cayabyab A, Gaston SM, Berger R, Tanzi RE, Halperin JJ, Herzfeldt B, Van den Bergh R, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Rao BS, Chattarji S, Kelleher RJ, III, Kandel ER, Duff K, Kirkwood A, Shen J. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MPF, Price DL, Tang F, Markowska AL, Borchelt DR. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to &#x3b2;-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis. 2005;18:602&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">15755686</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan JB, Visan I, Yuan JS, Guidos CJ. Requirement for Notch1 signals at sequential early stages of intrathymic T cell development. Nat Immunol. 2005;6:671&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">15951812</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, Ratovitsky T, Davenport F, Nordstedt C, Seeger M, Hardy J, Levey AI, Gandy SE, Jenkins NA, Copeland NG, Price DL, Sisodia SS. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron. 1996;17:181&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8755489</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda Y, Kondo M, Kelsoe G. Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J Exp Med. 2005;201:1771&#x2013;1780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1952536</ArticleId><ArticleId IdType="pubmed">15939792</ArticleId></ArticleIdList></Reference><Reference><Citation>Vehmas AK, Borchelt DR, Price DL, McCarthy D, Wills-Karp M, Peper MJ, Rudow G, Luyinbazi J, Siew LT, Troncoso JC. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip technology. DNA Cell Biol. 2001;20:713&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pubmed">11788049</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng AP, Aster JC. Multiple niches for Notch in cancer: context is everything. Curr Opin Genet Dev. 2004;14:48&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">15108805</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfer A, Bakker T, Wilson A, Nicolas M, Ioannidis V, Littman DR, Lee PP, Wilson CB, Held W, MacDonald HR, Radtke F. Inactivation of Notch 1 in immature thymocytes does not perturb CD4 or CD8T cell development. Nat Immunol. 2001;2:235&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224523</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, Zhang L, Higgins GA, Parker EM. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004;279:12876&#x2013;12882.</Citation><ArticleIdList><ArticleId IdType="pubmed">14709552</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong PC, Zheng H, Chen H, Becher MW, Sirinathsinghji DJ, Trumbauer ME, Chen HY, Price DL, Van der Ploeg LH, Sisodia SS. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature. 1997;387:288&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153393</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong PC, Li T, Price DL. Basic neurochemistry. Ed 7. Baltimore: Lippencott Williams &amp; Wilkins; 2005. Neurobiology of Alzheimer's disease.</Citation></Reference><Reference><Citation>Xia X, Qian S, Soriano S, Wu Y, Fletcher AM, Wang XJ, Koo EH, Wu X, Zheng H. Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis. Proc Natl Acad Sci USA. 2001;98:10863&#x2013;10868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58565</ArticleId><ArticleId IdType="pubmed">11517342</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu G, Gonzales V, Borchelt DR. Rapid detection of protein aggregates in the brains of Alzheimer patients and transgenic mouse models of amyloidosis. Alzheimer Dis Assoc Disord. 2002;16:191&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">12218651</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17914039</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>357</Volume><Issue>14</Issue><PubDate><Year>2007</Year><Month>Oct</Month><Day>04</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Donepezil for the treatment of agitation in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1382</StartPage><EndPage>1392</EndPage><MedlinePgn>1382-92</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Agitation is a common and distressing symptom in patients with Alzheimer's disease. Cholinesterase inhibitors improve cognitive outcomes in such patients, but the benefits of these drugs for behavioral disturbances are unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We randomly assigned 272 patients with Alzheimer's disease who had clinically significant agitation and no response to a brief psychosocial treatment program to receive 10 mg of donepezil per day (128 patients) or placebo (131 patients) for 12 weeks. The primary outcome was a change in the score on the Cohen-Mansfield Agitation Inventory (CMAI) (on a scale of 29 to 203, with higher scores indicating more agitation) at 12 weeks.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There was no significant difference between the effects of donepezil and those of placebo on the basis of the change in CMAI scores from baseline to 12 weeks (estimated mean difference in change [the value for donepezil minus that for placebo], -0.06; 95% confidence interval [CI], -4.35 to 4.22). Twenty-two of 108 patients (20.4%) in the placebo group and 22 of 113 (19.5%) in the donepezil group had a reduction of 30% or greater in the CMAI score (the value for donepezil minus that for placebo, -0.9 percentage point; 95% CI, -11.4 to 9.6). There were also no significant differences between the placebo and donepezil groups in scores for the Neuropsychiatric Inventory, the Neuropsychiatric Inventory Caregiver Distress Scale, or the Clinician's Global Impression of Change.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this 12-week trial, donepezil was not more effective than placebo in treating agitation in patients with Alzheimer's disease. (ClinicalTrials.gov number, NCT00142324 [ClinicalTrials.gov].).</AbstractText><CopyrightInformation>Copyright 2007 Massachusetts Medical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Howard</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Medical Research Council Neurogeneration Research Centre, Institute of Psychiatry, King's College London, London, United Kingdom. robert.howard@iop.kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juszczak</LastName><ForeName>Edmund</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Bentham</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Richard G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Bullock</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Alistair S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Jacoby</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Tony</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Knapp</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lindesay</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>John T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Wilcock</LastName><ForeName>Gordon</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Katona</LastName><ForeName>Cornelius</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Roy W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>DeCesare</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rodger</LastName><ForeName>Michaela</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><CollectiveName>CALM-AD Trial Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00142324</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>G0100070</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2007 Oct 4;357(14):1441-3. doi: 10.1056/NEJMe078128.</RefSource><PMID Version="1">17914047</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>ACP J Club. 2008 Mar-Apr;148(2):33.</RefSource><PMID Version="1">18311863</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Ment Health. 2008 Aug;11(3):84. doi: 10.1136/ebmh.11.3.84.</RefSource><PMID Version="1">18669686</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="N">Social Support</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17914039</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa066583</ArticleId><ArticleId IdType="pii">357/14/1382</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17920016</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Oct</Month><Day>04</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1.</ArticleTitle><Pagination><StartPage>66</StartPage><EndPage>78</EndPage><MedlinePgn>66-78</MedlinePgn></Pagination><Abstract><AbstractText>Mutations in the amyloid precursor protein (APP) cause early-onset Alzheimer's disease (AD), but the only genetic risk factor for late-onset AD is the varepsilon4 allele of apolipoprotein E (apoE), a major cholesterol carrier. Using Cre-lox conditional knockout mice, we demonstrate that lipoprotein receptor LRP1 expression regulates apoE and cholesterol levels within the CNS. We also found that deletion of APP and its homolog APLP2, or components of the gamma-secretase complex, significantly enhanced the expression and function of LRP1, which was reversed by forced expression of the APP intracellular domain (AICD). We further show that AICD, together with Fe65 and Tip60, interacts with the LRP1 promoter and suppresses its transcription. Together, our findings support that the gamma-secretase cleavage of APP plays a central role in regulating apoE and cholesterol metabolism in the CNS via LRP1 and establish a biological linkage between APP and apoE, the two major genetic determinants of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Washington University School of Medicine, St Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zerbinatti</LastName><ForeName>Celina V</ForeName><Initials>CV</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hoe</LastName><ForeName>Hyang-Sook</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Baiping</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Herz</LastName><ForeName>Joachim</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Muglia</LastName><ForeName>Louis</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG030128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 HL063762</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C486243">Apbb1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026503">Low Density Lipoprotein Receptor-Related Protein-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C486645">Lrp1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011973">Receptors, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.48</RegistryNumber><NameOfSubstance UI="D051548">Histone Acetyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.48</RegistryNumber><NameOfSubstance UI="C523065">Kat5 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.48</RegistryNumber><NameOfSubstance UI="D000074443">Lysine Acetyltransferase 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.4.-</RegistryNumber><NameOfSubstance UI="D000098830">AICDA (Activation-Induced Cytidine Deaminase)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.4.5</RegistryNumber><NameOfSubstance UI="D003564">Cytidine Deaminase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002461" MajorTopicYN="N">Cell Line, Transformed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047369" MajorTopicYN="N">Chromatin Immunoprecipitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003564" MajorTopicYN="N">Cytidine Deaminase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018507" MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051548" MajorTopicYN="N">Histone Acetyltransferases</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026503" MajorTopicYN="N">Low Density Lipoprotein Receptor-Related Protein-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074443" MajorTopicYN="N">Lysine Acetyltransferase 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011973" MajorTopicYN="N">Receptors, LDL</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015534" MajorTopicYN="N">Trans-Activators</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000098830" MajorTopicYN="N">AICDA (Activation-Induced Cytidine Deaminase)</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>10</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17920016</ArticleId><ArticleId IdType="mid">NIHMS32048</ArticleId><ArticleId IdType="pmc">PMC2045076</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2007.08.008</ArticleId><ArticleId IdType="pii">S0896-6273(07)00620-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, Dingwall C, De Strooper B, Dotti CG. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J. Cell Biol. 2004;167:953&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172459</ArticleId><ArticleId IdType="pubmed">15583033</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim CA, et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. USA. 2005;102:13461&#x2013;13466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek SH, Ohgi KA, Rose DW, Koo EH, Glass CK, Rosenfeld MG. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell. 2002;110:55&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">12150997</ArticleId></ArticleIdList></Reference><Reference><Citation>Borg JP, Ooi J, Levy E, Margolis B. The phosphotyrosine interaction domains of X11 and FE65 bind to distinct sites on the YENPTY motif of amyloid precursor protein. Mol. Cell. Biol. 1996;16:6229&#x2013;6241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC231626</ArticleId><ArticleId IdType="pubmed">8887653</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu G, Geuze HJ, Strous GJ, Schwartz AL. 39 kDa receptor-associated protein is an ER resident protein and molecular chaperone for LDL receptor-related protein. EMBO J. 1995;14:2269&#x2013;2280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC398334</ArticleId><ArticleId IdType="pubmed">7774585</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu G, Maksymovitch EA, Schwartz AL. Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells. J. Biol. Chem. 1993;268:13002&#x2013;13009.</Citation><ArticleIdList><ArticleId IdType="pubmed">8389767</ArticleId></ArticleIdList></Reference><Reference><Citation>Cam JA, Zerbinatti CV, Li Y, Bu G. Rapid endocytosis of the low density lipoprotein receptor-related protein modulates cell surface distribution and processing of the &#x3b2;-amyloid precursor protein. J. Biol. Chem. 2005;280:15464&#x2013;15470.</Citation><ArticleIdList><ArticleId IdType="pubmed">15705569</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Sudhof TC. A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. Science. 2001;293:115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Sudhof TC. Dissection of amyloid-&#x3b2; precursor protein-dependent transcriptional transactivation. J. Biol. Chem. 2004;279:24601&#x2013;24611.</Citation><ArticleIdList><ArticleId IdType="pubmed">15044485</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen AC, Selkoe DJ. Response to: Pardossi-Piquard et al., &#x201c;Presenilin-dependent transcriptional control of the abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP.&#x201d; Neuron 46, 541-554. Neuron. 2007;53:479&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">17296549</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Counter CM, Hahn WC, Wei W, Caddle SD, Beijersbergen RL, Lansdorp PM, Sedivy JM, Weinberg RA. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc. Natl. Acad. Sci. USA. 1998;95:14723&#x2013;14728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24516</ArticleId><ArticleId IdType="pubmed">9843956</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43:333&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294142</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng R, Wang H, Wang J, Shrom D, Zeng X, Tsien JZ. Forebrain degeneration and ventricle enlargement caused by double knockout of Alzheimer's presenilin-1 and presenilin-2. Proc. Natl. Acad. Sci. USA. 2004;101:8162&#x2013;8167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419574</ArticleId><ArticleId IdType="pubmed">15148382</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer JD, Demattos RB, McCormick LM, O'Dell M,A, Spinner ML, Bales KR, Paul SM, et al. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J. Biol. Chem. 2005;280:25754&#x2013;25759.</Citation><ArticleIdList><ArticleId IdType="pubmed">15888448</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm MOW, Grimm HS, Patzold AJ, Zinser EG, Halonen R, Duering M, Tschape J-A, et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat. Cell Bio. 2005;7:1118&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">16227967</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenette S, Chang Y, Hiesberger T, Richardson JA, Eckman CB, Eckman EA, Hammer RE, Herz J. Essential roles for the FE65 amyloid precursor protein-interacting proteins in brain development. EMBO J. 2006;25:420&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1383510</ArticleId><ArticleId IdType="pubmed">16407979</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamanaka H, Katoh-Fukui Y, Suzuki K, Kobayashi M, Suzuki R, Motegi Y, Nakahara Y, et al. Altered cholesterol metabolism in human apolipoprotein E4 knock-in mice. Hum. Mol. Genet. 2000;9:353&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">10655544</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert SS, Serneels L, Tolia A, Craessaerts K, Derks C, Filippov MA, Muller U, De Strooper B. Regulated intramembrane proteolysis of amyloid precursor protein and regulation of expression of putative target genes. EMBO Rep. 2006;7:739&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1500829</ArticleId><ArticleId IdType="pubmed">16729020</ArticleId></ArticleIdList></Reference><Reference><Citation>Herms J, Anliker B, Heber S, Ring S, Fuhrmann M, Kretzschmar H, Sisodia S, Muller U. Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. EMBO J. 2004;23:4106&#x2013;4115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524337</ArticleId><ArticleId IdType="pubmed">15385965</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz J, Bock HH. Lipoprotein receptors in the nervous system. Annu. Rev. Biochem. 2002;71:405&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">12045102</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz J, Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat. Rev. Neurosci. 2006;7:850&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pubmed">17053810</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz J, Clouthier DE, Hammer RE. LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell. 1992;71:411&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">1423604</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz J. Overview: the long and winding road to understanding Alzheimer's disease. Neuron. 2007;53:477&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">17296548</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 2000;97:2892&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y. Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies. Curr. Opin. Drug Discov. Devel. 2006;9:627&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">17002223</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, et al. Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J. Clin. Invest. 2000;106:1159&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC301422</ArticleId><ArticleId IdType="pubmed">11067868</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein E to &#x3b2;-amyloid. J. Biol. Chem. 1994;269:23403&#x2013;23406.</Citation><ArticleIdList><ArticleId IdType="pubmed">8089103</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledesma MD, Abad-Rodriguez J, Galvan C, Biondi E, Navarro P, Delacourte A, Dingwall C, Dotti CG. Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains. EMBO Rep. 2003;4:1190&#x2013;1196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1326416</ArticleId><ArticleId IdType="pubmed">14618158</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledesma MD, Dotti CG. Amyloid excess in Alzheimer's disease: What is cholesterol to be blamed for? FEBS Lett. 2006;580:5525&#x2013;5532.</Citation><ArticleIdList><ArticleId IdType="pubmed">16814780</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Chen J, Lu W, McCormick LM, Wang J, Bu G. Mesd binds to mature LDL-receptor-related protein-6 and antagonizes ligand binding. J. Cell Sci. 2005;118:5305&#x2013;5314.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263759</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Marzolo MP, Kerkhof P, Strous GJ, Bu G. The YXXL motif, but not the two NPXY motifs, serves as the dominant endocytosis signal For LDL receptor-related protein (LRP) J. Biol. Chem. 2000;275:17187&#x2013;17194.</Citation><ArticleIdList><ArticleId IdType="pubmed">10747918</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat. Neurosci. 2001;4:231&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">3283935</ArticleId></ArticleIdList></Reference><Reference><Citation>Moestrup SK, Gliemann J, Pallesen G. Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tiss. Res. 1992;269:375&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">1423505</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller T, Concannon CG, Ward MW, Walsh CM, Tirniceriu AL, Tribl F, Kogel D, Prehn JHM, Egensperger R. Modulation of gene expression and cytoskeletal dynamics by the amyloid precursor protein intracellular domain (AICD) Mol. Biol. Cell. 2007;18:201&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1751311</ArticleId><ArticleId IdType="pubmed">17093061</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardossi-Piquard R, Dunys J, Kawarai T, Sunyach C, Alves da Costa C, Vincent B, Sevalle J, Pimplikar S, St George-Hyslop P, Checler F. Response to Correspondence: Pardossi-Piquard et al., &#x201c;Presenilin-dependent transcriptional control of the abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP.&#x201d; Neuron 46, 541-554. Neuron. 2007;53:483&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">17296550</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardossi-Piquard R, Petit A, Kawarai T, Sunyach C, Alves da Costa C, Vincent B, Ring S, et al. Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron. 2005;46:541&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944124</ArticleId></ArticleIdList></Reference><Reference><Citation>Park I-H, Hwang EM, Hong HS, Boo JH, Oh SS, Lee J, Jung MW, et al. Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiol. Aging. 2003;24:637&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">12885571</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfrieger FW. Cholesterol homeostasis and function in neurons of the central nervous system. CMLS, Cell. Mol. Life Sci. 2003;60:1158&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11138592</ArticleId><ArticleId IdType="pubmed">12861382</ArticleId></ArticleIdList></Reference><Reference><Citation>Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J. Synapse formation and function is modulated by the amyloid precursor protein. J. Neurosci. 2006;26:7212&#x2013;7221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673945</ArticleId><ArticleId IdType="pubmed">16822978</ArticleId></ArticleIdList></Reference><Reference><Citation>Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: the cholesterol connection. Nat. Neurosci. 2003;6:345&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">12658281</ArticleId></ArticleIdList></Reference><Reference><Citation>Ring S, Weyer SW, Kilian SB, Waldron E, Pietrzik CU, Filippov MA, Herms J, et al. The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. J. Neurosci. 2007;27:7817&#x2013;7826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672885</ArticleId><ArticleId IdType="pubmed">17634375</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 2007;39:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohlmann A, Gotthardt M, Hammer RE, Herz J. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J. Clin. Invest. 1998;101:689&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC508614</ArticleId><ArticleId IdType="pubmed">9449704</ArticleId></ArticleIdList></Reference><Reference><Citation>Saganich MJ, Schroeder BE, Galvan V, Bredesen DE, Koo EH, Heinemann SF. Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP. J. Neurosci. 2006;26:13428&#x2013;13436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674728</ArticleId><ArticleId IdType="pubmed">17192425</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi S-Y, Beglopoulos V, Malkani S, Zhang D, Rao BSS, Chattarji S, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D, Kopan R. Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu. Rev. Neurosci. 2003;26:565&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730322</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Kelleher RJ., III The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism. Proc. Natl. Acad. Sci. USA. 2007;104:403&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1766397</ArticleId><ArticleId IdType="pubmed">17197420</ArticleId></ArticleIdList></Reference><Reference><Citation>Shobab LA, Hsiung G-YR, Feldman HH. Cholesterol in Alzheimer's disease. Lancet Neurol. 2005;4:841&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pubmed">16297842</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 2005;25:7278&#x2013;7287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsien JZ, Chen DF, Gerber D, Tom C, Mercer EH, Anderson DJ, Mayford M, Kandel ER, Tonegawa S. Subregion- and cell type-restricted gene knockout in mouse brain. Cell. 1996;87:1317&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pubmed">8980237</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Rotz RC, Kohli BM, Bosset J, Meier M, Suzuki T, Nitsch RM, Konietzko U. The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. J. Cell Sci. 2004;117:4435&#x2013;4448.</Citation><ArticleIdList><ArticleId IdType="pubmed">15331662</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J. Biol. Chem. 2004;279:40987&#x2013;40993.</Citation><ArticleIdList><ArticleId IdType="pubmed">15269217</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Yang G, Mosier DR, Chang P, Zaidi T, Gong Y-D, Zhao N-M, et al. Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-like protein 2. J. Neurosci. 2005;25:1219&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725967</ArticleId><ArticleId IdType="pubmed">15689559</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbinatti CV, Bu G. LRP and Alzheimer's disease. Rev. Neurosci. 2005;16:123&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">15959937</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbinatti CV, Wahrle SE, Kim H, Cam JA, Bales K, Paul SM, Holtzman DM, Bu G. Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. J. Biol. Chem. 2006;281:36180&#x2013;36186.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012232</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbinatti CV, Wozniak DF, Cirrito J, Cam JA, Osaka H, Bales KR, Zhuo M, Paul SM, Holtzman DM, Bu G. Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc. Natl. Acad. Sci. USA. 2004;101:1075&#x2013;1080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC327153</ArticleId><ArticleId IdType="pubmed">14732699</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YW, Wang R, Liu Q, Zhang H, Liao FF, Xu H. Presenilin/&#x3b3;-secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor expression. Proc. Natl. Acad. Sci. USA. 2007;104:10613&#x2013;10618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1888796</ArticleId><ArticleId IdType="pubmed">17556541</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Koo E. The amyloid precursor protein: beyond amyloid. Molecular Neurodegeneration. 2006;1:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1538601</ArticleId><ArticleId IdType="pubmed">16930452</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 2005;28:202&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">15808355</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17923627</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>10</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family.</ArticleTitle><Pagination><StartPage>1436</StartPage><EndPage>1446</EndPage><MedlinePgn>1436-46</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Progranulin gene (PGRN) haploinsufficiency was recently associated with ubiquitin-positive frontotemporal lobar degeneration linked to chromosome 17q21 (FTLDU-17).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess whether PGRN genetic variability contributed to other common neurodegenerative brain diseases, such as Alzheimer disease (AD) or Parkinson disease (PD).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Mutation analysis of PGRN.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Memory Clinic of the Middelheim General Hospital. Patients We analyzed 666 Belgian patients with AD and 255 with PD.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Results of PGRN sequencing, PGRN transcript analysis, short tandem repeat genotyping, and neuropathologic analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 2 patients with AD and 1 patient with PD who carried the null mutation IVS0 + 5G&gt;C, which we reported earlier in an extensively characterized Belgian founder family, DR8, segregating FTLDU. Postmortem pathologic diagnosis of the patient with PD revealed both FTLDU and Lewy body pathologic features. In addition, we identified in PGRN only 1 other null mutation, the nonsense mutation p.Arg535X, in 1 patient with probable AD. However, in vitro analysis predicted a PGRN C-truncated protein, although it remains to be elucidated if this shortened transcript leads to haploinsufficiency.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our mutation data indicated that null mutations are rare in patients with AD (3/666 = 0.45%) and PD (1/255 = 0.39%). Also, AD and PD clinical diagnoses in patients who carry PGRN null mutations likely result from etiologic heterogeneity rather than PGRN haploinsufficiency.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brouwers</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>VIB Department of Molecular Genetics, Neurodegenerative Brain Diseases Group, University of Antwerp CDE, Universiteitsplein 1, BE-2610 Antwerpen, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuytemans</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>van der Zee</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gijselinck</LastName><ForeName>Ilse</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Theuns</LastName><ForeName>Jessie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kumar-Singh</LastName><ForeName>Samir</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Pickut</LastName><ForeName>Barbara A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Pals</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Dermaut</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Bogaerts</LastName><ForeName>Veerle</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>De Pooter</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Serneels</LastName><ForeName>Sally</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Van den Broeck</LastName><ForeName>Marleen</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cuijt</LastName><ForeName>Ivy</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Mattheijssens</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Peeters</LastName><ForeName>Karin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Sciot</LastName><ForeName>Raf</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Jean-Jacques</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Cras</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Santens</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter P</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Cruts</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Van Broeckhoven</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Sleegers</LastName><ForeName>Kristel</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018389">Codon, Nonsense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492314">GRN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001530" MajorTopicYN="N">Belgium</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002886" MajorTopicYN="N">Chromosomes, Human, Pair 17</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018389" MajorTopicYN="N">Codon, Nonsense</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018703" MajorTopicYN="N">Founder Effect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020080" MajorTopicYN="N">Tandem Repeat Sequences</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17923627</ArticleId><ArticleId IdType="doi">10.1001/archneur.64.10.1436</ArticleId><ArticleId IdType="pii">64/10/1436</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17923630</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>10</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Imaging the Abeta-related neurotoxicity of Alzheimer disease.</ArticleTitle><Pagination><StartPage>1467</StartPage><EndPage>1477</EndPage><MedlinePgn>1467-77</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neurotoxicity related to the Abeta peptide is thought to be a primary mechanism of dysfunction in Alzheimer disease (AD). Although numerous imaging studies have observed brain dysfunction in AD, whether these imaged defects reflect Abeta-related neurotoxicity remains unknown.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To study Abeta-related neurotoxicity by means of functional imaging maps of the hippocampal formation in human patients and mouse models.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional study comparing humans with AD and control subjects, cross-sectional study of J20 mice, a transgenic mouse model of AD, and a longitudinal study of flurbiprofen administration to transgenic mice.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Alzheimer disease research center. Subjects Eleven subjects with probable Alzheimer disease and 11 age-matched controls, plus J20 mice and wild-type littermates.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">In the first study, human subjects and controls underwent magnetic resonance imaging. In the second study, mice underwent imaging at 3, 6, 12, 15, and 21 months of age, for a total of 57 imaging experiments. In the third study, 12 J20 mice underwent imaging repeatedly over time; 6 received flurbiprofen to ameliorate Abeta-related neurotoxicity and 6 received vehicle control.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Comparison of hippocampal functional maps.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among all hippocampal subregions, the entorhinal cortex was the dominant site of dysfunction observed in both human patients and J20 mice. Long-term administration of flurbiprofen rescued entorhinal cortex dysfunction in transgenic mice.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results establish that the neurotoxicity related to the Abeta peptide can be captured in vivo by functional imaging and suggest hippocampal subregions most vulnerable to its toxic effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Herman</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Robert S. Furchgott Center for Neural and Behavioral Sciences, State University of New York, Downstate Medical Center, Brooklyn, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Brickman</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Truman R</ForeName><Initials>TR</Initials></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG025161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG000946</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027476</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016861">Cyclooxygenase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>5GRO578KLP</RegistryNumber><NameOfSubstance UI="D005480">Flurbiprofen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001810" MajorTopicYN="N">Blood Volume</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016861" MajorTopicYN="N">Cyclooxygenase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005480" MajorTopicYN="N">Flurbiprofen</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020258" MajorTopicYN="N">Neurotoxicity Syndromes</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17923630</ArticleId><ArticleId IdType="doi">10.1001/archneur.64.10.1467</ArticleId><ArticleId IdType="pii">64/10/1467</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17923632</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>10</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease.</ArticleTitle><Pagination><StartPage>1489</StartPage><EndPage>1495</EndPage><MedlinePgn>1489-95</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer disease (AD) is the most common form of dementia worldwide. Mild cognitive impairment (MCI) is the recent terminology for patients with cognitive deficiencies in the absence of functional decline. Most patients with MCI harbor the pathologic changes of AD and demonstrate transition to dementia at a rate of 10% to 15% per year. Patients with AD and MCI experience progressive brain atrophy.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To analyze the structural magnetic resonance imaging data for 24 patients with amnestic MCI and 25 patients with mild AD using an advanced 3-dimensional cortical mapping technique.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional cohort design. Patients/</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analyzed the structural magnetic resonance imaging data of 24 amnestic MCI (mean MMSE, 28.1; SD, 1.7) and 25 mild AD patients (all MMSE scores, &gt;18; mean MMSE, 23.7; SD, 2.9) using an advanced 3-dimensional cortical mapping technique.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We observed significantly greater cortical atrophy in patients with mild AD. The entorhinal cortex, right more than left lateral temporal cortex, right parietal cortex, and bilateral precuneus showed 15% more atrophy and the remainder of the cortex primarily exhibited 10% to 15% more atrophy in patients with mild AD than in patients with amnestic MCI.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There are striking cortical differences between mild AD and the immediately preceding cognitive state of amnestic MCI. Cortical areas affected earlier in the disease process are more severely affected than those that are affected late. Our method may prove to be a reliable in vivo disease-tracking technique that can also be used for evaluating disease-modifying therapies in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, 10911 Westwood Blvd, Second Floor, Los Angeles, CA 90095, USA. lapostolova@mednet.ucla.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>Calen A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Akopyan</LastName><ForeName>Gohar G</ForeName><Initials>GG</Initials></Author><Author ValidYN="Y"><LastName>Dutton</LastName><ForeName>Rebecca A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Hayashi</LastName><ForeName>Kiralee M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EB01651</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U13 ES016515</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG026803</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 RR013642</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 RR021813</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>LM05639</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH071940</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 RR019771</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM005639</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR019771</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="N">Data Interpretation, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17923632</ArticleId><ArticleId IdType="mid">NIHMS327316</ArticleId><ArticleId IdType="pmc">PMC3197839</ArticleId><ArticleId IdType="doi">10.1001/archneur.64.10.1489</ArticleId><ArticleId IdType="pii">64/10/1489</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006;63(5):674&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682537</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Dickson DW. Neuropathology of Alzheimer&#x2019;s disease. In: Dickson DW, editor. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Basel, Switzerland: ISN Neuropath Press; 2003. pp. 47&#x2013;65.</Citation></Reference><Reference><Citation>Mesulam MM. Aging, Alzheimer&#x2019;s disease and dementia. In: Mesulam MM, editor. Principles of Behavioral and Cognitive Neurology. 2. Oxford, England: Oxford University Press; 2000. pp. 439&#x2013;510.</Citation></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, Schultz C, Braak E. Vulnerability of select neuronal types to Alzheimer&#x2019;s disease. Ann N Y Acad Sci. 2000;924:53&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193802</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58(12):1985&#x2013;1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">11735772</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004;62(4):591&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730165</ArticleId><ArticleId IdType="pubmed">14981176</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron JC, Ch&#xe9;telat G, Desgranges B, et al. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer&#x2019;s disease. Neuroimage. 2001;14(2):298&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">11467904</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidron D, Black SE, Stanchev P, et al. Quantitative MR volumetry in Alzheimer&#x2019;s disease: topographic markers and the effects of sex and education. Neurology. 1997;49(6):1504&#x2013;1512.</Citation><ArticleIdList><ArticleId IdType="pubmed">9409337</ArticleId></ArticleIdList></Reference><Reference><Citation>Busatto GF, Garrido GE, Almeida OP, et al. A voxel-based morphometry study of temporal lobe gray matter reductions in Alzheimer&#x2019;s disease. Neurobiol Aging. 2003;24(2):221&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">12498956</ArticleId></ArticleIdList></Reference><Reference><Citation>Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer&#x2019;s disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A. 2002;99(7):4703&#x2013;4707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123711</ArticleId><ArticleId IdType="pubmed">11930016</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Testa C, Zorzan A, et al. Detection of grey matter loss in mild Alzheimer&#x2019;s disease with voxel based morphometry. J Neurol Neurosurg Psychiatry. 2002;73(6):657&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1757361</ArticleId><ArticleId IdType="pubmed">12438466</ArticleId></ArticleIdList></Reference><Reference><Citation>Karas GB, Scheltens P, Rombouts SA, et al. Global and local gray matter loss in mild cognitive impairment and Alzheimer&#x2019;s disease. Neuroimage. 2004;23(2):708&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">15488420</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolova LG, Thompson PM. Brain mapping: a tool to study neurodegeneration [published online ahead of print May 7, 2007] Neurotherapeutics. 2007;4(3):387&#x2013;400. doi: 10.1016/j.nurt.2007.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nurt.2007.05.009</ArticleId><ArticleId IdType="pmc">PMC2634605</ArticleId><ArticleId IdType="pubmed">17599704</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolova LG, Dinov ID, Dutton RA, et al. 3D comparison of hippocampal atrophy in mild cognitive impairment and Alzheimer&#x2019;s disease [published online ahead of print October 3, 2006] Brain. 2006;129(pt 11):2867&#x2013;2873. doi: 10.1093/brain/awl274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl274</ArticleId><ArticleId IdType="pubmed">17018552</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr. 1994;18(2):192&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">8126267</ArticleId></ArticleIdList></Reference><Reference><Citation>Shattuck DW, Sandor-Leahy SR, Schaper KA, Rottenberg DA, Leahy RM. Magnetic resonance image tissue classification using a partial volume model. Neuroimage. 2001;13(5):856&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pubmed">11304082</ArticleId></ArticleIdList></Reference><Reference><Citation>Sowell ER, Mega MS, Zoumalan CI, Lindshield C, Rex DE.  Laboratory of Neuro Imaging. UCLA;  [Accessed July 16, 2007]. Gyral pattern delineation in 3D: surface curve protocol.  http://www.loni.ucla.edu/~esowell/new_sulcvar.html.</Citation></Reference><Reference><Citation>Ashburner J, Friston KJ. Voxel-based morphometry: the methods. Neuroimage. 2000;11(6 pt 1):805&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">10860804</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, Hayashi KM, Sowell ER, et al. Mapping cortical change in Alzheimer&#x2019;s disease, brain development, and schizophrenia. Neuroimage. 2004;23(suppl 1):S2&#x2013;S18.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501091</ArticleId></ArticleIdList></Reference><Reference><Citation>Janota I, Mountjoy CQ. Asymmetry of pathology in Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 1988;51(7):1011&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1033227</ArticleId><ArticleId IdType="pubmed">3204396</ArticleId></ArticleIdList></Reference><Reference><Citation>Moossy J, Zubenko GS, Martinez AJ, Rao GR, Kopp U, Hanin I. Lateralization of brain morphologic and cholinergic abnormalities in Alzheimer&#x2019;s disease. Arch Neurol. 1989;46(6):639&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">2730376</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, Hayashi KM, de Zubicaray G, et al. Dynamics of gray matter loss in Alzheimer&#x2019;s disease. J Neurosci. 2003;23(3):994&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741905</ArticleId><ArticleId IdType="pubmed">12574429</ArticleId></ArticleIdList></Reference><Reference><Citation>Luders E, Narr KL, Thompson PM, Rex DE, Jancke L, Toga AW. Hemispheric asymmetries in cortical thickness [published online ahead of print November 2, 2005] Cereb Cortex. 2006;16(8):1232&#x2013;1238. doi: 10.1093/cercor/bhj064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhj064</ArticleId><ArticleId IdType="pubmed">16267139</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron JC. Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. Neuroreport. 2002;13(15):1939&#x2013;1943.</Citation><ArticleIdList><ArticleId IdType="pubmed">12395096</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzali M, Filippi M, Magnani G, et al. The contribution of voxel-based morphometry in staging patients with mild cognitive impairment. Neurology. 2006;67 (3):453&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894107</ArticleId></ArticleIdList></Reference><Reference><Citation>Testa C, Laakso MP, Sabattoli F, et al. A comparison between the accuracy of voxel-based morphometry and hippocampal volumetry in Alzheimer&#x2019;s disease. J Magn Reson Imaging. 2004;19(3):274&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">14994294</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts SA, Barkhof F, Witter MP, Scheltens P. Unbiased whole-brain analysis of gray matter loss in Alzheimer&#x2019;s disease. Neurosci Lett. 2000;285(3):231&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">10806328</ArticleId></ArticleIdList></Reference><Reference><Citation>Good CD, Scahill RI, Fox NC, et al. Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. Neuroimage. 2002;17(1):29&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482066</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17928318</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>130</Volume><Issue>Pt 11</Issue><PubDate><Year>2007</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.</ArticleTitle><Pagination><StartPage>2837</StartPage><EndPage>2844</EndPage><MedlinePgn>2837-44</MedlinePgn></Pagination><Abstract><AbstractText>Beta-amyloid (Abeta) deposition is pathognomic for Alzheimer's disease (AD), but may occur in normal elderly people without apparent cognitive effect. Episodic memory impairment is an early and prominent sign of AD, but its relationship with Abeta burden in non-demented persons and in AD patients is unclear. We examined this relationship using 11C-PIB-PET as a quantitative marker of Abeta burden in vivo in healthy ageing (HA), mild cognitive impairment (MCI) and AD. Thirty-one AD, 33 MCI and 32 HA participants completed neuropsychological assessment and a 11C-PIB-PET brain scan. Multiple linear regression analyses were conducted relating episodic memory performance and other cognitive functions to Abeta burden. Ninety-seven percent of AD, 61% of MCI and 22% of HA cases had increased cortical PIB binding, indicating the presence of Abeta plaques. There was a strong relationship between impaired episodic memory performance and PIB binding, both in MCI and HA. This relationship was weaker in AD and less robust for non-memory cognitive domains. Abeta deposition in the asymptomatic elderly is associated with episodic memory impairment. This finding, together with the strong relationship between PIB binding and the severity of memory impairment in MCI, suggests that individuals with increased cortical PIB binding are on the path to Alzheimer's disease. The data also suggests that early intervention trials for AD targeted to non-demented individuals with cerebral Abeta deposition are warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pike</LastName><ForeName>Kerryn E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>School of Psychology, Psychiatry and Psychological Medicine, Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savage</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor L</ForeName><Initials>VL</Initials></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>Simon A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Maruff</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chester A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002250">Carbon Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002250" MajorTopicYN="N">Carbon Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002525" MajorTopicYN="N">Cerebellar Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17928318</ArticleId><ArticleId IdType="doi">10.1093/brain/awm238</ArticleId><ArticleId IdType="pii">awm238</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17934213</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1535-9476</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Molecular &amp; cellular proteomics : MCP</Title><ISOAbbreviation>Mol Cell Proteomics</ISOAbbreviation></Journal><ArticleTitle>The in vivo brain interactome of the amyloid precursor protein.</ArticleTitle><Pagination><StartPage>15</StartPage><EndPage>34</EndPage><MedlinePgn>15-34</MedlinePgn></Pagination><Abstract><AbstractText>Despite intense research efforts, the physiological function and molecular environment of the amyloid precursor protein has remained enigmatic. Here we describe the application of time-controlled transcardiac perfusion cross-linking, a method for the in vivo mapping of protein interactions in intact tissue, to study the interactome of the amyloid precursor protein (APP). To gain insights into the specificity of reported protein interactions the study was extended to the mammalian amyloid precursor-like proteins (APLP1 and APLP2). To rule out sampling bias as an explanation for differences in the individual datasets, a small scale quantitative iTRAQ (isobaric tags for relative and absolute quantitation)-based comparison of APP, APLP1, and APLP2 interactomes was carried out. An interactome map was derived that confirmed eight previously reported interactions of APP and revealed the identity of more than 30 additional proteins that reside in spatial proximity to APP in the brain. Subsequent validation studies confirmed a physiological interaction between APP and leucine-rich repeat and Ig domain-containing protein 1, demonstrated a strong influence of Ig domain-containing protein 1 on the proteolytic processing of APP, and consolidated similarities in the biology of APP and p75.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Centre for Research in Neurodegenerative Diseases and Departments of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markham</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Fusheng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Weerasekera</LastName><ForeName>Rasanjala</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Horne</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Wakutani</LastName><ForeName>Yosuke</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Bagshaw</LastName><ForeName>Rick</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Mathews</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Westaway</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Schmitt-Ulms</LastName><ForeName>Gerold</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>081864</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>GM61898</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Cell Proteomics</MedlineTA><NlmUniqueID>101125647</NlmUniqueID><ISSNLinking>1535-9476</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078201">Aplp1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492952">Aplp2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003432">Cross-Linking Reagents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091342">Endoplasmic Reticulum Chaperone BiP</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C523678">LINGO1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003432" MajorTopicYN="N">Cross-Linking Reagents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091342" MajorTopicYN="N">Endoplasmic Reticulum Chaperone BiP</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006360" MajorTopicYN="N">Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010477" MajorTopicYN="N">Perfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025941" MajorTopicYN="N">Protein Interaction Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17934213</ArticleId><ArticleId IdType="doi">10.1074/mcp.M700077-MCP200</ArticleId><ArticleId IdType="pii">S1535-9476(20)31249-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17934472</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-8956</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>11</Issue><PubDate><Year>2007</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.</ArticleTitle><Pagination><StartPage>1359</StartPage><EndPage>1362</EndPage><MedlinePgn>1359-62</MedlinePgn></Pagination><Abstract><AbstractText>A molecular test for Alzheimer's disease could lead to better treatment and therapies. We found 18 signaling proteins in blood plasma that can be used to classify blinded samples from Alzheimer's and control subjects with close to 90% accuracy and to identify patients who had mild cognitive impairment that progressed to Alzheimer's disease 2-6 years later. Biological analysis of the 18 proteins points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ray</LastName><ForeName>Sandip</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Satoris, Inc., 2686 Middlefield Road, Suite E, Redwood City, California 94063, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Britschgi</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Herbert</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Takeda-Uchimura</LastName><ForeName>Yoshiko</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Leah F</ForeName><Initials>LF</Initials></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Jutel</LastName><ForeName>Marek</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Leszek</LastName><ForeName>Jerzy</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Minthon</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>William H</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>So</LastName><ForeName>Yuen T</ForeName><Initials>YT</Initials></Author><Author ValidYN="Y"><LastName>Sparks</LastName><ForeName>D Larry</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Tabaton</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tinklenberg</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Yesavage</LastName><ForeName>Jerome A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Tibshirani</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG20603</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17934472</ArticleId><ArticleId IdType="doi">10.1038/nm1653</ArticleId><ArticleId IdType="pii">nm1653</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17941703</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1553-7358</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>9</Issue><PubDate><Year>2007</Year><Month>Sep</Month></PubDate></JournalIssue><Title>PLoS computational biology</Title><ISOAbbreviation>PLoS Comput Biol</ISOAbbreviation></Journal><ArticleTitle>Structural reorganisation and potential toxicity of oligomeric species formed during the assembly of amyloid fibrils.</ArticleTitle><Pagination><StartPage>1727</StartPage><EndPage>1738</EndPage><MedlinePgn>1727-38</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e173</ELocationID><Abstract><AbstractText>Increasing evidence indicates that oligomeric protein assemblies may represent the molecular species responsible for cytotoxicity in a range of neurological disorders including Alzheimer and Parkinson diseases. We use all-atom computer simulations to reveal that the process of oligomerization can be divided into two steps. The first is characterised by a hydrophobic coalescence resulting in the formation of molten oligomers in which hydrophobic residues are sequestered away from the solvent. In the second step, the oligomers undergo a process of reorganisation driven by interchain hydrogen bonding interactions that induce the formation of beta sheet rich assemblies in which hydrophobic groups can become exposed. Our results show that the process of aggregation into either ordered or amorphous species is largely determined by a competition between the hydrophobicity of the amino acid sequence and the tendency of polypeptide chains to form arrays of hydrogen bonds. We discuss how the increase in solvent-exposed hydrophobic surface resulting from such a competition offers an explanation for recent observations concerning the cytotoxicity of oligomeric species formed prior to mature amyloid fibrils.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheon</LastName><ForeName>Mookyung</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Iksoo</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Mohanty</LastName><ForeName>Sandipan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Luheshi</LastName><ForeName>Leila M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Dobson</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Vendruscolo</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Favrin</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Comput Biol</MedlineTA><NlmUniqueID>101238922</NlmUniqueID><ISSNLinking>1553-734X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019281" MajorTopicYN="N">Dimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008956" MajorTopicYN="Y">Models, Chemical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="Y">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020539" MajorTopicYN="N">Sequence Analysis, Protein</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Competing interests.</b> The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17941703</ArticleId><ArticleId IdType="pmc">PMC1976335</ArticleId><ArticleId IdType="doi">10.1371/journal.pcbi.0030173</ArticleId><ArticleId IdType="pii">07-PLCB-RA-0148</ArticleId><ArticleId IdType="sici">plcb-03-09-06</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ. Folding proteins in fatal ways. Nature. 2003;426:900&#x2013;904. doi: 10.1038/nature02264. Available:  http://dx.doi.org/10.1038/nature02264. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02264</ArticleId><ArticleId IdType="doi">10.1038/nature02264</ArticleId><ArticleId IdType="pubmed">14685251</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Mucke L. 100 years and counting: Prospects for defeating Alzheimer disease. Science. 2006;314:781&#x2013;784. doi: 10.1126/science.1132813.  http://dx.doi.org/10.1126/science.1132813. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1132813</ArticleId><ArticleId IdType="doi">10.1126/science.1132813</ArticleId><ArticleId IdType="pmc">PMC3544944</ArticleId><ArticleId IdType="pubmed">17082448</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansbury PT, Lashuel HA. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature. 2006;443:774&#x2013;779. doi: 10.1038/nature05290. Available:  http://dx.doi.org/10.1038/nature05290. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05290</ArticleId><ArticleId IdType="doi">10.1038/nature05290</ArticleId><ArticleId IdType="pubmed">17051203</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson CM. Protein misfolding, evolution and disease. Trends Biochem Sci. 1999;24:329&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">10470028</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson CM. Protein folding and misfolding. Nature. 2003;426:884&#x2013;890. doi: 10.1038/nature02261. Available:  http://dx.doi.org/10.1038/nature02261. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02261</ArticleId><ArticleId IdType="doi">10.1038/nature02261</ArticleId><ArticleId IdType="pubmed">14685248</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem. 2006;75:333&#x2013;366. doi: 10.1146/annurev.biochem.75.101304.123901. Available:  http://dx.doi.org/10.1146/annurev.biochem.75.101304.123901. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.75.101304.123901</ArticleId><ArticleId IdType="doi">10.1146/annurev.biochem.75.101304.123901</ArticleId><ArticleId IdType="pubmed">16756495</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper JD, Wong SS, Lieber CM, Lansbury PT. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol. 1997;4:119&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">9190286</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper JD, Lieber CM, Lansbury PT. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. Chem Biol. 1997;4:951&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427660</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem. 1997;272:22364&#x2013;22372.</Citation><ArticleIdList><ArticleId IdType="pubmed">9268388</ArticleId></ArticleIdList></Reference><Reference><Citation>Calamai M, Canale C, Relini A, Stefani M, Chiti F, et al.  Reversal of protein aggregation provides evidence for multiple aggregated states. J Mol Biol. 2005;346:603&#x2013;616. doi: 10.1016/j.jmb.2004.11.067. Available:  http://dx.doi.org/10.1016/j.jmb.2004.11.067. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2004.11.067</ArticleId><ArticleId IdType="doi">10.1016/j.jmb.2004.11.067</ArticleId><ArticleId IdType="pubmed">15670608</ArticleId></ArticleIdList></Reference><Reference><Citation>Bader R, Bamford R, Zurdo J, Luisi BF, Dobson CM. Probing the mechanism of amyloidogenesis through a tandem repeat of the pi3-sh3 domain suggests a generic model for protein aggregation and fibril formation. J Mol Biol. 2006;356:189&#x2013;208. doi: 10.1016/j.jmb.2005.11.034. Available:  http://dx.doi.org/10.1016/j.jmb.2005.11.034. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2005.11.034</ArticleId><ArticleId IdType="doi">10.1016/j.jmb.2005.11.034</ArticleId><ArticleId IdType="pubmed">16364365</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitan G, Lomakin A, Teplow DB. Amyloid beta-protein oligomerization: Prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J Biol Chem. 2001;276:35176&#x2013;35184. doi: 10.1074/jbc.M102223200. Available:  http://dx.doi.org/10.1074/jbc.M102223200. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M102223200</ArticleId><ArticleId IdType="doi">10.1074/jbc.M102223200</ArticleId><ArticleId IdType="pubmed">11441003</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, et al.  Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A. 2003;100:330&#x2013;335. doi: 10.1073/pnas.222681699.  http://dx.doi.org/10.1073/pnas.222681699. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.222681699</ArticleId><ArticleId IdType="doi">10.1073/pnas.222681699</ArticleId><ArticleId IdType="pmc">PMC140968</ArticleId><ArticleId IdType="pubmed">12506200</ArticleId></ArticleIdList></Reference><Reference><Citation>Serio TR, Cashikar AG, Kowal AS, Sawicki GJ, Moslehi JJ, et al. Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science. 2000;289:1317&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">10958771</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, et al. Morphology and toxicity of Abeta-(1&#x2013;42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem. 1996;271:20631&#x2013;20635.</Citation><ArticleIdList><ArticleId IdType="pubmed">8702810</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, et al.  Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539. doi: 10.1038/416535a. Available:  http://dx.doi.org/10.1038/416535a. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/416535a</ArticleId><ArticleId IdType="doi">10.1038/416535a</ArticleId><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ. Amyloid-beta oligomers: Their production, toxicity and therapeutic inhibition. Biochem Soc Trans. 2002;30:552&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196135</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, et al.  Alzheimer's disease-affected brain: Presence of oligomeric a beta ligands (addls) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A. 2003;100:10417&#x2013;10422. doi: 10.1073/pnas.1834302100. Available:  http://dx.doi.org/10.1073/pnas.1834302100. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1834302100</ArticleId><ArticleId IdType="doi">10.1073/pnas.1834302100</ArticleId><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, et al.  Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84. doi: 10.1038/nn1372. Available:  http://dx.doi.org/10.1038/nn1372. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1372</ArticleId><ArticleId IdType="doi">10.1038/nn1372</ArticleId><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112. doi: 10.1038/nrm2101. Available:  http://dx.doi.org/10.1038/nrm2101. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2101</ArticleId><ArticleId IdType="doi">10.1038/nrm2101</ArticleId><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, et al.  Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 2002;416:507&#x2013;511. doi: 10.1038/416507a. Available:  http://dx.doi.org/10.1038/416507a. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/416507a</ArticleId><ArticleId IdType="doi">10.1038/416507a</ArticleId><ArticleId IdType="pubmed">11932737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al.  Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489. doi: 10.1126/science.1079469. Available:  http://dx.doi.org/10.1126/science.1079469. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1079469</ArticleId><ArticleId IdType="doi">10.1126/science.1079469</ArticleId><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciantini M, Calloni G, Chiti F, Formigli L, Nosi D, et al.  Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J Biol Chem. 2004;279:31374&#x2013;31382. doi: 10.1074/jbc.M400348200. Available:  http://dx.doi.org/10.1074/jbc.M400348200. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M400348200</ArticleId><ArticleId IdType="doi">10.1074/jbc.M400348200</ArticleId><ArticleId IdType="pubmed">15133040</ArticleId></ArticleIdList></Reference><Reference><Citation>Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, et al.  The most infectious prion protein particles. Nature. 2005;437:257&#x2013;261. doi: 10.1038/nature03989. Available:  http://dx.doi.org/10.1038/nature03989. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03989</ArticleId><ArticleId IdType="doi">10.1038/nature03989</ArticleId><ArticleId IdType="pmc">PMC1513539</ArticleId><ArticleId IdType="pubmed">16148934</ArticleId></ArticleIdList></Reference><Reference><Citation>Baglioni S, Casamenti F, Bucciantini M, Luheshi LM, Taddei N, et al.  Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J Neurosci. 2006;26:8160&#x2013;8167. doi: 10.1523/JNEUROSCI.4809&#x2013;05.2006. Available:  http://dx.doi.org/10.1523/JNEUROSCI.4809&#x2013;05.2006. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4809&#x2013;05.2006</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4809-05.2006</ArticleId><ArticleId IdType="pmc">PMC6673784</ArticleId><ArticleId IdType="pubmed">16885229</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh D, Shin SY, Lee S, Kang JH, Kim SD, et al. Role of the hinge region and the tryptophan residue in the synthetic antimicrobial peptides, cecropin a(1&#x2013;8)-magainin 2(1&#x2013;12), and its analogues, on their antibiotic activities and structures. Biochemistry. 2000;39:11855&#x2013;11864.</Citation><ArticleIdList><ArticleId IdType="pubmed">11009597</ArticleId></ArticleIdList></Reference><Reference><Citation>Oma Y, Kino Y, Sasagawa N, Ishiura S. Comparative analysis of the cytotoxicity of homopolymeric amino acids. Biochim Biophys Acta. 2005;1748:174&#x2013;179. doi: 10.1016/j.bbapap.2004.12.017. Available:  http://dx.doi.org/10.1016/j.bbapap.2004.12.017. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2004.12.017</ArticleId><ArticleId IdType="doi">10.1016/j.bbapap.2004.12.017</ArticleId><ArticleId IdType="pubmed">15769594</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferre R, Badosa E, Feliu L, Planas M, Montesinos E, et al.  Inhibition of plant-pathogenic bacteria by short synthetic cecropin a-melittin hybrid peptides. Appl Environ Microbiol. 2006;72:3302&#x2013;3308. doi: 10.1128/AEM.72.5.3302&#x2013;3308.2006.  http://dx.doi.org/10.1128/AEM.72.5.3302&#x2013;3308.2006. Accessed 13 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.72.5.3302&#x2013;3308.2006</ArticleId><ArticleId IdType="doi">10.1128/AEM.72.5.3302-3308.2006</ArticleId><ArticleId IdType="pmc">PMC1472336</ArticleId><ArticleId IdType="pubmed">16672470</ArticleId></ArticleIdList></Reference><Reference><Citation>Plakoutsi G, Bemporad F, Calamai M, Taddei N, Dobson CM, et al.  Evidence for a mechanism of amyloid formation involving molecular reorganisation within native-like precursor aggregates. J Mol Biol. 2005;351:910&#x2013;922. doi: 10.1016/j.jmb.2005.06.043. Available:  http://dx.doi.org/10.1016/j.jmb.2005.06.043. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2005.06.043</ArticleId><ArticleId IdType="doi">10.1016/j.jmb.2005.06.043</ArticleId><ArticleId IdType="pubmed">16024042</ArticleId></ArticleIdList></Reference><Reference><Citation>Petty SA, Decatur SM. Experimental evidence for the reorganization of beta-strands within aggregates of the Abeta(16&#x2013;22) peptide. J Am Chem Soc. 2005;127:13488&#x2013;13489. doi: 10.1021/ja054663y. Available:  http://dx.doi.org/10.1021/ja054663y. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja054663y</ArticleId><ArticleId IdType="doi">10.1021/ja054663y</ArticleId><ArticleId IdType="pubmed">16190699</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerd&#xe0;-Costa N, Esteras-Chopo A, Avil&#xe9;s FX, Serrano L, Villegas V. Early kinetics of amyloid fibril formation reveals conformational reorganisation of initial aggregates. J Mol Biol. 2007;366:1351&#x2013;1363. doi: 10.1016/j.jmb.2006.12.007.  http://dx.doi.org/10.1016/j.jmb.2006.12.007. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2006.12.007</ArticleId><ArticleId IdType="doi">10.1016/j.jmb.2006.12.007</ArticleId><ArticleId IdType="pubmed">17204287</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellarin R, Caflisch A. Interpreting the aggregation kinetics of amyloid peptides. J Mol Biol. 2006;360:882&#x2013;892. doi: 10.1016/j.jmb.2006.05.033. Available:  http://dx.doi.org/10.1016/j.jmb.2006.05.033. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2006.05.033</ArticleId><ArticleId IdType="doi">10.1016/j.jmb.2006.05.033</ArticleId><ArticleId IdType="pubmed">16797587</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimov DK, Thirumalai D. Dissecting the assembly of Abeta16&#x2013;22 amyloid peptides into antiparallel beta sheets. Structure. 2003;11:295&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">12623017</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen PH, Li MS, Stock G, Straub JE, Thirumalai D. Monomer adds to preformed structured oligomers of Abeta-peptides by a two-stage dock-lock mechanism. Proc Natl Acad Sci U S A. 2007;104:111&#x2013;116. doi: 10.1073/pnas.0607440104. Available:  http://dx.doi.org/10.1073/pnas.0607440104. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0607440104</ArticleId><ArticleId IdType="doi">10.1073/pnas.0607440104</ArticleId><ArticleId IdType="pmc">PMC1766316</ArticleId><ArticleId IdType="pubmed">17190811</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler WP, Stimson ER, Jennings JM, Vinters HV, Ghilardi JR, et al. Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. Biochemistry. 2000;39:6288&#x2013;6295.</Citation><ArticleIdList><ArticleId IdType="pubmed">10828941</ArticleId></ArticleIdList></Reference><Reference><Citation>Thirumalai D, Klimov DK, Dima RI. Emerging ideas on the molecular basis of protein and peptide aggregation. Curr Opin Struct Biol. 2003;13:146&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">12727507</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HD, Hall CK. Molecular dynamics simulations of spontaneous fibril formation by random-coil peptides. Proc Natl Acad Sci U S A. 2004;101:16180&#x2013;16185. doi: 10.1073/pnas.0407273101. Available:  http://dx.doi.org/10.1073/pnas.0407273101. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0407273101</ArticleId><ArticleId IdType="doi">10.1073/pnas.0407273101</ArticleId><ArticleId IdType="pmc">PMC526199</ArticleId><ArticleId IdType="pubmed">15534217</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang W, Zhang S, Kamm RD, Karplus M. Kinetic control of dimer structure formation in amyloid fibrillogenesis. Proc Natl Acad Sci U S A. 2004;101:12916&#x2013;12921. doi: 10.1073/pnas.0402634101. Available:  http://dx.doi.org/10.1073/pnas.0402634101. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0402634101</ArticleId><ArticleId IdType="doi">10.1073/pnas.0402634101</ArticleId><ArticleId IdType="pmc">PMC516495</ArticleId><ArticleId IdType="pubmed">15326301</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchete NV, Tycko R, Hummer G. Molecular dynamics simulations of Alzheimer's beta-amyloid protofilaments. J Mol Biol. 2005;353:804&#x2013;821. doi: 10.1016/j.jmb.2005.08.066. Available:  http://dx.doi.org/10.1016/j.jmb.2005.08.066. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2005.08.066</ArticleId><ArticleId IdType="doi">10.1016/j.jmb.2005.08.066</ArticleId><ArticleId IdType="pubmed">16213524</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Paz ML, de Mori GMS, Serrano L, Colombo G. Sequence dependence of amyloid fibril formation: Insights from molecular dynamics simulations. J Mol Biol. 2005;349:583&#x2013;596. doi: 10.1016/j.jmb.2005.03.081.  http://dx.doi.org/10.1016/j.jmb.2005.03.081. Accessed 13 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2005.03.081</ArticleId><ArticleId IdType="doi">10.1016/j.jmb.2005.03.081</ArticleId><ArticleId IdType="pubmed">15882870</ArticleId></ArticleIdList></Reference><Reference><Citation>Khare SD, Ding F, Gwanmesia KN, Dokholyan NV. Molecular origin of polyglutamine aggregation in neurodegenerative diseases. PLoS Comput Biol. 2005;1:230&#x2013;235. doi: 10.1371/journal.pcbi.0010030.  http://dx.doi.org/10.1371/journal.pcbi.0010030. Accessed 13 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.0010030.</ArticleId><ArticleId IdType="doi">10.1371/journal.pcbi.0010030</ArticleId><ArticleId IdType="pmc">PMC1193989</ArticleId><ArticleId IdType="pubmed">16158094</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang TX, Marsella L, Trovato A, Seno F, Banavar JR, et al.  Common attributes of native-state structures of proteins, disordered proteins, and amyloid. Proc Natl Acad Sci U S A. 2006;103:6883&#x2013;6888. doi: 10.1073/pnas.0601824103. Available:  http://dx.doi.org/10.1073/pnas.0601824103. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0601824103</ArticleId><ArticleId IdType="doi">10.1073/pnas.0601824103</ArticleId><ArticleId IdType="pmc">PMC1458988</ArticleId><ArticleId IdType="pubmed">16624879</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma B, Nussinov R. Simulations as analytical tools to understand protein aggregation and predict amyloid conformation. Curr Opin Chem Biol. 2006;10:445&#x2013;452. doi: 10.1016/j.cbpa.2006.08.018. Available:  http://dx.doi.org/10.1016/j.cbpa.2006.08.018. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbpa.2006.08.018</ArticleId><ArticleId IdType="doi">10.1016/j.cbpa.2006.08.018</ArticleId><ArticleId IdType="pubmed">16935548</ArticleId></ArticleIdList></Reference><Reference><Citation>Teplow DB, Lazo ND, Bitan G, Bernstein S, Wyttenbach T, et al.  Elucidating amyloid beta-protein folding and assembly: A multidisciplinary approach. Acc Chem Res. 2006;39:635&#x2013;645. doi: 10.1021/ar050063s. Available:  http://dx.doi.org/10.1021/ar050063s. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ar050063s</ArticleId><ArticleId IdType="doi">10.1021/ar050063s</ArticleId><ArticleId IdType="pubmed">16981680</ArticleId></ArticleIdList></Reference><Reference><Citation>Boucher G, Mousseau N, Derreumaux P. Aggregating the amyloid Abeta(11&#x2013;25) peptide into a four-stranded beta-sheet structure. Proteins. 2006;65:877&#x2013;888. doi: 10.1002/prot.21134.  http://dx.doi.org/10.1002/prot.21134. Accessed 13 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.21134</ArticleId><ArticleId IdType="doi">10.1002/prot.21134</ArticleId><ArticleId IdType="pubmed">17019697</ArticleId></ArticleIdList></Reference><Reference><Citation>Santini S, Mousseau N, Derreumaux P. In silico assembly of Alzheimer's Abeta16&#x2013;22 peptide into beta-sheets. J Am Chem Soc. 2004;126:11509&#x2013;11516. doi: 10.1021/ja047286i. Available:  http://dx.doi.org/10.1021/ja047286i. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja047286i</ArticleId><ArticleId IdType="doi">10.1021/ja047286i</ArticleId><ArticleId IdType="pubmed">15366896</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbanc B, Cruz L, Ding F, Sammond D, Khare S, et al.  Molecular dynamics simulation of amyloid beta dimer formation. Biophys J. 2004;87:2310&#x2013;2321. doi: 10.1529/biophysj.104.040980. Available:  http://dx.doi.org/10.1529/biophysj.104.040980. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1529/biophysj.104.040980</ArticleId><ArticleId IdType="doi">10.1529/biophysj.104.040980</ArticleId><ArticleId IdType="pmc">PMC1304655</ArticleId><ArticleId IdType="pubmed">15454432</ArticleId></ArticleIdList></Reference><Reference><Citation>Irb&#xe4;ck A, Samuelsson B, Sjunnesson F, Wallin S. Thermodynamics of alpha- and beta-structure formation in proteins. Biophys J. 2003;85:1466&#x2013;1473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1303323</ArticleId><ArticleId IdType="pubmed">12944264</ArticleId></ArticleIdList></Reference><Reference><Citation>Favrin G, Irb&#xe4;ck A, Mohanty S. Oligomerization of amyloid Abeta16&#x2013;22 peptides using hydrogen bonds and hydrophobicity forces. Biophys J. 2004;87:3657&#x2013;3664. doi: 10.1529/biophysj.104.046839. Available:  http://dx.doi.org/10.1529/biophysj.104.046839. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1529/biophysj.104.046839</ArticleId><ArticleId IdType="doi">10.1529/biophysj.104.046839</ArticleId><ArticleId IdType="pmc">PMC1304880</ArticleId><ArticleId IdType="pubmed">15377534</ArticleId></ArticleIdList></Reference><Reference><Citation>Irb&#xe4;ck A, Sjunnesson F. Folding thermodynamics of three beta-sheet peptides: A model study. Proteins. 2004;56:110&#x2013;116. doi: 10.1002/prot.20157. Available:  http://dx.doi.org/10.1002/prot.20157. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.20157</ArticleId><ArticleId IdType="doi">10.1002/prot.20157</ArticleId><ArticleId IdType="pubmed">15162491</ArticleId></ArticleIdList></Reference><Reference><Citation>Irb&#xe4;ck A, Mohanty S. Folding thermodynamics of peptides. Biophys J. 2005;88:1560&#x2013;1569. doi: 10.1529/biophysj.104.050427.  http://dx.doi.org/10.1529/biophysj.104.050427. Accessed 13 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1529/biophysj.104.050427</ArticleId><ArticleId IdType="doi">10.1529/biophysj.104.050427</ArticleId><ArticleId IdType="pmc">PMC1305213</ArticleId><ArticleId IdType="pubmed">15613623</ArticleId></ArticleIdList></Reference><Reference><Citation>Irb&#xe4;ck A, Mohanty S. Profasi: A monte carlo simulation package for protein folding and aggregation. J Comput Chem. 2006;27:1548&#x2013;1555. doi: 10.1002/jcc.20452. Available:  http://dx.doi.org/10.1002/jcc.20452. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20452</ArticleId><ArticleId IdType="doi">10.1002/jcc.20452</ArticleId><ArticleId IdType="pubmed">16847934</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao MQ, Tzeng YJ, Chang LYX, Huang HB, Lin TH, et al.  The correlation between neurotoxicity, aggregative ability and secondary structure studied by sequence truncated Abeta peptides. FEBS Lett. 2007;581:1161&#x2013;1165. doi: 10.1016/j.febslet.2007.02.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2007.02.026</ArticleId><ArticleId IdType="pubmed">17328898</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashuel HA, Lansbury PT. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys. 2006;39:167&#x2013;201. doi: 10.1017/S0033583506004422. Available:  http://dx.doi.org/10.1017/S0033583506004422. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033583506004422</ArticleId><ArticleId IdType="doi">10.1017/S0033583506004422</ArticleId><ArticleId IdType="pubmed">16978447</ArticleId></ArticleIdList></Reference><Reference><Citation>Milojevic J, Esposito V, Das R, Melacini G. Understanding the molecular basis for the inhibition of the Alzheimer's Abeta-peptide oligomerization by human serum albumin using saturation transfer difference and off-resonance relaxation nmr spectroscopy. J Am Chem Soc. 2007.   10.1021/ja067367+.  http://dx.doi.org/10.1021/ja067367+.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja067367+</ArticleId><ArticleId IdType="doi">10.1021/ja067367+</ArticleId><ArticleId IdType="pubmed">17367135</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrotta R, Bauer R, Waninge R, Rischel C. Conformational characterization of oligomeric intermediates and aggregates in beta-lactoglobulin heat aggregation. Protein Sci. 2001;10:1312&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2374118</ArticleId><ArticleId IdType="pubmed">11420433</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwahara H, Yamasaki T, Hatakeyama T, Aoyagi H, Fujisawa T. Oligomerization process of the hemolytic lectin cel-iii purified from a sea cucumber, cucumaria echinata. J Biochem (Tokyo) 2002;131:751&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">11983084</ArticleId></ArticleIdList></Reference><Reference><Citation>Calamai M, Chiti F, Dobson CM. Amyloid fibril formation can proceed from different conformations of a partially unfolded protein. Biophys J. 2005;89:4201&#x2013;4210. doi: 10.1529/biophysj.105.068726. Available:  http://dx.doi.org/10.1529/biophysj.105.068726. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1529/biophysj.105.068726</ArticleId><ArticleId IdType="doi">10.1529/biophysj.105.068726</ArticleId><ArticleId IdType="pmc">PMC1366985</ArticleId><ArticleId IdType="pubmed">16169975</ArticleId></ArticleIdList></Reference><Reference><Citation>Balbach JJ, Ishii Y, Antzutkin ON, Leapman RD, Rizzo NW, et al. Amyloid fibril formation by a beta 16&#x2013;22, a seven-residue fragment of the Alzheimer's beta-amyloid peptide, and structural characterization by solid state nmr. Biochemistry. 2000;39:13748&#x2013;13759.</Citation><ArticleIdList><ArticleId IdType="pubmed">11076514</ArticleId></ArticleIdList></Reference><Reference><Citation>Favrin G, Irb&#xe4;ck A, Sjunnesson F. Monte carlo update for chain molecules: Biased gaussian steps in torsional space. J Chem Phys. 2001;114:8154&#x2013;8158.</Citation></Reference><Reference><Citation>Shimada J, Kussell EL, Shakhnovich EI. The folding thermodynamics and kinetics of crambin using an all-atom monte carlo simulation. J Mol Biol. 2001;308:79&#x2013;95. doi: 10.1006/jmbi.2001.4586. Available:  http://dx.doi.org/10.1006/jmbi.2001.4586. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmbi.2001.4586</ArticleId><ArticleId IdType="doi">10.1006/jmbi.2001.4586</ArticleId><ArticleId IdType="pubmed">11302709</ArticleId></ArticleIdList></Reference><Reference><Citation>ten Wolde PR, Ruiz-Montero, Frenkel D. Numerical evidence for bcc ordering at the surface of a critical fcc nucleus. Phys Rev Lett. 1995;75:2714&#x2013;2717.</Citation><ArticleIdList><ArticleId IdType="pubmed">10059386</ArticleId></ArticleIdList></Reference><Reference><Citation>Auer S, Frenkel D. Quantitative prediction of crystal-nucleation rates for spherical colloids: A computational approach. Annu Rev Phys Chem. 2004;55:333&#x2013;361. doi: 10.1146/annurev.physchem.55.091602.094402. Available:  http://dx.doi.org/10.1146/annurev.physchem.55.091602.094402. Accessed 8 August 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.physchem.55.091602.094402</ArticleId><ArticleId IdType="doi">10.1146/annurev.physchem.55.091602.094402</ArticleId><ArticleId IdType="pubmed">15117256</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17942401</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>282</Volume><Issue>50</Issue><PubDate><Year>2007</Year><Month>Dec</Month><Day>14</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease.</ArticleTitle><Pagination><StartPage>36275</StartPage><EndPage>36282</EndPage><MedlinePgn>36275-82</MedlinePgn></Pagination><Abstract><AbstractText>Compelling evidence indicates that excess consumption of sugar-sweetened beverages plays an important role in the epidemic of obesity, a major risk factor for type 2 diabetes mellitus. Type 2 diabetes mellitus has been associated with a higher incidence of Alzheimer disease (AD). High fat diets promote AD-like pathology in mice. It is not known whether consumption of excess sugar as in calorically sweetened beverages with an otherwise normal diet affects the development of AD. In the present study, we provided 10% sucrose-sweetened water to a transgenic mouse model of AD with a normal rodent diet. Compared with the control mice with no sucrose added in the water, the sucrose group gained more body weight and developed glucose intolerance, hyperinsulinemia, and hypercholesterolemia. These metabolic changes were associated with the exacerbation of memory impairment and a 2-3-fold increase in insoluble amyloid-beta protein levels and deposition in the brain. We further showed that the levels of expression and secretase-cleaved products of amyloid-beta precursor protein were not affected by sucrose intake. The steady-state levels of insulin-degrading enzyme did not change significantly, whereas there was a 2.5-fold increase in brain apoE levels. Therefore, we concluded that the up-regulation of apoE accelerated the aggregation of Abeta, resulting in the exacerbation of cerebral amyloidosis in sucrose-treated mice. These data underscore the potential role of dietary sugar in the pathogenesis of AD and suggest that controlling the consumption of sugar-sweetened beverages may be an effective way to curtail the risk of developing AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Dongfeng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Hailin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Terry L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ling</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG025949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013549">Sweetening Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>059QF0KO0R</RegistryNumber><NameOfSubstance UI="D014867">Water</NameOfSubstance></Chemical><Chemical><RegistryNumber>57-50-1</RegistryNumber><NameOfSubstance UI="D013395">Sucrose</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001628" MajorTopicYN="N">Beverages</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018149" MajorTopicYN="N">Glucose Intolerance</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006937" MajorTopicYN="N">Hypercholesterolemia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007333" MajorTopicYN="Y">Insulin Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013395" MajorTopicYN="N">Sucrose</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013549" MajorTopicYN="N">Sweetening Agents</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014867" MajorTopicYN="N">Water</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17942401</ArticleId><ArticleId IdType="doi">10.1074/jbc.M703561200</ArticleId><ArticleId IdType="pii">S0021-9258(18)46079-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17953662</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-4159</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of neurochemistry</Title><ISOAbbreviation>J Neurochem</ISOAbbreviation></Journal><ArticleTitle>Congo red and thioflavin-T analogs detect Abeta oligomers.</ArticleTitle><Pagination><StartPage>457</StartPage><EndPage>468</EndPage><MedlinePgn>457-68</MedlinePgn></Pagination><Abstract><AbstractText>Several small molecule ligands for amyloid-beta (Abeta) fibrils deposited in brain have been developed to facilitate radiological diagnosis of Alzheimer's disease (AD). Recently, the build-up of Abeta oligomers (AbetaO) in brain has been recognized as an additional hallmark of AD and may play a more significant role in early stages. Evidence suggests that quantitative assessment of AbetaO would provide a more accurate index of therapeutic effect of drug trials. Therefore, there is an urgent need to develop methods for efficient identification as well as structural analysis of AbetaO. We found that some well established amyloid ligands, analogs of Congo red and thioflavin-T (ThT), bind AbetaO with high affinity and detect AbetaO in vitro and in vivo. Binding studies revealed the presence of binding sites for Congo red- and thioflavin-T-analogs on AbetaO. Furthermore, these ligands can be used for imaging intracellular AbetaO in living cells and animals and as positive contrast agent for ultrastructural imaging of AbetaO, two applications useful for structural analysis of AbetaO in cells. We propose that by improving the binding affinity of current ligands, in vivo imaging of AbetaO is feasible by a 'signal subtraction' procedure. This approach may facilitate the identification of individuals with early AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maezawa</LastName><ForeName>Izumi</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>M.I.N.D. Institute and Department of Pathology, University of California Davis, Sacramento, California 95817, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Hyun-Seok</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ruiwu</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chun-Yi</ForeName><Initials>CY</Initials></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>R Holland</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Kung</LastName><ForeName>Mei-Ping</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Kung</LastName><ForeName>Hank F</ForeName><Initials>HF</Initials></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Kit S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Oddo</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Laferla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Lee-Way</ForeName><Initials>LW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurochem</MedlineTA><NlmUniqueID>2985190R</NlmUniqueID><ISSNLinking>0022-3042</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004396">Coloring Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>2390-54-7</RegistryNumber><NameOfSubstance UI="C009462">thioflavin T</NameOfSubstance></Chemical><Chemical><RegistryNumber>3U05FHG59S</RegistryNumber><NameOfSubstance UI="D003224">Congo Red</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004396" MajorTopicYN="Y">Coloring Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003224" MajorTopicYN="Y">Congo Red</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005456" MajorTopicYN="Y">Fluorescent Dyes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020349" MajorTopicYN="N">Surface Plasmon Resonance</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="Y">Thiazoles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17953662</ArticleId><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04972.x</ArticleId><ArticleId IdType="pii">JNC4972</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17953673</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2012</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-4159</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of neurochemistry</Title><ISOAbbreviation>J Neurochem</ISOAbbreviation></Journal><ArticleTitle>Soluble aggregates of the amyloid-beta protein activate endothelial monolayers for adhesion and subsequent transmigration of monocyte cells.</ArticleTitle><Pagination><StartPage>500</StartPage><EndPage>513</EndPage><MedlinePgn>500-13</MedlinePgn></Pagination><Abstract><AbstractText>Increasing evidence suggests that the deposition of amyloid plaques, composed primarily of the amyloid-beta protein (Abeta), within the cerebrovasculature is a frequent occurrence in Alzheimer's disease and may play a significant role in disease progression. Accordingly, the pathogenic mechanisms by which Abeta can alter vascular function may have therapeutic implications. Despite observations that Abeta elicits a number of physiological responses in endothelial cells, ranging from alteration of protein expression to cell death, the Abeta species accountable for these responses remains unexplored. In the current study, we show that isolated soluble Abeta aggregation intermediates activate human brain microvascular endothelial cells for both adhesion and subsequent transmigration of monocyte cells in the absence of endothelial cell death and monolayer disruption. In contrast, unaggregated Abeta monomer and mature Abeta fibril fail to induce any change in endothelial adhesion or transmigration. Correlations between average Abeta aggregate size and observed increases in adhesion illustrate that smaller soluble aggregates are more potent activators of endothelium. These results support previous studies demonstrating heightened neuronal activity of soluble Abeta aggregates, including Abeta-derived diffusible ligands, oligomers, and protofibrils, and further show that soluble aggregates also selectively exhibit activity in a vascular cell model.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gonzalez-Velasquez</LastName><ForeName>Francisco J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering, University of South Carolina, Swearingen Engineering Center, Columbia, South Carolina 29208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>Melissa A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurochem</MedlineTA><NlmUniqueID>2985190R</NlmUniqueID><ISSNLinking>0022-3042</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568985">OCLN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062793">Occludin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C569042">TJP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062826">Zonula Occludens-1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002448" MajorTopicYN="N">Cell Adhesion</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062793" MajorTopicYN="N">Occludin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014471" MajorTopicYN="N">Umbilical Veins</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062826" MajorTopicYN="N">Zonula Occludens-1 Protein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17953673</ArticleId><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04988.x</ArticleId><ArticleId IdType="pii">JNC4988</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">17953774</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><PubDate><Year>2007</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment.</ArticleTitle><Pagination><StartPage>20</StartPage><MedlinePgn>20</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent studies demonstrate that in addition to its modulatory effect on APP processing, in vivo application of Liver X Receptor agonist T0901317 (T0) to APP transgenic and non-transgenic mice decreases the level of Abeta42. Moreover, in young Tg2576 mice T0 completely reversed contextual memory deficits. Compared to other tissues, the regulatory functions of LXRs in brain remain largely unexplored and our knowledge so far is limited to the cholesterol transporters and apoE. In this study we applied T0 to APP23 mice for various times and examined gene and protein expression. We also performed a series of experiments with primary brain cells derived from wild type and LXR knockout mice subjected to various LXR agonist treatments and inflammatory stimuli.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We demonstrate an upregulation of genes related to lipid metabolism/transport, metabolism of xenobiotics and detoxification. Downregulated genes are involved in immune response and inflammation, cell death and apoptosis. Additional treatment experiments demonstrated an increase of soluble apolipoproteins E and A-I and a decrease of insoluble Abeta. In primary LXRwt but not in LXRalpha-/-beta-/- microglia and astrocytes LXR agonists suppressed the inflammatory response induced by LPS or fibrillar Abeta.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results show that LXR agonists could alleviate AD pathology by acting on amyloid deposition and brain inflammation. An increased understanding of the LXR controlled regulation of Abeta aggregation and clearance systems will lead to the development of more specific and powerful agonists targeting LXR for the treatment of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lefterov</LastName><ForeName>Iliya</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15219, USA. iliyal@pitt.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bookout</LastName><ForeName>Angie</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhu</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mangelsdorf</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Koldamova</LastName><ForeName>Radosveta</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R03 AG023304</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG028794</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17953774</ArticleId><ArticleId IdType="pmc">PMC2214725</ArticleId><ArticleId IdType="doi">10.1186/1750-1326-2-20</ArticleId><ArticleId IdType="pii">1750-1326-2-20</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hirsch-Reinshagen V, Wellington CL. Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer's disease. Curr Opin Lipidol. 2007;18:325&#x2013;332. doi: 10.1097/MOL.0b013e32813aeabf.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOL.0b013e32813aeabf</ArticleId><ArticleId IdType="pubmed">17495608</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R, Lefterov I. Role of LXR and ABCA1 in the Pathogenesis of Alzheimer's Disease - Implications for a New Therapeutic Approach. Curr Alzheimer Res. 2007;4:171&#x2013;178. doi: 10.2174/156720507780362227.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720507780362227</ArticleId><ArticleId IdType="pubmed">17430243</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellington CL. Cholesterol at the crossroads: Alzheimer's disease and lipid metabolism. Clinical Genetics. 2004;66:1&#x2013;16. doi: 10.1111/j.0009-9163.2004.00280.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0009-9163.2004.00280.x</ArticleId><ArticleId IdType="pubmed">15200500</ArticleId></ArticleIdList></Reference><Reference><Citation>Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol. 2003;17:985&#x2013;993. doi: 10.1210/me.2003-0061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.2003-0061</ArticleId><ArticleId IdType="pubmed">12690094</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaven SW, Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu Rev Med. 2006;57:313&#x2013;329. doi: 10.1146/annurev.med.57.121304.131428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.med.57.121304.131428</ArticleId><ArticleId IdType="pubmed">16409152</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinetti G, Fruchart JC, Staels B. Transcriptional regulation of macrophage cholesterol trafficking by PPARalpha and LXR. Biochem Soc Trans. 2006;34:1128&#x2013;1131. doi: 10.1042/BST0341128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST0341128</ArticleId><ArticleId IdType="pubmed">17073767</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med. 2003;9:213&#x2013;219. doi: 10.1038/nm820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm820</ArticleId><ArticleId IdType="pubmed">12524534</ArticleId></ArticleIdList></Reference><Reference><Citation>Valledor AF, Hsu LC, Ogawa S, Sawka-Verhelle D, Karin M, Glass CK. Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. Proc Natl Acad Sci U S A. 2004;101:17813&#x2013;17818. doi: 10.1073/pnas.0407749101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0407749101</ArticleId><ArticleId IdType="pmc">PMC539759</ArticleId><ArticleId IdType="pubmed">15601766</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest. 2006;116:607&#x2013;614. doi: 10.1172/JCI27883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI27883</ArticleId><ArticleId IdType="pmc">PMC1386115</ArticleId><ArticleId IdType="pubmed">16511593</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell. 2006;126:789&#x2013;799. doi: 10.1016/j.cell.2006.06.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.06.049</ArticleId><ArticleId IdType="pmc">PMC6211849</ArticleId><ArticleId IdType="pubmed">16923397</ArticleId></ArticleIdList></Reference><Reference><Citation>Oram JF, Heinecke JW. ATP-Binding Cassette Transporter A1: A Cell Cholesterol Exporter That Protects Against Cardiovascular Disease. Physiol Rev. 2005;85:1343&#x2013;1372. doi: 10.1152/physrev.00005.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00005.2005</ArticleId><ArticleId IdType="pubmed">16183915</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, Parkinson PF, Chan JY, Tansley GH, Hayden MR, Poirier J, Van NW, Wellington CL. The Absence of ABCA1 Decreases Soluble ApoE Levels but Does Not Diminish Amyloid Deposition in Two Murine Models of Alzheimer Disease. J Biol Chem. 2005;280:43243&#x2013;43256. doi: 10.1074/jbc.M508781200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M508781200</ArticleId><ArticleId IdType="pubmed">16207707</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL. Deficiency of ABCA1 Impairs Apolipoprotein E Metabolism in Brain. J Biol Chem. 2004;279:41197&#x2013;41207. doi: 10.1074/jbc.M407962200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M407962200</ArticleId><ArticleId IdType="pubmed">15269218</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R, Staufenbiel M, Lefterov I. Lack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice. J Biol Chem. 2005;280:43224&#x2013;43235. doi: 10.1074/jbc.M504513200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M504513200</ArticleId><ArticleId IdType="pubmed">16207713</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem. 2004;279:40987&#x2013;40993. doi: 10.1074/jbc.M407963200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M407963200</ArticleId><ArticleId IdType="pubmed">15269217</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM. Deletion of Abca1 Increases Ab Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease. J Biol Chem. 2005;280:43236&#x2013;43242. doi: 10.1074/jbc.M508780200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M508780200</ArticleId><ArticleId IdType="pubmed">16207708</ArticleId></ArticleIdList></Reference><Reference><Citation>Brendza RP, Bales KR, Paul SM, Holtzman DM. Role of apoE/Abeta interactions in Alzheimer's disease: insights from transgenic mouse models. Mol Psychiatry. 2002;7:132&#x2013;135. doi: 10.1038/sj.mp.4001006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.mp.4001006</ArticleId><ArticleId IdType="pubmed">11840304</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WS, Rahmanto AS, Kamili A, Rye KA, Guillemin GJ, Gelissen IC, Jessup W, Hill AF, Garner B. Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-beta peptide generation. J Biol Chem. 2007;282:2851&#x2013;2861. doi: 10.1074/jbc.M607831200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M607831200</ArticleId><ArticleId IdType="pubmed">17121837</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns MP, Vardanian L, Pajoohesh-Ganji A, Wang L, Cooper M, Harris DC, Duff K, Rebeck GW. The effects of ABCA1 on cholesterol efflux and Abeta levels in vitro and in vivo. J Neurochem. 2006</Citation><ArticleIdList><ArticleId IdType="pubmed">16771834</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova RP, Lefterov IM, Ikonomovic MD, Skoko J, Lefterov PI, Isanski BA, DeKosky ST, Lazo JS. 22R-Hydroxycholesterol and 9-cis-retinoic acid induce ABCA1 transporter expression and cholesterol efflux in brain cells and decrease Ab secretion. J Biol Chem. 2003;278:13244&#x2013;13256. doi: 10.1074/jbc.M300044200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M300044200</ArticleId><ArticleId IdType="pubmed">12547833</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, Walter M, Roth MG, Lazo JS. The Liver X Receptor Ligand T0901317 Decreases Amyloid b Production in Vitro and in a Mouse Model of Alzheimer's Disease. J Biol Chem. 2005;280:4079&#x2013;4088. doi: 10.1074/jbc.M411420200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M411420200</ArticleId><ArticleId IdType="pubmed">15557325</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, DeMattos RB, May PC, Li SD, Jiang XC, Eacho PI, Cao G, Paul SM. A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. Journal of Neurochemistry. 2004;88:623&#x2013;634. doi: 10.1111/j.1471-4159.2004.02183.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02183.x</ArticleId><ArticleId IdType="pubmed">14720212</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitney KD, Watson MA, Collins JL, Benson WG, Stone TM, Numerick MJ, Tippin TK, Wilson JG, Winegar DA, Kliewer SA. Regulation of cholesterol homeostasis by the liver x receptors in the central nervous system. Mol Endocrinol. 2002;16:1378&#x2013;1385. doi: 10.1210/me.16.6.1378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.16.6.1378</ArticleId><ArticleId IdType="pubmed">12040022</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J, III, Theisler C, Silberman S, Magnuson D, Gottardi-Littell N, Lee JM, Yager D, Crowley J, Sambamurti K, Rahman MM, Reiss AB, Eckman CB, Wolozin B. Differential Expression of Cholesterol Hydroxylases in Alzheimer's Disease. J Biol Chem. 2004;279:34674&#x2013;34681. doi: 10.1074/jbc.M402324200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M402324200</ArticleId><ArticleId IdType="pubmed">15148325</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Yao J, Kim TW, Tall AR. Expression of Liver X Receptor Target Genes Decreases Cellular Amyloid b Peptide Secretion. J Biol Chem. 2003;278:27688&#x2013;27694. doi: 10.1074/jbc.M300760200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M300760200</ArticleId><ArticleId IdType="pubmed">12754201</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, Ring RH, Kirksey Y, Aschmies S, Xu J, Kubek K, Hirst WD, Gonzales C, Chen Y, Murphy E, Leonard S, Vasylyev D, Oganesian A, Martone RL, Pangalos MN, Reinhart PH, Jacobsen JS. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci. 2007;34:621&#x2013;628. doi: 10.1016/j.mcn.2007.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2007.01.011</ArticleId><ArticleId IdType="pubmed">17336088</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE, Vinters HV, Tontonoz P. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. PNAS. 2007;104:10601&#x2013;10606. doi: 10.1073/pnas.0701096104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0701096104</ArticleId><ArticleId IdType="pmc">PMC1890560</ArticleId><ArticleId IdType="pubmed">17563384</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffensen KR, Neo SY, Stulnig TM, Vega VB, Rahman SS, Schuster GU, Gustafsson JA, Liu ET. Genome-wide expression profiling; a panel of mouse tissues discloses novel biological functions of liver X receptors in adrenals. J Mol Endocrinol. 2004;33:609&#x2013;622. doi: 10.1677/jme.1.01508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1677/jme.1.01508</ArticleId><ArticleId IdType="pubmed">15591022</ArticleId></ArticleIdList></Reference><Reference><Citation>Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med. 2004;10:719&#x2013;726. doi: 10.1038/nm1058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1058</ArticleId><ArticleId IdType="pubmed">15195085</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem. 1994;269:23403&#x2013;23406.</Citation><ArticleIdList><ArticleId IdType="pubmed">8089103</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova RP, Lefterov IM, Lefterova MI, Lazo JS. Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry. 2001;40:3553&#x2013;3560. doi: 10.1021/bi002186k.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi002186k</ArticleId><ArticleId IdType="pubmed">11297421</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12:1005&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. Journal of Neuroimmunology. 2007;184:69&#x2013;91. doi: 10.1016/j.jneuroim.2006.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2006.11.017</ArticleId><ArticleId IdType="pubmed">17222916</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornemann KD, Wiederhold KH, Pauli C, Ermini F, Stalder M, Schnell L, Sommer B, Jucker M, Staufenbiel M. Ab-Induced Inflammatory Processes in Microglia Cells of APP23 Transgenic Mice. Am J Pathol. 2001;158:63&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850262</ArticleId><ArticleId IdType="pubmed">11141480</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, Moir RD, Domnitz SB, Frosch MP, Windisch M, Kovacs DM. The ACAT Inhibitor CP-113,818 Markedly Reduces Amyloid Pathology in a Mouse Model of Alzheimer's Disease. Neuron. 2004;44:227&#x2013;238. doi: 10.1016/j.neuron.2004.08.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.08.043</ArticleId><ArticleId IdType="pubmed">15473963</ArticleId></ArticleIdList></Reference><Reference><Citation>Refolo LM, Pappolla MA, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7:321&#x2013;331. doi: 10.1006/nbdi.2000.0304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2000.0304</ArticleId><ArticleId IdType="pubmed">10964604</ArticleId></ArticleIdList></Reference><Reference><Citation>Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001;8:890&#x2013;899. doi: 10.1006/nbdi.2001.0422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2001.0422</ArticleId><ArticleId IdType="pubmed">11592856</ArticleId></ArticleIdList></Reference><Reference><Citation>Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC. Diet-induced hypercholesterolemia enhances brain Abeta accumulation in transgenic mice. Neuroreport. 2002;13:455&#x2013;459. doi: 10.1097/00001756-200203250-00019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200203250-00019</ArticleId><ArticleId IdType="pubmed">11930160</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, Scheff SW, Hunsaker JC, III, Liu H, Landers T, Gross DR. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 1994;126:88&#x2013;94. doi: 10.1006/exnr.1994.1044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1994.1044</ArticleId><ArticleId IdType="pubmed">8157129</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwolski C. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol. 2005;62:753&#x2013;757. doi: 10.1001/archneur.62.5.753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.62.5.753</ArticleId><ArticleId IdType="pubmed">15883262</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439&#x2013;1443. doi: 10.1001/archneur.57.10.1439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.57.10.1439</ArticleId><ArticleId IdType="pubmed">11030795</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, Ring RH, Kirksey Y, Aschmies S, Xu J, Kubek K, Hirst WD, Gonzales C, Chen Y, Murphy E, Leonard S, Vasylyev D, Oganesian A, Martone RL, Pangalos MN, Reinhart PH, Jacobsen JS. The LXR agonist TO901317 selectively lowers hippocampal Ab 42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Molecular and Cellular Neuroscience. 2007;34:621&#x2013;628. doi: 10.1016/j.mcn.2007.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2007.01.011</ArticleId><ArticleId IdType="pubmed">17336088</ArticleId></ArticleIdList></Reference><Reference><Citation>Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ, Tontonoz P. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci U S A. 2001;98:507&#x2013;512. doi: 10.1073/pnas.021488798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.021488798</ArticleId><ArticleId IdType="pmc">PMC14617</ArticleId><ArticleId IdType="pubmed">11149950</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentili C, Tutolo G, Pianezzi A, Cancedda R, scalzi Cancedda F. Cholesterol secretion and homeostasis in chondrocytes: a liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein A1 expression. Matrix Biology. 2005;24:35&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">15749000</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas MJ, Horani M, Mreyoud A, Plummer B, Wong NCW, Mooradian AD. Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF [alpha] and IL-1[beta] Biochimica et Biophysica Acta (BBA) - General Subjects. 2003;1623:120&#x2013;128. doi: 10.1016/j.bbagen.2003.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagen.2003.08.004</ArticleId><ArticleId IdType="pubmed">14572909</ArticleId></ArticleIdList></Reference><Reference><Citation>Han CY, Chiba T, Campbell JS, Fausto N, Chaisson M, Orasanu G, Plutzky J, Chait A. Reciprocal and Coordinate Regulation of Serum Amyloid A Versus Apolipoprotein A-I and Paraoxonase-1 by Inflammation in Murine Hepatocytes. Arterioscler Thromb Vasc Biol. 2006;26:1806&#x2013;1813. doi: 10.1161/01.ATV.0000227472.70734.ad.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.0000227472.70734.ad</ArticleId><ArticleId IdType="pubmed">16709944</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer TP, Schmidt RJ, Foxworthy P, Zhang Y, Dai J, Bensch WR, Kauffman RF, Gao H, Ryan TP, Jiang XC, Karathanasis SK, Eacho PI, Cao G. Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in Mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo. J Pharmacol Exp Ther. 2004;309:861&#x2013;868. doi: 10.1124/jpet.103.064535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.103.064535</ArticleId><ArticleId IdType="pubmed">14960661</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A. 2004;101:2173&#x2013;2178. doi: 10.1073/pnas.0308512100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0308512100</ArticleId><ArticleId IdType="pmc">PMC357071</ArticleId><ArticleId IdType="pubmed">14769913</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe WB, Blalock EM, Chen KC, Kadish I, Wang D, Barrett JE, Thibault O, Porter NM, Rose GM, Landfield PW. Hippocampal expression analyses reveal selective association of immediate-early, neuroenergetic, and myelinogenic pathways with cognitive impairment in aged rats. J Neurosci. 2007;27:3098&#x2013;3110. doi: 10.1523/JNEUROSCI.4163-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4163-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672456</ArticleId><ArticleId IdType="pubmed">17376971</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath AJ, Irving JA, Rossjohn J, Law RH, Bottomley SP, Quinsey NS, Pike RN, Coughlin PB, Whisstock JC. The murine orthologue of human antichymotrypsin: a structural paradigm for clade A3 serpins. J Biol Chem. 2005;280:43168&#x2013;43178. doi: 10.1074/jbc.M505598200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M505598200</ArticleId><ArticleId IdType="pubmed">16141197</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham CR, Selkoe DJ, Potter H. Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell. 1988;52:487&#x2013;501. doi: 10.1016/0092-8674(88)90462-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(88)90462-X</ArticleId><ArticleId IdType="pubmed">3257719</ArticleId></ArticleIdList></Reference><Reference><Citation>Padmanabhan J, Levy M, Dickson DW, Potter H. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. Brain. 2006;129:3020&#x2013;3034. doi: 10.1093/brain/awl255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl255</ArticleId><ArticleId IdType="pubmed">16987932</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter H, Wefes IM, Nilsson LN. The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiol Aging. 2001;22:923&#x2013;930. doi: 10.1016/S0197-4580(01)00308-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(01)00308-6</ArticleId><ArticleId IdType="pubmed">11755000</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A. 1997;94:13287&#x2013;13292. doi: 10.1073/pnas.94.24.13287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.24.13287</ArticleId><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookout AL, Cummins CL, Mangelsdorf DJ. High-throughput real-time quantitative reverse transcription PCR. In: M.Ausubel , R.Brent , R.E.Kingston , D.D.Moore , J.G.Seidman , J.A.Smith and K.Struhl , editor. Current Protocols in Molecular Biology. Hoboken, NJ, John Willey &amp; Sons, Inc.; 2005. p. 15.8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18265376</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang G, Shao L, DeKosky ST, Price JC, Mathis CA. Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-{beta} in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain. J Neurosci. 2005;25:10598&#x2013;10606. doi: 10.1523/JNEUROSCI.2990-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2990-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725842</ArticleId><ArticleId IdType="pubmed">16291932</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordle A, Landreth G. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. J Neurosci. 2005;25:299&#x2013;307. doi: 10.1523/JNEUROSCI.2544-04.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2544-04.2005</ArticleId><ArticleId IdType="pmc">PMC6725473</ArticleId><ArticleId IdType="pubmed">15647473</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17955233</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0028-3940</ISSN><JournalIssue CitedMedium="Print"><Volume>49</Volume><Issue>12</Issue><PubDate><Year>2007</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Neuroradiology</Title><ISOAbbreviation>Neuroradiology</ISOAbbreviation></Journal><ArticleTitle>Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study.</ArticleTitle><Pagination><StartPage>967</StartPage><EndPage>976</EndPage><MedlinePgn>967-76</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Alzheimer's disease (AD) usually first presents in elderly patients, but may also develop at an earlier age. Patients with an early age at onset tend to present with complaints other than memory impairment, such as visuospatial problems or apraxia, which may reflect a different distribution of cortical involvement. In this study we set out to investigate whether age at onset in patients with AD determines the pattern of atrophy on cerebral MRI scans.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We examined 55 patients with AD over a wide age range and analyzed their 3-D T1-weighted structural MRI scans in standard space using voxel-based morphometry (VBM). Regression analysis was performed to estimate loss of grey matter as a function of age, corrected for mini-mental state examination (MMSE) scores and sex.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The VBM analyses identified multiple areas (including the temporal and parietal lobes), showing more atrophy with advancing age. By contrast, a younger age at onset was found to be associated with lower grey matter density in the precuneus. Regionalized volumetric analysis of this region confirmed the existence of disproportionate atrophy in the precuneus in patients with early-onset AD. Application of a multivariate model with precuneus grey matter density as input, showed that precuneal and hippocampal atrophy are independent from each other. Additionally, we found that a smaller precuneus is associated with impaired visuospatial functioning.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings support the notion that age at onset modulates the distribution of cortical involvement, and that disproportionate precuneus atrophy is more prominent in patients with a younger age of onset.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karas</LastName><ForeName>Giorgos</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Radiology, Vrije Universiteit Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. GB.Karas@vumc.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Rombouts</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>van Schijndel</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Bethany</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>van der Flier</LastName><ForeName>Wiesje</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Vrenken</LastName><ForeName>Hugo</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Barkhof</LastName><ForeName>Frederik</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Neuroradiology</MedlineTA><NlmUniqueID>1302751</NlmUniqueID><ISSNLinking>0028-3940</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021621" MajorTopicYN="N">Imaging, Three-Dimensional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17955233</ArticleId><ArticleId IdType="doi">10.1007/s00234-007-0269-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 1999;249 Suppl 3:14-22</Citation><ArticleIdList><ArticleId IdType="pubmed">10654095</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Psychol. 2001 Jul;42(3):225-38</Citation><ArticleIdList><ArticleId IdType="pubmed">11501737</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2001 Jun;13(6 Pt 1):1065-72</Citation><ArticleIdList><ArticleId IdType="pubmed">11352612</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2002 Sep;17(1):479-89</Citation><ArticleIdList><ArticleId IdType="pubmed">12482100</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2001 Aug;14(2):439-53</Citation><ArticleIdList><ArticleId IdType="pubmed">11467917</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1994 Jul;44(7):1215-20</Citation><ArticleIdList><ArticleId IdType="pubmed">8035918</ArticleId></ArticleIdList></Reference><Reference><Citation>J Int Neuropsychol Soc. 2003 Jul;9(5):783-95</Citation><ArticleIdList><ArticleId IdType="pubmed">12901784</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):691-700</Citation><ArticleIdList><ArticleId IdType="pubmed">12023408</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2006 Oct 15;33(1):17-26</Citation><ArticleIdList><ArticleId IdType="pubmed">16904912</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2006 Jun;31(2):496-504</Citation><ArticleIdList><ArticleId IdType="pubmed">16473024</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1987 Nov-Dec;8(6):521-45</Citation><ArticleIdList><ArticleId IdType="pubmed">3323927</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2001 Oct;3(5):495-505</Citation><ArticleIdList><ArticleId IdType="pubmed">12214036</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):967-72</Citation><ArticleIdList><ArticleId IdType="pubmed">1431963</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2005 Oct;15(10):1561-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15716470</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2001 Dec;14(6):1361-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11707092</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1991;82(4):239-59</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1988;75(5):509-12</Citation><ArticleIdList><ArticleId IdType="pubmed">3376753</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2000 Jun;11(6 Pt 1):805-21</Citation><ArticleIdList><ArticleId IdType="pubmed">10860804</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychologia. 1998 Sep;36(9):945-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9740367</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2002 Aug;125(Pt 8):1772-81</Citation><ArticleIdList><ArticleId IdType="pubmed">12135968</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2003 Mar;18(3):769-88</Citation><ArticleIdList><ArticleId IdType="pubmed">12667854</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2005 Apr 1;25(2):408-16</Citation><ArticleIdList><ArticleId IdType="pubmed">15784419</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Sci. 2002 Aug 15;200(1-2):27-32</Citation><ArticleIdList><ArticleId IdType="pubmed">12127672</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2001 Apr;124(Pt 4):804-15</Citation><ArticleIdList><ArticleId IdType="pubmed">11287379</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2001;104(3):667-76</Citation><ArticleIdList><ArticleId IdType="pubmed">11440800</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2000 Mar;123 Pt 3:484-98</Citation><ArticleIdList><ArticleId IdType="pubmed">10686172</ArticleId></ArticleIdList></Reference><Reference><Citation>AJNR Am J Neuroradiol. 2005 Feb;26(2):333-40</Citation><ArticleIdList><ArticleId IdType="pubmed">15709131</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2002 Nov;17(3):1403-14</Citation><ArticleIdList><ArticleId IdType="pubmed">12414280</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2006 Mar;129(Pt 3):564-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16399806</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1998 May 8;280(5365):921-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9572740</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2005 Jan;76(1):112-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15608008</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 1998 Mar-Apr;9(2):63-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9524795</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1997 Sep 15;17(18):7103-10</Citation><ArticleIdList><ArticleId IdType="pubmed">9278544</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1984 Jul;34(7):939-44</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 1998 Sep;12(3):163-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9772018</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comput Assist Tomogr. 1998 Sep-Oct;22(5):838-43</Citation><ArticleIdList><ArticleId IdType="pubmed">9754126</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2004 Nov-Dec;12(6):596-605</Citation><ArticleIdList><ArticleId IdType="pubmed">15545327</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2002 Oct 28;13(15):1939-43</Citation><ArticleIdList><ArticleId IdType="pubmed">12395096</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2001 Aug;14(2):298-309</Citation><ArticleIdList><ArticleId IdType="pubmed">11467904</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2002 Aug;73(2):126-33</Citation><ArticleIdList><ArticleId IdType="pubmed">12122168</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17956719</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>02</Day></DateCompleted><DateRevised><Year>2007</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0092-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>131</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Presenilin: running with scissors in the membrane.</ArticleTitle><Pagination><StartPage>215</StartPage><EndPage>221</EndPage><MedlinePgn>215-21</MedlinePgn></Pagination><Abstract><AbstractText>The presenilin-containing gamma-secretase complex is an unusual membrane-embedded protease that processes a wide variety of integral membrane proteins, clearing protein stubs from the lipid bilayer and participating in critical signaling pathways. The protease is also central to Alzheimer's disease and certain cancers and is therefore an important therapeutic target. Here we highlight recent progress in deciphering the role of presenilin/gamma-secretase in biology and medicine and pose key questions for future study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. dselkoe@rics.bwh.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>41</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17956719</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2007.10.012</ArticleId><ArticleId IdType="pii">S0092-8674(07)01282-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17971867</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>10</Issue><PubDate><Year>2007</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Prognostic value of posteromedial cortex deactivation in mild cognitive impairment.</ArticleTitle><Pagination><StartPage>e1104</StartPage><MedlinePgn>e1104</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1104</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Normal subjects deactivate specific brain regions, notably the posteromedial cortex (PMC), during many tasks. Recent cross-sectional functional magnetic resonance imaging (fMRI) data suggests that deactivation during memory tasks is impaired in Alzheimer's disease (AD). The goal of this study was to prospectively determine the prognostic significance of PMC deactivation in mild cognitive impairment (MCI).</AbstractText><AbstractText Label="METHODOLOGY/PRINCIPAL FINDINGS" NlmCategory="RESULTS">75 subjects (34 MCI, 13 AD subjects and 28 controls) underwent baseline fMRI scanning during encoding of novel and familiar face-name pairs. MCI subjects were followed longitudinally to determine conversion to AD. Regression and analysis of covariance models were used to assess the effect of PMC activation/deactivation on conversion to dementia as well as in the longitudinal change in dementia measures. At longitudinal follow up of up to 3.5 years (mean 2.5+/-0.79 years), 11 MCI subjects converted to AD. The proportion of deactivators was significantly different across all groups: controls (79%), MCI-Nonconverters (73%), MCI-converters (45%), and AD (23%) (p&lt;0.05). Mean PMC activation magnitude parameter estimates, at baseline, were negative in the control (-0.57+/-0.12) and MCI-Nonconverter (-0.33+/-0.14) groups, and positive in the MCI-Converter (0.37+/-0.40) and AD (0.92+/-0.30) groups. The effect of diagnosis on PMC deactivation remained significant after adjusting for age, education and baseline Mini-Mental State Exam (p&lt;0.05). Baseline PMC activation magnitude was correlated with change in dementia ratings from baseline.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Loss of physiological functional deactivation in the PMC may have prognostic value in preclinical AD, and could aid in profiling subgroups of MCI subjects at greatest risk for progressive cognitive decline.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Alzheimer Imaging Research Laboratory and Brain Imaging and Analysis Center, Department of Radiology, Duke University Medical Center, Durham, North Carolina, United States of America. petre001@mc.duke.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prince</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lihong</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Hellegers</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>PM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG019728</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG019728</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020651" MajorTopicYN="N">Ventral Thalamic Nuclei</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>Dr. Doraiswamy has received research grant support and/or honoraria for consulting or speaking from several pharmaceutical or diagnostic companies and owns stock in Sonexa Therapeutics. Duke University and Dr. Doraiswamy hold a use patent for an unrelated treatment indication in children; that patent is unlicensed and he derives no income from it. Dr. Petrella has received research support from Eisai/Pfizer and AVID for other pilot studies. Dr. Wang and Ms. Hellegers have received salary support from several pharmaceutical companies for other studies. Dr. Prince has no conflicts to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>10</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17971867</ArticleId><ArticleId IdType="pmc">PMC2040216</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0001104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tanzi RE. The synaptic Abeta hypothesis of Alzheimer disease.[comment]. Nature Neuroscience. 2005;8:977&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">16047022</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature. 2006;443:768&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051202</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Dickson DW, Parisi JE, Xu YC, Cha RH, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology. 2002;58:750&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745935</ArticleId><ArticleId IdType="pubmed">11889239</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, Xu YC, O'Brien PC, Smith GE, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730146</ArticleId><ArticleId IdType="pubmed">10227624</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaye JA, Swihart T, Howieson D, Dame A, Moore MM, et al. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology. 1997;48:1297&#x2013;1304.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153461</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Perera GM, DeLaPaz R, Mayeux R, Stern Y, et al. Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Annals of Neurology. 1999;45:466&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">10211471</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts SA, Barkhof F, Veltman DJ, Machielsen WC, Witter MP, et al. Functional MR imaging in Alzheimer's disease during memory encoding. American Journal of Neuroradiology. 2000;21:1869&#x2013;1875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7974309</ArticleId><ArticleId IdType="pubmed">11110539</ArticleId></ArticleIdList></Reference><Reference><Citation>Machulda M, Ward H, Borowski B, Gunter J, Cha R, et al. Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients. Neurology. 2003;61:500&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744465</ArticleId><ArticleId IdType="pubmed">12939424</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Bates J, Chua E, Cocchiarella A, Rentz D, et al. FMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease. Journal of Neurology Neurosurgery and Psychiatry. 2003;74:44&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738201</ArticleId><ArticleId IdType="pubmed">12486265</ArticleId></ArticleIdList></Reference><Reference><Citation>Pariente J, Cole S, Henson R, Clare L, Kennedy A, et al. Alzheimer's patients engage an alternative network during a memory task. Annals of Neurology. 2005;58:870&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">16315273</ArticleId></ArticleIdList></Reference><Reference><Citation>Golby A, Silverberg G, Race E, Gabrieli S, O'Shea J, et al. Memory encoding in Alzheimer's disease: an fMRI study of explicit and implicit memory. Brain. 2005;128:773&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">15705615</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005;65:404&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335677</ArticleId><ArticleId IdType="pubmed">16087905</ArticleId></ArticleIdList></Reference><Reference><Citation>Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci. 2006;26:10222&#x2013;10231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674636</ArticleId><ArticleId IdType="pubmed">17021177</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrella JR, Krishnan S, Slavin MJ, Tran TT, Murty L, et al. Mild cognitive impairment: evaluation with 4-T functional MR imaging. Radiology. 2006;240:177&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">16684919</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Schmitz TW, Moritz CH, Meyerand ME, Rowley HA, et al. Activation of brain regions vulnerable to Alzheimer's disease: the effect of mild cognitive impairment. Neurobiology of Aging. 2006;27:1604&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2627778</ArticleId><ArticleId IdType="pubmed">16226349</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, et al. A default mode of brain function. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E [see comments]. New England Journal of Medicine. 1996;334:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig C, Snyder AZ, Bhakta M, O'Brien KC, McAvoy M, et al. Functional deactivations: change with age and dementia of the Alzheimer type. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:14504&#x2013;14509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC283621</ArticleId><ArticleId IdType="pubmed">14608034</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Human Brain Mapping. 2005;26:231&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871685</ArticleId><ArticleId IdType="pubmed">15954139</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrella JR, Wang L, Krishnan S, Slavin MJ, Prince SE, et al. Cortical Deactivation in Mild Cognitive Impairment: A High-Field fMRI Study. Radiology. 2007;245:224&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">17885190</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association: Guidelines for assessing the decision-making capacities of potential research subjects with cognitive impairment. American Journal of Psychiatry. 1998;155:1649&#x2013;1650.</Citation><ArticleIdList><ArticleId IdType="pubmed">9812160</ArticleId></ArticleIdList></Reference><Reference><Citation>Delis DC, Kramer JH, Kaplan E, Ober BA. New York: Psychological Corporation; 1987. The California Verbal Learning Test&#x2013;Research Edition.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler memory scale-3rd Ed. (WMS-III): Psychological Corporation. 1997</Citation></Reference><Reference><Citation>Folstein M, Folstein S, McHugh P. &#x201c;Mini Mental State&#x201d;: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck AT, Steer RA, Brown GK. San Antonio, TX: Psychological Corporation; 1996. Manual for the Beck Depression Inventory-II.</Citation></Reference><Reference><Citation>Hachinski V, Lassen N, Marshall J. Multi-infarct dementia: a cause of mental deterioration in the elderly. Lancet. 1974;2:207&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">4135618</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379&#x2013;2388.</Citation><ArticleIdList><ArticleId IdType="pubmed">15829527</ArticleId></ArticleIdList></Reference><Reference><Citation>Frackowiak RSJ, Friston KJ, Frith CD, Dolan RJ, Mazziotta JC, editors. 1997. Human Brain Function: Academic Press.</Citation></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, et al. A default mode of brain function. Proc Natl Acad Sci U S A. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci U S A. 2003;100:253&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140943</ArticleId><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Laufs H, Krakow K, Sterzer P, Eger E, Beyerle A, et al. Electroencephalographic signatures of attentional and cognitive default modes in spontaneous brain activity fluctuations at rest. Proc Natl Acad Sci U S A. 2003;100:11053&#x2013;11058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC196925</ArticleId><ArticleId IdType="pubmed">12958209</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:253&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140943</ArticleId><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, et al. Molecular, structural, and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory. Journal of Neuroscience. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Meguro K, Blaizot X, Kondoh Y, Le Mestric C, Baron JC, et al. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. Brain 122 ( Pt. 1999;8):1519&#x2013;1531.</Citation><ArticleIdList><ArticleId IdType="pubmed">10430835</ArticleId></ArticleIdList></Reference><Reference><Citation>Millien I, Blaizot X, Giffard C, Mezenge F, Insausti R, et al. Brain glucose hypometabolism after perirhinal lesions in baboons: implications for Alzheimer disease and aging. J Cereb Blood Flow Metab. 2002;22:1248&#x2013;1261.</Citation><ArticleIdList><ArticleId IdType="pubmed">12368664</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ, Marsden P, Lasserson D, Sheldon N, Lewis P, et al. FDG-PET analysis and findings in amnesia resulting from hypoxia. Memory. 1999;7:599&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">10659089</ArticleId></ArticleIdList></Reference><Reference><Citation>Aupee AM, Desgranges B, Eustache F, Lalevee C, de la Sayette V, et al. Voxel-based mapping of brain hypometabolism in permanent amnesia with PET. Neuroimage. 2001;13:1164&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pubmed">11352622</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuchter AF, Newton TF, Cook IA, Walter DO, Rosenberg-Thompson S, et al. Changes in brain functional connectivity in Alzheimer-type and multi-infarct dementia. Brain. 1992;115 ( Pt 5):1543&#x2013;1561.</Citation><ArticleIdList><ArticleId IdType="pubmed">1422803</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady CL, McIntosh AR, Beig S, Keightley ML, Burian H, et al. Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's disease. J Neurosci. 2003;23:986&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741917</ArticleId><ArticleId IdType="pubmed">12574428</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Schuff N, Jahng GH, Bayne W, Mori S, et al. Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease.[see comment]. Neurology. 2007;68:13&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941719</ArticleId><ArticleId IdType="pubmed">17200485</ArticleId></ArticleIdList></Reference><Reference><Citation>Stam CJ, Jones BF, Nolte G, Breakspear M, Scheltens P. Small-world networks and functional connectivity in Alzheimer's disease. Cerebral Cortex. 2007;17:92&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">16452642</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Zang Y, He Y, Liang M, Zhang X, et al. Changes in hippocampal connectivity in the early stages of Alzheimer's disease: evidence from resting state fMRI. Neuroimage. 2006;31:496&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">16473024</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Bates JF, Atiya M, Killiany RJ, et al. Medial temporal lobe function and structure in mild cognitive impairment. Annals of Neurology. 2004;56:27&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335689</ArticleId><ArticleId IdType="pubmed">15236399</ArticleId></ArticleIdList></Reference><Reference><Citation>Huettel SA, Singerman JD, McCarthy G. The effects of aging upon the hemodynamic response measured by functional MRI. Neuroimage. 2001;13:161&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">11133319</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer JB, Zhao Z, Desmond JE, Glover GH, Gabrieli JD. Making memories: brain activity that predicts how well visual experience will be remembered. Science. 1998;281:1185&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">9712581</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17973577</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7885</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>11</Issue><PubDate><Year>2007</Year><Month>Oct</Month><Day>30</Day></PubDate></JournalIssue><Title>PLoS biology</Title><ISOAbbreviation>PLoS Biol</ISOAbbreviation></Journal><ArticleTitle>Systematic in vivo analysis of the intrinsic determinants of amyloid Beta pathogenicity.</ArticleTitle><Pagination><StartPage>e290</StartPage><MedlinePgn>e290</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e290</ELocationID><Abstract><AbstractText>Protein aggregation into amyloid fibrils and protofibrillar aggregates is associated with a number of the most common neurodegenerative diseases. We have established, using a computational approach, that knowledge of the primary sequences of proteins is sufficient to predict their in vitro aggregation propensities. Here we demonstrate, using rational mutagenesis of the Abeta42 peptide based on such computational predictions of aggregation propensity, the existence of a strong correlation between the propensity of Abeta42 to form protofibrils and its effect on neuronal dysfunction and degeneration in a Drosophila model of Alzheimer disease. Our findings provide a quantitative description of the molecular basis for the pathogenicity of Abeta and link directly and systematically the intrinsic properties of biomolecules, predicted in silico and confirmed in vitro, to pathogenic events taking place in a living organism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luheshi</LastName><ForeName>Leila M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tartaglia</LastName><ForeName>Gian Gaetano</ForeName><Initials>GG</Initials></Author><Author ValidYN="Y"><LastName>Brorsson</LastName><ForeName>Ann-Christin</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Pawar</LastName><ForeName>Amol P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>Ian E</ForeName><Initials>IE</Initials></Author><Author ValidYN="Y"><LastName>Chiti</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Vendruscolo</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lomas</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Dobson</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Crowther</LastName><ForeName>Damian C</ForeName><Initials>DC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0500306</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Biol</MedlineTA><NlmUniqueID>101183755</NlmUniqueID><ISSNLinking>1544-9173</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>PLoS Biol. 2007 Nov;5(11):e313. doi: 10.1371/journal.pbio.0050313.</RefSource><PMID Version="1">20076652</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008124" MajorTopicYN="N">Locomotion</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Competing interests.</b> The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>10</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17973577</ArticleId><ArticleId IdType="pmc">PMC2043051</ArticleId><ArticleId IdType="doi">10.1371/journal.pbio.0050290</ArticleId><ArticleId IdType="pii">07-PLBI-RA-2184</ArticleId><ArticleId IdType="sici">plbi-05-11-08</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem. 2006;75:333&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">16756495</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Folding proteins in fatal ways. Nature. 2003;426:900&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">14685251</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnhart MM, Chapman MR. Curli biogenesis and function. Annu Rev Microbiol. 2006;60:131&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838481</ArticleId><ArticleId IdType="pubmed">16704339</ArticleId></ArticleIdList></Reference><Reference><Citation>Uptain SM, Lindquist S. Prions as protein-based genetic elements. Annu Rev Microbiol. 2002;56:703&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">12142498</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler DM, Koulov AV, Alory-Jost C, Marks MS, Balch WE, et al. Functional amyloid formation within mammalian tissue. PLoS Biol. 2006;4:e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288039</ArticleId><ArticleId IdType="pubmed">16300414</ArticleId></ArticleIdList></Reference><Reference><Citation>Fandrich M, Dobson CM. The behaviour of polyamino acids reveals an inverse side chain effect in amyloid structure formation. EMBO J. 2002;21:5682&#x2013;5690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC131070</ArticleId><ArticleId IdType="pubmed">12411486</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson CM. Protein misfolding, evolution and disease. Trends Biochem Sci. 1999;24:329&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">10470028</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Stefani M, Taddei N, Ramponi G, Dobson CM. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature. 2003;424:805&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">12917692</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Escamilla AM, Rousseau F, Schymkowitz J, Serrano L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol. 2004;22:1302&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pubmed">15361882</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawar AP, Dubay KF, Zurdo J, Chiti F, Vendruscolo M, et al. Prediction of &#x201c;aggregation-prone&#x201d; and &#x201c;aggregation-susceptible&#x201d; regions in proteins associated with neurodegenerative diseases. J Mol Biol. 2005;350:379&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">15925383</ArticleId></ArticleIdList></Reference><Reference><Citation>Bukau B, Weissman J, Horwich A. Molecular chaperones and protein quality control. Cell. 2006;125:443&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">16678092</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther DC, Kinghorn KJ, Miranda E, Page R, Curry JA, et al. Intraneuronal Ab, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience. 2005;132:123&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">15780472</ArticleId></ArticleIdList></Reference><Reference><Citation>Finelli A, Kelkar A, Song HJ, Yang H, Konsolaki M. A model for studying Alzheimer's Abeta42-induced toxicity in Drosophila melanogaster. Mol Cell Neurosci. 2004;26:365&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">15234342</ArticleId></ArticleIdList></Reference><Reference><Citation>Iijima K, Liu HP, Chiang AS, Hearn SA, Konsolaki M, et al. Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: A potential model for Alzheimer's disease. Proc Natl Acad Sci U S A. 2004;101:6623&#x2013;6628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC404095</ArticleId><ArticleId IdType="pubmed">15069204</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilen J, Bonini NM. Drosophila as a model for human neurodegenerative disease. Annu Rev Genet. 2005;39:153&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">16285856</ArticleId></ArticleIdList></Reference><Reference><Citation>Gidalevitz T, Ben-Zvi A, Ho KH, Brignull HR, Morimoto RI. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science. 2006;311:1471&#x2013;1474.</Citation><ArticleIdList><ArticleId IdType="pubmed">16469881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Onstead L, Randle S, Price R, Smithson L, et al. Abeta40 inhibits amyloid deposition In vivo. J Neurosci. 2007;27:627&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672801</ArticleId><ArticleId IdType="pubmed">17234594</ArticleId></ArticleIdList></Reference><Reference><Citation>Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem. 1996;271:22908&#x2013;22914.</Citation><ArticleIdList><ArticleId IdType="pubmed">8798471</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchanan RL, Benzer S. Defective glia in the drosophila brain degeneration mutant drop-dead. Neuron. 1993;10:839&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pubmed">8494644</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, et al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2002;22:1858&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758862</ArticleId><ArticleId IdType="pubmed">11880515</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002;5:452&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941374</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. Opposing activities protect against age-onset proteotoxicity. Science. 2006;313:1604&#x2013;1610.</Citation><ArticleIdList><ArticleId IdType="pubmed">16902091</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol. 2006;572:477&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779683</ArticleId><ArticleId IdType="pubmed">16469784</ArticleId></ArticleIdList></Reference><Reference><Citation>DuBay KF, Pawar AP, Chiti F, Zurdo J, Dobson CM, et al. Prediction of the absolute aggregation rates of amyloidogenic polypeptide chains. J Mol Biol. 2004;341:1317&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pubmed">15302561</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartaglia GG, Pechmann S, Dobson CM, Vendruscolo M. Life on the edge: a link between gene expression levels and aggregation rates of human proteins. Trends Biochem Sci. 2007;32:204&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">17419062</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38:24&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369530</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson CM. An accidental breach of a protein's natural defenses. Nat Struct Mol Biol. 2006;13:295&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">16715043</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsubuki S, Takaki Y, Saido TC. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet. 2003;361:1957&#x2013;1958.</Citation><ArticleIdList><ArticleId IdType="pubmed">12801742</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Taddei N, Baroni F, Capanni C, Stefani M, et al. Kinetic partitioning of protein folding and aggregation. Nat Struct Biol. 2002;9:137&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">11799398</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17980964</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0304-3940</ISSN><JournalIssue CitedMedium="Print"><Volume>429</Volume><Issue>2-3</Issue><PubDate><Year>2007</Year><Month>Dec</Month><Day>18</Day></PubDate></JournalIssue><Title>Neuroscience letters</Title><ISOAbbreviation>Neurosci Lett</ISOAbbreviation></Journal><ArticleTitle>Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation.</ArticleTitle><Pagination><StartPage>95</StartPage><EndPage>100</EndPage><MedlinePgn>95-100</MedlinePgn></Pagination><Abstract><AbstractText>It is uncertain whether environmental factors contribute to the formation of senile plaques and neurofibrillary tangles, the abnormal features that define the Alzheimer's disease (AD) brain. We previously proposed that herpes simplex virus type 1 (HSV1) is a strong risk factor for AD when it is present in the brains of people who possess the type 4 allele of the apolipoprotein E gene (APOE-epsilon4); however a direct biochemical link between viral infection and the development of the AD pathological features has never previously been examined. Here we show that infection of cultured neuronal and glial cells with HSV1 leads to a dramatic increase in the intracellular levels of beta-amyloid (Abeta) 1-40 and 1-42, whilst levels of amyloid precursor protein (APP) in cells decrease. Similarly, Abeta1-42 deposits are present in mouse brain after HSV1 infection. In the cultured cells the mechanism involves increased Abeta production, rather than merely greater retention of cellular Abeta, as levels of beta-site APP-cleaving enzyme (BACE-1) and of nicastrin, a component of gamma-secretase, both increase in HSV1-infected cells. These novel data show that HSV1 can directly contribute to the development of senile plaques.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wozniak</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Faculty of Life Sciences, The University of Manchester, PO Box 88, Sackville Street, Manchester M60 1QD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Itzhaki</LastName><ForeName>Ruth F</ForeName><Initials>RF</Initials></Author><Author ValidYN="Y"><LastName>Shipley</LastName><ForeName>Suzanne J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Dobson</LastName><ForeName>Curtis B</ForeName><Initials>CB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Neurosci Lett</MedlineTA><NlmUniqueID>7600130</NlmUniqueID><ISSNLinking>0304-3940</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C413604">nicastrin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020803" MajorTopicYN="N">Encephalitis, Herpes Simplex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018259" MajorTopicYN="N">Herpesvirus 1, Human</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013312" MajorTopicYN="N">Stress, Physiological</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014775" MajorTopicYN="N">Virus Activation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17980964</ArticleId><ArticleId IdType="doi">10.1016/j.neulet.2007.09.077</ArticleId><ArticleId IdType="pii">S0304-3940(07)01078-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17982457</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>12</Issue><PubDate><Year>2007</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>A survey of genetic human cortical gene expression.</ArticleTitle><Pagination><StartPage>1494</StartPage><EndPage>1499</EndPage><MedlinePgn>1494-9</MedlinePgn></Pagination><Abstract><AbstractText>It is widely assumed that genetic differences in gene expression underpin much of the difference among individuals and many of the quantitative traits of interest to geneticists. Despite this, there has been little work on genetic variability in human gene expression and almost none in the human brain, because tools for assessing this genetic variability have not been available. Now, with whole-genome SNP genotyping arrays and whole-transcriptome expression arrays, such experiments have become feasible. We have carried out whole-genome genotyping and expression analysis on a series of 193 neuropathologically normal human brain samples using the Affymetrix GeneChip Human Mapping 500K Array Set and Illumina HumanRefseq-8 Expression BeadChip platforms. Here we present data showing that 58% of the transcriptome is cortically expressed in at least 5% of our samples and that of these cortically expressed transcripts, 21% have expression profiles that correlate with their genotype. These genetic-expression effects should be useful in determining the underlying biology of associations with common diseases of the human brain and in guiding the analysis of the genomic regions involved in the control of normal gene expression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Amanda J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, Porter Neuroscience Building, National Institutes of Health Main Campus, Bethesda, Maryland 20892, USA. amyers@med.miami.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibbs</LastName><ForeName>J Raphael</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Webster</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Rohrer</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Alice</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Marlowe</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Kaleem</LastName><ForeName>Mona</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Doris</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Bryden</LastName><ForeName>Leslie</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Nath</LastName><ForeName>Priti</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Zismann</LastName><ForeName>Victoria L</ForeName><Initials>VL</Initials></Author><Author ValidYN="Y"><LastName>Joshipura</LastName><ForeName>Keta</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Huentelman</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Hu-Lince</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Coon</LastName><ForeName>Keith D</ForeName><Initials>KD</Initials></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>David W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Pearson</LastName><ForeName>John V</ForeName><Initials>JV</Initials></Author><Author ValidYN="Y"><LastName>Holmans</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Heward</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Stephan</LastName><ForeName>Dietrich</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE8919</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>UO1HL084744</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24NS051872</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>NS39764</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05144</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG19610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-AG13846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G9810900</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50-AG08671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH60451</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="Y">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="Y">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17982457</ArticleId><ArticleId IdType="doi">10.1038/ng.2007.16</ArticleId><ArticleId IdType="pii">ng.2007.16</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17989220</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>46</Issue><PubDate><Year>2007</Year><Month>Nov</Month><Day>13</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Mutations in ionotropic AMPA receptor 3 alter channel properties and are associated with moderate cognitive impairment in humans.</ArticleTitle><Pagination><StartPage>18163</StartPage><EndPage>18168</EndPage><MedlinePgn>18163-8</MedlinePgn></Pagination><Abstract><AbstractText>Ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (iGluRs) mediate the majority of excitatory synaptic transmission in the CNS and are essential for the induction and maintenance of long-term potentiation and long-term depression, two cellular models of learning and memory. We identified a genomic deletion (0.4 Mb) involving the entire GRIA3 (encoding iGluR3) by using an X-array comparative genomic hybridization (CGH) and four missense variants (G833R, M706T, R631S, and R450Q) in functional domains of iGluR3 by sequencing 400 males with X-linked mental retardation (XLMR). Three variants were found in males with moderate MR and were absent in 500 control males. Expression studies in HEK293 cells showed that G833R resulted in a 78% reduction of iGluR3 due to protein misfolding. Whole-cell recording studies of iGluR3 homomers in HEK293 cells revealed that neither iGluR3-M706T (S2 domain) nor iGluR3-R631S (near channel core) had substantial channel function, whereas R450Q (S1 domain) was associated with accelerated receptor desensitization. When forming heteromeric receptors with iGluR2 in HEK293 cells, all four iGluR3 variants had altered desensitization kinetics. Our study provides the genetic and functional evidence that mutant iGluR3 with altered kinetic properties is associated with moderate cognitive impairment in humans.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Ye</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Genetic Medicine and Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arai</LastName><ForeName>Amy C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Rumbaugh</LastName><ForeName>Gavin</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Srivastava</LastName><ForeName>Anand K</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Gillian</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Hayashi</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Erika</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yuwu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lilei</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Jayson</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Boyle</LastName><ForeName>Jackie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tarpey</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Raymond</LastName><ForeName>F Lucy</ForeName><Initials>FL</Initials></Author><Author ValidYN="Y"><LastName>Nevelsteen</LastName><ForeName>Joke</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Froyen</LastName><ForeName>Guy</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Stratton</LastName><ForeName>Mike</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Futreal</LastName><ForeName>Andy</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gecz</LastName><ForeName>Jozef</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Stevenson</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Charles E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Valle</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Huganir</LastName><ForeName>Richard L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Tao</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS041020</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS036715</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 HD024061</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 HD044789</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS036715</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD26202</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>NS36715</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD044789</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS41020</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD026202</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD24061</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C104723">glutamate receptor ionotropic, AMPA 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038901" MajorTopicYN="N">X-Linked Intellectual Disability</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="Y">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>5</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17989220</ArticleId><ArticleId IdType="pmc">PMC2084314</ArticleId><ArticleId IdType="doi">10.1073/pnas.0708699104</ArticleId><ArticleId IdType="pii">0708699104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McLaren J, Bryson S. Am J Ment Retard. 1987;92:243&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">3322329</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow Y, Tolmie J. J Med Genet. 1998;35:177&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1051238</ArticleId><ArticleId IdType="pubmed">9541099</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston M. Eur J Paediatr Neurol. 2003;7:105&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">12788036</ArticleId></ArticleIdList></Reference><Reference><Citation>Chelly J, Mandel J. Nat Rev Genet. 2001;2:669&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">11533716</ArticleId></ArticleIdList></Reference><Reference><Citation>McQueen P, Spence M, Garner J, Pereira L, Winsor E. Am J Ment Defic. 1987;91:460&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">2952009</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevenson R, Procopio-Allen A, Schroer R, Collins J. Am J Med Genet. 2003;123:29&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">14556243</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevenson R. Curr Opin Pediatr. 2005;17:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">16282777</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropers H, Hamel B. Nat Rev Genet. 2005;6:46&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">15630421</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevenson R, Schwartz C. Cytogenet Cell Genet. 2002;99:265&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeburg P. Trends Neurosci. 1993;16:359&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">7694406</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollmann M, Heinemann S. Annu Rev Neurosci. 1994;17:31&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">8210177</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer M, Armstrong N. Annu Rev Physiol. 2004;66:161&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">14977400</ArticleId></ArticleIdList></Reference><Reference><Citation>Simeone T, Sanchez R, Rho J. J Child Neurol. 2004;19:343&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">15224708</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuusinen A, Arvola M, Keinanen K. EMBO J. 1995;14:6327&#x2013;6332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC394757</ArticleId><ArticleId IdType="pubmed">8557052</ArticleId></ArticleIdList></Reference><Reference><Citation>Wo Z, Oswald R. Trends Neurosci. 1995;18:161&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">7539962</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss T, Collingridge G. Nature. 1993;361:31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">8421494</ArticleId></ArticleIdList></Reference><Reference><Citation>Bredt D, Nicoll R. Neuron. 2003;40:361&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">14556714</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanillo D, Sprengel R, Hvalby O, Jensen V, Burnashev N, Rozov A, Kaiser K, Koster H, Borchardt T, Worley P, et al. Science. 1999;284:1805&#x2013;1811.</Citation><ArticleIdList><ArticleId IdType="pubmed">10364547</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Jie C, Obie C, Abidi F, Schwartz C, Stevenson R, Valle D, Wang T. Genome Res. 2007;17:641&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1855181</ArticleId><ArticleId IdType="pubmed">17416750</ArticleId></ArticleIdList></Reference><Reference><Citation>Denning G, Anderson M, Amara J, Marshall J, Smith A, Welsh M. Nature. 1992;358:761&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">1380673</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenteany G, Standaert R, Lane W, Choi S, Corey E, Schreiber S. Science. 1995;268:726&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">7732382</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai A, Lynch G. Brain Res. 1992;598:173&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">1486479</ArticleId></ArticleIdList></Reference><Reference><Citation>Staubli U, Perez Y, Xu F, Rogers G, Ingvar M, Stone-Elander S, Lynch G. Proc Natl Acad Sci USA. 1994;91:11158&#x2013;11162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45186</ArticleId><ArticleId IdType="pubmed">7972026</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai A, Xia Y, Suzuki E. Neuroscience. 2004;123:1011&#x2013;1024.</Citation><ArticleIdList><ArticleId IdType="pubmed">14751292</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson J, Lieu T, Petchpradub V, LeDuc B, Ngo H, Rogers G, Lynch G. J Neurosci. 1995;15:8023&#x2013;8030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577953</ArticleId><ArticleId IdType="pubmed">8613739</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampson R, Rogers G, Lynch G, Deadwyler S. J Neurosci. 1998;18:2748&#x2013;2763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793114</ArticleId><ArticleId IdType="pubmed">9502832</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch G, Granger R, Ambros-Ingerson J, Davis C, Kessler M, Schehr R. Exp Neurol. 1997;145:89&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">9184112</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingvar M, Ambros-Ingerson J, Davis M, Granger R, Kessler M, Rogers G, Schehr R, Lynch G. Exp Neurol. 1997;146:553&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pubmed">9270067</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng Y, Zhang Y, Jia Z. Neuron. 2003;39:163&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">12848940</ArticleId></ArticleIdList></Reference><Reference><Citation>Gecz J, Barnett S, Liu J, Hollway G, Donnelly A, Eyre H, Eshkevari H, Baltazar R, Grunn A, Nagaraja R, et al. Genomics. 1999;62:356&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10644433</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarpey P, Raymond F, O'Meara S, Edkins S, Teague J, Butler A, Dicks E, Stevens C, Tofts C, Avis T, et al. Am J Hum Genet. 2007;80:345&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1785336</ArticleId><ArticleId IdType="pubmed">17236139</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond F, Tarpey P, Edkns S, Tofts C., O'Meara S, Teague J, Butler A, Stevens C, Barthorpe S, Buck G, et al. Am J Hum Genet. 2007;80:982&#x2013;987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1852737</ArticleId><ArticleId IdType="pubmed">17436253</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambrook J, Russel DW, editors. Molecular Cloning: A Laboratory Manual. 3rd Ed. Cold Spring Harbor, NY: Cold Spring Harbor Lab Press; 2000. pp. 7.42&#x2013;7.45.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17989306</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>45</Issue><PubDate><Year>2007</Year><Month>Nov</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin.</ArticleTitle><Pagination><StartPage>12413</StartPage><EndPage>12418</EndPage><MedlinePgn>12413-8</MedlinePgn></Pagination><Abstract><AbstractText>Degeneration of dopaminergic neurons in the substantia nigra is characteristic for Parkinson's disease (PD), the second most common neurodegenerative disorder. Mitochondrial dysfunction is believed to contribute to the etiology of PD. Although most cases are sporadic, recent evidence points to a number of genes involved in familial variants of PD. Among them, a loss-of-function of phosphatase and tensin homolog-induced kinase 1 (PINK1; PARK6) is associated with rare cases of autosomal recessive parkinsonism. In HeLa cells, RNA interference-mediated downregulation of PINK1 results in abnormal mitochondrial morphology and altered membrane potential. Morphological changes of mitochondria can be rescued by expression of wild-type PINK1 but not by PD-associated PINK1 mutants. Moreover, primary cells derived from patients with two different PINK1 mutants showed a similar defect in mitochondrial morphology. Human parkin but not PD-associated mutants could rescue mitochondrial pathology in human cells like wild-type PINK1. Our results may therefore suggest that PINK1 deficiency in humans results in mitochondrial abnormalities associated with cellular stress, a pathological phenotype, which can be ameliorated by enhanced expression of parkin.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Exner</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Integrated Protein Science Munich and Adolf-Butenandt-Institute, Department of Biochemistry, Laboratory for Alzheimer's and Parkinson's Disease Research, Ludwig-Maximilians-University, 80336 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Treske</LastName><ForeName>Bettina</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Paquet</LastName><ForeName>Dominik</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Holmstr&#xf6;m</LastName><ForeName>Kira</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Schiesling</LastName><ForeName>Carola</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gispert</LastName><ForeName>Suzana</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Carballo-Carbajal</LastName><ForeName>Iria</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hoepken</LastName><ForeName>Hans-Hermann</ForeName><Initials>HH</Initials></Author><Author ValidYN="Y"><LastName>Gasser</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kr&#xfc;ger</LastName><ForeName>Rejko</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Winklhofer</LastName><ForeName>Konstanze F</ForeName><Initials>KF</Initials></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Reichert</LastName><ForeName>Andreas S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Auburger</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kahle</LastName><ForeName>Philipp J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Schmid</LastName><ForeName>Bettina</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="C111567">parkin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C433927">PTEN-induced putative kinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051336" MajorTopicYN="N">Mitochondrial Membranes</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044767" MajorTopicYN="N">Ubiquitin-Protein Ligases</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>5</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17989306</ArticleId><ArticleId IdType="pmc">PMC6673250</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0719-07.2007</ArticleId><ArticleId IdType="pii">27/45/12413</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol. 1998;152:879&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858234</ArticleId><ArticleId IdType="pubmed">9546347</ArticleId></ArticleIdList></Reference><Reference><Citation>Beilina A, Van Der Brug M, Ahmad R, Kesavapany S, Miller DW, Petsko GA, Cookson MR. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc Natl Acad Sci USA. 2005;102:5703&#x2013;5708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556294</ArticleId><ArticleId IdType="pubmed">15824318</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299:256&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">12446870</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci. 2005;8:657&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834418</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA, Guo M. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature. 2006;441:1162&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">16672981</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi S, Muqit MM, Stanyer L, Healy DG, Abou-Sleiman PM, Hargreaves I, Heales S, Ganguly M, Parsons L, Lees AJ, Latchman DS, Holton JL, Wood NW, Revesz T. PINK1 protein in normal human brain and Parkinson's disease. Brain. 2006;129:1720&#x2013;1731.</Citation><ArticleIdList><ArticleId IdType="pubmed">16702191</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasser T. Genetics of Parkinson's disease. Curr Opin Neurol. 2005;18:363&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">16003110</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA. 2003;100:4078&#x2013;4083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC153051</ArticleId><ArticleId IdType="pubmed">12642658</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffith G. Berlin: Springer; 1993. Fine structure immunocytochemistry.</Citation></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Henn IH, Bouman L, Schlehe JS, Schlierf A, Schramm JE, Wegener E, Nakaso K, Culmsee C, Beringer B, Krappmann D, Tatzelt J, Winklhofer KF. Parkin mediates neuroprotection through activation of I&#x3ba;B kinase/nuclear factor-&#x3ba;B signaling. J Neurosci. 2007;27:1868&#x2013;1878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673568</ArticleId><ArticleId IdType="pubmed">17314283</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoepken HH, Gispert S, Morales B, Wingerter O, Del Turco D, Mulsch A, Nussbaum RL, Muller K, Drose S, Brandt U, Deller T, Wirth B, Kudin AP, Kunz WS, Auburger G. Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol Dis. 2006;25:401&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">17141510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahle PJ, Haass C. How does parkin ligate ubiquitin to Parkinson's disease? EMBO Rep. 2004;5:681&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1299099</ArticleId><ArticleId IdType="pubmed">15229644</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler KR, Hamscho N, Morales B, Menzel C, Barrero F, Vives F, Gispert S, Auburger G. Dopaminergic function in a family with the PARK6 form of autosomal recessive Parkinson's syndrome. J Neural Transm. 2005;112:1345&#x2013;1353.</Citation><ArticleIdList><ArticleId IdType="pubmed">15785866</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">9560156</ArticleId></ArticleIdList></Reference><Reference><Citation>Muqit MM, Feany MB. Modelling neurodegenerative diseases in Drosophila: a fruitful approach? Nat Rev Neurosci. 2002;3:237&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">11994755</ArticleId></ArticleIdList></Reference><Reference><Citation>Muqit MM, Abou-Sleiman PM, Saurin AT, Harvey K, Gandhi S, Deas E, Eaton S, Payne Smith MD, Venner K, Matilla A, Healy DG, Gilks WP, Lees AJ, Holton J, Revesz T, Parker PJ, Harvey RJ, Wood NW, Latchman DS. Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J Neurochem. 2006;98:156&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">16805805</ArticleId></ArticleIdList></Reference><Reference><Citation>Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004;44:595&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541308</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, Chung J. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature. 2006;441:1157&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pubmed">16672980</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez FA, Palmiter RD. Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci USA. 2005;102:2174&#x2013;2179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC548311</ArticleId><ArticleId IdType="pubmed">15684050</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Johnson J, Lang AE, Gulick C, Gwinn-Hardy K, Kawarai T, Sato C, Morgan A, Werner J, Nussbaum R, Petit A, Okun MS, McInerney A, Mandel R, Groen JL, Fernandez HH, Postuma R, Foote KD, Salehi-Rad S, Liang Y, et al. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol. 2004;61:1898&#x2013;1904.</Citation><ArticleIdList><ArticleId IdType="pubmed">15596610</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Cookson MR. Mitochondria and dopamine: new insights into recessive parkinsonism. Neuron. 2004;43:301&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294138</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvestri L, Caputo V, Bellacchio E, Atorino L, Dallapiccola B, Valente EM, Casari G. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet. 2005;14:3477&#x2013;3492.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207731</ArticleId></ArticleIdList></Reference><Reference><Citation>Skulachev VP. Mitochondrial filaments and clusters as intracellular power-transmitting cables. Trends Biochem Sci. 2001;26:23&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">11165513</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004;304:1158&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">15087508</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel F, Bornhovd C, Neupert W, Reichert AS. Dynamic subcompartmentalization of the mitochondrial inner membrane. J Cell Biol. 2006;175:237&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064565</ArticleId><ArticleId IdType="pubmed">17043137</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Gehrke S, Imai Y, Huang Z, Ouyang Y, Wang JW, Yang L, Beal MF, Vogel H, Lu B. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci USA. 2006;103:10793&#x2013;10798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1502310</ArticleId><ArticleId IdType="pubmed">16818890</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Shimoji M, Thomas B, Moore DJ, Yu SW, Marupudi NI, Torp R, Torgner IA, Ottersen OP, Dawson TM, Dawson VL. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet. 2005;14:2063&#x2013;2073.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944198</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541309</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17991865</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>318</Volume><Issue>5852</Issue><PubDate><Year>2007</Year><Month>Nov</Month><Day>09</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Magnetic resonance spectroscopy identifies neural progenitor cells in the live human brain.</ArticleTitle><Pagination><StartPage>980</StartPage><EndPage>985</EndPage><MedlinePgn>980-5</MedlinePgn></Pagination><Abstract><AbstractText>The identification of neural stem and progenitor cells (NPCs) by in vivo brain imaging could have important implications for diagnostic, prognostic, and therapeutic purposes. We describe a metabolic biomarker for the detection and quantification of NPCs in the human brain in vivo. We used proton nuclear magnetic resonance spectroscopy to identify and characterize a biomarker in which NPCs are enriched and demonstrated its use as a reference for monitoring neurogenesis. To detect low concentrations of NPCs in vivo, we developed a signal processing method that enabled the use of magnetic resonance spectroscopy for the analysis of the NPC biomarker in both the rodent brain and the hippocampus of live humans. Our findings thus open the possibility of investigating the role of NPCs and neurogenesis in a wide variety of human brain disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Manganas</LastName><ForeName>Louis N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>SUNY Stony Brook, Stony Brook, NY 11794, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xueying</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yao</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Hazel</LastName><ForeName>Raphael D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>S David</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Wagshul</LastName><ForeName>Mark E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Henn</LastName><ForeName>Fritz</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Benveniste</LastName><ForeName>Helene</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Djuric</LastName><ForeName>Petar M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Enikolopov</LastName><ForeName>Grigori</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Maletic-Savatic</LastName><ForeName>Mirjana</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-NS32764</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008444</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5K08 NS044276</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS053875</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS044276</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21NS05875-1</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32DK07521-16</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS032764</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DK007521</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005227">Fatty Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011522">Protons</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2007 Nov 9;318(5852):899-900. doi: 10.1126/science.318.5852.899a.</RefSource><PMID Version="1">17991833</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2008 Aug 1;321(5889):640. doi: 10.1126/science.1153058.</RefSource><PMID Version="1">18669844</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2008 Aug 1;321(5889):640. doi: 10.1126/science.1153484.</RefSource><PMID Version="1">18669845</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2008 Aug 1;321(5889):640. doi: 10.1126/science.1153997.</RefSource><PMID Version="1">18669846</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053687" MajorTopicYN="N">Adult Stem Cells</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053595" MajorTopicYN="N">Embryonic Stem Cells</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005227" MajorTopicYN="N">Fatty Acids</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011522" MajorTopicYN="N">Protons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012815" MajorTopicYN="N">Signal Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>5</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17991865</ArticleId><ArticleId IdType="mid">NIHMS369203</ArticleId><ArticleId IdType="pmc">PMC4039561</ArticleId><ArticleId IdType="doi">10.1126/science.1147851</ArticleId><ArticleId IdType="pii">318/5852/980</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lie DC, Song H, Colamarino SA, Ming GL, Gage FH. Annu. Rev. Pharmacol. Toxicol. 2004;44:399.</Citation><ArticleIdList><ArticleId IdType="pubmed">14744252</ArticleId></ArticleIdList></Reference><Reference><Citation>Ming GL, Song H. Annu. Rev. Neurosci. 2005;28:223.</Citation><ArticleIdList><ArticleId IdType="pubmed">16022595</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis MA, et al. Science. 2007;315:1243.</Citation><ArticleIdList><ArticleId IdType="pubmed">17303719</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman SA, Windrem MS. Philos. Trans. R. Soc. London Ser. B. 2006;361:1463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1664668</ArticleId><ArticleId IdType="pubmed">16939969</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicchetti F, et al. Contrast Media Mol. Imaging. 2007;2:130.</Citation><ArticleIdList><ArticleId IdType="pubmed">17583908</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin BB, et al. Nucl. Med. Commun. 2003;24:1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">14569169</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbab AS, Liu W, Frank JA. Expert Rev. Med. Devices. 2006;3:427.</Citation><ArticleIdList><ArticleId IdType="pubmed">16866640</ArticleId></ArticleIdList></Reference><Reference><Citation>Viant MR. Methods Mol. Biol. 2007;358:229.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035689</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross B, Bluml S. Anat. Rec. 2001;265:54. (New Anat).</Citation><ArticleIdList><ArticleId IdType="pubmed">11323770</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinno H, et al. J. Neurol. Sci. 2007;260:132.</Citation><ArticleIdList><ArticleId IdType="pubmed">17540407</ArticleId></ArticleIdList></Reference><Reference><Citation>Stengel A, et al. Magn. Reson. Med. 2004;52:228.</Citation><ArticleIdList><ArticleId IdType="pubmed">15282804</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayana PA. J. Neuroimaging. 2005;15:46S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1351238</ArticleId><ArticleId IdType="pubmed">16385018</ArticleId></ArticleIdList></Reference><Reference><Citation>Mignone JL, Kukekov V, Chiang AS, Steindler D, Enikolopov G. J. Comp. Neurol. 2004;469:311.</Citation><ArticleIdList><ArticleId IdType="pubmed">14730584</ArticleId></ArticleIdList></Reference><Reference><Citation>Mignone JL, et al. Cell Cycle. 2007;6:2161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3789384</ArticleId><ArticleId IdType="pubmed">17873521</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhardwaj RD. Proc. Natl. Acad. Sci. U.S.A. 2006;103:12564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1567918</ArticleId><ArticleId IdType="pubmed">16901981</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Kempermann G, Gage FH. Nat. Neurosci. 1999;2:266.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195220</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Kuhn HG, Gage FH. Nature. 1997;386:493.</Citation><ArticleIdList><ArticleId IdType="pubmed">9087407</ArticleId></ArticleIdList></Reference><Reference><Citation>Encinas JM, Vaahtokari A, Enikolopov G. Proc. Natl. Acad. Sci. U.S.A. 2006;103:8233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1461404</ArticleId><ArticleId IdType="pubmed">16702546</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner-Schmidt JL, Duman RS. Hippocampus. 2006;16:239.</Citation><ArticleIdList><ArticleId IdType="pubmed">16425236</ArticleId></ArticleIdList></Reference><Reference><Citation>Madsen TM, et al. Biol. Psychiatry. 2000;47:1043.</Citation><ArticleIdList><ArticleId IdType="pubmed">10862803</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera TD, et al. J. Neurosci. 2007;27:4894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672102</ArticleId><ArticleId IdType="pubmed">17475797</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparling ML, Zidovetzki R, Muller L, Chan SI. Anal. Biochem. 1989;178:67.</Citation><ArticleIdList><ArticleId IdType="pubmed">2729581</ArticleId></ArticleIdList></Reference><Reference><Citation>Barkhuijsen H, de Beer R, van Ormondt D. J. Magn. Reson. 1987;73:553.</Citation><ArticleIdList><ArticleId IdType="pubmed">3831681</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavassila S, et al. J. Magn. Reson. Anal. 1997;3:87.</Citation></Reference><Reference><Citation>Stoica P, Sandgren N, Selen Y, Vanhamme L, Van Huffel S. J. Magn. Reson. 2003;165:80.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568518</ArticleId></ArticleIdList></Reference><Reference><Citation>Dieterle F, Ross A, Schlotterbeck G, Senn H. Anal. Chem. 2006;78:4281.</Citation><ArticleIdList><ArticleId IdType="pubmed">16808434</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn HG, Dickinson-Anson H, Gage FH. J. Neurosci. 1996;16:2027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578509</ArticleId><ArticleId IdType="pubmed">8604047</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson PS, et al. Nat. Med. 1998;4:1313.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809557</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17995921</PMID><DateCompleted><Year>2008</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2008</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2990</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neuropathology and applied neurobiology</Title><ISOAbbreviation>Neuropathol Appl Neurobiol</ISOAbbreviation></Journal><ArticleTitle>Neuronal binucleation in Alzheimer disease hippocampus.</ArticleTitle><Pagination><StartPage>457</StartPage><EndPage>465</EndPage><MedlinePgn>457-65</MedlinePgn></Pagination><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The literature and teachings instruct that neurones in the adult brain are fully differentiated, quiescent cells that never divide. Somewhat surprisingly, and counter to such dogma, susceptible neurones in Alzheimer disease display an activated cell cycle phenotype. However, whether this leads to a coordinated procession through the cell cycle is unclear, particularly whether neurones enter anaphase and beyond. To begin to address this issue, in this study we sought to determine whether nuclear division occurs in these neurones.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We examined a series of 101 archived, routinely stained hippocampal sections collected at post mortem for neuropathological evaluation for evidence of neuronal binucleation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We report for the first time, binucleated neurones within the hippocampus in cases of Alzheimer disease but not in control cases (P &lt; 0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">While a relatively rare event, occurring once every 20,000 neurones, this morphological evidence that neuronal cells within the cortical regions of the adult human brain in Alzheimer disease contain two nuclei supports the hypothesis that neuronal cells can re-enter into a coordinated cell cycle that culminates in nuclear division.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>X</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pathology, Case Western Reserve University, Cleveland 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siedlak</LastName><ForeName>S L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Castellani</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>11</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropathol Appl Neurobiol</MedlineTA><NlmUniqueID>7609829</NlmUniqueID><ISSNLinking>0305-1846</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17995921</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2990.2007.00908.x</ArticleId><ArticleId IdType="pii">NAN908</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18003904</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>47</Issue><PubDate><Year>2007</Year><Month>Nov</Month><Day>20</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Selective changes of resting-state networks in individuals at risk for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>18760</StartPage><EndPage>18765</EndPage><MedlinePgn>18760-5</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is a neurodegenerative disorder that prominently affects cerebral connectivity. Assessing the functional connectivity at rest, recent functional MRI (fMRI) studies reported on the existence of resting-state networks (RSNs). RSNs are characterized by spatially coherent, spontaneous fluctuations in the blood oxygen level-dependent signal and are made up of regional patterns commonly involved in functions such as sensory, attention, or default mode processing. In AD, the default mode network (DMN) is affected by reduced functional connectivity and atrophy. In this work, we analyzed functional and structural MRI data from healthy elderly (n = 16) and patients with amnestic mild cognitive impairment (aMCI) (n = 24), a syndrome of high risk for developing AD. Two questions were addressed: (i) Are any RSNs altered in aMCI? (ii) Do changes in functional connectivity relate to possible structural changes? Independent component analysis of resting-state fMRI data identified eight spatially consistent RSNs. Only selected areas of the DMN and the executive attention network demonstrated reduced network-related activity in the patient group. Voxel-based morphometry revealed atrophy in both medial temporal lobes (MTL) of the patients. The functional connectivity between both hippocampi in the MTLs and the posterior cingulate of the DMN was present in healthy controls but absent in patients. We conclude that in individuals at risk for AD, a specific subset of RSNs is altered, likely representing effects of ongoing early neurodegeneration. We interpret our finding as a proof of principle, demonstrating that functional brain disorders can be characterized by functional-disconnectivity profiles of RSNs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sorg</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Klinikum Rechts der Isar, Technische Universit&#xe4;t M&#xfc;nchen, Ismaningerstrasse 22, 81675 Munich, Germany. c.sorg@lrz.tum.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riedl</LastName><ForeName>Valentin</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>M&#xfc;hlau</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Calhoun</LastName><ForeName>Vince D</ForeName><Initials>VD</Initials></Author><Author ValidYN="Y"><LastName>Eichele</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>L&#xe4;er</LastName><ForeName>Leonhard</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Drzezga</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>F&#xf6;rstl</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kurz</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Zimmer</LastName><ForeName>Claus</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Wohlschl&#xe4;ger</LastName><ForeName>Afra M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006262" MajorTopicYN="N">Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>11</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18003904</ArticleId><ArticleId IdType="pmc">PMC2141850</ArticleId><ArticleId IdType="doi">10.1073/pnas.0708803104</ArticleId><ArticleId IdType="pii">0708803104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H. Lancet. 2006;368:387&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, et al. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Meguro K, LeMestric C, Landeau B, Desgranges B, Eustache F, Baron JC. J Neurol Neurosurg Psychiatry. 2001;71:315&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737577</ArticleId><ArticleId IdType="pubmed">11511703</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Proc Natl Acad Sci USA. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavenex P, Suzuki WA, Amaral DG. J Comp Neurol. 2002;447:394&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">11992524</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaizot X, Meguro K, Millien I, Baron JC, Chavoix C. J Neurosci. 2002;22:9166&#x2013;9170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758045</ArticleId><ArticleId IdType="pubmed">12417640</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoesen GW. J Neuropsychiatry Clin Neurosci. 1997;9:331&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">9276838</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Liang M, Wang L, Tian L, Zhang X, Li K, Jiang T. Hum Brain Mapp. 2007;28:967&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871392</ArticleId><ArticleId IdType="pubmed">17133390</ArticleId></ArticleIdList></Reference><Reference><Citation>Delbeuck X, Van der Linden M, Collette F. Neuropsychol Rev. 2003;13:79&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">12887040</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, et al. Lancet. 2006;367:1262&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pubmed">16631882</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Arch Neurol. 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, Rentz DM, Bertram L, Mullin K, Tanzi RE, Blacker D, et al. Neurology. 2005;65:404&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335677</ArticleId><ArticleId IdType="pubmed">16087905</ArticleId></ArticleIdList></Reference><Reference><Citation>Dannhauser TM, Walker Z, Stevens T, Lee L, Seal M, Shergill SS. Brain. 2005;128:1418&#x2013;1427.</Citation><ArticleIdList><ArticleId IdType="pubmed">15705612</ArticleId></ArticleIdList></Reference><Reference><Citation>Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL, DePeau K, Rentz DM, Selkoe DJ, Blacker D, et al. J Neurosci. 2006;26:10222&#x2013;10231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674636</ArticleId><ArticleId IdType="pubmed">17021177</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoub TR, DeToledo-Morrell L, Stebbins GT, Leurgans S, Bennett DA, Shah RC. Proc Natl Acad Sci USA. 2006;103:10041&#x2013;10045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1479867</ArticleId><ArticleId IdType="pubmed">16785436</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Zang Y, He Y, Liang M, Zhang X, Tian L, Wu T, Jiang T, Li K. NeuroImage. 2006;31:496&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">16473024</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Vincent JL. NeuroImage. 2007;37:1091&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">17368915</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Raichle ME. Nat Rev Neurosci. 2007;8:700&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">17704812</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, Mintun MA. Annu Rev Neurosci. 2006;29:449&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">16776593</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews PM, Honey GD, Bullmore ET. Nat Rev Neurosci. 2006;7:732&#x2013;744.</Citation><ArticleIdList><ArticleId IdType="pubmed">16924262</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME. Proc Natl Acad Sci USA. 2005;102:9673&#x2013;9678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1157105</ArticleId><ArticleId IdType="pubmed">15976020</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampson M, Peterson BS, Skudlarski P, Gatenby JC, Gore JC. Hum Brain Mapp. 2002;15:247&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6872035</ArticleId><ArticleId IdType="pubmed">11835612</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswal B, Yetkin FZ, Haughton VM, Hyde JS. Magn Reson Med. 1995;34:537&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">8524021</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckmann CF, Smith SM. IEEE Trans Med Imaging. 2004;23:137&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">14964560</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux JS, Rombouts SA, Barkhof F, Scheltens P, Stam CJ, Smith SM, Beckmann CF. Proc Natl Acad Sci USA. 2006;103:13848&#x2013;13853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1564249</ArticleId><ArticleId IdType="pubmed">16945915</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Corbetta M, Snyder AZ, Vincent JL, Raichle ME. Proc Natl Acad Sci USA. 2006;103:10046&#x2013;10051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1480402</ArticleId><ArticleId IdType="pubmed">16788060</ArticleId></ArticleIdList></Reference><Reference><Citation>Fransson P. Hum Brain Mapp. 2005;26:15&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871700</ArticleId><ArticleId IdType="pubmed">15852468</ArticleId></ArticleIdList></Reference><Reference><Citation>Laufs H, Kleinschmidt A, Beyerle A, Eger E, Salek-Haddadi A, Preibisch C, Krakow K. NeuroImage. 2003;19:1463&#x2013;1476.</Citation><ArticleIdList><ArticleId IdType="pubmed">12948703</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantini D, Perrucci MG, Del Gratta C, Romani GL, Corbetta M. Proc Natl Acad Sci USA. 2007;104:13170&#x2013;13175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941820</ArticleId><ArticleId IdType="pubmed">17670949</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Patel GH, Fox MD, Snyder AZ, Baker JT, Van Essen DC, Zempel JM, Snyder LH, Corbetta M, Raichle ME. Nature. 2007;447:83&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">17476267</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. Proc Natl Acad Sci USA. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, Snyder AZ. NeuroImage. 2007;37:1083&#x2013;1090.</Citation><ArticleIdList><ArticleId IdType="pubmed">17719799</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbetta M, Shulman GL. Nat Rev Neurosci. 2002;3:201&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">11994752</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon BJ, Buckner RL. J Neurosci. 2004;24:10084&#x2013;10092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730171</ArticleId><ArticleId IdType="pubmed">15537877</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Snyder AZ, Fox MD, Shannon BJ, Andrews JR, Raichle ME, Buckner RL. J Neurophysiol. 2006;96:3517&#x2013;3531.</Citation><ArticleIdList><ArticleId IdType="pubmed">16899645</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzsaki G, Draguhn A. Science. 2004;304:1926&#x2013;1929.</Citation><ArticleIdList><ArticleId IdType="pubmed">15218136</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun VD, Adali T. IEEE Eng Med Biol Mag. 2006;25:79&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">16568940</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun VD, Adali T, Pearlson GD, Pekar JJ. Hum Brain Mapp. 2001;14:140&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871952</ArticleId><ArticleId IdType="pubmed">11559959</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmithorst VJ, Holland SK. J Magn Reson Imaging. 2004;19:365&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265794</ArticleId><ArticleId IdType="pubmed">14994306</ArticleId></ArticleIdList></Reference><Reference><Citation>Grefkes C, Fink GR. J Anat. 2005;207:3&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1571496</ArticleId><ArticleId IdType="pubmed">16011542</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca M, Beckmann CF, De Stefano N, Matthews PM, Smith SM. NeuroImage. 2006;29:1359&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pubmed">16260155</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Petersen RC, Negash S, Weigand SD, Kantarci K, Ivnik RJ, Knopman DS, Boeve BF, Smith GE, Jack CR., Jr Arch Neurol. 2007;64:1130&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735186</ArticleId><ArticleId IdType="pubmed">17698703</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P. Hum Brain Mapp. 2005;26:231&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871685</ArticleId><ArticleId IdType="pubmed">15954139</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, et al. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckmann CF, Smith SM. NeuroImage. 2005;25:294&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734364</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong J, Parsons LM, Gao JH, Fox PT. Hum Brain Mapp. 1999;8:151&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6873334</ArticleId><ArticleId IdType="pubmed">10524607</ArticleId></ArticleIdList></Reference><Reference><Citation>Alescio-Lautier B, Michel BF, Herrera C, Elahmadi A, Chambon C, Touzet C, Paban V. Neuropsychologia. 2007;45:1948&#x2013;1960.</Citation><ArticleIdList><ArticleId IdType="pubmed">17275041</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusnard DA, Raichle ME, Raichle ME. Nat Rev Neurosci. 2001;2:685&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584306</ArticleId></ArticleIdList></Reference><Reference><Citation>Addis DR, Wong AT, Schacter DL. Neuropsychologia. 2007;45:1363&#x2013;1377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1894691</ArticleId><ArticleId IdType="pubmed">17126370</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherkassky VL, Kana RK, Keller TA, Just MA. NeuroReport. 2006;17:1687&#x2013;1690.</Citation><ArticleIdList><ArticleId IdType="pubmed">17047454</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Flores BH, Menon V, Glover GH, Solvason HB, Kenna H, Reiss AL, Schatzberg AF. Biol Psychiatry. 2007;62:429&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2001244</ArticleId><ArticleId IdType="pubmed">17210143</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang M, Zhou Y, Jiang T, Liu Z, Tian L, Liu H, Hao Y. NeuroReport. 2006;17:209&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">16407773</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrity AG, Pearlson GD, McKiernan K, Lloyd D, Kiehl KA, Calhoun VD. Am J Psychiatry. 2007;164:450&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">17329470</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C. Neurology. 1989;39:1159&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">2771064</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjaly ZM, Marshall JC, Stephan KE, Gurd JM, Zilles K, Fink GR. NeuroImage. 2003;19:674&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">12880798</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YO, Adali T, Calhoun VD. Hum Brain Mapp. 2007;28:1251&#x2013;1266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871474</ArticleId><ArticleId IdType="pubmed">17274023</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18003925</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>48</Issue><PubDate><Year>2007</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism.</ArticleTitle><Pagination><StartPage>19067</StartPage><EndPage>19072</EndPage><MedlinePgn>19067-72</MedlinePgn></Pagination><Abstract><AbstractText>Having a parent affected with late-onset Alzheimer's disease (AD) is a risk factor for developing AD among cognitively normal subjects. We examined whether cognitively normal subjects with a parental family history of AD show cerebral metabolic rate of glucose (CMRglc) reductions consistent with AD as compared with those without a family history and whether there are parent gender effects. Forty-nine 50- to 80-year-old normal subjects were examined who received clinical, neuropsychological, and 2-[(18)F]fluoro-2-deoxy-d-glucose-positron emission tomography examinations, including 16 subjects with a maternal (FHm) and eight with a paternal (FHp) family history of AD and 25 with no family history (FH(-)). FH groups were comparable for demographic and neuropsychological measures. As compared with both FH(-) and FHp groups, FHm subjects showed CMRglc reductions in the same regions as clinically affected AD patients, involving the posterior cingulate cortex/precuneus, parietotemporal and frontal cortices, and medial temporal lobes (P &lt; 0.05, corrected for multiple comparisons). These effects remained significant after accounting for possible risk factors for AD, including age, gender, education, apolipoprotein E genotype, and subjective memory complaints. No CMRglc differences were found between FHp and FH(-) subjects. This study shows a relationship between reduced CMRglc in AD-vulnerable brain regions and a maternal family history of AD in cognitively normal individuals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mosconi</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, New York University School of Medicine, 560 First Avenue, New York, NY 10016, USA. lisa.mosconi@med.nyu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brys</LastName><ForeName>Miroslaw</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Switalski</LastName><ForeName>Remigiusz</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Mistur</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Glodzik</LastName><ForeName>Lidia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Pirraglia</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Tsui</LastName><ForeName>Wai</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>De Santi</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG022374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000096</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013616</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG012101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01-RR0096</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13616</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG12101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):18881-2. doi: 10.1073/pnas.0709690104.</RefSource><PMID Version="1">18025455</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005462" MajorTopicYN="N">Fluorine Radioisotopes</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050259" MajorTopicYN="N">Genes, Mitochondrial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018740" MajorTopicYN="N">Genetic Heterogeneity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018392" MajorTopicYN="Y">Genomic Imprinting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009035" MajorTopicYN="N">Mothers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>5</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18003925</ArticleId><ArticleId IdType="pmc">PMC2141909</ArticleId><ArticleId IdType="doi">10.1073/pnas.0705036104</ArticleId><ArticleId IdType="pii">0705036104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Farrer LA, Cuples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Rish N, Dujin CM. J Am Med Assoc. 1997;278:1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Cupples LA, Farrer LA, Sadovnick AD, Relkin N, Whitehouse P, Green Genet Med. 2004;6:192&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">15266206</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, Cupples LA, Go R, Benke KS, Edeki T, Griffith PA, Williams M, Hipps Y, Graff-Radford N, Bachman D, et al. J Am Med Assoc. 2002;287:329&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790212</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman JM, Ciresi G, Smith CJ, Marin DB, Schnaider-Beeri M. Arch Gen Psychiatry. 2005;62:565&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">15867110</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Neuron. 2001;32:181&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">11683989</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L. Eur J Nucl Med Mol Imaging. 2005;32:486&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">15747152</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy AM, Newman SK, Frackowiak RS, Cunningham VJ, Roques P, Stevens J, Neary D, Bruton CJ, Warrington EK, Rossor MN. Brain. 1995;118:185&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">7895004</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Sorbi S, de Leon MJ, Li Y, Nacmias B, Bessi V, Tsui WH, Myoung PS, Fayyaz M, Caffarra P, et al. J Nucl Med. 2006;47:1778&#x2013;1786.</Citation><ArticleIdList><ArticleId IdType="pubmed">17079810</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Ann Neurol. 1997;42:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron JC. Neurology. 2003;60:1374&#x2013;1377.</Citation><ArticleIdList><ArticleId IdType="pubmed">12707450</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, Salmon E, Baron JC, De Cristofaro MTR, Padovani A, et al. Neurology. 2004;63:2332&#x2013;2340.</Citation><ArticleIdList><ArticleId IdType="pubmed">15623696</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A. Eur J Nucl Med Mol Imaging. 2003;30:1104&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pubmed">12764551</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Cummings J, et al. Lancet. 2006;367:1262&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pubmed">16631882</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball MJ, Hachinski V, Fox A, Kirshen AJ, Fisman M, Blume W, Kral VA, Fox H. Lancet. 1985;1:14&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">2856948</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, Convit A, Wolf OT, Tarshish CY, De Santi S, Rusinek H, Tsui W, Kandil E, Scherer AJ, Roche A, et al. Proc Natl Acad Sci USA. 2001;98:10966&#x2013;10971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58582</ArticleId><ArticleId IdType="pubmed">11526211</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, De Santi S, Li J, Tsui WH, Li Y, Boppana M, Rusinek H, de Leon MJ. Neurobiol Aging. 2007 Jan 10; doi: 10.1016/j.neurobiolaging.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging</ArticleId><ArticleId IdType="pmc">PMC2430185</ArticleId><ArticleId IdType="pubmed">17222480</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Ercoli LM, Silverman DHS, Huang SC, Komo S, Bookheimer S, Lavretsky H, Miller K, Siddarth P, Rasgon NL, et al. Proc Natl Acad Sci USA. 2000;97:6037&#x2013;6042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18554</ArticleId><ArticleId IdType="pubmed">10811879</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Proc Natl Acad Sci USA. 2001;98:3334&#x2013;3339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30654</ArticleId><ArticleId IdType="pubmed">11248079</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Proc Natl Acad Sci USA. 2004;101:284&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A. J Nucl Med. 2005;46:1625&#x2013;1632.</Citation><ArticleIdList><ArticleId IdType="pubmed">16204712</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Schmitz TW, Trivedi MA, Ries ML, Torgerson BM, Carlsson CM, Ashtana S, Hermann BP, Sager MA. J Neurosci. 2006;26:6076&#x2013;6069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684824</ArticleId><ArticleId IdType="pubmed">16738250</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Okonek A, Mandelkern MA, LaRue A, Chang L, Khonsary A, Ropchan JR, Blahd WH. Int Psychogeriatr. 1994;6:23&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">8054492</ArticleId></ArticleIdList></Reference><Reference><Citation>Edland SD, Silverman JM, Peskind ER, Tsuang D, Wijsman E, Morris JC. Neurology. 1996;47:254&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">8710088</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenkrantz D, Silverman JM, Smith CJ, Birstein S, Marin D, Mohs RC, Davis KL. Am J Med Genet. 1999;88:378&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">10402505</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassett SS, Avramopoulos D, Fallin D. Am J Med Genet. 2002;114:679&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">12210287</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MT, Beal MF. Nature. 2006;443:787&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051205</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas JJ, Kates JR. Cell. 1976;7:397&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">181145</ArticleId></ArticleIdList></Reference><Reference><Citation>Trimmer PA, Swerdlow RH, Parks JK, Keeney PM, Bennett JP, Jr, Miller SW, Davies RE, Parker WD., Jr Exp Neurol. 2000;162:37&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">10716887</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow RH, Parks JK, Cassarino DS, Maguire DJ, Maguire RS, Bennett JP, Jr, Davis RE, Parker WD., Jr Neurology. 1997;49:918&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">9339668</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutisya EM, Bowling AC, Beal MF. J Neurochem. 1994;63:2179&#x2013;2184.</Citation><ArticleIdList><ArticleId IdType="pubmed">7964738</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Petersen RB, Perry G, et al. J Neurosci. 2001;21:3017&#x2013;3023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762571</ArticleId><ArticleId IdType="pubmed">11312286</ArticleId></ArticleIdList></Reference><Reference><Citation>Valla J, Berndt JD, Gonzales-Lima F. J Neurosci. 2001;21:4923&#x2013;4930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762373</ArticleId><ArticleId IdType="pubmed">11425920</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonian NA, Hyman BT. J Neuropathol Exp Neurol. 1994;53:508&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">8083692</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Ed. Washington, DC: Am Psychiatr Assoc; 1994.</Citation></Reference><Reference><Citation>Kawas C, Segal J, Stewart WF, Corrada M, Thal LJ. Arch Neurol. 1994;51:901&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pubmed">8080390</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachinski VC, Lassen NA, Marshall J. Lancet. 1974;2:207&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">4135618</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanley JA, McNeil JS. Radiology. 1983;148:839&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pubmed">6878708</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Ferris SH, de Leon MJ, Crook T. Am J Psychiatry. 1982;139:1136&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pubmed">7114305</ArticleId></ArticleIdList></Reference><Reference><Citation>George AE, de Leon MJ, Kalnin A, Rosner L, Goodgold A, Chase N. Am J Neuroradiol. 1986;7:567&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8334676</ArticleId><ArticleId IdType="pubmed">3088934</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendriem B, Dewey SL, Schlyer DJ, Wolf AP, Volkow ND. IEEE Trans Nucl Sci. 1991;10:216&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">18222819</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M. J Neurochem. 1977;28:897&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pubmed">864466</ArticleId></ArticleIdList></Reference><Reference><Citation>Reivich M, Alavi A, Wolf A, Fowler J, Russell J, Arnett C, MacGregor RR, Shiue CY, Atkins H, Anand A, et al. J Cereb Blood Flow Metab. 1985;5:179&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">3988820</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston KJ, Holmes AP, Worsley KJ, Poline J-P, Frith CD, Frackowiak RSJ. Hum Brain Mapp. 1995;2:189&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">20408193</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Tsui WH, De Santi S, Rusinek H, Li J, Convit A, Li Y, de Leon MJ. Neurology. 2005;64:1860&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pubmed">15955934</ArticleId></ArticleIdList></Reference><Reference><Citation>Talairach J, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain. Stuttgart, Germany: Thieme; 1988.</Citation></Reference><Reference><Citation>Worsley KJ, Marrett S, Neelin P, Vandal AC, Friston KJ, Evans AC. Hum Brain Mapp. 1996;4:58&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">20408186</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18026096</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1097-6256</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>12</Issue><PubDate><Year>2007</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions.</ArticleTitle><Pagination><StartPage>1544</StartPage><EndPage>1553</EndPage><MedlinePgn>1544-53</MedlinePgn></Pagination><Abstract><AbstractText>Microglia are crucially important myeloid cells in the CNS and constitute the first immunological barrier against pathogens and environmental insults. The factors controlling microglia recruitment from the blood remain elusive and the direct circulating microglia precursor has not yet been identified in vivo. Using a panel of bone marrow chimeric and adoptive transfer experiments, we found that circulating Ly-6C(hi)CCR2(+) monocytes were preferentially recruited to the lesioned brain and differentiated into microglia. Notably, microglia engraftment in CNS pathologies, which are not associated with overt blood-brain barrier disruption, required previous conditioning of brain (for example, by direct tissue irradiation). Our results identify Ly-6C(hi)CCR2(+) monocytes as direct precursors of microglia in the adult brain and establish the importance of local factors in the adult CNS for microglia engraftment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mildner</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, Georg August University, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Hauke</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Nitsche</LastName><ForeName>Mirko</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Merkler</LastName><ForeName>Doron</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hanisch</LastName><ForeName>Uwe-Karsten</ForeName><Initials>UK</Initials></Author><Author ValidYN="Y"><LastName>Mack</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Heikenwalder</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Br&#xfc;ck</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Priller</LastName><ForeName>Josef</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Prinz</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491049">Aif1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000950">Antigens, Ly</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002135">Calcium-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515335">Ccr2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055666">Lipopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008840">Microfilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508075">Pam(3)CSK(4) peptide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054390">Receptors, CCR2</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.2.1.11</RegistryNumber><NameOfSubstance UI="D010751">Phosphopyruvate Hydratase</NameOfSubstance></Chemical><Chemical><RegistryNumber>G34N38R2N1</RegistryNumber><NameOfSubstance UI="D001973">Bromodeoxyuridine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000950" MajorTopicYN="N">Antigens, Ly</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019771" MajorTopicYN="N">Axotomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001854" MajorTopicYN="N">Bone Marrow Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001973" MajorTopicYN="N">Bromodeoxyuridine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002135" MajorTopicYN="N">Calcium-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055666" MajorTopicYN="N">Lipopeptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008840" MajorTopicYN="N">Microfilament Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010751" MajorTopicYN="N">Phosphopyruvate Hydratase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054390" MajorTopicYN="N">Receptors, CCR2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18026096</ArticleId><ArticleId IdType="doi">10.1038/nn2015</ArticleId><ArticleId IdType="pii">nn2015</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18026097</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1097-6256</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>12</Issue><PubDate><Year>2007</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Local self-renewal can sustain CNS microglia maintenance and function throughout adult life.</ArticleTitle><Pagination><StartPage>1538</StartPage><EndPage>1543</EndPage><MedlinePgn>1538-43</MedlinePgn></Pagination><Abstract><AbstractText>Microgliosis is a common response to multiple types of damage in the CNS. However, the origin of the cells involved in this process is still controversial and the relative importance of local expansion versus recruitment of microglia progenitors from the bloodstream is unclear. Here, we investigated the origin of microglia using chimeric animals obtained by parabiosis. We found no evidence of microglia progenitor recruitment from the circulation in denervation or CNS neurodegenerative disease, suggesting that maintenance and local expansion of microglia are solely dependent on the self-renewal of CNS resident cells in these models.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ajami</LastName><ForeName>Bahareh</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>University of British Columbia, The Biomedical Research Centre, 2222 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Jami L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Krieger</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Tetzlaff</LastName><ForeName>Wolfram</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Fabio M V</ForeName><Initials>FM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491049">Aif1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002135">Calcium-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008840">Microfilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C109415">SOD1 G93A protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019771" MajorTopicYN="N">Axotomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016026" MajorTopicYN="N">Bone Marrow Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002135" MajorTopicYN="N">Calcium-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002493" MajorTopicYN="N">Central Nervous System Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005155" MajorTopicYN="N">Facial Nerve Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008840" MajorTopicYN="N">Microfilament Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010227" MajorTopicYN="N">Parabiosis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011828" MajorTopicYN="N">Radiation Chimera</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18026097</ArticleId><ArticleId IdType="doi">10.1038/nn2014</ArticleId><ArticleId IdType="pii">nn2014</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18026102</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>12</Issue><PubDate><Year>2007</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Cystatin C modulates cerebral beta-amyloidosis.</ArticleTitle><Pagination><StartPage>1437</StartPage><EndPage>1439</EndPage><MedlinePgn>1437-9</MedlinePgn></Pagination><Abstract><AbstractText>The CST3 Thr25 allele of CST3, which encodes cystatin C, leads to reduced cystatin C secretion and conveys susceptibility to Alzheimer's disease. Here we show that overexpression of human cystatin C in brains of APP-transgenic mice reduces cerebral amyloid-beta deposition and that cystatin C binds amyloid-beta and inhibits its fibril formation. Our results suggest that cystatin C concentrations modulate cerebral amyloidosis risk and provide an opportunity for genetic risk assessment and therapeutic interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaeser</LastName><ForeName>Stephan A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie-Institute for Clinical Brain Research, University of T&#xfc;bingen, Otfried-M&#xfc;ller Strasse 27, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herzig</LastName><ForeName>Martin C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Coomaraswamy</LastName><ForeName>Janaky</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kilger</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Selenica</LastName><ForeName>Maj-Linda</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Winkler</LastName><ForeName>David T</ForeName><Initials>DT</Initials></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Efrat</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Grubb</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C525030">CST3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C525031">Cst3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055316">Cystatin C</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015891">Cystatins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="Y">Amyloidosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054022" MajorTopicYN="N">Cerebrum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055316" MajorTopicYN="N">Cystatin C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015891" MajorTopicYN="N">Cystatins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18026102</ArticleId><ArticleId IdType="doi">10.1038/ng.2007.23</ArticleId><ArticleId IdType="pii">ng.2007.23</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18026100</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>12</Issue><PubDate><Year>2007</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models.</ArticleTitle><Pagination><StartPage>1440</StartPage><EndPage>1442</EndPage><MedlinePgn>1440-2</MedlinePgn></Pagination><Abstract><AbstractText>Using transgenic mice expressing human cystatin C (encoded by CST3), we show that cystatin C binds soluble amyloid-beta peptide and inhibits cerebral amyloid deposition in amyloid-beta precursor protein (APP) transgenic mice. Cystatin C expression twice that of the endogenous mouse cystatin C was sufficient to substantially diminish amyloid-beta deposition. Thus, cystatin C has a protective role in Alzheimer's disease pathogenesis, and modulation of cystatin C concentrations may have therapeutic implications for the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mi</LastName><ForeName>Weiqian</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Nathan S. Kline Institute, Orangeburg, New York 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pawlik</LastName><ForeName>Monika</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sastre</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Sonia S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Radvinsky</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Andrew M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Sommer</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Stephen D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>Ralph A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Mathews</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Efrat</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS42029</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C525030">CST3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C525031">Cst3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055316">Cystatin C</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015891">Cystatins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055316" MajorTopicYN="N">Cystatin C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015891" MajorTopicYN="N">Cystatins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18026100</ArticleId><ArticleId IdType="doi">10.1038/ng.2007.29</ArticleId><ArticleId IdType="pii">ng.2007.29</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>